bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
telemedicine is an umlsterm, time is an umlsterm, time is an umlsterm, economic is an umlsterm, need is an umlsterm, all is an umlsterm	DerRadiologe.70370294.eng.abstr_task1	Sentence: The discussion about the implementation of telemedicine and teleresourcing and its consequences has been under way for some time now . The rate at which telemedical applications are being developed , leaves little time for consideration of the economic , scientific and social aspects . There is a need for integration of all the existing fragments into one coherent telemedical concept . Different aspects of telemedical concepts are discussed . Instructions: please typing these entity words according to sentence: telemedicine, time, time, economic, need, all Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The discussion about the implementation of telemedicine and teleresourcing and its consequences has been under way for some time now . The rate at which telemedical applications are being developed , leaves little time for consideration of the economic , scientific and social aspects . There is a need for integration of all the existing fragments into one coherent telemedical concept . Different aspects of telemedical concepts are discussed .	[ "The", "discussion", "about", "the", "implementation", "of", "telemedicine", "and", "teleresourcing", "and", "its", "consequences", "has", "been", "under", "way", "for", "some", "time", "now", ".", "The", "rate", "at", "which", "telemedical", "applications", "are", "being", "developed", ",", "leaves", "little", "time", "for", "consideration", "of", "the", "economic", ",", "scientific", "and", "social", "aspects", ".", "There", "is", "a", "need", "for", "integration", "of", "all", "the", "existing", "fragments", "into", "one", "coherent", "telemedical", "concept", ".", "Different", "aspects", "of", "telemedical", "concepts", "are", "discussed", "." ]	[ "umlsterm" ]
telemedicine, time, time, economic, need, all	DerRadiologe.70370294.eng.abstr_task2	Sentence: The discussion about the implementation of telemedicine and teleresourcing and its consequences has been under way for some time now . The rate at which telemedical applications are being developed , leaves little time for consideration of the economic , scientific and social aspects . There is a need for integration of all the existing fragments into one coherent telemedical concept . Different aspects of telemedical concepts are discussed . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The discussion about the implementation of telemedicine and teleresourcing and its consequences has been under way for some time now . The rate at which telemedical applications are being developed , leaves little time for consideration of the economic , scientific and social aspects . There is a need for integration of all the existing fragments into one coherent telemedical concept . Different aspects of telemedical concepts are discussed .	[ "The", "discussion", "about", "the", "implementation", "of", "telemedicine", "and", "teleresourcing", "and", "its", "consequences", "has", "been", "under", "way", "for", "some", "time", "now", ".", "The", "rate", "at", "which", "telemedical", "applications", "are", "being", "developed", ",", "leaves", "little", "time", "for", "consideration", "of", "the", "economic", ",", "scientific", "and", "social", "aspects", ".", "There", "is", "a", "need", "for", "integration", "of", "all", "the", "existing", "fragments", "into", "one", "coherent", "telemedical", "concept", ".", "Different", "aspects", "of", "telemedical", "concepts", "are", "discussed", "." ]	[ "umlsterm" ]
fatty acid is a CHEMICAL, GPCRs is a GENE-N	23409763_task0	Sentence: The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-N", "O" ]	The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs.	[ "The", "therapeutic", "potential", "of", "allosteric", "ligands", "for", "free", "fatty", "acid", "sensitive", "GPCRs", "." ]	[ "GENE-N", "CHEMICAL" ]
fatty acid is a CHEMICAL, GPCRs is a GENE-N	23409763_task1	Sentence: The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. Instructions: please typing these entity words according to sentence: fatty acid, GPCRs Options: GENE-N, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-N", "O" ]	The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs.	[ "The", "therapeutic", "potential", "of", "allosteric", "ligands", "for", "free", "fatty", "acid", "sensitive", "GPCRs", "." ]	[ "GENE-N", "CHEMICAL" ]
fatty acid, GPCRs	23409763_task2	Sentence: The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-N", "O" ]	The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs.	[ "The", "therapeutic", "potential", "of", "allosteric", "ligands", "for", "free", "fatty", "acid", "sensitive", "GPCRs", "." ]	[ "GENE-N", "CHEMICAL" ]
TNXB is a gene	27_task0	Sentence: TNXB locus may be a candidate gene predisposing to schizophrenia. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: gene	[ "B-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	TNXB locus may be a candidate gene predisposing to schizophrenia.	[ "TNXB", " ", "locus", "may", "be", "a", "candidate", "gene", "predisposing", "to", "schizophrenia", "." ]	[ "variant", "gene" ]
TNXB is a gene	27_task1	Sentence: TNXB locus may be a candidate gene predisposing to schizophrenia. Instructions: please typing these entity words according to sentence: TNXB Options: gene	[ "B-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	TNXB locus may be a candidate gene predisposing to schizophrenia.	[ "TNXB", " ", "locus", "may", "be", "a", "candidate", "gene", "predisposing", "to", "schizophrenia", "." ]	[ "variant", "gene" ]
TNXB	27_task2	Sentence: TNXB locus may be a candidate gene predisposing to schizophrenia. Instructions: please extract entity words from the input sentence	[ "B-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	TNXB locus may be a candidate gene predisposing to schizophrenia.	[ "TNXB", " ", "locus", "may", "be", "a", "candidate", "gene", "predisposing", "to", "schizophrenia", "." ]	[ "variant", "gene" ]
ATP - binding cassette transporter is a GENE-N, ABCB1 is a GENE-Y, BCRP is a GENE-Y, ABCG2 is a GENE-Y, Aβ is a GENE-Y, multidrug transporters is a GENE-N, ABCA1 is a GENE-Y, ABCA7 is a GENE-Y, ABCB1 is a GENE-Y, ABCC2 is a GENE-Y, ABCG2 is a GENE-Y, APOE4 is a GENE-Y, ABCA7 is a GENE-Y, ABCB1 is a GENE-Y, ABCB1 is a GENE-Y, 2677G > T is a GENE-N, ABCC2 is a GENE-Y, 3972C > T is a GENE-N, ABCB1 is a GENE-Y, ABC - transporters is a GENE-N, Aβ is a GENE-Y	33213_task0	Sentence: Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ. We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls. Materials & methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2. In addition, the APOE4 status was analyzed. Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study. Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females. This association of ABCB1 2677G>T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005). However, only ABCC2 3972C>T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants. Other transporters showed a lack of association. Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD. Original submitted 8 October 2012; Revision submitted 22 January 2013. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N	[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ. We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls. Materials & methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2. In addition, the APOE4 status was analyzed. Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study. Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females. This association of ABCB1 2677G>T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005). However, only ABCC2 3972C>T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants. Other transporters showed a lack of association. Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD. Original submitted 8 October 2012; Revision submitted 22 January 2013.	[ "Association", "of", "ATP", "-", "binding", "cassette", "transporter", "variants", "with", "the", "risk", "of", "Alzheimer", "'s", "disease", ".", "\n", "Aim", ":", "A", "number", "of", "studies", "have", "demonstrated", "that", "ABCB1", "and", "BCRP", "(", "ABCG2", ")", "actively", "transport", "Aβ", ".", "We", "aimed", "to", "investigate", "the", "association", "of", "genetic", "variants", "of", "selected", "multidrug", "transporters", "with", "Alzheimer", "'s", "disease", "(", "AD", ")", "in", "histopathologically", "confirmed", "AD", "cases", "and", "controls", ".", "Materials", "&", "methods", ":", "DNA", "from", "brain", "tissue", "of", "71", "AD", "cases", "with", "Consortium", "to", "Establish", "a", "Registry", "for", "Alzheimer", "'s", "Disease", "(", "CERAD", ")", "neuropathological", "stages", "B", "/", "C", "and", "81", "controls", "was", "genotyped", "for", "selected", "variants", "in", "ABCA1", ",", "ABCA7", ",", "ABCB1", ",", "ABCC2", "and", "ABCG2", ".", "In", "addition", ",", "the", "APOE4", "status", "was", "analyzed", ".", "Results", ":", "The", "novel", "ABCA7", "SNP", ",", "rs3752246", ",", "tended", "to", "be", "associated", "with", "AD", "in", "our", "study", ".", "Variants", "in", "ABCB1", "were", "significantly", "less", "frequent", "in", "AD", "cases", "older", "than", "65", "years", "of", "age", "and", "among", "females", ".", "This", "association", "of", "ABCB1", "2677G", ">", "T", "(", "rs2032582", ")", "was", "more", "pronounced", "in", "APOE4-negative", "cases", "(", "p", "=", "0.005", ")", ".", "However", ",", "only", "ABCC2", "3972C", ">", "T", "(", "rs3740066", ")", "was", "significantly", "associated", "with", "AD", "risk", "after", "logistic", "regression", "analysis", "including", "all", "variants", ".", "Other", "transporters", "showed", "a", "lack", "of", "association", ".", "Conclusion", ":", "Our", "results", "support", "the", "hypothesis", "that", "ABCB1", "and", "possibly", "other", "ABC", "-", "transporters", "are", "involved", "in", "the", "process", "of", "Aβ", "accumulation", "in", "the", "aging", "brain", "and", "may", "modulate", "the", "risk", "for", "AD", "in", "an", "allele", "-", "specific", "manner", ",", "and", "thus", "might", "represent", "a", "new", "target", "for", "prevention", "and", "treatment", "of", "AD", ".", "Original", "submitted", "8", "October", "2012", ";", "Revision", "submitted", "22", "January", "2013", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
ATP - binding cassette transporter is a GENE-N, ABCB1 is a GENE-Y, BCRP is a GENE-Y, ABCG2 is a GENE-Y, Aβ is a GENE-Y, multidrug transporters is a GENE-N, ABCA1 is a GENE-Y, ABCA7 is a GENE-Y, ABCB1 is a GENE-Y, ABCC2 is a GENE-Y, ABCG2 is a GENE-Y, APOE4 is a GENE-Y, ABCA7 is a GENE-Y, ABCB1 is a GENE-Y, ABCB1 is a GENE-Y, 2677G > T is a GENE-N, ABCC2 is a GENE-Y, 3972C > T is a GENE-N, ABCB1 is a GENE-Y, ABC - transporters is a GENE-N, Aβ is a GENE-Y	33213_task1	Sentence: Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ. We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls. Materials & methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2. In addition, the APOE4 status was analyzed. Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study. Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females. This association of ABCB1 2677G>T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005). However, only ABCC2 3972C>T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants. Other transporters showed a lack of association. Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD. Original submitted 8 October 2012; Revision submitted 22 January 2013. Instructions: please typing these entity words according to sentence: ATP - binding cassette transporter, ABCB1, BCRP, ABCG2, Aβ, multidrug transporters, ABCA1, ABCA7, ABCB1, ABCC2, ABCG2, APOE4, ABCA7, ABCB1, ABCB1, 2677G > T, ABCC2, 3972C > T, ABCB1, ABC - transporters, Aβ Options: GENE-Y, GENE-N	[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ. We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls. Materials & methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2. In addition, the APOE4 status was analyzed. Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study. Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females. This association of ABCB1 2677G>T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005). However, only ABCC2 3972C>T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants. Other transporters showed a lack of association. Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD. Original submitted 8 October 2012; Revision submitted 22 January 2013.	[ "Association", "of", "ATP", "-", "binding", "cassette", "transporter", "variants", "with", "the", "risk", "of", "Alzheimer", "'s", "disease", ".", "\n", "Aim", ":", "A", "number", "of", "studies", "have", "demonstrated", "that", "ABCB1", "and", "BCRP", "(", "ABCG2", ")", "actively", "transport", "Aβ", ".", "We", "aimed", "to", "investigate", "the", "association", "of", "genetic", "variants", "of", "selected", "multidrug", "transporters", "with", "Alzheimer", "'s", "disease", "(", "AD", ")", "in", "histopathologically", "confirmed", "AD", "cases", "and", "controls", ".", "Materials", "&", "methods", ":", "DNA", "from", "brain", "tissue", "of", "71", "AD", "cases", "with", "Consortium", "to", "Establish", "a", "Registry", "for", "Alzheimer", "'s", "Disease", "(", "CERAD", ")", "neuropathological", "stages", "B", "/", "C", "and", "81", "controls", "was", "genotyped", "for", "selected", "variants", "in", "ABCA1", ",", "ABCA7", ",", "ABCB1", ",", "ABCC2", "and", "ABCG2", ".", "In", "addition", ",", "the", "APOE4", "status", "was", "analyzed", ".", "Results", ":", "The", "novel", "ABCA7", "SNP", ",", "rs3752246", ",", "tended", "to", "be", "associated", "with", "AD", "in", "our", "study", ".", "Variants", "in", "ABCB1", "were", "significantly", "less", "frequent", "in", "AD", "cases", "older", "than", "65", "years", "of", "age", "and", "among", "females", ".", "This", "association", "of", "ABCB1", "2677G", ">", "T", "(", "rs2032582", ")", "was", "more", "pronounced", "in", "APOE4-negative", "cases", "(", "p", "=", "0.005", ")", ".", "However", ",", "only", "ABCC2", "3972C", ">", "T", "(", "rs3740066", ")", "was", "significantly", "associated", "with", "AD", "risk", "after", "logistic", "regression", "analysis", "including", "all", "variants", ".", "Other", "transporters", "showed", "a", "lack", "of", "association", ".", "Conclusion", ":", "Our", "results", "support", "the", "hypothesis", "that", "ABCB1", "and", "possibly", "other", "ABC", "-", "transporters", "are", "involved", "in", "the", "process", "of", "Aβ", "accumulation", "in", "the", "aging", "brain", "and", "may", "modulate", "the", "risk", "for", "AD", "in", "an", "allele", "-", "specific", "manner", ",", "and", "thus", "might", "represent", "a", "new", "target", "for", "prevention", "and", "treatment", "of", "AD", ".", "Original", "submitted", "8", "October", "2012", ";", "Revision", "submitted", "22", "January", "2013", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
ATP - binding cassette transporter, ABCB1, BCRP, ABCG2, Aβ, multidrug transporters, ABCA1, ABCA7, ABCB1, ABCC2, ABCG2, APOE4, ABCA7, ABCB1, ABCB1, 2677G > T, ABCC2, 3972C > T, ABCB1, ABC - transporters, Aβ	33213_task2	Sentence: Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ. We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls. Materials & methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2. In addition, the APOE4 status was analyzed. Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study. Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females. This association of ABCB1 2677G>T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005). However, only ABCC2 3972C>T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants. Other transporters showed a lack of association. Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD. Original submitted 8 October 2012; Revision submitted 22 January 2013. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ. We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls. Materials & methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2. In addition, the APOE4 status was analyzed. Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study. Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females. This association of ABCB1 2677G>T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005). However, only ABCC2 3972C>T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants. Other transporters showed a lack of association. Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD. Original submitted 8 October 2012; Revision submitted 22 January 2013.	[ "Association", "of", "ATP", "-", "binding", "cassette", "transporter", "variants", "with", "the", "risk", "of", "Alzheimer", "'s", "disease", ".", "\n", "Aim", ":", "A", "number", "of", "studies", "have", "demonstrated", "that", "ABCB1", "and", "BCRP", "(", "ABCG2", ")", "actively", "transport", "Aβ", ".", "We", "aimed", "to", "investigate", "the", "association", "of", "genetic", "variants", "of", "selected", "multidrug", "transporters", "with", "Alzheimer", "'s", "disease", "(", "AD", ")", "in", "histopathologically", "confirmed", "AD", "cases", "and", "controls", ".", "Materials", "&", "methods", ":", "DNA", "from", "brain", "tissue", "of", "71", "AD", "cases", "with", "Consortium", "to", "Establish", "a", "Registry", "for", "Alzheimer", "'s", "Disease", "(", "CERAD", ")", "neuropathological", "stages", "B", "/", "C", "and", "81", "controls", "was", "genotyped", "for", "selected", "variants", "in", "ABCA1", ",", "ABCA7", ",", "ABCB1", ",", "ABCC2", "and", "ABCG2", ".", "In", "addition", ",", "the", "APOE4", "status", "was", "analyzed", ".", "Results", ":", "The", "novel", "ABCA7", "SNP", ",", "rs3752246", ",", "tended", "to", "be", "associated", "with", "AD", "in", "our", "study", ".", "Variants", "in", "ABCB1", "were", "significantly", "less", "frequent", "in", "AD", "cases", "older", "than", "65", "years", "of", "age", "and", "among", "females", ".", "This", "association", "of", "ABCB1", "2677G", ">", "T", "(", "rs2032582", ")", "was", "more", "pronounced", "in", "APOE4-negative", "cases", "(", "p", "=", "0.005", ")", ".", "However", ",", "only", "ABCC2", "3972C", ">", "T", "(", "rs3740066", ")", "was", "significantly", "associated", "with", "AD", "risk", "after", "logistic", "regression", "analysis", "including", "all", "variants", ".", "Other", "transporters", "showed", "a", "lack", "of", "association", ".", "Conclusion", ":", "Our", "results", "support", "the", "hypothesis", "that", "ABCB1", "and", "possibly", "other", "ABC", "-", "transporters", "are", "involved", "in", "the", "process", "of", "Aβ", "accumulation", "in", "the", "aging", "brain", "and", "may", "modulate", "the", "risk", "for", "AD", "in", "an", "allele", "-", "specific", "manner", ",", "and", "thus", "might", "represent", "a", "new", "target", "for", "prevention", "and", "treatment", "of", "AD", ".", "Original", "submitted", "8", "October", "2012", ";", "Revision", "submitted", "22", "January", "2013", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
AIDS is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Dokumentation is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Konzentration is an umlsterm, Beratungen is an umlsterm, Behandlungen is an umlsterm, Behandlung is an umlsterm, Therapieschemata is an umlsterm, HIV - Infektion is an umlsterm, Virusnachweis is an umlsterm, PCR is an umlsterm, Behandlung is an umlsterm, Krankenversicherung is an umlsterm, Behandlung is an umlsterm, Beratung is an umlsterm, Berater is an umlsterm	Bundesgesundheitsblatt.0043s045.ger.abstr_task0	Sentence: Innerhalb der letzten zwoelf Monate haben bundesweit 68 auf AIDS spezialisierte Einrichtungen mindestens in einem Fall eine Beratung und 19 eine Behandlung zur nicht-beruflichen HIV-Postexpositionsprophylaxe ( PEP ) durchgefuehrt . 531 Faellen einer Beratung stehen 143 Faelle gegenueber , in denen eine Behandlung empfohlen wurde . Die Dokumentation der Faelle erweist sich im Bereich der Beratung als lueckenhaft . Die Studie belegt 123 Faelle , in denen eine Behandlung erfolgte , von denen 67 durch die berichtenden Einrichtungen versorgt wurden ( davon 37 an nur zwei Einrichtungen ) . Sowohl bei Beratung als auch bei Behandlung zeigt sich eine Konzentration der Faelle auf einzelne Einrichtungen . Der Zeitpunkt der Beratungen und Behandlungen liegt bei 51,6% bzw. 91,1% innerhalb der fuer besonders wirksam erachteten 24 Stunden nach der Exposition . Die Behandlung erfolgt mit zehn unterschiedlichen Therapieschemata , die durch fuenf alternative Regimes ergaenzt werden . In der Mehrzahl der Faelle wird zum Nachweis oder Ausschluss einer HIV-Infektion neben dem HIV-Antikoerpertest und dem Western Blot ein Virusnachweis mittels bDNA oder PCR durchgefuehrt . Die Kosten der Behandlung traegt ueberwiegend die gesetzliche Krankenversicherung . Der Versuch eines Anrufers , sich im Bereich der klinischen und niedergelassenen aerztlichen Versorgung am Wochenende ueber die Moeglichkeit einer PEP zu informieren , scheitert in ueber der Haelfte der Faelle . Dabei ist vor allem der Bereich der aerztlichen Notrufzentralen offensichtlich nicht auf die entsprechenden Fragestellungen vorbereitet . In 25 von 33 Gespraechen sind die erreichten Ansprechpartner entweder nicht mit den Deutsch-Oesterreichischen Empfehlungen vertraut ( z.B. beziehen sich vier Faelle auf die alten Empfehlungen zur beruflichen PEP ) , erklaeren sich fuer nicht zustaendig oder bauen durch Beratungsstil und Einbestellung zu einem ungeeigneten Zeitpunkt Huerden auf , die einer angemessenen Behandlung entgegenstehen . Gleichwohl erhaelt der Anrufer in acht Faellen eine fachgerechte Beratung . Dies gelingt zum einen , weil durch mehrfache Anrufe oder Vermittlung letztlich ein kompetenter Gespraechspartner angetroffen werden kann . Zum anderen sind die Berater bereit , telefonisch darzulegen , warum und durch welche Vorgehensweise sie bereit sind , in diesem Fall eine HIV-PEP durchzufuehren . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Innerhalb der letzten zwoelf Monate haben bundesweit 68 auf AIDS spezialisierte Einrichtungen mindestens in einem Fall eine Beratung und 19 eine Behandlung zur nicht-beruflichen HIV-Postexpositionsprophylaxe ( PEP ) durchgefuehrt . 531 Faellen einer Beratung stehen 143 Faelle gegenueber , in denen eine Behandlung empfohlen wurde . Die Dokumentation der Faelle erweist sich im Bereich der Beratung als lueckenhaft . Die Studie belegt 123 Faelle , in denen eine Behandlung erfolgte , von denen 67 durch die berichtenden Einrichtungen versorgt wurden ( davon 37 an nur zwei Einrichtungen ) . Sowohl bei Beratung als auch bei Behandlung zeigt sich eine Konzentration der Faelle auf einzelne Einrichtungen . Der Zeitpunkt der Beratungen und Behandlungen liegt bei 51,6% bzw. 91,1% innerhalb der fuer besonders wirksam erachteten 24 Stunden nach der Exposition . Die Behandlung erfolgt mit zehn unterschiedlichen Therapieschemata , die durch fuenf alternative Regimes ergaenzt werden . In der Mehrzahl der Faelle wird zum Nachweis oder Ausschluss einer HIV-Infektion neben dem HIV-Antikoerpertest und dem Western Blot ein Virusnachweis mittels bDNA oder PCR durchgefuehrt . Die Kosten der Behandlung traegt ueberwiegend die gesetzliche Krankenversicherung . Der Versuch eines Anrufers , sich im Bereich der klinischen und niedergelassenen aerztlichen Versorgung am Wochenende ueber die Moeglichkeit einer PEP zu informieren , scheitert in ueber der Haelfte der Faelle . Dabei ist vor allem der Bereich der aerztlichen Notrufzentralen offensichtlich nicht auf die entsprechenden Fragestellungen vorbereitet . In 25 von 33 Gespraechen sind die erreichten Ansprechpartner entweder nicht mit den Deutsch-Oesterreichischen Empfehlungen vertraut ( z.B. beziehen sich vier Faelle auf die alten Empfehlungen zur beruflichen PEP ) , erklaeren sich fuer nicht zustaendig oder bauen durch Beratungsstil und Einbestellung zu einem ungeeigneten Zeitpunkt Huerden auf , die einer angemessenen Behandlung entgegenstehen . Gleichwohl erhaelt der Anrufer in acht Faellen eine fachgerechte Beratung . Dies gelingt zum einen , weil durch mehrfache Anrufe oder Vermittlung letztlich ein kompetenter Gespraechspartner angetroffen werden kann . Zum anderen sind die Berater bereit , telefonisch darzulegen , warum und durch welche Vorgehensweise sie bereit sind , in diesem Fall eine HIV-PEP durchzufuehren .	[ "Innerhalb", "der", "letzten", "zwoelf", "Monate", "haben", "bundesweit", "68", "auf", "AIDS", "spezialisierte", "Einrichtungen", "mindestens", "in", "einem", "Fall", "eine", "Beratung", "und", "19", "eine", "Behandlung", "zur", "nicht", "-", "beruflichen", "HIV", "-", "Postexpositionsprophylaxe", "(", "PEP", ")", "durchgefuehrt", ".", "531", "Faellen", "einer", "Beratung", "stehen", "143", "Faelle", "gegenueber", ",", "in", "denen", "eine", "Behandlung", "empfohlen", "wurde", ".", "Die", "Dokumentation", "der", "Faelle", "erweist", "sich", "im", "Bereich", "der", "Beratung", "als", "lueckenhaft", ".", "Die", "Studie", "belegt", "123", "Faelle", ",", "in", "denen", "eine", "Behandlung", "erfolgte", ",", "von", "denen", "67", "durch", "die", "berichtenden", "Einrichtungen", "versorgt", "wurden", "(", "davon", "37", "an", "nur", "zwei", "Einrichtungen", ")", ".", "Sowohl", "bei", "Beratung", "als", "auch", "bei", "Behandlung", "zeigt", "sich", "eine", "Konzentration", "der", "Faelle", "auf", "einzelne", "Einrichtungen", ".", "Der", "Zeitpunkt", "der", "Beratungen", "und", "Behandlungen", "liegt", "bei", "51,6", "%", "bzw", ".", "91,1", "%", "innerhalb", "der", "fuer", "besonders", "wirksam", "erachteten", "24", "Stunden", "nach", "der", "Exposition", ".", "Die", "Behandlung", "erfolgt", "mit", "zehn", "unterschiedlichen", "Therapieschemata", ",", "die", "durch", "fuenf", "alternative", "Regimes", "ergaenzt", "werden", ".", "In", "der", "Mehrzahl", "der", "Faelle", "wird", "zum", "Nachweis", "oder", "Ausschluss", "einer", "HIV", "-", "Infektion", "neben", "dem", "HIV", "-", "Antikoerpertest", "und", "dem", "Western", "Blot", "ein", "Virusnachweis", "mittels", "bDNA", "oder", "PCR", "durchgefuehrt", ".", "Die", "Kosten", "der", "Behandlung", "traegt", "ueberwiegend", "die", "gesetzliche", "Krankenversicherung", ".", "Der", "Versuch", "eines", "Anrufers", ",", "sich", "im", "Bereich", "der", "klinischen", "und", "niedergelassenen", "aerztlichen", "Versorgung", "am", "Wochenende", "ueber", "die", "Moeglichkeit", "einer", "PEP", "zu", "informieren", ",", "scheitert", "in", "ueber", "der", "Haelfte", "der", "Faelle", ".", "Dabei", "ist", "vor", "allem", "der", "Bereich", "der", "aerztlichen", "Notrufzentralen", "offensichtlich", "nicht", "auf", "die", "entsprechenden", "Fragestellungen", "vorbereitet", ".", "In", "25", "von", "33", "Gespraechen", "sind", "die", "erreichten", "Ansprechpartner", "entweder", "nicht", "mit", "den", "Deutsch", "-", "Oesterreichischen", "Empfehlungen", "vertraut", "(", "z.", "B.", "beziehen", "sich", "vier", "Faelle", "auf", "die", "alten", "Empfehlungen", "zur", "beruflichen", "PEP", ")", ",", "erklaeren", "sich", "fuer", "nicht", "zustaendig", "oder", "bauen", "durch", "Beratungsstil", "und", "Einbestellung", "zu", "einem", "ungeeigneten", "Zeitpunkt", "Huerden", "auf", ",", "die", "einer", "angemessenen", "Behandlung", "entgegenstehen", ".", "Gleichwohl", "erhaelt", "der", "Anrufer", "in", "acht", "Faellen", "eine", "fachgerechte", "Beratung", ".", "Dies", "gelingt", "zum", "einen", ",", "weil", "durch", "mehrfache", "Anrufe", "oder", "Vermittlung", "letztlich", "ein", "kompetenter", "Gespraechspartner", "angetroffen", "werden", "kann", ".", "Zum", "anderen", "sind", "die", "Berater", "bereit", ",", "telefonisch", "darzulegen", ",", "warum", "und", "durch", "welche", "Vorgehensweise", "sie", "bereit", "sind", ",", "in", "diesem", "Fall", "eine", "HIV", "-", "PEP", "durchzufuehren", "." ]	[ "umlsterm" ]
AIDS is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Dokumentation is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Konzentration is an umlsterm, Beratungen is an umlsterm, Behandlungen is an umlsterm, Behandlung is an umlsterm, Therapieschemata is an umlsterm, HIV - Infektion is an umlsterm, Virusnachweis is an umlsterm, PCR is an umlsterm, Behandlung is an umlsterm, Krankenversicherung is an umlsterm, Behandlung is an umlsterm, Beratung is an umlsterm, Berater is an umlsterm	Bundesgesundheitsblatt.0043s045.ger.abstr_task1	Sentence: Innerhalb der letzten zwoelf Monate haben bundesweit 68 auf AIDS spezialisierte Einrichtungen mindestens in einem Fall eine Beratung und 19 eine Behandlung zur nicht-beruflichen HIV-Postexpositionsprophylaxe ( PEP ) durchgefuehrt . 531 Faellen einer Beratung stehen 143 Faelle gegenueber , in denen eine Behandlung empfohlen wurde . Die Dokumentation der Faelle erweist sich im Bereich der Beratung als lueckenhaft . Die Studie belegt 123 Faelle , in denen eine Behandlung erfolgte , von denen 67 durch die berichtenden Einrichtungen versorgt wurden ( davon 37 an nur zwei Einrichtungen ) . Sowohl bei Beratung als auch bei Behandlung zeigt sich eine Konzentration der Faelle auf einzelne Einrichtungen . Der Zeitpunkt der Beratungen und Behandlungen liegt bei 51,6% bzw. 91,1% innerhalb der fuer besonders wirksam erachteten 24 Stunden nach der Exposition . Die Behandlung erfolgt mit zehn unterschiedlichen Therapieschemata , die durch fuenf alternative Regimes ergaenzt werden . In der Mehrzahl der Faelle wird zum Nachweis oder Ausschluss einer HIV-Infektion neben dem HIV-Antikoerpertest und dem Western Blot ein Virusnachweis mittels bDNA oder PCR durchgefuehrt . Die Kosten der Behandlung traegt ueberwiegend die gesetzliche Krankenversicherung . Der Versuch eines Anrufers , sich im Bereich der klinischen und niedergelassenen aerztlichen Versorgung am Wochenende ueber die Moeglichkeit einer PEP zu informieren , scheitert in ueber der Haelfte der Faelle . Dabei ist vor allem der Bereich der aerztlichen Notrufzentralen offensichtlich nicht auf die entsprechenden Fragestellungen vorbereitet . In 25 von 33 Gespraechen sind die erreichten Ansprechpartner entweder nicht mit den Deutsch-Oesterreichischen Empfehlungen vertraut ( z.B. beziehen sich vier Faelle auf die alten Empfehlungen zur beruflichen PEP ) , erklaeren sich fuer nicht zustaendig oder bauen durch Beratungsstil und Einbestellung zu einem ungeeigneten Zeitpunkt Huerden auf , die einer angemessenen Behandlung entgegenstehen . Gleichwohl erhaelt der Anrufer in acht Faellen eine fachgerechte Beratung . Dies gelingt zum einen , weil durch mehrfache Anrufe oder Vermittlung letztlich ein kompetenter Gespraechspartner angetroffen werden kann . Zum anderen sind die Berater bereit , telefonisch darzulegen , warum und durch welche Vorgehensweise sie bereit sind , in diesem Fall eine HIV-PEP durchzufuehren . Instructions: please typing these entity words according to sentence: AIDS, Beratung, Behandlung, Beratung, Behandlung, Dokumentation, Beratung, Behandlung, Beratung, Behandlung, Konzentration, Beratungen, Behandlungen, Behandlung, Therapieschemata, HIV - Infektion, Virusnachweis, PCR, Behandlung, Krankenversicherung, Behandlung, Beratung, Berater Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Innerhalb der letzten zwoelf Monate haben bundesweit 68 auf AIDS spezialisierte Einrichtungen mindestens in einem Fall eine Beratung und 19 eine Behandlung zur nicht-beruflichen HIV-Postexpositionsprophylaxe ( PEP ) durchgefuehrt . 531 Faellen einer Beratung stehen 143 Faelle gegenueber , in denen eine Behandlung empfohlen wurde . Die Dokumentation der Faelle erweist sich im Bereich der Beratung als lueckenhaft . Die Studie belegt 123 Faelle , in denen eine Behandlung erfolgte , von denen 67 durch die berichtenden Einrichtungen versorgt wurden ( davon 37 an nur zwei Einrichtungen ) . Sowohl bei Beratung als auch bei Behandlung zeigt sich eine Konzentration der Faelle auf einzelne Einrichtungen . Der Zeitpunkt der Beratungen und Behandlungen liegt bei 51,6% bzw. 91,1% innerhalb der fuer besonders wirksam erachteten 24 Stunden nach der Exposition . Die Behandlung erfolgt mit zehn unterschiedlichen Therapieschemata , die durch fuenf alternative Regimes ergaenzt werden . In der Mehrzahl der Faelle wird zum Nachweis oder Ausschluss einer HIV-Infektion neben dem HIV-Antikoerpertest und dem Western Blot ein Virusnachweis mittels bDNA oder PCR durchgefuehrt . Die Kosten der Behandlung traegt ueberwiegend die gesetzliche Krankenversicherung . Der Versuch eines Anrufers , sich im Bereich der klinischen und niedergelassenen aerztlichen Versorgung am Wochenende ueber die Moeglichkeit einer PEP zu informieren , scheitert in ueber der Haelfte der Faelle . Dabei ist vor allem der Bereich der aerztlichen Notrufzentralen offensichtlich nicht auf die entsprechenden Fragestellungen vorbereitet . In 25 von 33 Gespraechen sind die erreichten Ansprechpartner entweder nicht mit den Deutsch-Oesterreichischen Empfehlungen vertraut ( z.B. beziehen sich vier Faelle auf die alten Empfehlungen zur beruflichen PEP ) , erklaeren sich fuer nicht zustaendig oder bauen durch Beratungsstil und Einbestellung zu einem ungeeigneten Zeitpunkt Huerden auf , die einer angemessenen Behandlung entgegenstehen . Gleichwohl erhaelt der Anrufer in acht Faellen eine fachgerechte Beratung . Dies gelingt zum einen , weil durch mehrfache Anrufe oder Vermittlung letztlich ein kompetenter Gespraechspartner angetroffen werden kann . Zum anderen sind die Berater bereit , telefonisch darzulegen , warum und durch welche Vorgehensweise sie bereit sind , in diesem Fall eine HIV-PEP durchzufuehren .	[ "Innerhalb", "der", "letzten", "zwoelf", "Monate", "haben", "bundesweit", "68", "auf", "AIDS", "spezialisierte", "Einrichtungen", "mindestens", "in", "einem", "Fall", "eine", "Beratung", "und", "19", "eine", "Behandlung", "zur", "nicht", "-", "beruflichen", "HIV", "-", "Postexpositionsprophylaxe", "(", "PEP", ")", "durchgefuehrt", ".", "531", "Faellen", "einer", "Beratung", "stehen", "143", "Faelle", "gegenueber", ",", "in", "denen", "eine", "Behandlung", "empfohlen", "wurde", ".", "Die", "Dokumentation", "der", "Faelle", "erweist", "sich", "im", "Bereich", "der", "Beratung", "als", "lueckenhaft", ".", "Die", "Studie", "belegt", "123", "Faelle", ",", "in", "denen", "eine", "Behandlung", "erfolgte", ",", "von", "denen", "67", "durch", "die", "berichtenden", "Einrichtungen", "versorgt", "wurden", "(", "davon", "37", "an", "nur", "zwei", "Einrichtungen", ")", ".", "Sowohl", "bei", "Beratung", "als", "auch", "bei", "Behandlung", "zeigt", "sich", "eine", "Konzentration", "der", "Faelle", "auf", "einzelne", "Einrichtungen", ".", "Der", "Zeitpunkt", "der", "Beratungen", "und", "Behandlungen", "liegt", "bei", "51,6", "%", "bzw", ".", "91,1", "%", "innerhalb", "der", "fuer", "besonders", "wirksam", "erachteten", "24", "Stunden", "nach", "der", "Exposition", ".", "Die", "Behandlung", "erfolgt", "mit", "zehn", "unterschiedlichen", "Therapieschemata", ",", "die", "durch", "fuenf", "alternative", "Regimes", "ergaenzt", "werden", ".", "In", "der", "Mehrzahl", "der", "Faelle", "wird", "zum", "Nachweis", "oder", "Ausschluss", "einer", "HIV", "-", "Infektion", "neben", "dem", "HIV", "-", "Antikoerpertest", "und", "dem", "Western", "Blot", "ein", "Virusnachweis", "mittels", "bDNA", "oder", "PCR", "durchgefuehrt", ".", "Die", "Kosten", "der", "Behandlung", "traegt", "ueberwiegend", "die", "gesetzliche", "Krankenversicherung", ".", "Der", "Versuch", "eines", "Anrufers", ",", "sich", "im", "Bereich", "der", "klinischen", "und", "niedergelassenen", "aerztlichen", "Versorgung", "am", "Wochenende", "ueber", "die", "Moeglichkeit", "einer", "PEP", "zu", "informieren", ",", "scheitert", "in", "ueber", "der", "Haelfte", "der", "Faelle", ".", "Dabei", "ist", "vor", "allem", "der", "Bereich", "der", "aerztlichen", "Notrufzentralen", "offensichtlich", "nicht", "auf", "die", "entsprechenden", "Fragestellungen", "vorbereitet", ".", "In", "25", "von", "33", "Gespraechen", "sind", "die", "erreichten", "Ansprechpartner", "entweder", "nicht", "mit", "den", "Deutsch", "-", "Oesterreichischen", "Empfehlungen", "vertraut", "(", "z.", "B.", "beziehen", "sich", "vier", "Faelle", "auf", "die", "alten", "Empfehlungen", "zur", "beruflichen", "PEP", ")", ",", "erklaeren", "sich", "fuer", "nicht", "zustaendig", "oder", "bauen", "durch", "Beratungsstil", "und", "Einbestellung", "zu", "einem", "ungeeigneten", "Zeitpunkt", "Huerden", "auf", ",", "die", "einer", "angemessenen", "Behandlung", "entgegenstehen", ".", "Gleichwohl", "erhaelt", "der", "Anrufer", "in", "acht", "Faellen", "eine", "fachgerechte", "Beratung", ".", "Dies", "gelingt", "zum", "einen", ",", "weil", "durch", "mehrfache", "Anrufe", "oder", "Vermittlung", "letztlich", "ein", "kompetenter", "Gespraechspartner", "angetroffen", "werden", "kann", ".", "Zum", "anderen", "sind", "die", "Berater", "bereit", ",", "telefonisch", "darzulegen", ",", "warum", "und", "durch", "welche", "Vorgehensweise", "sie", "bereit", "sind", ",", "in", "diesem", "Fall", "eine", "HIV", "-", "PEP", "durchzufuehren", "." ]	[ "umlsterm" ]
AIDS, Beratung, Behandlung, Beratung, Behandlung, Dokumentation, Beratung, Behandlung, Beratung, Behandlung, Konzentration, Beratungen, Behandlungen, Behandlung, Therapieschemata, HIV - Infektion, Virusnachweis, PCR, Behandlung, Krankenversicherung, Behandlung, Beratung, Berater	Bundesgesundheitsblatt.0043s045.ger.abstr_task2	Sentence: Innerhalb der letzten zwoelf Monate haben bundesweit 68 auf AIDS spezialisierte Einrichtungen mindestens in einem Fall eine Beratung und 19 eine Behandlung zur nicht-beruflichen HIV-Postexpositionsprophylaxe ( PEP ) durchgefuehrt . 531 Faellen einer Beratung stehen 143 Faelle gegenueber , in denen eine Behandlung empfohlen wurde . Die Dokumentation der Faelle erweist sich im Bereich der Beratung als lueckenhaft . Die Studie belegt 123 Faelle , in denen eine Behandlung erfolgte , von denen 67 durch die berichtenden Einrichtungen versorgt wurden ( davon 37 an nur zwei Einrichtungen ) . Sowohl bei Beratung als auch bei Behandlung zeigt sich eine Konzentration der Faelle auf einzelne Einrichtungen . Der Zeitpunkt der Beratungen und Behandlungen liegt bei 51,6% bzw. 91,1% innerhalb der fuer besonders wirksam erachteten 24 Stunden nach der Exposition . Die Behandlung erfolgt mit zehn unterschiedlichen Therapieschemata , die durch fuenf alternative Regimes ergaenzt werden . In der Mehrzahl der Faelle wird zum Nachweis oder Ausschluss einer HIV-Infektion neben dem HIV-Antikoerpertest und dem Western Blot ein Virusnachweis mittels bDNA oder PCR durchgefuehrt . Die Kosten der Behandlung traegt ueberwiegend die gesetzliche Krankenversicherung . Der Versuch eines Anrufers , sich im Bereich der klinischen und niedergelassenen aerztlichen Versorgung am Wochenende ueber die Moeglichkeit einer PEP zu informieren , scheitert in ueber der Haelfte der Faelle . Dabei ist vor allem der Bereich der aerztlichen Notrufzentralen offensichtlich nicht auf die entsprechenden Fragestellungen vorbereitet . In 25 von 33 Gespraechen sind die erreichten Ansprechpartner entweder nicht mit den Deutsch-Oesterreichischen Empfehlungen vertraut ( z.B. beziehen sich vier Faelle auf die alten Empfehlungen zur beruflichen PEP ) , erklaeren sich fuer nicht zustaendig oder bauen durch Beratungsstil und Einbestellung zu einem ungeeigneten Zeitpunkt Huerden auf , die einer angemessenen Behandlung entgegenstehen . Gleichwohl erhaelt der Anrufer in acht Faellen eine fachgerechte Beratung . Dies gelingt zum einen , weil durch mehrfache Anrufe oder Vermittlung letztlich ein kompetenter Gespraechspartner angetroffen werden kann . Zum anderen sind die Berater bereit , telefonisch darzulegen , warum und durch welche Vorgehensweise sie bereit sind , in diesem Fall eine HIV-PEP durchzufuehren . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Innerhalb der letzten zwoelf Monate haben bundesweit 68 auf AIDS spezialisierte Einrichtungen mindestens in einem Fall eine Beratung und 19 eine Behandlung zur nicht-beruflichen HIV-Postexpositionsprophylaxe ( PEP ) durchgefuehrt . 531 Faellen einer Beratung stehen 143 Faelle gegenueber , in denen eine Behandlung empfohlen wurde . Die Dokumentation der Faelle erweist sich im Bereich der Beratung als lueckenhaft . Die Studie belegt 123 Faelle , in denen eine Behandlung erfolgte , von denen 67 durch die berichtenden Einrichtungen versorgt wurden ( davon 37 an nur zwei Einrichtungen ) . Sowohl bei Beratung als auch bei Behandlung zeigt sich eine Konzentration der Faelle auf einzelne Einrichtungen . Der Zeitpunkt der Beratungen und Behandlungen liegt bei 51,6% bzw. 91,1% innerhalb der fuer besonders wirksam erachteten 24 Stunden nach der Exposition . Die Behandlung erfolgt mit zehn unterschiedlichen Therapieschemata , die durch fuenf alternative Regimes ergaenzt werden . In der Mehrzahl der Faelle wird zum Nachweis oder Ausschluss einer HIV-Infektion neben dem HIV-Antikoerpertest und dem Western Blot ein Virusnachweis mittels bDNA oder PCR durchgefuehrt . Die Kosten der Behandlung traegt ueberwiegend die gesetzliche Krankenversicherung . Der Versuch eines Anrufers , sich im Bereich der klinischen und niedergelassenen aerztlichen Versorgung am Wochenende ueber die Moeglichkeit einer PEP zu informieren , scheitert in ueber der Haelfte der Faelle . Dabei ist vor allem der Bereich der aerztlichen Notrufzentralen offensichtlich nicht auf die entsprechenden Fragestellungen vorbereitet . In 25 von 33 Gespraechen sind die erreichten Ansprechpartner entweder nicht mit den Deutsch-Oesterreichischen Empfehlungen vertraut ( z.B. beziehen sich vier Faelle auf die alten Empfehlungen zur beruflichen PEP ) , erklaeren sich fuer nicht zustaendig oder bauen durch Beratungsstil und Einbestellung zu einem ungeeigneten Zeitpunkt Huerden auf , die einer angemessenen Behandlung entgegenstehen . Gleichwohl erhaelt der Anrufer in acht Faellen eine fachgerechte Beratung . Dies gelingt zum einen , weil durch mehrfache Anrufe oder Vermittlung letztlich ein kompetenter Gespraechspartner angetroffen werden kann . Zum anderen sind die Berater bereit , telefonisch darzulegen , warum und durch welche Vorgehensweise sie bereit sind , in diesem Fall eine HIV-PEP durchzufuehren .	[ "Innerhalb", "der", "letzten", "zwoelf", "Monate", "haben", "bundesweit", "68", "auf", "AIDS", "spezialisierte", "Einrichtungen", "mindestens", "in", "einem", "Fall", "eine", "Beratung", "und", "19", "eine", "Behandlung", "zur", "nicht", "-", "beruflichen", "HIV", "-", "Postexpositionsprophylaxe", "(", "PEP", ")", "durchgefuehrt", ".", "531", "Faellen", "einer", "Beratung", "stehen", "143", "Faelle", "gegenueber", ",", "in", "denen", "eine", "Behandlung", "empfohlen", "wurde", ".", "Die", "Dokumentation", "der", "Faelle", "erweist", "sich", "im", "Bereich", "der", "Beratung", "als", "lueckenhaft", ".", "Die", "Studie", "belegt", "123", "Faelle", ",", "in", "denen", "eine", "Behandlung", "erfolgte", ",", "von", "denen", "67", "durch", "die", "berichtenden", "Einrichtungen", "versorgt", "wurden", "(", "davon", "37", "an", "nur", "zwei", "Einrichtungen", ")", ".", "Sowohl", "bei", "Beratung", "als", "auch", "bei", "Behandlung", "zeigt", "sich", "eine", "Konzentration", "der", "Faelle", "auf", "einzelne", "Einrichtungen", ".", "Der", "Zeitpunkt", "der", "Beratungen", "und", "Behandlungen", "liegt", "bei", "51,6", "%", "bzw", ".", "91,1", "%", "innerhalb", "der", "fuer", "besonders", "wirksam", "erachteten", "24", "Stunden", "nach", "der", "Exposition", ".", "Die", "Behandlung", "erfolgt", "mit", "zehn", "unterschiedlichen", "Therapieschemata", ",", "die", "durch", "fuenf", "alternative", "Regimes", "ergaenzt", "werden", ".", "In", "der", "Mehrzahl", "der", "Faelle", "wird", "zum", "Nachweis", "oder", "Ausschluss", "einer", "HIV", "-", "Infektion", "neben", "dem", "HIV", "-", "Antikoerpertest", "und", "dem", "Western", "Blot", "ein", "Virusnachweis", "mittels", "bDNA", "oder", "PCR", "durchgefuehrt", ".", "Die", "Kosten", "der", "Behandlung", "traegt", "ueberwiegend", "die", "gesetzliche", "Krankenversicherung", ".", "Der", "Versuch", "eines", "Anrufers", ",", "sich", "im", "Bereich", "der", "klinischen", "und", "niedergelassenen", "aerztlichen", "Versorgung", "am", "Wochenende", "ueber", "die", "Moeglichkeit", "einer", "PEP", "zu", "informieren", ",", "scheitert", "in", "ueber", "der", "Haelfte", "der", "Faelle", ".", "Dabei", "ist", "vor", "allem", "der", "Bereich", "der", "aerztlichen", "Notrufzentralen", "offensichtlich", "nicht", "auf", "die", "entsprechenden", "Fragestellungen", "vorbereitet", ".", "In", "25", "von", "33", "Gespraechen", "sind", "die", "erreichten", "Ansprechpartner", "entweder", "nicht", "mit", "den", "Deutsch", "-", "Oesterreichischen", "Empfehlungen", "vertraut", "(", "z.", "B.", "beziehen", "sich", "vier", "Faelle", "auf", "die", "alten", "Empfehlungen", "zur", "beruflichen", "PEP", ")", ",", "erklaeren", "sich", "fuer", "nicht", "zustaendig", "oder", "bauen", "durch", "Beratungsstil", "und", "Einbestellung", "zu", "einem", "ungeeigneten", "Zeitpunkt", "Huerden", "auf", ",", "die", "einer", "angemessenen", "Behandlung", "entgegenstehen", ".", "Gleichwohl", "erhaelt", "der", "Anrufer", "in", "acht", "Faellen", "eine", "fachgerechte", "Beratung", ".", "Dies", "gelingt", "zum", "einen", ",", "weil", "durch", "mehrfache", "Anrufe", "oder", "Vermittlung", "letztlich", "ein", "kompetenter", "Gespraechspartner", "angetroffen", "werden", "kann", ".", "Zum", "anderen", "sind", "die", "Berater", "bereit", ",", "telefonisch", "darzulegen", ",", "warum", "und", "durch", "welche", "Vorgehensweise", "sie", "bereit", "sind", ",", "in", "diesem", "Fall", "eine", "HIV", "-", "PEP", "durchzufuehren", "." ]	[ "umlsterm" ]
anthracene is a compound, DMBA is a compound, HER2 is a protein	DS.d1548_task0	Sentence: Because both TCDD and HFD are associated with increased breast cancer risk, we examined their effects on metabolic syndrome-associated phenotypes in three mouse models of breast cancer: 7,12-dimethylbenz(a) anthracene (DMBA), Tg(MMTV-Neu)202Mul/J (HER2), and TgN(MMTV-PyMT)634Mul/J (PyMT), all on an FVB/N genetic background. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Because both TCDD and HFD are associated with increased breast cancer risk, we examined their effects on metabolic syndrome-associated phenotypes in three mouse models of breast cancer: 7,12-dimethylbenz(a) anthracene (DMBA), Tg(MMTV-Neu)202Mul/J (HER2), and TgN(MMTV-PyMT)634Mul/J (PyMT), all on an FVB/N genetic background.	[ "Because", "both", "TCDD", "and", "HFD", "are", "associated", "with", "increased", "breast", "cancer", "risk", ",", "we", "examined", "their", "effects", "on", "metabolic", "syndrome", "-", "associated", "phenotypes", "in", "three", "mouse", "models", "of", "breast", "cancer", ":", "7,12-dimethylbenz(a", ")", "anthracene", "(", "DMBA", ")", ",", "Tg(MMTV", "-", "Neu)202Mul", "/", "J", "(", "HER2", ")", ",", "and", "TgN(MMTV", "-", "PyMT)634Mul", "/", "J", "(", "PyMT", ")", ",", "all", "on", "an", "FVB", "/", "N", "genetic", "background", "." ]	[ "compound", "protein" ]
anthracene is a compound, DMBA is a compound, HER2 is a protein	DS.d1548_task1	Sentence: Because both TCDD and HFD are associated with increased breast cancer risk, we examined their effects on metabolic syndrome-associated phenotypes in three mouse models of breast cancer: 7,12-dimethylbenz(a) anthracene (DMBA), Tg(MMTV-Neu)202Mul/J (HER2), and TgN(MMTV-PyMT)634Mul/J (PyMT), all on an FVB/N genetic background. Instructions: please typing these entity words according to sentence: anthracene, DMBA, HER2 Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Because both TCDD and HFD are associated with increased breast cancer risk, we examined their effects on metabolic syndrome-associated phenotypes in three mouse models of breast cancer: 7,12-dimethylbenz(a) anthracene (DMBA), Tg(MMTV-Neu)202Mul/J (HER2), and TgN(MMTV-PyMT)634Mul/J (PyMT), all on an FVB/N genetic background.	[ "Because", "both", "TCDD", "and", "HFD", "are", "associated", "with", "increased", "breast", "cancer", "risk", ",", "we", "examined", "their", "effects", "on", "metabolic", "syndrome", "-", "associated", "phenotypes", "in", "three", "mouse", "models", "of", "breast", "cancer", ":", "7,12-dimethylbenz(a", ")", "anthracene", "(", "DMBA", ")", ",", "Tg(MMTV", "-", "Neu)202Mul", "/", "J", "(", "HER2", ")", ",", "and", "TgN(MMTV", "-", "PyMT)634Mul", "/", "J", "(", "PyMT", ")", ",", "all", "on", "an", "FVB", "/", "N", "genetic", "background", "." ]	[ "compound", "protein" ]
anthracene, DMBA, HER2	DS.d1548_task2	Sentence: Because both TCDD and HFD are associated with increased breast cancer risk, we examined their effects on metabolic syndrome-associated phenotypes in three mouse models of breast cancer: 7,12-dimethylbenz(a) anthracene (DMBA), Tg(MMTV-Neu)202Mul/J (HER2), and TgN(MMTV-PyMT)634Mul/J (PyMT), all on an FVB/N genetic background. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Because both TCDD and HFD are associated with increased breast cancer risk, we examined their effects on metabolic syndrome-associated phenotypes in three mouse models of breast cancer: 7,12-dimethylbenz(a) anthracene (DMBA), Tg(MMTV-Neu)202Mul/J (HER2), and TgN(MMTV-PyMT)634Mul/J (PyMT), all on an FVB/N genetic background.	[ "Because", "both", "TCDD", "and", "HFD", "are", "associated", "with", "increased", "breast", "cancer", "risk", ",", "we", "examined", "their", "effects", "on", "metabolic", "syndrome", "-", "associated", "phenotypes", "in", "three", "mouse", "models", "of", "breast", "cancer", ":", "7,12-dimethylbenz(a", ")", "anthracene", "(", "DMBA", ")", ",", "Tg(MMTV", "-", "Neu)202Mul", "/", "J", "(", "HER2", ")", ",", "and", "TgN(MMTV", "-", "PyMT)634Mul", "/", "J", "(", "PyMT", ")", ",", "all", "on", "an", "FVB", "/", "N", "genetic", "background", "." ]	[ "compound", "protein" ]
cysG is a Protein, CysG is a Protein, CysG is a Protein, cysG is a Protein, CysG is a Protein, CysG is a Protein, CysG is a Protein, cysG is a Protein, CysG is a Protein, CysG is a Protein	541_task0	Sentence: Gene dissection demonstrates that the Escherichia coli cysG gene encodes a multifunctional protein. The C-terminus of the Escherichia coli CysG protein, consisting of amino acids 202-457, was expressed as a recombinant protein using gene dissection methodology. Analysis of the activity of this truncated protein, termed CysGA, revealed that it was able to methylate uroporphyrinogen III in the same S-adenosyl-L-methionine (SAM)-dependent manner as the complete CysG protein. However, this truncated protein was not able to complement E. coli cysG cells, thereby suggesting that the first 201 amino acids of the CysG protein had an enzymic activity associated with the conversion of dihydrosirohydrochlorin into sirohaem. Analysis of the N-terminus of the CysG protein revealed the presence of a putative pyridine dinucleotide binding site. When the purified CysG protein was incubated with NADP+, uroporphyrinogen III and SAM the enzyme was found to catalyse a coenzyme-mediated dehydrogenation to form sirohydrochlorin. The CysGA protein on the other hand showed no such coenzyme-dependent activity. Analysis of the porphyrinoid material isolated from strains harbouring plasmids containing the complete and truncated cysG genes suggested that the CysG protein was also involved in ferrochelation. The evidence presented in this paper suggests that the CysG protein is a multifunctional protein involved in SAM-dependent methylation, pyridine dinucleotide dependent dehydrogenation and ferrochelation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Gene dissection demonstrates that the Escherichia coli cysG gene encodes a multifunctional protein. The C-terminus of the Escherichia coli CysG protein, consisting of amino acids 202-457, was expressed as a recombinant protein using gene dissection methodology. Analysis of the activity of this truncated protein, termed CysGA, revealed that it was able to methylate uroporphyrinogen III in the same S-adenosyl-L-methionine (SAM)-dependent manner as the complete CysG protein. However, this truncated protein was not able to complement E. coli cysG cells, thereby suggesting that the first 201 amino acids of the CysG protein had an enzymic activity associated with the conversion of dihydrosirohydrochlorin into sirohaem. Analysis of the N-terminus of the CysG protein revealed the presence of a putative pyridine dinucleotide binding site. When the purified CysG protein was incubated with NADP+, uroporphyrinogen III and SAM the enzyme was found to catalyse a coenzyme-mediated dehydrogenation to form sirohydrochlorin. The CysGA protein on the other hand showed no such coenzyme-dependent activity. Analysis of the porphyrinoid material isolated from strains harbouring plasmids containing the complete and truncated cysG genes suggested that the CysG protein was also involved in ferrochelation. The evidence presented in this paper suggests that the CysG protein is a multifunctional protein involved in SAM-dependent methylation, pyridine dinucleotide dependent dehydrogenation and ferrochelation.	[ "Gene", "dissection", "demonstrates", "that", "the", "Escherichia", "coli", "cysG", "gene", "encodes", "a", "multifunctional", "protein", ".", "\n", "The", "C", "-", "terminus", "of", "the", "Escherichia", "coli", "CysG", "protein", ",", "consisting", "of", "amino", "acids", "202", "-", "457", ",", "was", "expressed", "as", "a", "recombinant", "protein", "using", "gene", "dissection", "methodology", ".", "Analysis", "of", "the", "activity", "of", "this", "truncated", "protein", ",", "termed", "CysGA", ",", "revealed", "that", "it", "was", "able", "to", "methylate", "uroporphyrinogen", "III", "in", "the", "same", "S", "-", "adenosyl", "-", "L", "-", "methionine", "(", "SAM)-dependent", "manner", "as", "the", "complete", "CysG", "protein", ".", "However", ",", "this", "truncated", "protein", "was", "not", "able", "to", "complement", "E.", "coli", "cysG", "cells", ",", "thereby", "suggesting", "that", "the", "first", "201", "amino", "acids", "of", "the", "CysG", "protein", "had", "an", "enzymic", "activity", "associated", "with", "the", "conversion", "of", "dihydrosirohydrochlorin", "into", "sirohaem", ".", "Analysis", "of", "the", "N", "-", "terminus", "of", "the", "CysG", "protein", "revealed", "the", "presence", "of", "a", "putative", "pyridine", "dinucleotide", "binding", "site", ".", "When", "the", "purified", "CysG", "protein", "was", "incubated", "with", "NADP+", ",", "uroporphyrinogen", "III", "and", "SAM", "the", "enzyme", "was", "found", "to", "catalyse", "a", "coenzyme", "-", "mediated", "dehydrogenation", "to", "form", "sirohydrochlorin", ".", "The", "CysGA", "protein", "on", "the", "other", "hand", "showed", "no", "such", "coenzyme", "-", "dependent", "activity", ".", "Analysis", "of", "the", "porphyrinoid", "material", "isolated", "from", "strains", "harbouring", "plasmids", "containing", "the", "complete", "and", "truncated", "cysG", "genes", "suggested", "that", "the", "CysG", "protein", "was", "also", "involved", "in", "ferrochelation", ".", "The", "evidence", "presented", "in", "this", "paper", "suggests", "that", "the", "CysG", "protein", "is", "a", "multifunctional", "protein", "involved", "in", "SAM", "-", "dependent", "methylation", ",", "pyridine", "dinucleotide", "dependent", "dehydrogenation", "and", "ferrochelation", ".", "\n" ]	[ "Protein" ]
cysG is a Protein, CysG is a Protein, CysG is a Protein, cysG is a Protein, CysG is a Protein, CysG is a Protein, CysG is a Protein, cysG is a Protein, CysG is a Protein, CysG is a Protein	541_task1	Sentence: Gene dissection demonstrates that the Escherichia coli cysG gene encodes a multifunctional protein. The C-terminus of the Escherichia coli CysG protein, consisting of amino acids 202-457, was expressed as a recombinant protein using gene dissection methodology. Analysis of the activity of this truncated protein, termed CysGA, revealed that it was able to methylate uroporphyrinogen III in the same S-adenosyl-L-methionine (SAM)-dependent manner as the complete CysG protein. However, this truncated protein was not able to complement E. coli cysG cells, thereby suggesting that the first 201 amino acids of the CysG protein had an enzymic activity associated with the conversion of dihydrosirohydrochlorin into sirohaem. Analysis of the N-terminus of the CysG protein revealed the presence of a putative pyridine dinucleotide binding site. When the purified CysG protein was incubated with NADP+, uroporphyrinogen III and SAM the enzyme was found to catalyse a coenzyme-mediated dehydrogenation to form sirohydrochlorin. The CysGA protein on the other hand showed no such coenzyme-dependent activity. Analysis of the porphyrinoid material isolated from strains harbouring plasmids containing the complete and truncated cysG genes suggested that the CysG protein was also involved in ferrochelation. The evidence presented in this paper suggests that the CysG protein is a multifunctional protein involved in SAM-dependent methylation, pyridine dinucleotide dependent dehydrogenation and ferrochelation. Instructions: please typing these entity words according to sentence: cysG, CysG, CysG, cysG, CysG, CysG, CysG, cysG, CysG, CysG Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Gene dissection demonstrates that the Escherichia coli cysG gene encodes a multifunctional protein. The C-terminus of the Escherichia coli CysG protein, consisting of amino acids 202-457, was expressed as a recombinant protein using gene dissection methodology. Analysis of the activity of this truncated protein, termed CysGA, revealed that it was able to methylate uroporphyrinogen III in the same S-adenosyl-L-methionine (SAM)-dependent manner as the complete CysG protein. However, this truncated protein was not able to complement E. coli cysG cells, thereby suggesting that the first 201 amino acids of the CysG protein had an enzymic activity associated with the conversion of dihydrosirohydrochlorin into sirohaem. Analysis of the N-terminus of the CysG protein revealed the presence of a putative pyridine dinucleotide binding site. When the purified CysG protein was incubated with NADP+, uroporphyrinogen III and SAM the enzyme was found to catalyse a coenzyme-mediated dehydrogenation to form sirohydrochlorin. The CysGA protein on the other hand showed no such coenzyme-dependent activity. Analysis of the porphyrinoid material isolated from strains harbouring plasmids containing the complete and truncated cysG genes suggested that the CysG protein was also involved in ferrochelation. The evidence presented in this paper suggests that the CysG protein is a multifunctional protein involved in SAM-dependent methylation, pyridine dinucleotide dependent dehydrogenation and ferrochelation.	[ "Gene", "dissection", "demonstrates", "that", "the", "Escherichia", "coli", "cysG", "gene", "encodes", "a", "multifunctional", "protein", ".", "\n", "The", "C", "-", "terminus", "of", "the", "Escherichia", "coli", "CysG", "protein", ",", "consisting", "of", "amino", "acids", "202", "-", "457", ",", "was", "expressed", "as", "a", "recombinant", "protein", "using", "gene", "dissection", "methodology", ".", "Analysis", "of", "the", "activity", "of", "this", "truncated", "protein", ",", "termed", "CysGA", ",", "revealed", "that", "it", "was", "able", "to", "methylate", "uroporphyrinogen", "III", "in", "the", "same", "S", "-", "adenosyl", "-", "L", "-", "methionine", "(", "SAM)-dependent", "manner", "as", "the", "complete", "CysG", "protein", ".", "However", ",", "this", "truncated", "protein", "was", "not", "able", "to", "complement", "E.", "coli", "cysG", "cells", ",", "thereby", "suggesting", "that", "the", "first", "201", "amino", "acids", "of", "the", "CysG", "protein", "had", "an", "enzymic", "activity", "associated", "with", "the", "conversion", "of", "dihydrosirohydrochlorin", "into", "sirohaem", ".", "Analysis", "of", "the", "N", "-", "terminus", "of", "the", "CysG", "protein", "revealed", "the", "presence", "of", "a", "putative", "pyridine", "dinucleotide", "binding", "site", ".", "When", "the", "purified", "CysG", "protein", "was", "incubated", "with", "NADP+", ",", "uroporphyrinogen", "III", "and", "SAM", "the", "enzyme", "was", "found", "to", "catalyse", "a", "coenzyme", "-", "mediated", "dehydrogenation", "to", "form", "sirohydrochlorin", ".", "The", "CysGA", "protein", "on", "the", "other", "hand", "showed", "no", "such", "coenzyme", "-", "dependent", "activity", ".", "Analysis", "of", "the", "porphyrinoid", "material", "isolated", "from", "strains", "harbouring", "plasmids", "containing", "the", "complete", "and", "truncated", "cysG", "genes", "suggested", "that", "the", "CysG", "protein", "was", "also", "involved", "in", "ferrochelation", ".", "The", "evidence", "presented", "in", "this", "paper", "suggests", "that", "the", "CysG", "protein", "is", "a", "multifunctional", "protein", "involved", "in", "SAM", "-", "dependent", "methylation", ",", "pyridine", "dinucleotide", "dependent", "dehydrogenation", "and", "ferrochelation", ".", "\n" ]	[ "Protein" ]
cysG, CysG, CysG, cysG, CysG, CysG, CysG, cysG, CysG, CysG	541_task2	Sentence: Gene dissection demonstrates that the Escherichia coli cysG gene encodes a multifunctional protein. The C-terminus of the Escherichia coli CysG protein, consisting of amino acids 202-457, was expressed as a recombinant protein using gene dissection methodology. Analysis of the activity of this truncated protein, termed CysGA, revealed that it was able to methylate uroporphyrinogen III in the same S-adenosyl-L-methionine (SAM)-dependent manner as the complete CysG protein. However, this truncated protein was not able to complement E. coli cysG cells, thereby suggesting that the first 201 amino acids of the CysG protein had an enzymic activity associated with the conversion of dihydrosirohydrochlorin into sirohaem. Analysis of the N-terminus of the CysG protein revealed the presence of a putative pyridine dinucleotide binding site. When the purified CysG protein was incubated with NADP+, uroporphyrinogen III and SAM the enzyme was found to catalyse a coenzyme-mediated dehydrogenation to form sirohydrochlorin. The CysGA protein on the other hand showed no such coenzyme-dependent activity. Analysis of the porphyrinoid material isolated from strains harbouring plasmids containing the complete and truncated cysG genes suggested that the CysG protein was also involved in ferrochelation. The evidence presented in this paper suggests that the CysG protein is a multifunctional protein involved in SAM-dependent methylation, pyridine dinucleotide dependent dehydrogenation and ferrochelation. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Gene dissection demonstrates that the Escherichia coli cysG gene encodes a multifunctional protein. The C-terminus of the Escherichia coli CysG protein, consisting of amino acids 202-457, was expressed as a recombinant protein using gene dissection methodology. Analysis of the activity of this truncated protein, termed CysGA, revealed that it was able to methylate uroporphyrinogen III in the same S-adenosyl-L-methionine (SAM)-dependent manner as the complete CysG protein. However, this truncated protein was not able to complement E. coli cysG cells, thereby suggesting that the first 201 amino acids of the CysG protein had an enzymic activity associated with the conversion of dihydrosirohydrochlorin into sirohaem. Analysis of the N-terminus of the CysG protein revealed the presence of a putative pyridine dinucleotide binding site. When the purified CysG protein was incubated with NADP+, uroporphyrinogen III and SAM the enzyme was found to catalyse a coenzyme-mediated dehydrogenation to form sirohydrochlorin. The CysGA protein on the other hand showed no such coenzyme-dependent activity. Analysis of the porphyrinoid material isolated from strains harbouring plasmids containing the complete and truncated cysG genes suggested that the CysG protein was also involved in ferrochelation. The evidence presented in this paper suggests that the CysG protein is a multifunctional protein involved in SAM-dependent methylation, pyridine dinucleotide dependent dehydrogenation and ferrochelation.	[ "Gene", "dissection", "demonstrates", "that", "the", "Escherichia", "coli", "cysG", "gene", "encodes", "a", "multifunctional", "protein", ".", "\n", "The", "C", "-", "terminus", "of", "the", "Escherichia", "coli", "CysG", "protein", ",", "consisting", "of", "amino", "acids", "202", "-", "457", ",", "was", "expressed", "as", "a", "recombinant", "protein", "using", "gene", "dissection", "methodology", ".", "Analysis", "of", "the", "activity", "of", "this", "truncated", "protein", ",", "termed", "CysGA", ",", "revealed", "that", "it", "was", "able", "to", "methylate", "uroporphyrinogen", "III", "in", "the", "same", "S", "-", "adenosyl", "-", "L", "-", "methionine", "(", "SAM)-dependent", "manner", "as", "the", "complete", "CysG", "protein", ".", "However", ",", "this", "truncated", "protein", "was", "not", "able", "to", "complement", "E.", "coli", "cysG", "cells", ",", "thereby", "suggesting", "that", "the", "first", "201", "amino", "acids", "of", "the", "CysG", "protein", "had", "an", "enzymic", "activity", "associated", "with", "the", "conversion", "of", "dihydrosirohydrochlorin", "into", "sirohaem", ".", "Analysis", "of", "the", "N", "-", "terminus", "of", "the", "CysG", "protein", "revealed", "the", "presence", "of", "a", "putative", "pyridine", "dinucleotide", "binding", "site", ".", "When", "the", "purified", "CysG", "protein", "was", "incubated", "with", "NADP+", ",", "uroporphyrinogen", "III", "and", "SAM", "the", "enzyme", "was", "found", "to", "catalyse", "a", "coenzyme", "-", "mediated", "dehydrogenation", "to", "form", "sirohydrochlorin", ".", "The", "CysGA", "protein", "on", "the", "other", "hand", "showed", "no", "such", "coenzyme", "-", "dependent", "activity", ".", "Analysis", "of", "the", "porphyrinoid", "material", "isolated", "from", "strains", "harbouring", "plasmids", "containing", "the", "complete", "and", "truncated", "cysG", "genes", "suggested", "that", "the", "CysG", "protein", "was", "also", "involved", "in", "ferrochelation", ".", "The", "evidence", "presented", "in", "this", "paper", "suggests", "that", "the", "CysG", "protein", "is", "a", "multifunctional", "protein", "involved", "in", "SAM", "-", "dependent", "methylation", ",", "pyridine", "dinucleotide", "dependent", "dehydrogenation", "and", "ferrochelation", ".", "\n" ]	[ "Protein" ]
observations is an umlsterm, persons is an umlsterm, sexually abused is an umlsterm, finding is an umlsterm, research is an umlsterm, occurrence is an umlsterm, persons is an umlsterm, role is an umlsterm, introjection is an umlsterm, masochism is an umlsterm, understanding is an umlsterm, behavior is an umlsterm, persons is an umlsterm, treatment is an umlsterm, persons is an umlsterm	Psychotherapeut.80430117.eng.abstr_task0	Sentence: Clinical observations consistently show that persons physically or sexually abused in infancy tend to become revictimized in subsequent relationships and , further , that these abusive relationships show a high degree of stability . One major finding of attachment research is the high occurrence of insecure attachment to primary attachment figures in abused persons . Among the typical patterns of relationship , role reversal ( parentification ) has been emphasized . From the psychoanalytic point of view , the theory of introjection of abusive relationships along with the newer theories on masochism have been making invaluable contributions to an understanding of the attachment behavior of abused persons . Finally , some consequences for the treatment of traumatized persons are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Clinical observations consistently show that persons physically or sexually abused in infancy tend to become revictimized in subsequent relationships and , further , that these abusive relationships show a high degree of stability . One major finding of attachment research is the high occurrence of insecure attachment to primary attachment figures in abused persons . Among the typical patterns of relationship , role reversal ( parentification ) has been emphasized . From the psychoanalytic point of view , the theory of introjection of abusive relationships along with the newer theories on masochism have been making invaluable contributions to an understanding of the attachment behavior of abused persons . Finally , some consequences for the treatment of traumatized persons are discussed .	[ "Clinical", "observations", "consistently", "show", "that", "persons", "physically", "or", "sexually", "abused", "in", "infancy", "tend", "to", "become", "revictimized", "in", "subsequent", "relationships", "and", ",", "further", ",", "that", "these", "abusive", "relationships", "show", "a", "high", "degree", "of", "stability", ".", "One", "major", "finding", "of", "attachment", "research", "is", "the", "high", "occurrence", "of", "insecure", "attachment", "to", "primary", "attachment", "figures", "in", "abused", "persons", ".", "Among", "the", "typical", "patterns", "of", "relationship", ",", "role", "reversal", "(", "parentification", ")", "has", "been", "emphasized", ".", "From", "the", "psychoanalytic", "point", "of", "view", ",", "the", "theory", "of", "introjection", "of", "abusive", "relationships", "along", "with", "the", "newer", "theories", "on", "masochism", "have", "been", "making", "invaluable", "contributions", "to", "an", "understanding", "of", "the", "attachment", "behavior", "of", "abused", "persons", ".", "Finally", ",", "some", "consequences", "for", "the", "treatment", "of", "traumatized", "persons", "are", "discussed", "." ]	[ "umlsterm" ]
observations is an umlsterm, persons is an umlsterm, sexually abused is an umlsterm, finding is an umlsterm, research is an umlsterm, occurrence is an umlsterm, persons is an umlsterm, role is an umlsterm, introjection is an umlsterm, masochism is an umlsterm, understanding is an umlsterm, behavior is an umlsterm, persons is an umlsterm, treatment is an umlsterm, persons is an umlsterm	Psychotherapeut.80430117.eng.abstr_task1	Sentence: Clinical observations consistently show that persons physically or sexually abused in infancy tend to become revictimized in subsequent relationships and , further , that these abusive relationships show a high degree of stability . One major finding of attachment research is the high occurrence of insecure attachment to primary attachment figures in abused persons . Among the typical patterns of relationship , role reversal ( parentification ) has been emphasized . From the psychoanalytic point of view , the theory of introjection of abusive relationships along with the newer theories on masochism have been making invaluable contributions to an understanding of the attachment behavior of abused persons . Finally , some consequences for the treatment of traumatized persons are discussed . Instructions: please typing these entity words according to sentence: observations, persons, sexually abused, finding, research, occurrence, persons, role, introjection, masochism, understanding, behavior, persons, treatment, persons Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Clinical observations consistently show that persons physically or sexually abused in infancy tend to become revictimized in subsequent relationships and , further , that these abusive relationships show a high degree of stability . One major finding of attachment research is the high occurrence of insecure attachment to primary attachment figures in abused persons . Among the typical patterns of relationship , role reversal ( parentification ) has been emphasized . From the psychoanalytic point of view , the theory of introjection of abusive relationships along with the newer theories on masochism have been making invaluable contributions to an understanding of the attachment behavior of abused persons . Finally , some consequences for the treatment of traumatized persons are discussed .	[ "Clinical", "observations", "consistently", "show", "that", "persons", "physically", "or", "sexually", "abused", "in", "infancy", "tend", "to", "become", "revictimized", "in", "subsequent", "relationships", "and", ",", "further", ",", "that", "these", "abusive", "relationships", "show", "a", "high", "degree", "of", "stability", ".", "One", "major", "finding", "of", "attachment", "research", "is", "the", "high", "occurrence", "of", "insecure", "attachment", "to", "primary", "attachment", "figures", "in", "abused", "persons", ".", "Among", "the", "typical", "patterns", "of", "relationship", ",", "role", "reversal", "(", "parentification", ")", "has", "been", "emphasized", ".", "From", "the", "psychoanalytic", "point", "of", "view", ",", "the", "theory", "of", "introjection", "of", "abusive", "relationships", "along", "with", "the", "newer", "theories", "on", "masochism", "have", "been", "making", "invaluable", "contributions", "to", "an", "understanding", "of", "the", "attachment", "behavior", "of", "abused", "persons", ".", "Finally", ",", "some", "consequences", "for", "the", "treatment", "of", "traumatized", "persons", "are", "discussed", "." ]	[ "umlsterm" ]
observations, persons, sexually abused, finding, research, occurrence, persons, role, introjection, masochism, understanding, behavior, persons, treatment, persons	Psychotherapeut.80430117.eng.abstr_task2	Sentence: Clinical observations consistently show that persons physically or sexually abused in infancy tend to become revictimized in subsequent relationships and , further , that these abusive relationships show a high degree of stability . One major finding of attachment research is the high occurrence of insecure attachment to primary attachment figures in abused persons . Among the typical patterns of relationship , role reversal ( parentification ) has been emphasized . From the psychoanalytic point of view , the theory of introjection of abusive relationships along with the newer theories on masochism have been making invaluable contributions to an understanding of the attachment behavior of abused persons . Finally , some consequences for the treatment of traumatized persons are discussed . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Clinical observations consistently show that persons physically or sexually abused in infancy tend to become revictimized in subsequent relationships and , further , that these abusive relationships show a high degree of stability . One major finding of attachment research is the high occurrence of insecure attachment to primary attachment figures in abused persons . Among the typical patterns of relationship , role reversal ( parentification ) has been emphasized . From the psychoanalytic point of view , the theory of introjection of abusive relationships along with the newer theories on masochism have been making invaluable contributions to an understanding of the attachment behavior of abused persons . Finally , some consequences for the treatment of traumatized persons are discussed .	[ "Clinical", "observations", "consistently", "show", "that", "persons", "physically", "or", "sexually", "abused", "in", "infancy", "tend", "to", "become", "revictimized", "in", "subsequent", "relationships", "and", ",", "further", ",", "that", "these", "abusive", "relationships", "show", "a", "high", "degree", "of", "stability", ".", "One", "major", "finding", "of", "attachment", "research", "is", "the", "high", "occurrence", "of", "insecure", "attachment", "to", "primary", "attachment", "figures", "in", "abused", "persons", ".", "Among", "the", "typical", "patterns", "of", "relationship", ",", "role", "reversal", "(", "parentification", ")", "has", "been", "emphasized", ".", "From", "the", "psychoanalytic", "point", "of", "view", ",", "the", "theory", "of", "introjection", "of", "abusive", "relationships", "along", "with", "the", "newer", "theories", "on", "masochism", "have", "been", "making", "invaluable", "contributions", "to", "an", "understanding", "of", "the", "attachment", "behavior", "of", "abused", "persons", ".", "Finally", ",", "some", "consequences", "for", "the", "treatment", "of", "traumatized", "persons", "are", "discussed", "." ]	[ "umlsterm" ]
patients is an umlsterm, pain is an umlsterm, postoperative period is an umlsterm, technologies is an umlsterm, drugs is an umlsterm, pain management is an umlsterm, incidence is an umlsterm, postoperative pain is an umlsterm, pain therapy is an umlsterm	DerAnaesthesist.7046s143.eng.abstr_task0	Sentence: Many patients still suffer from unnessesary pain in the postoperative period . Waiting for new technologies or drugs will not improve the status of acute pain management . The establishment of an acute service is needed to reduce the incidence of postoperative pain . Acute pain therapy is one of the great challenges we have to take up . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Many patients still suffer from unnessesary pain in the postoperative period . Waiting for new technologies or drugs will not improve the status of acute pain management . The establishment of an acute service is needed to reduce the incidence of postoperative pain . Acute pain therapy is one of the great challenges we have to take up .	[ "Many", "patients", "still", "suffer", "from", "unnessesary", "pain", "in", "the", "postoperative", "period", ".", "Waiting", "for", "new", "technologies", "or", "drugs", "will", "not", "improve", "the", "status", "of", "acute", "pain", "management", ".", "The", "establishment", "of", "an", "acute", "service", "is", "needed", "to", "reduce", "the", "incidence", "of", "postoperative", "pain", ".", "Acute", "pain", "therapy", "is", "one", "of", "the", "great", "challenges", "we", "have", "to", "take", "up", "." ]	[ "umlsterm" ]
patients is an umlsterm, pain is an umlsterm, postoperative period is an umlsterm, technologies is an umlsterm, drugs is an umlsterm, pain management is an umlsterm, incidence is an umlsterm, postoperative pain is an umlsterm, pain therapy is an umlsterm	DerAnaesthesist.7046s143.eng.abstr_task1	Sentence: Many patients still suffer from unnessesary pain in the postoperative period . Waiting for new technologies or drugs will not improve the status of acute pain management . The establishment of an acute service is needed to reduce the incidence of postoperative pain . Acute pain therapy is one of the great challenges we have to take up . Instructions: please typing these entity words according to sentence: patients, pain, postoperative period, technologies, drugs, pain management, incidence, postoperative pain, pain therapy Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Many patients still suffer from unnessesary pain in the postoperative period . Waiting for new technologies or drugs will not improve the status of acute pain management . The establishment of an acute service is needed to reduce the incidence of postoperative pain . Acute pain therapy is one of the great challenges we have to take up .	[ "Many", "patients", "still", "suffer", "from", "unnessesary", "pain", "in", "the", "postoperative", "period", ".", "Waiting", "for", "new", "technologies", "or", "drugs", "will", "not", "improve", "the", "status", "of", "acute", "pain", "management", ".", "The", "establishment", "of", "an", "acute", "service", "is", "needed", "to", "reduce", "the", "incidence", "of", "postoperative", "pain", ".", "Acute", "pain", "therapy", "is", "one", "of", "the", "great", "challenges", "we", "have", "to", "take", "up", "." ]	[ "umlsterm" ]
patients, pain, postoperative period, technologies, drugs, pain management, incidence, postoperative pain, pain therapy	DerAnaesthesist.7046s143.eng.abstr_task2	Sentence: Many patients still suffer from unnessesary pain in the postoperative period . Waiting for new technologies or drugs will not improve the status of acute pain management . The establishment of an acute service is needed to reduce the incidence of postoperative pain . Acute pain therapy is one of the great challenges we have to take up . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Many patients still suffer from unnessesary pain in the postoperative period . Waiting for new technologies or drugs will not improve the status of acute pain management . The establishment of an acute service is needed to reduce the incidence of postoperative pain . Acute pain therapy is one of the great challenges we have to take up .	[ "Many", "patients", "still", "suffer", "from", "unnessesary", "pain", "in", "the", "postoperative", "period", ".", "Waiting", "for", "new", "technologies", "or", "drugs", "will", "not", "improve", "the", "status", "of", "acute", "pain", "management", ".", "The", "establishment", "of", "an", "acute", "service", "is", "needed", "to", "reduce", "the", "incidence", "of", "postoperative", "pain", ".", "Acute", "pain", "therapy", "is", "one", "of", "the", "great", "challenges", "we", "have", "to", "take", "up", "." ]	[ "umlsterm" ]
Schmerzen is an umlsterm, Schmerzen is an umlsterm, Therapie is an umlsterm, Kompressionssyndrom is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Gewichtsabnahme is an umlsterm, Schmerzen is an umlsterm, medikamentoese Therapie is an umlsterm, farbkodierten is an umlsterm, Zwerchfells is an umlsterm, Verdachtsdiagnose is an umlsterm, Dokumentation is an umlsterm, Pankreasarkaden is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm, Kompressionssyndrom is an umlsterm, Gewichtsabnahme is an umlsterm, Leidensdruck is an umlsterm, Schmerzen is an umlsterm, Schmerzen is an umlsterm, Flussbeschleunigung is an umlsterm, Patienten is an umlsterm, Aorta is an umlsterm, Omentum minus is an umlsterm, Zwerchfellschenkels is an umlsterm, Plexus coeliacus is an umlsterm, Reststenose is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Kompressionssyndroms is an umlsterm, Stenose is an umlsterm, Schmerzen is an umlsterm, Schmerzen is an umlsterm, Gewichtsabnahme is an umlsterm, Tumorkompression is an umlsterm, Pankreatitis is an umlsterm	Gefaesschirurgie.90040028.ger.abstr_task0	Sentence: Epigastrische Schmerzen und postprandiale abdominelle Schmerzen sind haeufig , sprechen jedoch oft auf eine konventionelle Therapie nicht an . In wenigen Faellen kann ein Kompressionssyndrom des Truncus coeliacus vorliegen , das nur auf eine operative Therapie anspricht . Die Schwierigkeit besteht in der Festlegung der Kriterien , die zur Stellung der Operationsindikation fuehren . Aus diesem Grund wurden 61 Patienten mit Gewichtsabnahme und epigastrischen Schmerzen , bei denen andere Krankheitsbilder ausgeschlossen waren und die auf eine medikamentoese Therapie bzw. diaetetische Massnahme nicht ansprachen , einer farbkodierten Duplexsonographie des Abdomens unterzogen . Die Kriterien fuer den Verdacht des Vorliegens einer ligamentaeren Trunkusstenose waren eine maximale Flussgeschwindigkeit im Trunkus von ueber 200 cm/s , eine Fixation in In- und Exspirationsstellung des Zwerchfells und der sonographische Nachweis eines Stealeffekts mit Flussumkehr aus der A. mesenterica superior . Die Verdachtsdiagnose ligamentaere Trunkusstenose wurde angiographisch erhaertet mit der Dokumentation des Stealeffekts aus der A. mesenterica superior ueber Pankreasarkaden mit Darstellung des distalen Anteils des Truncus coeliacus . Bei 21 von 61 Patienten wurde die Diagnose " Kompressionssyndrom des Truncus coeliacus " gestellt . Bei Vorliegen der Kriterien Gewichtsabnahme mehr als 5 kg , erheblicher Leidensdruck durch epigastrische Schmerzen und postprandiale Schmerzen , Flussbeschleunigung im Truncus coeliacus ueber 200 cm/s und Fixation in Inspirationsstellung und eines Stealeffekts mit Flussumkehr in der A. mesenterica superior wurden die Patienten operiert n=10). ( Die Operation bestand in allen 10 Faellen in einer Freilegung der suprarenalen Aorta durch das Omentum minus und der Darstellung des Abgangs des Truncus coeliacus , in der Durchtrennung des Ligamentum arcuatum medianum und Einkerbung des rechten Zwerchfellschenkels sowie in der Resektion von Anteilen des Plexus coeliacus . Intraoperativ wurde die Reststenose nach Durchtrennung des Ligamentum arcuatum dilatiert und falls erforderlich , eine Gefaessrekonstruktion durchgefuehrt ; 80% der Patienten waren nach durchschnittlich 28 Monaten voellig beschwerdefrei , 10% waren gebessert und 1 Patient ohne Aenderung der praeoperativen Beschwerden . Schlussfolgerung : Voraussetzung fuer die erfolgreiche Operation des Kompressionssyndroms des Truncus coeliacus sind : 1. Der mittels farbcodierter Duplexsonographie gefuehrte Nachweis einer auch in Inspirationsstellung fixierten Stenose des Truncus . 2. Die Mesenteriko- und Zoeliakographie mit Nachweis des Stealeffekts . 3. Nahrungsabhaengige Symptomentrias : Epigastrische Schmerzen , postprandiale Schmerzen und Gewichtsabnahme . 4. Ausschluss anderer Ursachen , wie zum Beispiel Tumorkompression , chronische Pankreatitis u.a. . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Epigastrische Schmerzen und postprandiale abdominelle Schmerzen sind haeufig , sprechen jedoch oft auf eine konventionelle Therapie nicht an . In wenigen Faellen kann ein Kompressionssyndrom des Truncus coeliacus vorliegen , das nur auf eine operative Therapie anspricht . Die Schwierigkeit besteht in der Festlegung der Kriterien , die zur Stellung der Operationsindikation fuehren . Aus diesem Grund wurden 61 Patienten mit Gewichtsabnahme und epigastrischen Schmerzen , bei denen andere Krankheitsbilder ausgeschlossen waren und die auf eine medikamentoese Therapie bzw. diaetetische Massnahme nicht ansprachen , einer farbkodierten Duplexsonographie des Abdomens unterzogen . Die Kriterien fuer den Verdacht des Vorliegens einer ligamentaeren Trunkusstenose waren eine maximale Flussgeschwindigkeit im Trunkus von ueber 200 cm/s , eine Fixation in In- und Exspirationsstellung des Zwerchfells und der sonographische Nachweis eines Stealeffekts mit Flussumkehr aus der A. mesenterica superior . Die Verdachtsdiagnose ligamentaere Trunkusstenose wurde angiographisch erhaertet mit der Dokumentation des Stealeffekts aus der A. mesenterica superior ueber Pankreasarkaden mit Darstellung des distalen Anteils des Truncus coeliacus . Bei 21 von 61 Patienten wurde die Diagnose " Kompressionssyndrom des Truncus coeliacus " gestellt . Bei Vorliegen der Kriterien Gewichtsabnahme mehr als 5 kg , erheblicher Leidensdruck durch epigastrische Schmerzen und postprandiale Schmerzen , Flussbeschleunigung im Truncus coeliacus ueber 200 cm/s und Fixation in Inspirationsstellung und eines Stealeffekts mit Flussumkehr in der A. mesenterica superior wurden die Patienten operiert n=10). ( Die Operation bestand in allen 10 Faellen in einer Freilegung der suprarenalen Aorta durch das Omentum minus und der Darstellung des Abgangs des Truncus coeliacus , in der Durchtrennung des Ligamentum arcuatum medianum und Einkerbung des rechten Zwerchfellschenkels sowie in der Resektion von Anteilen des Plexus coeliacus . Intraoperativ wurde die Reststenose nach Durchtrennung des Ligamentum arcuatum dilatiert und falls erforderlich , eine Gefaessrekonstruktion durchgefuehrt ; 80% der Patienten waren nach durchschnittlich 28 Monaten voellig beschwerdefrei , 10% waren gebessert und 1 Patient ohne Aenderung der praeoperativen Beschwerden . Schlussfolgerung : Voraussetzung fuer die erfolgreiche Operation des Kompressionssyndroms des Truncus coeliacus sind : 1. Der mittels farbcodierter Duplexsonographie gefuehrte Nachweis einer auch in Inspirationsstellung fixierten Stenose des Truncus . 2. Die Mesenteriko- und Zoeliakographie mit Nachweis des Stealeffekts . 3. Nahrungsabhaengige Symptomentrias : Epigastrische Schmerzen , postprandiale Schmerzen und Gewichtsabnahme . 4. Ausschluss anderer Ursachen , wie zum Beispiel Tumorkompression , chronische Pankreatitis u.a. .	[ "Epigastrische", "Schmerzen", "und", "postprandiale", "abdominelle", "Schmerzen", "sind", "haeufig", ",", "sprechen", "jedoch", "oft", "auf", "eine", "konventionelle", "Therapie", "nicht", "an", ".", "In", "wenigen", "Faellen", "kann", "ein", "Kompressionssyndrom", "des", "Truncus", "coeliacus", "vorliegen", ",", "das", "nur", "auf", "eine", "operative", "Therapie", "anspricht", ".", "Die", "Schwierigkeit", "besteht", "in", "der", "Festlegung", "der", "Kriterien", ",", "die", "zur", "Stellung", "der", "Operationsindikation", "fuehren", ".", "Aus", "diesem", "Grund", "wurden", "61", "Patienten", "mit", "Gewichtsabnahme", "und", "epigastrischen", "Schmerzen", ",", "bei", "denen", "andere", "Krankheitsbilder", "ausgeschlossen", "waren", "und", "die", "auf", "eine", "medikamentoese", "Therapie", "bzw", ".", "diaetetische", "Massnahme", "nicht", "ansprachen", ",", "einer", "farbkodierten", "Duplexsonographie", "des", "Abdomens", "unterzogen", ".", "Die", "Kriterien", "fuer", "den", "Verdacht", "des", "Vorliegens", "einer", "ligamentaeren", "Trunkusstenose", "waren", "eine", "maximale", "Flussgeschwindigkeit", "im", "Trunkus", "von", "ueber", "200", "cm", "/", "s", ",", "eine", "Fixation", "in", "In-", "und", "Exspirationsstellung", "des", "Zwerchfells", "und", "der", "sonographische", "Nachweis", "eines", "Stealeffekts", "mit", "Flussumkehr", "aus", "der", "A.", "mesenterica", "superior", ".", "Die", "Verdachtsdiagnose", "ligamentaere", "Trunkusstenose", "wurde", "angiographisch", "erhaertet", "mit", "der", "Dokumentation", "des", "Stealeffekts", "aus", "der", "A.", "mesenterica", "superior", "ueber", "Pankreasarkaden", "mit", "Darstellung", "des", "distalen", "Anteils", "des", "Truncus", "coeliacus", ".", "Bei", "21", "von", "61", "Patienten", "wurde", "die", "Diagnose", "\"", "Kompressionssyndrom", "des", "Truncus", "coeliacus", "\"", "gestellt", ".", "Bei", "Vorliegen", "der", "Kriterien", "Gewichtsabnahme", "mehr", "als", "5", "kg", ",", "erheblicher", "Leidensdruck", "durch", "epigastrische", "Schmerzen", "und", "postprandiale", "Schmerzen", ",", "Flussbeschleunigung", "im", "Truncus", "coeliacus", "ueber", "200", "cm", "/", "s", "und", "Fixation", "in", "Inspirationsstellung", "und", "eines", "Stealeffekts", "mit", "Flussumkehr", "in", "der", "A.", "mesenterica", "superior", "wurden", "die", "Patienten", "operiert", "n=10", ")", ".", "(", "Die", "Operation", "bestand", "in", "allen", "10", "Faellen", "in", "einer", "Freilegung", "der", "suprarenalen", "Aorta", "durch", "das", "Omentum", "minus", "und", "der", "Darstellung", "des", "Abgangs", "des", "Truncus", "coeliacus", ",", "in", "der", "Durchtrennung", "des", "Ligamentum", "arcuatum", "medianum", "und", "Einkerbung", "des", "rechten", "Zwerchfellschenkels", "sowie", "in", "der", "Resektion", "von", "Anteilen", "des", "Plexus", "coeliacus", ".", "Intraoperativ", "wurde", "die", "Reststenose", "nach", "Durchtrennung", "des", "Ligamentum", "arcuatum", "dilatiert", "und", "falls", "erforderlich", ",", "eine", "Gefaessrekonstruktion", "durchgefuehrt", ";", "80", "%", "der", "Patienten", "waren", "nach", "durchschnittlich", "28", "Monaten", "voellig", "beschwerdefrei", ",", "10", "%", "waren", "gebessert", "und", "1", "Patient", "ohne", "Aenderung", "der", "praeoperativen", "Beschwerden", ".", "Schlussfolgerung", ":", "Voraussetzung", "fuer", "die", "erfolgreiche", "Operation", "des", "Kompressionssyndroms", "des", "Truncus", "coeliacus", "sind", ":", "1", ".", "Der", "mittels", "farbcodierter", "Duplexsonographie", "gefuehrte", "Nachweis", "einer", "auch", "in", "Inspirationsstellung", "fixierten", "Stenose", "des", "Truncus", ".", "2", ".", "Die", "Mesenteriko-", "und", "Zoeliakographie", "mit", "Nachweis", "des", "Stealeffekts", ".", "3", ".", "Nahrungsabhaengige", "Symptomentrias", ":", "Epigastrische", "Schmerzen", ",", "postprandiale", "Schmerzen", "und", "Gewichtsabnahme", ".", "4", ".", "Ausschluss", "anderer", "Ursachen", ",", "wie", "zum", "Beispiel", "Tumorkompression", ",", "chronische", "Pankreatitis", "u.a", ".", "." ]	[ "umlsterm" ]
Schmerzen is an umlsterm, Schmerzen is an umlsterm, Therapie is an umlsterm, Kompressionssyndrom is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Gewichtsabnahme is an umlsterm, Schmerzen is an umlsterm, medikamentoese Therapie is an umlsterm, farbkodierten is an umlsterm, Zwerchfells is an umlsterm, Verdachtsdiagnose is an umlsterm, Dokumentation is an umlsterm, Pankreasarkaden is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm, Kompressionssyndrom is an umlsterm, Gewichtsabnahme is an umlsterm, Leidensdruck is an umlsterm, Schmerzen is an umlsterm, Schmerzen is an umlsterm, Flussbeschleunigung is an umlsterm, Patienten is an umlsterm, Aorta is an umlsterm, Omentum minus is an umlsterm, Zwerchfellschenkels is an umlsterm, Plexus coeliacus is an umlsterm, Reststenose is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Kompressionssyndroms is an umlsterm, Stenose is an umlsterm, Schmerzen is an umlsterm, Schmerzen is an umlsterm, Gewichtsabnahme is an umlsterm, Tumorkompression is an umlsterm, Pankreatitis is an umlsterm	Gefaesschirurgie.90040028.ger.abstr_task1	Sentence: Epigastrische Schmerzen und postprandiale abdominelle Schmerzen sind haeufig , sprechen jedoch oft auf eine konventionelle Therapie nicht an . In wenigen Faellen kann ein Kompressionssyndrom des Truncus coeliacus vorliegen , das nur auf eine operative Therapie anspricht . Die Schwierigkeit besteht in der Festlegung der Kriterien , die zur Stellung der Operationsindikation fuehren . Aus diesem Grund wurden 61 Patienten mit Gewichtsabnahme und epigastrischen Schmerzen , bei denen andere Krankheitsbilder ausgeschlossen waren und die auf eine medikamentoese Therapie bzw. diaetetische Massnahme nicht ansprachen , einer farbkodierten Duplexsonographie des Abdomens unterzogen . Die Kriterien fuer den Verdacht des Vorliegens einer ligamentaeren Trunkusstenose waren eine maximale Flussgeschwindigkeit im Trunkus von ueber 200 cm/s , eine Fixation in In- und Exspirationsstellung des Zwerchfells und der sonographische Nachweis eines Stealeffekts mit Flussumkehr aus der A. mesenterica superior . Die Verdachtsdiagnose ligamentaere Trunkusstenose wurde angiographisch erhaertet mit der Dokumentation des Stealeffekts aus der A. mesenterica superior ueber Pankreasarkaden mit Darstellung des distalen Anteils des Truncus coeliacus . Bei 21 von 61 Patienten wurde die Diagnose " Kompressionssyndrom des Truncus coeliacus " gestellt . Bei Vorliegen der Kriterien Gewichtsabnahme mehr als 5 kg , erheblicher Leidensdruck durch epigastrische Schmerzen und postprandiale Schmerzen , Flussbeschleunigung im Truncus coeliacus ueber 200 cm/s und Fixation in Inspirationsstellung und eines Stealeffekts mit Flussumkehr in der A. mesenterica superior wurden die Patienten operiert n=10). ( Die Operation bestand in allen 10 Faellen in einer Freilegung der suprarenalen Aorta durch das Omentum minus und der Darstellung des Abgangs des Truncus coeliacus , in der Durchtrennung des Ligamentum arcuatum medianum und Einkerbung des rechten Zwerchfellschenkels sowie in der Resektion von Anteilen des Plexus coeliacus . Intraoperativ wurde die Reststenose nach Durchtrennung des Ligamentum arcuatum dilatiert und falls erforderlich , eine Gefaessrekonstruktion durchgefuehrt ; 80% der Patienten waren nach durchschnittlich 28 Monaten voellig beschwerdefrei , 10% waren gebessert und 1 Patient ohne Aenderung der praeoperativen Beschwerden . Schlussfolgerung : Voraussetzung fuer die erfolgreiche Operation des Kompressionssyndroms des Truncus coeliacus sind : 1. Der mittels farbcodierter Duplexsonographie gefuehrte Nachweis einer auch in Inspirationsstellung fixierten Stenose des Truncus . 2. Die Mesenteriko- und Zoeliakographie mit Nachweis des Stealeffekts . 3. Nahrungsabhaengige Symptomentrias : Epigastrische Schmerzen , postprandiale Schmerzen und Gewichtsabnahme . 4. Ausschluss anderer Ursachen , wie zum Beispiel Tumorkompression , chronische Pankreatitis u.a. . Instructions: please typing these entity words according to sentence: Schmerzen, Schmerzen, Therapie, Kompressionssyndrom, Therapie, Patienten, Gewichtsabnahme, Schmerzen, medikamentoese Therapie, farbkodierten, Zwerchfells, Verdachtsdiagnose, Dokumentation, Pankreasarkaden, Patienten, Diagnose, Kompressionssyndrom, Gewichtsabnahme, Leidensdruck, Schmerzen, Schmerzen, Flussbeschleunigung, Patienten, Aorta, Omentum minus, Zwerchfellschenkels, Plexus coeliacus, Reststenose, Patienten, Patient, Kompressionssyndroms, Stenose, Schmerzen, Schmerzen, Gewichtsabnahme, Tumorkompression, Pankreatitis Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Epigastrische Schmerzen und postprandiale abdominelle Schmerzen sind haeufig , sprechen jedoch oft auf eine konventionelle Therapie nicht an . In wenigen Faellen kann ein Kompressionssyndrom des Truncus coeliacus vorliegen , das nur auf eine operative Therapie anspricht . Die Schwierigkeit besteht in der Festlegung der Kriterien , die zur Stellung der Operationsindikation fuehren . Aus diesem Grund wurden 61 Patienten mit Gewichtsabnahme und epigastrischen Schmerzen , bei denen andere Krankheitsbilder ausgeschlossen waren und die auf eine medikamentoese Therapie bzw. diaetetische Massnahme nicht ansprachen , einer farbkodierten Duplexsonographie des Abdomens unterzogen . Die Kriterien fuer den Verdacht des Vorliegens einer ligamentaeren Trunkusstenose waren eine maximale Flussgeschwindigkeit im Trunkus von ueber 200 cm/s , eine Fixation in In- und Exspirationsstellung des Zwerchfells und der sonographische Nachweis eines Stealeffekts mit Flussumkehr aus der A. mesenterica superior . Die Verdachtsdiagnose ligamentaere Trunkusstenose wurde angiographisch erhaertet mit der Dokumentation des Stealeffekts aus der A. mesenterica superior ueber Pankreasarkaden mit Darstellung des distalen Anteils des Truncus coeliacus . Bei 21 von 61 Patienten wurde die Diagnose " Kompressionssyndrom des Truncus coeliacus " gestellt . Bei Vorliegen der Kriterien Gewichtsabnahme mehr als 5 kg , erheblicher Leidensdruck durch epigastrische Schmerzen und postprandiale Schmerzen , Flussbeschleunigung im Truncus coeliacus ueber 200 cm/s und Fixation in Inspirationsstellung und eines Stealeffekts mit Flussumkehr in der A. mesenterica superior wurden die Patienten operiert n=10). ( Die Operation bestand in allen 10 Faellen in einer Freilegung der suprarenalen Aorta durch das Omentum minus und der Darstellung des Abgangs des Truncus coeliacus , in der Durchtrennung des Ligamentum arcuatum medianum und Einkerbung des rechten Zwerchfellschenkels sowie in der Resektion von Anteilen des Plexus coeliacus . Intraoperativ wurde die Reststenose nach Durchtrennung des Ligamentum arcuatum dilatiert und falls erforderlich , eine Gefaessrekonstruktion durchgefuehrt ; 80% der Patienten waren nach durchschnittlich 28 Monaten voellig beschwerdefrei , 10% waren gebessert und 1 Patient ohne Aenderung der praeoperativen Beschwerden . Schlussfolgerung : Voraussetzung fuer die erfolgreiche Operation des Kompressionssyndroms des Truncus coeliacus sind : 1. Der mittels farbcodierter Duplexsonographie gefuehrte Nachweis einer auch in Inspirationsstellung fixierten Stenose des Truncus . 2. Die Mesenteriko- und Zoeliakographie mit Nachweis des Stealeffekts . 3. Nahrungsabhaengige Symptomentrias : Epigastrische Schmerzen , postprandiale Schmerzen und Gewichtsabnahme . 4. Ausschluss anderer Ursachen , wie zum Beispiel Tumorkompression , chronische Pankreatitis u.a. .	[ "Epigastrische", "Schmerzen", "und", "postprandiale", "abdominelle", "Schmerzen", "sind", "haeufig", ",", "sprechen", "jedoch", "oft", "auf", "eine", "konventionelle", "Therapie", "nicht", "an", ".", "In", "wenigen", "Faellen", "kann", "ein", "Kompressionssyndrom", "des", "Truncus", "coeliacus", "vorliegen", ",", "das", "nur", "auf", "eine", "operative", "Therapie", "anspricht", ".", "Die", "Schwierigkeit", "besteht", "in", "der", "Festlegung", "der", "Kriterien", ",", "die", "zur", "Stellung", "der", "Operationsindikation", "fuehren", ".", "Aus", "diesem", "Grund", "wurden", "61", "Patienten", "mit", "Gewichtsabnahme", "und", "epigastrischen", "Schmerzen", ",", "bei", "denen", "andere", "Krankheitsbilder", "ausgeschlossen", "waren", "und", "die", "auf", "eine", "medikamentoese", "Therapie", "bzw", ".", "diaetetische", "Massnahme", "nicht", "ansprachen", ",", "einer", "farbkodierten", "Duplexsonographie", "des", "Abdomens", "unterzogen", ".", "Die", "Kriterien", "fuer", "den", "Verdacht", "des", "Vorliegens", "einer", "ligamentaeren", "Trunkusstenose", "waren", "eine", "maximale", "Flussgeschwindigkeit", "im", "Trunkus", "von", "ueber", "200", "cm", "/", "s", ",", "eine", "Fixation", "in", "In-", "und", "Exspirationsstellung", "des", "Zwerchfells", "und", "der", "sonographische", "Nachweis", "eines", "Stealeffekts", "mit", "Flussumkehr", "aus", "der", "A.", "mesenterica", "superior", ".", "Die", "Verdachtsdiagnose", "ligamentaere", "Trunkusstenose", "wurde", "angiographisch", "erhaertet", "mit", "der", "Dokumentation", "des", "Stealeffekts", "aus", "der", "A.", "mesenterica", "superior", "ueber", "Pankreasarkaden", "mit", "Darstellung", "des", "distalen", "Anteils", "des", "Truncus", "coeliacus", ".", "Bei", "21", "von", "61", "Patienten", "wurde", "die", "Diagnose", "\"", "Kompressionssyndrom", "des", "Truncus", "coeliacus", "\"", "gestellt", ".", "Bei", "Vorliegen", "der", "Kriterien", "Gewichtsabnahme", "mehr", "als", "5", "kg", ",", "erheblicher", "Leidensdruck", "durch", "epigastrische", "Schmerzen", "und", "postprandiale", "Schmerzen", ",", "Flussbeschleunigung", "im", "Truncus", "coeliacus", "ueber", "200", "cm", "/", "s", "und", "Fixation", "in", "Inspirationsstellung", "und", "eines", "Stealeffekts", "mit", "Flussumkehr", "in", "der", "A.", "mesenterica", "superior", "wurden", "die", "Patienten", "operiert", "n=10", ")", ".", "(", "Die", "Operation", "bestand", "in", "allen", "10", "Faellen", "in", "einer", "Freilegung", "der", "suprarenalen", "Aorta", "durch", "das", "Omentum", "minus", "und", "der", "Darstellung", "des", "Abgangs", "des", "Truncus", "coeliacus", ",", "in", "der", "Durchtrennung", "des", "Ligamentum", "arcuatum", "medianum", "und", "Einkerbung", "des", "rechten", "Zwerchfellschenkels", "sowie", "in", "der", "Resektion", "von", "Anteilen", "des", "Plexus", "coeliacus", ".", "Intraoperativ", "wurde", "die", "Reststenose", "nach", "Durchtrennung", "des", "Ligamentum", "arcuatum", "dilatiert", "und", "falls", "erforderlich", ",", "eine", "Gefaessrekonstruktion", "durchgefuehrt", ";", "80", "%", "der", "Patienten", "waren", "nach", "durchschnittlich", "28", "Monaten", "voellig", "beschwerdefrei", ",", "10", "%", "waren", "gebessert", "und", "1", "Patient", "ohne", "Aenderung", "der", "praeoperativen", "Beschwerden", ".", "Schlussfolgerung", ":", "Voraussetzung", "fuer", "die", "erfolgreiche", "Operation", "des", "Kompressionssyndroms", "des", "Truncus", "coeliacus", "sind", ":", "1", ".", "Der", "mittels", "farbcodierter", "Duplexsonographie", "gefuehrte", "Nachweis", "einer", "auch", "in", "Inspirationsstellung", "fixierten", "Stenose", "des", "Truncus", ".", "2", ".", "Die", "Mesenteriko-", "und", "Zoeliakographie", "mit", "Nachweis", "des", "Stealeffekts", ".", "3", ".", "Nahrungsabhaengige", "Symptomentrias", ":", "Epigastrische", "Schmerzen", ",", "postprandiale", "Schmerzen", "und", "Gewichtsabnahme", ".", "4", ".", "Ausschluss", "anderer", "Ursachen", ",", "wie", "zum", "Beispiel", "Tumorkompression", ",", "chronische", "Pankreatitis", "u.a", ".", "." ]	[ "umlsterm" ]
Schmerzen, Schmerzen, Therapie, Kompressionssyndrom, Therapie, Patienten, Gewichtsabnahme, Schmerzen, medikamentoese Therapie, farbkodierten, Zwerchfells, Verdachtsdiagnose, Dokumentation, Pankreasarkaden, Patienten, Diagnose, Kompressionssyndrom, Gewichtsabnahme, Leidensdruck, Schmerzen, Schmerzen, Flussbeschleunigung, Patienten, Aorta, Omentum minus, Zwerchfellschenkels, Plexus coeliacus, Reststenose, Patienten, Patient, Kompressionssyndroms, Stenose, Schmerzen, Schmerzen, Gewichtsabnahme, Tumorkompression, Pankreatitis	Gefaesschirurgie.90040028.ger.abstr_task2	Sentence: Epigastrische Schmerzen und postprandiale abdominelle Schmerzen sind haeufig , sprechen jedoch oft auf eine konventionelle Therapie nicht an . In wenigen Faellen kann ein Kompressionssyndrom des Truncus coeliacus vorliegen , das nur auf eine operative Therapie anspricht . Die Schwierigkeit besteht in der Festlegung der Kriterien , die zur Stellung der Operationsindikation fuehren . Aus diesem Grund wurden 61 Patienten mit Gewichtsabnahme und epigastrischen Schmerzen , bei denen andere Krankheitsbilder ausgeschlossen waren und die auf eine medikamentoese Therapie bzw. diaetetische Massnahme nicht ansprachen , einer farbkodierten Duplexsonographie des Abdomens unterzogen . Die Kriterien fuer den Verdacht des Vorliegens einer ligamentaeren Trunkusstenose waren eine maximale Flussgeschwindigkeit im Trunkus von ueber 200 cm/s , eine Fixation in In- und Exspirationsstellung des Zwerchfells und der sonographische Nachweis eines Stealeffekts mit Flussumkehr aus der A. mesenterica superior . Die Verdachtsdiagnose ligamentaere Trunkusstenose wurde angiographisch erhaertet mit der Dokumentation des Stealeffekts aus der A. mesenterica superior ueber Pankreasarkaden mit Darstellung des distalen Anteils des Truncus coeliacus . Bei 21 von 61 Patienten wurde die Diagnose " Kompressionssyndrom des Truncus coeliacus " gestellt . Bei Vorliegen der Kriterien Gewichtsabnahme mehr als 5 kg , erheblicher Leidensdruck durch epigastrische Schmerzen und postprandiale Schmerzen , Flussbeschleunigung im Truncus coeliacus ueber 200 cm/s und Fixation in Inspirationsstellung und eines Stealeffekts mit Flussumkehr in der A. mesenterica superior wurden die Patienten operiert n=10). ( Die Operation bestand in allen 10 Faellen in einer Freilegung der suprarenalen Aorta durch das Omentum minus und der Darstellung des Abgangs des Truncus coeliacus , in der Durchtrennung des Ligamentum arcuatum medianum und Einkerbung des rechten Zwerchfellschenkels sowie in der Resektion von Anteilen des Plexus coeliacus . Intraoperativ wurde die Reststenose nach Durchtrennung des Ligamentum arcuatum dilatiert und falls erforderlich , eine Gefaessrekonstruktion durchgefuehrt ; 80% der Patienten waren nach durchschnittlich 28 Monaten voellig beschwerdefrei , 10% waren gebessert und 1 Patient ohne Aenderung der praeoperativen Beschwerden . Schlussfolgerung : Voraussetzung fuer die erfolgreiche Operation des Kompressionssyndroms des Truncus coeliacus sind : 1. Der mittels farbcodierter Duplexsonographie gefuehrte Nachweis einer auch in Inspirationsstellung fixierten Stenose des Truncus . 2. Die Mesenteriko- und Zoeliakographie mit Nachweis des Stealeffekts . 3. Nahrungsabhaengige Symptomentrias : Epigastrische Schmerzen , postprandiale Schmerzen und Gewichtsabnahme . 4. Ausschluss anderer Ursachen , wie zum Beispiel Tumorkompression , chronische Pankreatitis u.a. . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Epigastrische Schmerzen und postprandiale abdominelle Schmerzen sind haeufig , sprechen jedoch oft auf eine konventionelle Therapie nicht an . In wenigen Faellen kann ein Kompressionssyndrom des Truncus coeliacus vorliegen , das nur auf eine operative Therapie anspricht . Die Schwierigkeit besteht in der Festlegung der Kriterien , die zur Stellung der Operationsindikation fuehren . Aus diesem Grund wurden 61 Patienten mit Gewichtsabnahme und epigastrischen Schmerzen , bei denen andere Krankheitsbilder ausgeschlossen waren und die auf eine medikamentoese Therapie bzw. diaetetische Massnahme nicht ansprachen , einer farbkodierten Duplexsonographie des Abdomens unterzogen . Die Kriterien fuer den Verdacht des Vorliegens einer ligamentaeren Trunkusstenose waren eine maximale Flussgeschwindigkeit im Trunkus von ueber 200 cm/s , eine Fixation in In- und Exspirationsstellung des Zwerchfells und der sonographische Nachweis eines Stealeffekts mit Flussumkehr aus der A. mesenterica superior . Die Verdachtsdiagnose ligamentaere Trunkusstenose wurde angiographisch erhaertet mit der Dokumentation des Stealeffekts aus der A. mesenterica superior ueber Pankreasarkaden mit Darstellung des distalen Anteils des Truncus coeliacus . Bei 21 von 61 Patienten wurde die Diagnose " Kompressionssyndrom des Truncus coeliacus " gestellt . Bei Vorliegen der Kriterien Gewichtsabnahme mehr als 5 kg , erheblicher Leidensdruck durch epigastrische Schmerzen und postprandiale Schmerzen , Flussbeschleunigung im Truncus coeliacus ueber 200 cm/s und Fixation in Inspirationsstellung und eines Stealeffekts mit Flussumkehr in der A. mesenterica superior wurden die Patienten operiert n=10). ( Die Operation bestand in allen 10 Faellen in einer Freilegung der suprarenalen Aorta durch das Omentum minus und der Darstellung des Abgangs des Truncus coeliacus , in der Durchtrennung des Ligamentum arcuatum medianum und Einkerbung des rechten Zwerchfellschenkels sowie in der Resektion von Anteilen des Plexus coeliacus . Intraoperativ wurde die Reststenose nach Durchtrennung des Ligamentum arcuatum dilatiert und falls erforderlich , eine Gefaessrekonstruktion durchgefuehrt ; 80% der Patienten waren nach durchschnittlich 28 Monaten voellig beschwerdefrei , 10% waren gebessert und 1 Patient ohne Aenderung der praeoperativen Beschwerden . Schlussfolgerung : Voraussetzung fuer die erfolgreiche Operation des Kompressionssyndroms des Truncus coeliacus sind : 1. Der mittels farbcodierter Duplexsonographie gefuehrte Nachweis einer auch in Inspirationsstellung fixierten Stenose des Truncus . 2. Die Mesenteriko- und Zoeliakographie mit Nachweis des Stealeffekts . 3. Nahrungsabhaengige Symptomentrias : Epigastrische Schmerzen , postprandiale Schmerzen und Gewichtsabnahme . 4. Ausschluss anderer Ursachen , wie zum Beispiel Tumorkompression , chronische Pankreatitis u.a. .	[ "Epigastrische", "Schmerzen", "und", "postprandiale", "abdominelle", "Schmerzen", "sind", "haeufig", ",", "sprechen", "jedoch", "oft", "auf", "eine", "konventionelle", "Therapie", "nicht", "an", ".", "In", "wenigen", "Faellen", "kann", "ein", "Kompressionssyndrom", "des", "Truncus", "coeliacus", "vorliegen", ",", "das", "nur", "auf", "eine", "operative", "Therapie", "anspricht", ".", "Die", "Schwierigkeit", "besteht", "in", "der", "Festlegung", "der", "Kriterien", ",", "die", "zur", "Stellung", "der", "Operationsindikation", "fuehren", ".", "Aus", "diesem", "Grund", "wurden", "61", "Patienten", "mit", "Gewichtsabnahme", "und", "epigastrischen", "Schmerzen", ",", "bei", "denen", "andere", "Krankheitsbilder", "ausgeschlossen", "waren", "und", "die", "auf", "eine", "medikamentoese", "Therapie", "bzw", ".", "diaetetische", "Massnahme", "nicht", "ansprachen", ",", "einer", "farbkodierten", "Duplexsonographie", "des", "Abdomens", "unterzogen", ".", "Die", "Kriterien", "fuer", "den", "Verdacht", "des", "Vorliegens", "einer", "ligamentaeren", "Trunkusstenose", "waren", "eine", "maximale", "Flussgeschwindigkeit", "im", "Trunkus", "von", "ueber", "200", "cm", "/", "s", ",", "eine", "Fixation", "in", "In-", "und", "Exspirationsstellung", "des", "Zwerchfells", "und", "der", "sonographische", "Nachweis", "eines", "Stealeffekts", "mit", "Flussumkehr", "aus", "der", "A.", "mesenterica", "superior", ".", "Die", "Verdachtsdiagnose", "ligamentaere", "Trunkusstenose", "wurde", "angiographisch", "erhaertet", "mit", "der", "Dokumentation", "des", "Stealeffekts", "aus", "der", "A.", "mesenterica", "superior", "ueber", "Pankreasarkaden", "mit", "Darstellung", "des", "distalen", "Anteils", "des", "Truncus", "coeliacus", ".", "Bei", "21", "von", "61", "Patienten", "wurde", "die", "Diagnose", "\"", "Kompressionssyndrom", "des", "Truncus", "coeliacus", "\"", "gestellt", ".", "Bei", "Vorliegen", "der", "Kriterien", "Gewichtsabnahme", "mehr", "als", "5", "kg", ",", "erheblicher", "Leidensdruck", "durch", "epigastrische", "Schmerzen", "und", "postprandiale", "Schmerzen", ",", "Flussbeschleunigung", "im", "Truncus", "coeliacus", "ueber", "200", "cm", "/", "s", "und", "Fixation", "in", "Inspirationsstellung", "und", "eines", "Stealeffekts", "mit", "Flussumkehr", "in", "der", "A.", "mesenterica", "superior", "wurden", "die", "Patienten", "operiert", "n=10", ")", ".", "(", "Die", "Operation", "bestand", "in", "allen", "10", "Faellen", "in", "einer", "Freilegung", "der", "suprarenalen", "Aorta", "durch", "das", "Omentum", "minus", "und", "der", "Darstellung", "des", "Abgangs", "des", "Truncus", "coeliacus", ",", "in", "der", "Durchtrennung", "des", "Ligamentum", "arcuatum", "medianum", "und", "Einkerbung", "des", "rechten", "Zwerchfellschenkels", "sowie", "in", "der", "Resektion", "von", "Anteilen", "des", "Plexus", "coeliacus", ".", "Intraoperativ", "wurde", "die", "Reststenose", "nach", "Durchtrennung", "des", "Ligamentum", "arcuatum", "dilatiert", "und", "falls", "erforderlich", ",", "eine", "Gefaessrekonstruktion", "durchgefuehrt", ";", "80", "%", "der", "Patienten", "waren", "nach", "durchschnittlich", "28", "Monaten", "voellig", "beschwerdefrei", ",", "10", "%", "waren", "gebessert", "und", "1", "Patient", "ohne", "Aenderung", "der", "praeoperativen", "Beschwerden", ".", "Schlussfolgerung", ":", "Voraussetzung", "fuer", "die", "erfolgreiche", "Operation", "des", "Kompressionssyndroms", "des", "Truncus", "coeliacus", "sind", ":", "1", ".", "Der", "mittels", "farbcodierter", "Duplexsonographie", "gefuehrte", "Nachweis", "einer", "auch", "in", "Inspirationsstellung", "fixierten", "Stenose", "des", "Truncus", ".", "2", ".", "Die", "Mesenteriko-", "und", "Zoeliakographie", "mit", "Nachweis", "des", "Stealeffekts", ".", "3", ".", "Nahrungsabhaengige", "Symptomentrias", ":", "Epigastrische", "Schmerzen", ",", "postprandiale", "Schmerzen", "und", "Gewichtsabnahme", ".", "4", ".", "Ausschluss", "anderer", "Ursachen", ",", "wie", "zum", "Beispiel", "Tumorkompression", ",", "chronische", "Pankreatitis", "u.a", ".", "." ]	[ "umlsterm" ]
arformoterol is a CHEMICAL	17472819_task0	Sentence: Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.	[ "Nebulized", "arformoterol", "in", "patients", "with", "COPD", ":", "a", "12-week", ",", "multicenter", ",", "randomized", ",", "double", "-", "blind", ",", "double", "-", "dummy", ",", "placebo-", "and", "active", "-", "controlled", "trial", "." ]	[ "CHEMICAL", "GENE-Y" ]
arformoterol is a CHEMICAL	17472819_task1	Sentence: Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Instructions: please typing these entity words according to sentence: arformoterol Options: CHEMICAL	[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.	[ "Nebulized", "arformoterol", "in", "patients", "with", "COPD", ":", "a", "12-week", ",", "multicenter", ",", "randomized", ",", "double", "-", "blind", ",", "double", "-", "dummy", ",", "placebo-", "and", "active", "-", "controlled", "trial", "." ]	[ "CHEMICAL", "GENE-Y" ]
arformoterol	17472819_task2	Sentence: Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Instructions: please extract entity words from the input sentence	[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.	[ "Nebulized", "arformoterol", "in", "patients", "with", "COPD", ":", "a", "12-week", ",", "multicenter", ",", "randomized", ",", "double", "-", "blind", ",", "double", "-", "dummy", ",", "placebo-", "and", "active", "-", "controlled", "trial", "." ]	[ "CHEMICAL", "GENE-Y" ]
chemotherapy is an umlsterm, therapy is an umlsterm, head is an umlsterm, neck cancer is an umlsterm, survival rates is an umlsterm, All is an umlsterm, patients is an umlsterm, stage is an umlsterm, disease is an umlsterm, survival rates is an umlsterm, date is an umlsterm, chemotherapy is an umlsterm, disease is an umlsterm, patients is an umlsterm, disease is an umlsterm, stages is an umlsterm, Patients is an umlsterm, chemotherapy is an umlsterm, surgery is an umlsterm, radiotherapy is an umlsterm, arm is an umlsterm, standard is an umlsterm, treatment is an umlsterm, surgery is an umlsterm, radiotherapy is an umlsterm, arm is an umlsterm, Patients is an umlsterm, tumour is an umlsterm, neck is an umlsterm, disease is an umlsterm, chemotherapy is an umlsterm, patients is an umlsterm, head is an umlsterm, neck cancer is an umlsterm, overall is an umlsterm, survival is an umlsterm, arm is an umlsterm, arm is an umlsterm, Disease - free survival is an umlsterm, arm is an umlsterm, arm is an umlsterm, role is an umlsterm, chemotherapy is an umlsterm, patients is an umlsterm, carcinomas is an umlsterm, oral cavity is an umlsterm, tonsils is an umlsterm, stage is an umlsterm, disease is an umlsterm, surgery is an umlsterm	HNO.90470899.eng.abstr_task0	Sentence: Although induction chemotherapy administered prior to local therapy produces encouraging initial response rates in head and neck cancer , randomized studies have failed to demonstrate an improvement in survival rates . All randomized studies included only patients with advanced stage III and IV disease . In our opinion , this is the main reason for the low rate of complete responses demonstrated in the randomized trials ( maximum 18% ) . Frei et al. estimate that a 40%-50% complete response rate is necessary before improved survival rates are seen . To date , such complete response rates with induction chemotherapy have only been attainable in resectable T2-T3, N0-N2 disease . Therefore , we initiated a prospective randomized trial including only patients with the mentioned disease stages . Patients ( pts ) were randomized to receive either induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy ( arm A , 70 pts ) or standard treatment with surgery and radiotherapy ( arm B , 74 pts ) . Patients were classified according to primary tumour site and neck disease . The observed remission rate after chemotherapy confirmed the primary estimated rate for this subgroup of patients with head and neck cancer ( CR : 43% , PR : 37% , NR : 15% , PD : 5% ) . After a follow-up of 12-96 months overall survival was 58% in arm A and 45% in arm B ( n.s. ) . Disease-free survival in arm A ( 61% ) is statistically significantly better than in arm B ( 43% , P=0.03). Therefore , we recommend further controlled trials to investigate the role of induction chemotherapy in patients with primary resectable carcinomas of the oral cavity and tonsils and stage T2-T3 and N0-N2 disease prior to surgery . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Although induction chemotherapy administered prior to local therapy produces encouraging initial response rates in head and neck cancer , randomized studies have failed to demonstrate an improvement in survival rates . All randomized studies included only patients with advanced stage III and IV disease . In our opinion , this is the main reason for the low rate of complete responses demonstrated in the randomized trials ( maximum 18% ) . Frei et al. estimate that a 40%-50% complete response rate is necessary before improved survival rates are seen . To date , such complete response rates with induction chemotherapy have only been attainable in resectable T2-T3, N0-N2 disease . Therefore , we initiated a prospective randomized trial including only patients with the mentioned disease stages . Patients ( pts ) were randomized to receive either induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy ( arm A , 70 pts ) or standard treatment with surgery and radiotherapy ( arm B , 74 pts ) . Patients were classified according to primary tumour site and neck disease . The observed remission rate after chemotherapy confirmed the primary estimated rate for this subgroup of patients with head and neck cancer ( CR : 43% , PR : 37% , NR : 15% , PD : 5% ) . After a follow-up of 12-96 months overall survival was 58% in arm A and 45% in arm B ( n.s. ) . Disease-free survival in arm A ( 61% ) is statistically significantly better than in arm B ( 43% , P=0.03). Therefore , we recommend further controlled trials to investigate the role of induction chemotherapy in patients with primary resectable carcinomas of the oral cavity and tonsils and stage T2-T3 and N0-N2 disease prior to surgery .	[ "Although", "induction", "chemotherapy", "administered", "prior", "to", "local", "therapy", "produces", "encouraging", "initial", "response", "rates", "in", "head", "and", "neck", "cancer", ",", "randomized", "studies", "have", "failed", "to", "demonstrate", "an", "improvement", "in", "survival", "rates", ".", "All", "randomized", "studies", "included", "only", "patients", "with", "advanced", "stage", "III", "and", "IV", "disease", ".", "In", "our", "opinion", ",", "this", "is", "the", "main", "reason", "for", "the", "low", "rate", "of", "complete", "responses", "demonstrated", "in", "the", "randomized", "trials", "(", "maximum", "18", "%", ")", ".", "Frei", "et", "al", ".", "estimate", "that", "a", "40%-50", "%", "complete", "response", "rate", "is", "necessary", "before", "improved", "survival", "rates", "are", "seen", ".", "To", "date", ",", "such", "complete", "response", "rates", "with", "induction", "chemotherapy", "have", "only", "been", "attainable", "in", "resectable", "T2-T3", ",", "N0-N2", "disease", ".", "Therefore", ",", "we", "initiated", "a", "prospective", "randomized", "trial", "including", "only", "patients", "with", "the", "mentioned", "disease", "stages", ".", "Patients", "(", "pts", ")", "were", "randomized", "to", "receive", "either", "induction", "chemotherapy", "with", "three", "cycles", "of", "carboplatin/5-FU", "prior", "to", "surgery", "and", "radiotherapy", "(", "arm", "A", ",", "70", "pts", ")", "or", "standard", "treatment", "with", "surgery", "and", "radiotherapy", "(", "arm", "B", ",", "74", "pts", ")", ".", "Patients", "were", "classified", "according", "to", "primary", "tumour", "site", "and", "neck", "disease", ".", "The", "observed", "remission", "rate", "after", "chemotherapy", "confirmed", "the", "primary", "estimated", "rate", "for", "this", "subgroup", "of", "patients", "with", "head", "and", "neck", "cancer", "(", "CR", ":", "43", "%", ",", "PR", ":", "37", "%", ",", "NR", ":", "15", "%", ",", "PD", ":", "5", "%", ")", ".", "After", "a", "follow", "-", "up", "of", "12", "-", "96", "months", "overall", "survival", "was", "58", "%", "in", "arm", "A", "and", "45", "%", "in", "arm", "B", "(", "n.s", ".", ")", ".", "Disease", "-", "free", "survival", "in", "arm", "A", "(", "61", "%", ")", "is", "statistically", "significantly", "better", "than", "in", "arm", "B", "(", "43", "%", ",", "P=0.03", ")", ".", "Therefore", ",", "we", "recommend", "further", "controlled", "trials", "to", "investigate", "the", "role", "of", "induction", "chemotherapy", "in", "patients", "with", "primary", "resectable", "carcinomas", "of", "the", "oral", "cavity", "and", "tonsils", "and", "stage", "T2-T3", "and", "N0-N2", "disease", "prior", "to", "surgery", "." ]	[ "umlsterm" ]
chemotherapy is an umlsterm, therapy is an umlsterm, head is an umlsterm, neck cancer is an umlsterm, survival rates is an umlsterm, All is an umlsterm, patients is an umlsterm, stage is an umlsterm, disease is an umlsterm, survival rates is an umlsterm, date is an umlsterm, chemotherapy is an umlsterm, disease is an umlsterm, patients is an umlsterm, disease is an umlsterm, stages is an umlsterm, Patients is an umlsterm, chemotherapy is an umlsterm, surgery is an umlsterm, radiotherapy is an umlsterm, arm is an umlsterm, standard is an umlsterm, treatment is an umlsterm, surgery is an umlsterm, radiotherapy is an umlsterm, arm is an umlsterm, Patients is an umlsterm, tumour is an umlsterm, neck is an umlsterm, disease is an umlsterm, chemotherapy is an umlsterm, patients is an umlsterm, head is an umlsterm, neck cancer is an umlsterm, overall is an umlsterm, survival is an umlsterm, arm is an umlsterm, arm is an umlsterm, Disease - free survival is an umlsterm, arm is an umlsterm, arm is an umlsterm, role is an umlsterm, chemotherapy is an umlsterm, patients is an umlsterm, carcinomas is an umlsterm, oral cavity is an umlsterm, tonsils is an umlsterm, stage is an umlsterm, disease is an umlsterm, surgery is an umlsterm	HNO.90470899.eng.abstr_task1	Sentence: Although induction chemotherapy administered prior to local therapy produces encouraging initial response rates in head and neck cancer , randomized studies have failed to demonstrate an improvement in survival rates . All randomized studies included only patients with advanced stage III and IV disease . In our opinion , this is the main reason for the low rate of complete responses demonstrated in the randomized trials ( maximum 18% ) . Frei et al. estimate that a 40%-50% complete response rate is necessary before improved survival rates are seen . To date , such complete response rates with induction chemotherapy have only been attainable in resectable T2-T3, N0-N2 disease . Therefore , we initiated a prospective randomized trial including only patients with the mentioned disease stages . Patients ( pts ) were randomized to receive either induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy ( arm A , 70 pts ) or standard treatment with surgery and radiotherapy ( arm B , 74 pts ) . Patients were classified according to primary tumour site and neck disease . The observed remission rate after chemotherapy confirmed the primary estimated rate for this subgroup of patients with head and neck cancer ( CR : 43% , PR : 37% , NR : 15% , PD : 5% ) . After a follow-up of 12-96 months overall survival was 58% in arm A and 45% in arm B ( n.s. ) . Disease-free survival in arm A ( 61% ) is statistically significantly better than in arm B ( 43% , P=0.03). Therefore , we recommend further controlled trials to investigate the role of induction chemotherapy in patients with primary resectable carcinomas of the oral cavity and tonsils and stage T2-T3 and N0-N2 disease prior to surgery . Instructions: please typing these entity words according to sentence: chemotherapy, therapy, head, neck cancer, survival rates, All, patients, stage, disease, survival rates, date, chemotherapy, disease, patients, disease, stages, Patients, chemotherapy, surgery, radiotherapy, arm, standard, treatment, surgery, radiotherapy, arm, Patients, tumour, neck, disease, chemotherapy, patients, head, neck cancer, overall, survival, arm, arm, Disease - free survival, arm, arm, role, chemotherapy, patients, carcinomas, oral cavity, tonsils, stage, disease, surgery Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Although induction chemotherapy administered prior to local therapy produces encouraging initial response rates in head and neck cancer , randomized studies have failed to demonstrate an improvement in survival rates . All randomized studies included only patients with advanced stage III and IV disease . In our opinion , this is the main reason for the low rate of complete responses demonstrated in the randomized trials ( maximum 18% ) . Frei et al. estimate that a 40%-50% complete response rate is necessary before improved survival rates are seen . To date , such complete response rates with induction chemotherapy have only been attainable in resectable T2-T3, N0-N2 disease . Therefore , we initiated a prospective randomized trial including only patients with the mentioned disease stages . Patients ( pts ) were randomized to receive either induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy ( arm A , 70 pts ) or standard treatment with surgery and radiotherapy ( arm B , 74 pts ) . Patients were classified according to primary tumour site and neck disease . The observed remission rate after chemotherapy confirmed the primary estimated rate for this subgroup of patients with head and neck cancer ( CR : 43% , PR : 37% , NR : 15% , PD : 5% ) . After a follow-up of 12-96 months overall survival was 58% in arm A and 45% in arm B ( n.s. ) . Disease-free survival in arm A ( 61% ) is statistically significantly better than in arm B ( 43% , P=0.03). Therefore , we recommend further controlled trials to investigate the role of induction chemotherapy in patients with primary resectable carcinomas of the oral cavity and tonsils and stage T2-T3 and N0-N2 disease prior to surgery .	[ "Although", "induction", "chemotherapy", "administered", "prior", "to", "local", "therapy", "produces", "encouraging", "initial", "response", "rates", "in", "head", "and", "neck", "cancer", ",", "randomized", "studies", "have", "failed", "to", "demonstrate", "an", "improvement", "in", "survival", "rates", ".", "All", "randomized", "studies", "included", "only", "patients", "with", "advanced", "stage", "III", "and", "IV", "disease", ".", "In", "our", "opinion", ",", "this", "is", "the", "main", "reason", "for", "the", "low", "rate", "of", "complete", "responses", "demonstrated", "in", "the", "randomized", "trials", "(", "maximum", "18", "%", ")", ".", "Frei", "et", "al", ".", "estimate", "that", "a", "40%-50", "%", "complete", "response", "rate", "is", "necessary", "before", "improved", "survival", "rates", "are", "seen", ".", "To", "date", ",", "such", "complete", "response", "rates", "with", "induction", "chemotherapy", "have", "only", "been", "attainable", "in", "resectable", "T2-T3", ",", "N0-N2", "disease", ".", "Therefore", ",", "we", "initiated", "a", "prospective", "randomized", "trial", "including", "only", "patients", "with", "the", "mentioned", "disease", "stages", ".", "Patients", "(", "pts", ")", "were", "randomized", "to", "receive", "either", "induction", "chemotherapy", "with", "three", "cycles", "of", "carboplatin/5-FU", "prior", "to", "surgery", "and", "radiotherapy", "(", "arm", "A", ",", "70", "pts", ")", "or", "standard", "treatment", "with", "surgery", "and", "radiotherapy", "(", "arm", "B", ",", "74", "pts", ")", ".", "Patients", "were", "classified", "according", "to", "primary", "tumour", "site", "and", "neck", "disease", ".", "The", "observed", "remission", "rate", "after", "chemotherapy", "confirmed", "the", "primary", "estimated", "rate", "for", "this", "subgroup", "of", "patients", "with", "head", "and", "neck", "cancer", "(", "CR", ":", "43", "%", ",", "PR", ":", "37", "%", ",", "NR", ":", "15", "%", ",", "PD", ":", "5", "%", ")", ".", "After", "a", "follow", "-", "up", "of", "12", "-", "96", "months", "overall", "survival", "was", "58", "%", "in", "arm", "A", "and", "45", "%", "in", "arm", "B", "(", "n.s", ".", ")", ".", "Disease", "-", "free", "survival", "in", "arm", "A", "(", "61", "%", ")", "is", "statistically", "significantly", "better", "than", "in", "arm", "B", "(", "43", "%", ",", "P=0.03", ")", ".", "Therefore", ",", "we", "recommend", "further", "controlled", "trials", "to", "investigate", "the", "role", "of", "induction", "chemotherapy", "in", "patients", "with", "primary", "resectable", "carcinomas", "of", "the", "oral", "cavity", "and", "tonsils", "and", "stage", "T2-T3", "and", "N0-N2", "disease", "prior", "to", "surgery", "." ]	[ "umlsterm" ]
chemotherapy, therapy, head, neck cancer, survival rates, All, patients, stage, disease, survival rates, date, chemotherapy, disease, patients, disease, stages, Patients, chemotherapy, surgery, radiotherapy, arm, standard, treatment, surgery, radiotherapy, arm, Patients, tumour, neck, disease, chemotherapy, patients, head, neck cancer, overall, survival, arm, arm, Disease - free survival, arm, arm, role, chemotherapy, patients, carcinomas, oral cavity, tonsils, stage, disease, surgery	HNO.90470899.eng.abstr_task2	Sentence: Although induction chemotherapy administered prior to local therapy produces encouraging initial response rates in head and neck cancer , randomized studies have failed to demonstrate an improvement in survival rates . All randomized studies included only patients with advanced stage III and IV disease . In our opinion , this is the main reason for the low rate of complete responses demonstrated in the randomized trials ( maximum 18% ) . Frei et al. estimate that a 40%-50% complete response rate is necessary before improved survival rates are seen . To date , such complete response rates with induction chemotherapy have only been attainable in resectable T2-T3, N0-N2 disease . Therefore , we initiated a prospective randomized trial including only patients with the mentioned disease stages . Patients ( pts ) were randomized to receive either induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy ( arm A , 70 pts ) or standard treatment with surgery and radiotherapy ( arm B , 74 pts ) . Patients were classified according to primary tumour site and neck disease . The observed remission rate after chemotherapy confirmed the primary estimated rate for this subgroup of patients with head and neck cancer ( CR : 43% , PR : 37% , NR : 15% , PD : 5% ) . After a follow-up of 12-96 months overall survival was 58% in arm A and 45% in arm B ( n.s. ) . Disease-free survival in arm A ( 61% ) is statistically significantly better than in arm B ( 43% , P=0.03). Therefore , we recommend further controlled trials to investigate the role of induction chemotherapy in patients with primary resectable carcinomas of the oral cavity and tonsils and stage T2-T3 and N0-N2 disease prior to surgery . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Although induction chemotherapy administered prior to local therapy produces encouraging initial response rates in head and neck cancer , randomized studies have failed to demonstrate an improvement in survival rates . All randomized studies included only patients with advanced stage III and IV disease . In our opinion , this is the main reason for the low rate of complete responses demonstrated in the randomized trials ( maximum 18% ) . Frei et al. estimate that a 40%-50% complete response rate is necessary before improved survival rates are seen . To date , such complete response rates with induction chemotherapy have only been attainable in resectable T2-T3, N0-N2 disease . Therefore , we initiated a prospective randomized trial including only patients with the mentioned disease stages . Patients ( pts ) were randomized to receive either induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy ( arm A , 70 pts ) or standard treatment with surgery and radiotherapy ( arm B , 74 pts ) . Patients were classified according to primary tumour site and neck disease . The observed remission rate after chemotherapy confirmed the primary estimated rate for this subgroup of patients with head and neck cancer ( CR : 43% , PR : 37% , NR : 15% , PD : 5% ) . After a follow-up of 12-96 months overall survival was 58% in arm A and 45% in arm B ( n.s. ) . Disease-free survival in arm A ( 61% ) is statistically significantly better than in arm B ( 43% , P=0.03). Therefore , we recommend further controlled trials to investigate the role of induction chemotherapy in patients with primary resectable carcinomas of the oral cavity and tonsils and stage T2-T3 and N0-N2 disease prior to surgery .	[ "Although", "induction", "chemotherapy", "administered", "prior", "to", "local", "therapy", "produces", "encouraging", "initial", "response", "rates", "in", "head", "and", "neck", "cancer", ",", "randomized", "studies", "have", "failed", "to", "demonstrate", "an", "improvement", "in", "survival", "rates", ".", "All", "randomized", "studies", "included", "only", "patients", "with", "advanced", "stage", "III", "and", "IV", "disease", ".", "In", "our", "opinion", ",", "this", "is", "the", "main", "reason", "for", "the", "low", "rate", "of", "complete", "responses", "demonstrated", "in", "the", "randomized", "trials", "(", "maximum", "18", "%", ")", ".", "Frei", "et", "al", ".", "estimate", "that", "a", "40%-50", "%", "complete", "response", "rate", "is", "necessary", "before", "improved", "survival", "rates", "are", "seen", ".", "To", "date", ",", "such", "complete", "response", "rates", "with", "induction", "chemotherapy", "have", "only", "been", "attainable", "in", "resectable", "T2-T3", ",", "N0-N2", "disease", ".", "Therefore", ",", "we", "initiated", "a", "prospective", "randomized", "trial", "including", "only", "patients", "with", "the", "mentioned", "disease", "stages", ".", "Patients", "(", "pts", ")", "were", "randomized", "to", "receive", "either", "induction", "chemotherapy", "with", "three", "cycles", "of", "carboplatin/5-FU", "prior", "to", "surgery", "and", "radiotherapy", "(", "arm", "A", ",", "70", "pts", ")", "or", "standard", "treatment", "with", "surgery", "and", "radiotherapy", "(", "arm", "B", ",", "74", "pts", ")", ".", "Patients", "were", "classified", "according", "to", "primary", "tumour", "site", "and", "neck", "disease", ".", "The", "observed", "remission", "rate", "after", "chemotherapy", "confirmed", "the", "primary", "estimated", "rate", "for", "this", "subgroup", "of", "patients", "with", "head", "and", "neck", "cancer", "(", "CR", ":", "43", "%", ",", "PR", ":", "37", "%", ",", "NR", ":", "15", "%", ",", "PD", ":", "5", "%", ")", ".", "After", "a", "follow", "-", "up", "of", "12", "-", "96", "months", "overall", "survival", "was", "58", "%", "in", "arm", "A", "and", "45", "%", "in", "arm", "B", "(", "n.s", ".", ")", ".", "Disease", "-", "free", "survival", "in", "arm", "A", "(", "61", "%", ")", "is", "statistically", "significantly", "better", "than", "in", "arm", "B", "(", "43", "%", ",", "P=0.03", ")", ".", "Therefore", ",", "we", "recommend", "further", "controlled", "trials", "to", "investigate", "the", "role", "of", "induction", "chemotherapy", "in", "patients", "with", "primary", "resectable", "carcinomas", "of", "the", "oral", "cavity", "and", "tonsils", "and", "stage", "T2-T3", "and", "N0-N2", "disease", "prior", "to", "surgery", "." ]	[ "umlsterm" ]
ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, N - methyl - D - aspartate receptor is a GENE-N, Ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, N - methyl - D - aspartate receptors is a GENE-N, GluN1 is a GENE-Y, GluN2B is a GENE-Y, ifenprodil , is a CHEMICAL, zinc is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, amino is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, zinc is a CHEMICAL, GluN1 is a GENE-Y, GluN2A is a GENE-Y, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y	30398_task0	Sentence: Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Ifenprodil is an allosteric inhibitor of GluN1/GluN2B N-methyl-D-aspartate receptors. Despite its widespread use as a prototype for drug development and a subtype-selective tool for physiologic experiments, its precise effect on GluN1/GluN2B gating is yet to be fully understood. Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/GluN2B amino terminal domain dimer by an induced-fit mechanism. To delineate the effect of this unique binding on GluN1/GluN2B receptor gating, we recorded steady-state currents from cell-attached and outside-out patches. At pH 7.9 in cell-attached patches, ifenprodil increased the occupancy of the long-lived shut conformations, thereby reducing the open probability of the receptor with no change in the mean open time. In addition, ifenprodil selectively affected the area of shut time constants, but not the time constants themselves. Kinetic analyses suggested that ifenprodil prevents the transition of the receptor to an open state and increases its dwell time in an intrinsically occurring closed conformation or desensitized state. We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites. Our data also uncover the potential pH-dependent action of ifenprodil on gating. At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Ifenprodil is an allosteric inhibitor of GluN1/GluN2B N-methyl-D-aspartate receptors. Despite its widespread use as a prototype for drug development and a subtype-selective tool for physiologic experiments, its precise effect on GluN1/GluN2B gating is yet to be fully understood. Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/GluN2B amino terminal domain dimer by an induced-fit mechanism. To delineate the effect of this unique binding on GluN1/GluN2B receptor gating, we recorded steady-state currents from cell-attached and outside-out patches. At pH 7.9 in cell-attached patches, ifenprodil increased the occupancy of the long-lived shut conformations, thereby reducing the open probability of the receptor with no change in the mean open time. In addition, ifenprodil selectively affected the area of shut time constants, but not the time constants themselves. Kinetic analyses suggested that ifenprodil prevents the transition of the receptor to an open state and increases its dwell time in an intrinsically occurring closed conformation or desensitized state. We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites. Our data also uncover the potential pH-dependent action of ifenprodil on gating. At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.	[ "Effect", "of", "ifenprodil", "on", "GluN1", "/", "GluN2B", "N", "-", "methyl", "-", "D", "-", "aspartate", "receptor", "gating", ".", "\n", "Ifenprodil", "is", "an", "allosteric", "inhibitor", "of", "GluN1", "/", "GluN2B", "N", "-", "methyl", "-", "D", "-", "aspartate", "receptors", ".", "Despite", "its", "widespread", "use", "as", "a", "prototype", "for", "drug", "development", "and", "a", "subtype", "-", "selective", "tool", "for", "physiologic", "experiments", ",", "its", "precise", "effect", "on", "GluN1", "/", "GluN2B", "gating", "is", "yet", "to", "be", "fully", "understood", ".", "Interestingly", ",", "recent", "crystallographic", "evidence", "identified", "that", "ifenprodil", ",", "unlike", "zinc", ",", "binds", "at", "the", "interface", "of", "the", "GluN1", "/", "GluN2B", "amino", "terminal", "domain", "dimer", "by", "an", "induced", "-", "fit", "mechanism", ".", "To", "delineate", "the", "effect", "of", "this", "unique", "binding", "on", "GluN1", "/", "GluN2B", "receptor", "gating", ",", "we", "recorded", "steady", "-", "state", "currents", "from", "cell", "-", "attached", "and", "outside", "-", "out", "patches", ".", "At", "pH", "7.9", "in", "cell", "-", "attached", "patches", ",", "ifenprodil", "increased", "the", "occupancy", "of", "the", "long", "-", "lived", "shut", "conformations", ",", "thereby", "reducing", "the", "open", "probability", "of", "the", "receptor", "with", "no", "change", "in", "the", "mean", "open", "time", ".", "In", "addition", ",", "ifenprodil", "selectively", "affected", "the", "area", "of", "shut", "time", "constants", ",", "but", "not", "the", "time", "constants", "themselves", ".", "Kinetic", "analyses", "suggested", "that", "ifenprodil", "prevents", "the", "transition", "of", "the", "receptor", "to", "an", "open", "state", "and", "increases", "its", "dwell", "time", "in", "an", "intrinsically", "occurring", "closed", "conformation", "or", "desensitized", "state", ".", "We", "found", "distinct", "differences", "in", "the", "action", "of", "ifenprodil", "at", "GluN1", "/", "GluN2B", "in", "comparison", "with", "previous", "studies", "on", "the", "effect", "of", "zinc", "on", "GluN1", "/", "GluN2A", "gating", ",", "which", "may", "arise", "due", "to", "their", "unique", "binding", "sites", ".", "Our", "data", "also", "uncover", "the", "potential", "pH", "-", "dependent", "action", "of", "ifenprodil", "on", "gating", ".", "At", "a", "low", "pH", "(", "pH", "7.4", ")", ",", "but", "not", "pH", "7.9", ",", "ifenprodil", "reduces", "the", "mean", "open", "time", "of", "GluN1", "/", "GluN2B", "receptors", ",", "which", "may", "be", "responsible", "for", "its", "usefulness", "as", "a", "context", "-", "dependent", "inhibitor", "in", "conditions", "like", "ischemia", "and", "stroke", ",", "when", "the", "pH", "of", "the", "extracellular", "milieu", "becomes", "acidic", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, N - methyl - D - aspartate receptor is a GENE-N, Ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, N - methyl - D - aspartate receptors is a GENE-N, GluN1 is a GENE-Y, GluN2B is a GENE-Y, ifenprodil , is a CHEMICAL, zinc is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, amino is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, zinc is a CHEMICAL, GluN1 is a GENE-Y, GluN2A is a GENE-Y, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y	30398_task1	Sentence: Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Ifenprodil is an allosteric inhibitor of GluN1/GluN2B N-methyl-D-aspartate receptors. Despite its widespread use as a prototype for drug development and a subtype-selective tool for physiologic experiments, its precise effect on GluN1/GluN2B gating is yet to be fully understood. Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/GluN2B amino terminal domain dimer by an induced-fit mechanism. To delineate the effect of this unique binding on GluN1/GluN2B receptor gating, we recorded steady-state currents from cell-attached and outside-out patches. At pH 7.9 in cell-attached patches, ifenprodil increased the occupancy of the long-lived shut conformations, thereby reducing the open probability of the receptor with no change in the mean open time. In addition, ifenprodil selectively affected the area of shut time constants, but not the time constants themselves. Kinetic analyses suggested that ifenprodil prevents the transition of the receptor to an open state and increases its dwell time in an intrinsically occurring closed conformation or desensitized state. We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites. Our data also uncover the potential pH-dependent action of ifenprodil on gating. At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic. Instructions: please typing these entity words according to sentence: ifenprodil, GluN1, GluN2B, N - methyl - D - aspartate receptor, Ifenprodil, GluN1, GluN2B, N - methyl - D - aspartate receptors, GluN1, GluN2B, ifenprodil ,, zinc, GluN1, GluN2B, amino, GluN1, GluN2B, ifenprodil, ifenprodil, ifenprodil, ifenprodil, GluN1, GluN2B, zinc, GluN1, GluN2A, ifenprodil, ifenprodil, GluN1, GluN2B Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Ifenprodil is an allosteric inhibitor of GluN1/GluN2B N-methyl-D-aspartate receptors. Despite its widespread use as a prototype for drug development and a subtype-selective tool for physiologic experiments, its precise effect on GluN1/GluN2B gating is yet to be fully understood. Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/GluN2B amino terminal domain dimer by an induced-fit mechanism. To delineate the effect of this unique binding on GluN1/GluN2B receptor gating, we recorded steady-state currents from cell-attached and outside-out patches. At pH 7.9 in cell-attached patches, ifenprodil increased the occupancy of the long-lived shut conformations, thereby reducing the open probability of the receptor with no change in the mean open time. In addition, ifenprodil selectively affected the area of shut time constants, but not the time constants themselves. Kinetic analyses suggested that ifenprodil prevents the transition of the receptor to an open state and increases its dwell time in an intrinsically occurring closed conformation or desensitized state. We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites. Our data also uncover the potential pH-dependent action of ifenprodil on gating. At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.	[ "Effect", "of", "ifenprodil", "on", "GluN1", "/", "GluN2B", "N", "-", "methyl", "-", "D", "-", "aspartate", "receptor", "gating", ".", "\n", "Ifenprodil", "is", "an", "allosteric", "inhibitor", "of", "GluN1", "/", "GluN2B", "N", "-", "methyl", "-", "D", "-", "aspartate", "receptors", ".", "Despite", "its", "widespread", "use", "as", "a", "prototype", "for", "drug", "development", "and", "a", "subtype", "-", "selective", "tool", "for", "physiologic", "experiments", ",", "its", "precise", "effect", "on", "GluN1", "/", "GluN2B", "gating", "is", "yet", "to", "be", "fully", "understood", ".", "Interestingly", ",", "recent", "crystallographic", "evidence", "identified", "that", "ifenprodil", ",", "unlike", "zinc", ",", "binds", "at", "the", "interface", "of", "the", "GluN1", "/", "GluN2B", "amino", "terminal", "domain", "dimer", "by", "an", "induced", "-", "fit", "mechanism", ".", "To", "delineate", "the", "effect", "of", "this", "unique", "binding", "on", "GluN1", "/", "GluN2B", "receptor", "gating", ",", "we", "recorded", "steady", "-", "state", "currents", "from", "cell", "-", "attached", "and", "outside", "-", "out", "patches", ".", "At", "pH", "7.9", "in", "cell", "-", "attached", "patches", ",", "ifenprodil", "increased", "the", "occupancy", "of", "the", "long", "-", "lived", "shut", "conformations", ",", "thereby", "reducing", "the", "open", "probability", "of", "the", "receptor", "with", "no", "change", "in", "the", "mean", "open", "time", ".", "In", "addition", ",", "ifenprodil", "selectively", "affected", "the", "area", "of", "shut", "time", "constants", ",", "but", "not", "the", "time", "constants", "themselves", ".", "Kinetic", "analyses", "suggested", "that", "ifenprodil", "prevents", "the", "transition", "of", "the", "receptor", "to", "an", "open", "state", "and", "increases", "its", "dwell", "time", "in", "an", "intrinsically", "occurring", "closed", "conformation", "or", "desensitized", "state", ".", "We", "found", "distinct", "differences", "in", "the", "action", "of", "ifenprodil", "at", "GluN1", "/", "GluN2B", "in", "comparison", "with", "previous", "studies", "on", "the", "effect", "of", "zinc", "on", "GluN1", "/", "GluN2A", "gating", ",", "which", "may", "arise", "due", "to", "their", "unique", "binding", "sites", ".", "Our", "data", "also", "uncover", "the", "potential", "pH", "-", "dependent", "action", "of", "ifenprodil", "on", "gating", ".", "At", "a", "low", "pH", "(", "pH", "7.4", ")", ",", "but", "not", "pH", "7.9", ",", "ifenprodil", "reduces", "the", "mean", "open", "time", "of", "GluN1", "/", "GluN2B", "receptors", ",", "which", "may", "be", "responsible", "for", "its", "usefulness", "as", "a", "context", "-", "dependent", "inhibitor", "in", "conditions", "like", "ischemia", "and", "stroke", ",", "when", "the", "pH", "of", "the", "extracellular", "milieu", "becomes", "acidic", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
ifenprodil, GluN1, GluN2B, N - methyl - D - aspartate receptor, Ifenprodil, GluN1, GluN2B, N - methyl - D - aspartate receptors, GluN1, GluN2B, ifenprodil ,, zinc, GluN1, GluN2B, amino, GluN1, GluN2B, ifenprodil, ifenprodil, ifenprodil, ifenprodil, GluN1, GluN2B, zinc, GluN1, GluN2A, ifenprodil, ifenprodil, GluN1, GluN2B	30398_task2	Sentence: Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Ifenprodil is an allosteric inhibitor of GluN1/GluN2B N-methyl-D-aspartate receptors. Despite its widespread use as a prototype for drug development and a subtype-selective tool for physiologic experiments, its precise effect on GluN1/GluN2B gating is yet to be fully understood. Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/GluN2B amino terminal domain dimer by an induced-fit mechanism. To delineate the effect of this unique binding on GluN1/GluN2B receptor gating, we recorded steady-state currents from cell-attached and outside-out patches. At pH 7.9 in cell-attached patches, ifenprodil increased the occupancy of the long-lived shut conformations, thereby reducing the open probability of the receptor with no change in the mean open time. In addition, ifenprodil selectively affected the area of shut time constants, but not the time constants themselves. Kinetic analyses suggested that ifenprodil prevents the transition of the receptor to an open state and increases its dwell time in an intrinsically occurring closed conformation or desensitized state. We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites. Our data also uncover the potential pH-dependent action of ifenprodil on gating. At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Ifenprodil is an allosteric inhibitor of GluN1/GluN2B N-methyl-D-aspartate receptors. Despite its widespread use as a prototype for drug development and a subtype-selective tool for physiologic experiments, its precise effect on GluN1/GluN2B gating is yet to be fully understood. Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/GluN2B amino terminal domain dimer by an induced-fit mechanism. To delineate the effect of this unique binding on GluN1/GluN2B receptor gating, we recorded steady-state currents from cell-attached and outside-out patches. At pH 7.9 in cell-attached patches, ifenprodil increased the occupancy of the long-lived shut conformations, thereby reducing the open probability of the receptor with no change in the mean open time. In addition, ifenprodil selectively affected the area of shut time constants, but not the time constants themselves. Kinetic analyses suggested that ifenprodil prevents the transition of the receptor to an open state and increases its dwell time in an intrinsically occurring closed conformation or desensitized state. We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites. Our data also uncover the potential pH-dependent action of ifenprodil on gating. At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.	[ "Effect", "of", "ifenprodil", "on", "GluN1", "/", "GluN2B", "N", "-", "methyl", "-", "D", "-", "aspartate", "receptor", "gating", ".", "\n", "Ifenprodil", "is", "an", "allosteric", "inhibitor", "of", "GluN1", "/", "GluN2B", "N", "-", "methyl", "-", "D", "-", "aspartate", "receptors", ".", "Despite", "its", "widespread", "use", "as", "a", "prototype", "for", "drug", "development", "and", "a", "subtype", "-", "selective", "tool", "for", "physiologic", "experiments", ",", "its", "precise", "effect", "on", "GluN1", "/", "GluN2B", "gating", "is", "yet", "to", "be", "fully", "understood", ".", "Interestingly", ",", "recent", "crystallographic", "evidence", "identified", "that", "ifenprodil", ",", "unlike", "zinc", ",", "binds", "at", "the", "interface", "of", "the", "GluN1", "/", "GluN2B", "amino", "terminal", "domain", "dimer", "by", "an", "induced", "-", "fit", "mechanism", ".", "To", "delineate", "the", "effect", "of", "this", "unique", "binding", "on", "GluN1", "/", "GluN2B", "receptor", "gating", ",", "we", "recorded", "steady", "-", "state", "currents", "from", "cell", "-", "attached", "and", "outside", "-", "out", "patches", ".", "At", "pH", "7.9", "in", "cell", "-", "attached", "patches", ",", "ifenprodil", "increased", "the", "occupancy", "of", "the", "long", "-", "lived", "shut", "conformations", ",", "thereby", "reducing", "the", "open", "probability", "of", "the", "receptor", "with", "no", "change", "in", "the", "mean", "open", "time", ".", "In", "addition", ",", "ifenprodil", "selectively", "affected", "the", "area", "of", "shut", "time", "constants", ",", "but", "not", "the", "time", "constants", "themselves", ".", "Kinetic", "analyses", "suggested", "that", "ifenprodil", "prevents", "the", "transition", "of", "the", "receptor", "to", "an", "open", "state", "and", "increases", "its", "dwell", "time", "in", "an", "intrinsically", "occurring", "closed", "conformation", "or", "desensitized", "state", ".", "We", "found", "distinct", "differences", "in", "the", "action", "of", "ifenprodil", "at", "GluN1", "/", "GluN2B", "in", "comparison", "with", "previous", "studies", "on", "the", "effect", "of", "zinc", "on", "GluN1", "/", "GluN2A", "gating", ",", "which", "may", "arise", "due", "to", "their", "unique", "binding", "sites", ".", "Our", "data", "also", "uncover", "the", "potential", "pH", "-", "dependent", "action", "of", "ifenprodil", "on", "gating", ".", "At", "a", "low", "pH", "(", "pH", "7.4", ")", ",", "but", "not", "pH", "7.9", ",", "ifenprodil", "reduces", "the", "mean", "open", "time", "of", "GluN1", "/", "GluN2B", "receptors", ",", "which", "may", "be", "responsible", "for", "its", "usefulness", "as", "a", "context", "-", "dependent", "inhibitor", "in", "conditions", "like", "ischemia", "and", "stroke", ",", "when", "the", "pH", "of", "the", "extracellular", "milieu", "becomes", "acidic", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
IgE is a gene	9_task0	Sentence: Association of tumor necrosis factor polymorphisms with asthma and serum total IgE . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: gene	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O" ]	Association of tumor necrosis factor polymorphisms with asthma and serum total IgE .	[ "Association", "of", "tumor", "necrosis", "factor", "polymorphisms", "with", "asthma", "and", "serum", "total", " ", "IgE", "." ]	[ "gene" ]
IgE is a gene	9_task1	Sentence: Association of tumor necrosis factor polymorphisms with asthma and serum total IgE . Instructions: please typing these entity words according to sentence: IgE Options: gene	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O" ]	Association of tumor necrosis factor polymorphisms with asthma and serum total IgE .	[ "Association", "of", "tumor", "necrosis", "factor", "polymorphisms", "with", "asthma", "and", "serum", "total", " ", "IgE", "." ]	[ "gene" ]
IgE	9_task2	Sentence: Association of tumor necrosis factor polymorphisms with asthma and serum total IgE . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O" ]	Association of tumor necrosis factor polymorphisms with asthma and serum total IgE .	[ "Association", "of", "tumor", "necrosis", "factor", "polymorphisms", "with", "asthma", "and", "serum", "total", " ", "IgE", "." ]	[ "gene" ]
vivo protein - DNA interactions is an other_name, human beta - globin locus is a DNA_domain_or_region, erythroid cells is a cell_type, fetal or the adult globin gene program is a (OR other_name other_name)	30930_task0	Sentence: Globin gene switching. In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, DNA_domain_or_region, (OR other_name other_name), other_name	[ "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "O", "O", "B-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "O" ]	Globin gene switching. In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program.	[ "Globin", "gene", "switching", ".", "In", "vivo", "protein", "-", "DNA", "interactions", "of", "the", "human", "beta", "-", "globin", "locus", "in", "erythroid", "cells", "expressing", "the", "fetal", "or", "the", "adult", "globin", "gene", "program", "." ]	[ "(OR other_name other_name)", "other_name", "(AND DNA_domain_or_region DNA_domain_or_region)", "(OR DNA_domain_or_region DNA_domain_or_region)", "cell_type", "", "DNA_family_or_group", "DNA_domain_or_region", "protein_complex", "protein_molecule" ]
vivo protein - DNA interactions is an other_name, human beta - globin locus is a DNA_domain_or_region, erythroid cells is a cell_type, fetal or the adult globin gene program is a (OR other_name other_name)	30930_task1	Sentence: Globin gene switching. In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program. Instructions: please typing these entity words according to sentence: vivo protein - DNA interactions, human beta - globin locus, erythroid cells, fetal or the adult globin gene program Options: cell_type, DNA_domain_or_region, (OR other_name other_name), other_name	[ "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "O", "O", "B-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "O" ]	Globin gene switching. In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program.	[ "Globin", "gene", "switching", ".", "In", "vivo", "protein", "-", "DNA", "interactions", "of", "the", "human", "beta", "-", "globin", "locus", "in", "erythroid", "cells", "expressing", "the", "fetal", "or", "the", "adult", "globin", "gene", "program", "." ]	[ "(OR other_name other_name)", "other_name", "(AND DNA_domain_or_region DNA_domain_or_region)", "(OR DNA_domain_or_region DNA_domain_or_region)", "cell_type", "", "DNA_family_or_group", "DNA_domain_or_region", "protein_complex", "protein_molecule" ]
vivo protein - DNA interactions, human beta - globin locus, erythroid cells, fetal or the adult globin gene program	30930_task2	Sentence: Globin gene switching. In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "O", "O", "B-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "O" ]	Globin gene switching. In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program.	[ "Globin", "gene", "switching", ".", "In", "vivo", "protein", "-", "DNA", "interactions", "of", "the", "human", "beta", "-", "globin", "locus", "in", "erythroid", "cells", "expressing", "the", "fetal", "or", "the", "adult", "globin", "gene", "program", "." ]	[ "(OR other_name other_name)", "other_name", "(AND DNA_domain_or_region DNA_domain_or_region)", "(OR DNA_domain_or_region DNA_domain_or_region)", "cell_type", "", "DNA_family_or_group", "DNA_domain_or_region", "protein_complex", "protein_molecule" ]
inhaled budesonide is a Intervention_Pharmacological, fluticasone propionate is a Intervention_Pharmacological, normal subjects . is a Participant_Condition, nine healthy subjects is a Participant_Condition, 800 micrograms day-1 of budesonide Turbohaler ( B800 ) is a Intervention_Pharmacological, fluticasone Diskhaler 750 micrograms day-1 is a Intervention_Pharmacological, hypothalmic - pituitary adrenal ( HPA ) axis activity is a Outcome_Physical, bone metabolism is a Outcome_Physical, post tetracosactrin serum cortisol is a Outcome_Physical, dose - response effect is a Outcome_Other, difference is a Outcome_Other	82818_task0	Sentence: A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects . 1 . The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices . 2 . A randomised , single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler ( B800 ) for 1 week , followed by 1 week of 1600 micrograms day-1 ( B1600 ) , or fluticasone Diskhaler 750 micrograms day-1 ( F750 ) for 1 week followed by 1 week of 1500 micrograms day-1 ( F1500 ) . There was a 1 week washout between treatments with fluticasone or budesonide . A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects . 3 . Parameters of hypothalmic-pituitary adrenal ( HPA ) axis activity and bone metabolism were measured at baseline ( B0/F0 ) , at the end of each week of treatment and after the 1 week washout ( F0 or B0 ) . 4 . Both fluticasone and budesonide significantly ( P < 0.05 ) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged . No dose-response effect was observed with either drug , and there was no significant difference between treatment with fluticasone or budesonide . 5 . Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin , although the higher doses of both drugs significantly reduced fasting urinary calcium levels . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects . 1 . The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices . 2 . A randomised , single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler ( B800 ) for 1 week , followed by 1 week of 1600 micrograms day-1 ( B1600 ) , or fluticasone Diskhaler 750 micrograms day-1 ( F750 ) for 1 week followed by 1 week of 1500 micrograms day-1 ( F1500 ) . There was a 1 week washout between treatments with fluticasone or budesonide . A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects . 3 . Parameters of hypothalmic-pituitary adrenal ( HPA ) axis activity and bone metabolism were measured at baseline ( B0/F0 ) , at the end of each week of treatment and after the 1 week washout ( F0 or B0 ) . 4 . Both fluticasone and budesonide significantly ( P < 0.05 ) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged . No dose-response effect was observed with either drug , and there was no significant difference between treatment with fluticasone or budesonide . 5 . Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin , although the higher doses of both drugs significantly reduced fasting urinary calcium levels . ( ABSTRACT TRUNCATED AT 250 WORDS )	[ "A", "comparison", "of", "the", "systemic", "bioactivity", "of", "inhaled", "budesonide", "and", "fluticasone", "propionate", "in", "normal", "subjects", ".", "1", ".", "The", "aim", "of", "this", "study", "was", "to", "compare", "the", "systemic", "bioactivity", "of", "low", "and", "high", "doses", "of", "inhaled", "budesonide", "and", "fluticasone", "propionate", "given", "by", "respective", "dry", "powder", "inhaler", "devices", ".", "2", ".", "A", "randomised", ",", "single", "blind", "cross", "-", "over", "design", "was", "used", "in", "nine", "healthy", "subjects", "who", "were", "given", "800", "micrograms", "day-1", "of", "budesonide", "Turbohaler", "(", "B800", ")", "for", "1", "week", ",", "followed", "by", "1", "week", "of", "1600", "micrograms", "day-1", "(", "B1600", ")", ",", "or", "fluticasone", "Diskhaler", "750", "micrograms", "day-1", "(", "F750", ")", "for", "1", "week", "followed", "by", "1", "week", "of", "1500", "micrograms", "day-1", "(", "F1500", ")", ".", "There", "was", "a", "1", "week", "washout", "between", "treatments", "with", "fluticasone", "or", "budesonide", ".", "A", "twice", "daily", "dosing", "regime", "was", "used", "and", "mouth", "-", "rinsing", "was", "employed", "to", "reduce", "gut", "bioavailability", "as", "well", "as", "to", "obviate", "local", "adverse", "effects", ".", "3", ".", "Parameters", "of", "hypothalmic", "-", "pituitary", "adrenal", "(", "HPA", ")", "axis", "activity", "and", "bone", "metabolism", "were", "measured", "at", "baseline", "(", "B0", "/", "F0", ")", ",", "at", "the", "end", "of", "each", "week", "of", "treatment", "and", "after", "the", "1", "week", "washout", "(", "F0", "or", "B0", ")", ".", "4", ".", "Both", "fluticasone", "and", "budesonide", "significantly", "(", "P", "<", "0.05", ")", "attenuated", "the", "post", "tetracosactrin", "serum", "cortisol", "at", "low", "and", "high", "doses", "whilst", "early", "morning", "cortisol", "was", "unchanged", ".", "No", "dose", "-", "response", "effect", "was", "observed", "with", "either", "drug", ",", "and", "there", "was", "no", "significant", "difference", "between", "treatment", "with", "fluticasone", "or", "budesonide", ".", "5", ".", "Neither", "budesonide", "nor", "fluticasone", "produced", "significant", "suppression", "of", "plasma", "osteocalcin", ",", "although", "the", "higher", "doses", "of", "both", "drugs", "significantly", "reduced", "fasting", "urinary", "calcium", "levels", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Outcome_Other" ]
inhaled budesonide is a Intervention_Pharmacological, fluticasone propionate is a Intervention_Pharmacological, normal subjects . is a Participant_Condition, nine healthy subjects is a Participant_Condition, 800 micrograms day-1 of budesonide Turbohaler ( B800 ) is a Intervention_Pharmacological, fluticasone Diskhaler 750 micrograms day-1 is a Intervention_Pharmacological, hypothalmic - pituitary adrenal ( HPA ) axis activity is a Outcome_Physical, bone metabolism is a Outcome_Physical, post tetracosactrin serum cortisol is a Outcome_Physical, dose - response effect is a Outcome_Other, difference is a Outcome_Other	82818_task1	Sentence: A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects . 1 . The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices . 2 . A randomised , single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler ( B800 ) for 1 week , followed by 1 week of 1600 micrograms day-1 ( B1600 ) , or fluticasone Diskhaler 750 micrograms day-1 ( F750 ) for 1 week followed by 1 week of 1500 micrograms day-1 ( F1500 ) . There was a 1 week washout between treatments with fluticasone or budesonide . A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects . 3 . Parameters of hypothalmic-pituitary adrenal ( HPA ) axis activity and bone metabolism were measured at baseline ( B0/F0 ) , at the end of each week of treatment and after the 1 week washout ( F0 or B0 ) . 4 . Both fluticasone and budesonide significantly ( P < 0.05 ) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged . No dose-response effect was observed with either drug , and there was no significant difference between treatment with fluticasone or budesonide . 5 . Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin , although the higher doses of both drugs significantly reduced fasting urinary calcium levels . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please typing these entity words according to sentence: inhaled budesonide, fluticasone propionate, normal subjects ., nine healthy subjects, 800 micrograms day-1 of budesonide Turbohaler ( B800 ), fluticasone Diskhaler 750 micrograms day-1, hypothalmic - pituitary adrenal ( HPA ) axis activity, bone metabolism, post tetracosactrin serum cortisol, dose - response effect, difference Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects . 1 . The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices . 2 . A randomised , single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler ( B800 ) for 1 week , followed by 1 week of 1600 micrograms day-1 ( B1600 ) , or fluticasone Diskhaler 750 micrograms day-1 ( F750 ) for 1 week followed by 1 week of 1500 micrograms day-1 ( F1500 ) . There was a 1 week washout between treatments with fluticasone or budesonide . A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects . 3 . Parameters of hypothalmic-pituitary adrenal ( HPA ) axis activity and bone metabolism were measured at baseline ( B0/F0 ) , at the end of each week of treatment and after the 1 week washout ( F0 or B0 ) . 4 . Both fluticasone and budesonide significantly ( P < 0.05 ) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged . No dose-response effect was observed with either drug , and there was no significant difference between treatment with fluticasone or budesonide . 5 . Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin , although the higher doses of both drugs significantly reduced fasting urinary calcium levels . ( ABSTRACT TRUNCATED AT 250 WORDS )	[ "A", "comparison", "of", "the", "systemic", "bioactivity", "of", "inhaled", "budesonide", "and", "fluticasone", "propionate", "in", "normal", "subjects", ".", "1", ".", "The", "aim", "of", "this", "study", "was", "to", "compare", "the", "systemic", "bioactivity", "of", "low", "and", "high", "doses", "of", "inhaled", "budesonide", "and", "fluticasone", "propionate", "given", "by", "respective", "dry", "powder", "inhaler", "devices", ".", "2", ".", "A", "randomised", ",", "single", "blind", "cross", "-", "over", "design", "was", "used", "in", "nine", "healthy", "subjects", "who", "were", "given", "800", "micrograms", "day-1", "of", "budesonide", "Turbohaler", "(", "B800", ")", "for", "1", "week", ",", "followed", "by", "1", "week", "of", "1600", "micrograms", "day-1", "(", "B1600", ")", ",", "or", "fluticasone", "Diskhaler", "750", "micrograms", "day-1", "(", "F750", ")", "for", "1", "week", "followed", "by", "1", "week", "of", "1500", "micrograms", "day-1", "(", "F1500", ")", ".", "There", "was", "a", "1", "week", "washout", "between", "treatments", "with", "fluticasone", "or", "budesonide", ".", "A", "twice", "daily", "dosing", "regime", "was", "used", "and", "mouth", "-", "rinsing", "was", "employed", "to", "reduce", "gut", "bioavailability", "as", "well", "as", "to", "obviate", "local", "adverse", "effects", ".", "3", ".", "Parameters", "of", "hypothalmic", "-", "pituitary", "adrenal", "(", "HPA", ")", "axis", "activity", "and", "bone", "metabolism", "were", "measured", "at", "baseline", "(", "B0", "/", "F0", ")", ",", "at", "the", "end", "of", "each", "week", "of", "treatment", "and", "after", "the", "1", "week", "washout", "(", "F0", "or", "B0", ")", ".", "4", ".", "Both", "fluticasone", "and", "budesonide", "significantly", "(", "P", "<", "0.05", ")", "attenuated", "the", "post", "tetracosactrin", "serum", "cortisol", "at", "low", "and", "high", "doses", "whilst", "early", "morning", "cortisol", "was", "unchanged", ".", "No", "dose", "-", "response", "effect", "was", "observed", "with", "either", "drug", ",", "and", "there", "was", "no", "significant", "difference", "between", "treatment", "with", "fluticasone", "or", "budesonide", ".", "5", ".", "Neither", "budesonide", "nor", "fluticasone", "produced", "significant", "suppression", "of", "plasma", "osteocalcin", ",", "although", "the", "higher", "doses", "of", "both", "drugs", "significantly", "reduced", "fasting", "urinary", "calcium", "levels", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Outcome_Other" ]
inhaled budesonide, fluticasone propionate, normal subjects ., nine healthy subjects, 800 micrograms day-1 of budesonide Turbohaler ( B800 ), fluticasone Diskhaler 750 micrograms day-1, hypothalmic - pituitary adrenal ( HPA ) axis activity, bone metabolism, post tetracosactrin serum cortisol, dose - response effect, difference	82818_task2	Sentence: A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects . 1 . The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices . 2 . A randomised , single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler ( B800 ) for 1 week , followed by 1 week of 1600 micrograms day-1 ( B1600 ) , or fluticasone Diskhaler 750 micrograms day-1 ( F750 ) for 1 week followed by 1 week of 1500 micrograms day-1 ( F1500 ) . There was a 1 week washout between treatments with fluticasone or budesonide . A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects . 3 . Parameters of hypothalmic-pituitary adrenal ( HPA ) axis activity and bone metabolism were measured at baseline ( B0/F0 ) , at the end of each week of treatment and after the 1 week washout ( F0 or B0 ) . 4 . Both fluticasone and budesonide significantly ( P < 0.05 ) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged . No dose-response effect was observed with either drug , and there was no significant difference between treatment with fluticasone or budesonide . 5 . Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin , although the higher doses of both drugs significantly reduced fasting urinary calcium levels . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects . 1 . The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices . 2 . A randomised , single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler ( B800 ) for 1 week , followed by 1 week of 1600 micrograms day-1 ( B1600 ) , or fluticasone Diskhaler 750 micrograms day-1 ( F750 ) for 1 week followed by 1 week of 1500 micrograms day-1 ( F1500 ) . There was a 1 week washout between treatments with fluticasone or budesonide . A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects . 3 . Parameters of hypothalmic-pituitary adrenal ( HPA ) axis activity and bone metabolism were measured at baseline ( B0/F0 ) , at the end of each week of treatment and after the 1 week washout ( F0 or B0 ) . 4 . Both fluticasone and budesonide significantly ( P < 0.05 ) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged . No dose-response effect was observed with either drug , and there was no significant difference between treatment with fluticasone or budesonide . 5 . Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin , although the higher doses of both drugs significantly reduced fasting urinary calcium levels . ( ABSTRACT TRUNCATED AT 250 WORDS )	[ "A", "comparison", "of", "the", "systemic", "bioactivity", "of", "inhaled", "budesonide", "and", "fluticasone", "propionate", "in", "normal", "subjects", ".", "1", ".", "The", "aim", "of", "this", "study", "was", "to", "compare", "the", "systemic", "bioactivity", "of", "low", "and", "high", "doses", "of", "inhaled", "budesonide", "and", "fluticasone", "propionate", "given", "by", "respective", "dry", "powder", "inhaler", "devices", ".", "2", ".", "A", "randomised", ",", "single", "blind", "cross", "-", "over", "design", "was", "used", "in", "nine", "healthy", "subjects", "who", "were", "given", "800", "micrograms", "day-1", "of", "budesonide", "Turbohaler", "(", "B800", ")", "for", "1", "week", ",", "followed", "by", "1", "week", "of", "1600", "micrograms", "day-1", "(", "B1600", ")", ",", "or", "fluticasone", "Diskhaler", "750", "micrograms", "day-1", "(", "F750", ")", "for", "1", "week", "followed", "by", "1", "week", "of", "1500", "micrograms", "day-1", "(", "F1500", ")", ".", "There", "was", "a", "1", "week", "washout", "between", "treatments", "with", "fluticasone", "or", "budesonide", ".", "A", "twice", "daily", "dosing", "regime", "was", "used", "and", "mouth", "-", "rinsing", "was", "employed", "to", "reduce", "gut", "bioavailability", "as", "well", "as", "to", "obviate", "local", "adverse", "effects", ".", "3", ".", "Parameters", "of", "hypothalmic", "-", "pituitary", "adrenal", "(", "HPA", ")", "axis", "activity", "and", "bone", "metabolism", "were", "measured", "at", "baseline", "(", "B0", "/", "F0", ")", ",", "at", "the", "end", "of", "each", "week", "of", "treatment", "and", "after", "the", "1", "week", "washout", "(", "F0", "or", "B0", ")", ".", "4", ".", "Both", "fluticasone", "and", "budesonide", "significantly", "(", "P", "<", "0.05", ")", "attenuated", "the", "post", "tetracosactrin", "serum", "cortisol", "at", "low", "and", "high", "doses", "whilst", "early", "morning", "cortisol", "was", "unchanged", ".", "No", "dose", "-", "response", "effect", "was", "observed", "with", "either", "drug", ",", "and", "there", "was", "no", "significant", "difference", "between", "treatment", "with", "fluticasone", "or", "budesonide", ".", "5", ".", "Neither", "budesonide", "nor", "fluticasone", "produced", "significant", "suppression", "of", "plasma", "osteocalcin", ",", "although", "the", "higher", "doses", "of", "both", "drugs", "significantly", "reduced", "fasting", "urinary", "calcium", "levels", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Outcome_Other" ]
Latent Membrane Protein 1 is a Protein, Akt is a Protein, Stat3 is a Protein, Latent membrane protein 1 is a Protein, LMP1 is a Protein, LMP1 is a Protein, Akt is a Protein, Stat3 is a Protein, LMP1 is a Protein, IL4 is a Protein, Stat6 is a Protein, Stat3 is a Protein, Akt is a Protein, Stat3 is a Protein, Latent membrane protein 1 is a Protein, LMP1 is a Protein, LMP1 is a Protein, Akt is a Protein, Stat3 is a Protein, Stat3 is a Protein, Akt is a Protein, LMP1 is a Protein	38_task0	Sentence: EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B Cell Lymphomas Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated cell cycle markers, and inhibitors of Akt, NFkappaB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas. Author Summary Epstein-Barr virus (EBV) is linked to the development of multiple cancers, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is expressed in many EBV-associated cancers and is responsible for most of the altered cellular growth properties that are induced by EBV infection. This study reveals that LMP1 induces lymphomas in B-1a lymphocytes, a cell type that is susceptible to transformation in aged mice. The lymphomas require Akt, NFkappaB, and Stat3 signaling for enhanced growth and survival. The activation of the Stat3, Akt, and NFkappaB signaling pathways likely underlies the ability of LMP1 to promote malignant transformation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B Cell Lymphomas Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated cell cycle markers, and inhibitors of Akt, NFkappaB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas. Author Summary Epstein-Barr virus (EBV) is linked to the development of multiple cancers, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is expressed in many EBV-associated cancers and is responsible for most of the altered cellular growth properties that are induced by EBV infection. This study reveals that LMP1 induces lymphomas in B-1a lymphocytes, a cell type that is susceptible to transformation in aged mice. The lymphomas require Akt, NFkappaB, and Stat3 signaling for enhanced growth and survival. The activation of the Stat3, Akt, and NFkappaB signaling pathways likely underlies the ability of LMP1 to promote malignant transformation.	[ "EBV", "Latent", "Membrane", "Protein", "1", "Activates", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "in", "B", "Cell", "Lymphomas", "\n", "Latent", "membrane", "protein", "1", "(", "LMP1", ")", "is", "the", "major", "oncoprotein", "of", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", ".", "In", "transgenic", "mice", ",", "LMP1", "promotes", "increased", "lymphoma", "development", "by", "12", "mo", "of", "age", ".", "This", "study", "reveals", "that", "lymphoma", "develops", "in", "B-1a", "lymphocytes", ",", "a", "population", "that", "is", "associated", "with", "transformation", "in", "older", "mice", ".", "The", "lymphoma", "cells", "have", "deregulated", "cell", "cycle", "markers", ",", "and", "inhibitors", "of", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "block", "the", "enhanced", "viability", "of", "LMP1", "transgenic", "lymphocytes", "and", "lymphoma", "cells", "in", "vitro", ".", "Lymphoma", "cells", "are", "independent", "of", "IL4", "/", "Stat6", "signaling", "for", "survival", "and", "proliferation", ",", "but", "have", "constitutively", "activated", "Stat3", "signaling", ".", "These", "same", "targets", "are", "also", "deregulated", "in", "wild", "-", "type", "B-1a", "lymphomas", "that", "arise", "spontaneously", "through", "age", "predisposition", ".", "These", "results", "suggest", "that", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "pathways", "may", "serve", "as", "effective", "targets", "in", "the", "treatment", "of", "EBV", "-", "associated", "B", "cell", "lymphomas", ".", "\n", "Author", "Summary", "\n", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "is", "linked", "to", "the", "development", "of", "multiple", "cancers", ",", "including", "post", "-", "transplant", "lymphoma", ",", "Hodgkin", "disease", ",", "and", "nasopharyngeal", "carcinoma", ".", "Latent", "membrane", "protein", "1", "(", "LMP1", ")", "is", "expressed", "in", "many", "EBV", "-", "associated", "cancers", "and", "is", "responsible", "for", "most", "of", "the", "altered", "cellular", "growth", "properties", "that", "are", "induced", "by", "EBV", "infection", ".", "This", "study", "reveals", "that", "LMP1", "induces", "lymphomas", "in", "B-1a", "lymphocytes", ",", "a", "cell", "type", "that", "is", "susceptible", "to", "transformation", "in", "aged", "mice", ".", "The", "lymphomas", "require", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "signaling", "for", "enhanced", "growth", "and", "survival", ".", "The", "activation", "of", "the", "Stat3", ",", "Akt", ",", "and", "NFkappaB", "signaling", "pathways", "likely", "underlies", "the", "ability", "of", "LMP1", "to", "promote", "malignant", "transformation", ".", "\n" ]	[ "Protein" ]
Latent Membrane Protein 1 is a Protein, Akt is a Protein, Stat3 is a Protein, Latent membrane protein 1 is a Protein, LMP1 is a Protein, LMP1 is a Protein, Akt is a Protein, Stat3 is a Protein, LMP1 is a Protein, IL4 is a Protein, Stat6 is a Protein, Stat3 is a Protein, Akt is a Protein, Stat3 is a Protein, Latent membrane protein 1 is a Protein, LMP1 is a Protein, LMP1 is a Protein, Akt is a Protein, Stat3 is a Protein, Stat3 is a Protein, Akt is a Protein, LMP1 is a Protein	38_task1	Sentence: EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B Cell Lymphomas Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated cell cycle markers, and inhibitors of Akt, NFkappaB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas. Author Summary Epstein-Barr virus (EBV) is linked to the development of multiple cancers, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is expressed in many EBV-associated cancers and is responsible for most of the altered cellular growth properties that are induced by EBV infection. This study reveals that LMP1 induces lymphomas in B-1a lymphocytes, a cell type that is susceptible to transformation in aged mice. The lymphomas require Akt, NFkappaB, and Stat3 signaling for enhanced growth and survival. The activation of the Stat3, Akt, and NFkappaB signaling pathways likely underlies the ability of LMP1 to promote malignant transformation. Instructions: please typing these entity words according to sentence: Latent Membrane Protein 1, Akt, Stat3, Latent membrane protein 1, LMP1, LMP1, Akt, Stat3, LMP1, IL4, Stat6, Stat3, Akt, Stat3, Latent membrane protein 1, LMP1, LMP1, Akt, Stat3, Stat3, Akt, LMP1 Options: Protein	[ "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B Cell Lymphomas Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated cell cycle markers, and inhibitors of Akt, NFkappaB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas. Author Summary Epstein-Barr virus (EBV) is linked to the development of multiple cancers, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is expressed in many EBV-associated cancers and is responsible for most of the altered cellular growth properties that are induced by EBV infection. This study reveals that LMP1 induces lymphomas in B-1a lymphocytes, a cell type that is susceptible to transformation in aged mice. The lymphomas require Akt, NFkappaB, and Stat3 signaling for enhanced growth and survival. The activation of the Stat3, Akt, and NFkappaB signaling pathways likely underlies the ability of LMP1 to promote malignant transformation.	[ "EBV", "Latent", "Membrane", "Protein", "1", "Activates", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "in", "B", "Cell", "Lymphomas", "\n", "Latent", "membrane", "protein", "1", "(", "LMP1", ")", "is", "the", "major", "oncoprotein", "of", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", ".", "In", "transgenic", "mice", ",", "LMP1", "promotes", "increased", "lymphoma", "development", "by", "12", "mo", "of", "age", ".", "This", "study", "reveals", "that", "lymphoma", "develops", "in", "B-1a", "lymphocytes", ",", "a", "population", "that", "is", "associated", "with", "transformation", "in", "older", "mice", ".", "The", "lymphoma", "cells", "have", "deregulated", "cell", "cycle", "markers", ",", "and", "inhibitors", "of", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "block", "the", "enhanced", "viability", "of", "LMP1", "transgenic", "lymphocytes", "and", "lymphoma", "cells", "in", "vitro", ".", "Lymphoma", "cells", "are", "independent", "of", "IL4", "/", "Stat6", "signaling", "for", "survival", "and", "proliferation", ",", "but", "have", "constitutively", "activated", "Stat3", "signaling", ".", "These", "same", "targets", "are", "also", "deregulated", "in", "wild", "-", "type", "B-1a", "lymphomas", "that", "arise", "spontaneously", "through", "age", "predisposition", ".", "These", "results", "suggest", "that", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "pathways", "may", "serve", "as", "effective", "targets", "in", "the", "treatment", "of", "EBV", "-", "associated", "B", "cell", "lymphomas", ".", "\n", "Author", "Summary", "\n", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "is", "linked", "to", "the", "development", "of", "multiple", "cancers", ",", "including", "post", "-", "transplant", "lymphoma", ",", "Hodgkin", "disease", ",", "and", "nasopharyngeal", "carcinoma", ".", "Latent", "membrane", "protein", "1", "(", "LMP1", ")", "is", "expressed", "in", "many", "EBV", "-", "associated", "cancers", "and", "is", "responsible", "for", "most", "of", "the", "altered", "cellular", "growth", "properties", "that", "are", "induced", "by", "EBV", "infection", ".", "This", "study", "reveals", "that", "LMP1", "induces", "lymphomas", "in", "B-1a", "lymphocytes", ",", "a", "cell", "type", "that", "is", "susceptible", "to", "transformation", "in", "aged", "mice", ".", "The", "lymphomas", "require", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "signaling", "for", "enhanced", "growth", "and", "survival", ".", "The", "activation", "of", "the", "Stat3", ",", "Akt", ",", "and", "NFkappaB", "signaling", "pathways", "likely", "underlies", "the", "ability", "of", "LMP1", "to", "promote", "malignant", "transformation", ".", "\n" ]	[ "Protein" ]
Latent Membrane Protein 1, Akt, Stat3, Latent membrane protein 1, LMP1, LMP1, Akt, Stat3, LMP1, IL4, Stat6, Stat3, Akt, Stat3, Latent membrane protein 1, LMP1, LMP1, Akt, Stat3, Stat3, Akt, LMP1	38_task2	Sentence: EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B Cell Lymphomas Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated cell cycle markers, and inhibitors of Akt, NFkappaB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas. Author Summary Epstein-Barr virus (EBV) is linked to the development of multiple cancers, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is expressed in many EBV-associated cancers and is responsible for most of the altered cellular growth properties that are induced by EBV infection. This study reveals that LMP1 induces lymphomas in B-1a lymphocytes, a cell type that is susceptible to transformation in aged mice. The lymphomas require Akt, NFkappaB, and Stat3 signaling for enhanced growth and survival. The activation of the Stat3, Akt, and NFkappaB signaling pathways likely underlies the ability of LMP1 to promote malignant transformation. Instructions: please extract entity words from the input sentence	[ "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B Cell Lymphomas Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated cell cycle markers, and inhibitors of Akt, NFkappaB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas. Author Summary Epstein-Barr virus (EBV) is linked to the development of multiple cancers, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is expressed in many EBV-associated cancers and is responsible for most of the altered cellular growth properties that are induced by EBV infection. This study reveals that LMP1 induces lymphomas in B-1a lymphocytes, a cell type that is susceptible to transformation in aged mice. The lymphomas require Akt, NFkappaB, and Stat3 signaling for enhanced growth and survival. The activation of the Stat3, Akt, and NFkappaB signaling pathways likely underlies the ability of LMP1 to promote malignant transformation.	[ "EBV", "Latent", "Membrane", "Protein", "1", "Activates", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "in", "B", "Cell", "Lymphomas", "\n", "Latent", "membrane", "protein", "1", "(", "LMP1", ")", "is", "the", "major", "oncoprotein", "of", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", ".", "In", "transgenic", "mice", ",", "LMP1", "promotes", "increased", "lymphoma", "development", "by", "12", "mo", "of", "age", ".", "This", "study", "reveals", "that", "lymphoma", "develops", "in", "B-1a", "lymphocytes", ",", "a", "population", "that", "is", "associated", "with", "transformation", "in", "older", "mice", ".", "The", "lymphoma", "cells", "have", "deregulated", "cell", "cycle", "markers", ",", "and", "inhibitors", "of", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "block", "the", "enhanced", "viability", "of", "LMP1", "transgenic", "lymphocytes", "and", "lymphoma", "cells", "in", "vitro", ".", "Lymphoma", "cells", "are", "independent", "of", "IL4", "/", "Stat6", "signaling", "for", "survival", "and", "proliferation", ",", "but", "have", "constitutively", "activated", "Stat3", "signaling", ".", "These", "same", "targets", "are", "also", "deregulated", "in", "wild", "-", "type", "B-1a", "lymphomas", "that", "arise", "spontaneously", "through", "age", "predisposition", ".", "These", "results", "suggest", "that", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "pathways", "may", "serve", "as", "effective", "targets", "in", "the", "treatment", "of", "EBV", "-", "associated", "B", "cell", "lymphomas", ".", "\n", "Author", "Summary", "\n", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "is", "linked", "to", "the", "development", "of", "multiple", "cancers", ",", "including", "post", "-", "transplant", "lymphoma", ",", "Hodgkin", "disease", ",", "and", "nasopharyngeal", "carcinoma", ".", "Latent", "membrane", "protein", "1", "(", "LMP1", ")", "is", "expressed", "in", "many", "EBV", "-", "associated", "cancers", "and", "is", "responsible", "for", "most", "of", "the", "altered", "cellular", "growth", "properties", "that", "are", "induced", "by", "EBV", "infection", ".", "This", "study", "reveals", "that", "LMP1", "induces", "lymphomas", "in", "B-1a", "lymphocytes", ",", "a", "cell", "type", "that", "is", "susceptible", "to", "transformation", "in", "aged", "mice", ".", "The", "lymphomas", "require", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "signaling", "for", "enhanced", "growth", "and", "survival", ".", "The", "activation", "of", "the", "Stat3", ",", "Akt", ",", "and", "NFkappaB", "signaling", "pathways", "likely", "underlies", "the", "ability", "of", "LMP1", "to", "promote", "malignant", "transformation", ".", "\n" ]	[ "Protein" ]
Patienten is an umlsterm, Sekretion is an umlsterm, Kortisol is an umlsterm, ACTH is an umlsterm, Adrenalektomie is an umlsterm	DerAnaesthesist.70460303.ger.abstr_task0	Sentence: An 10 Patienten wurde die spontane und stimulierte ( Corticotropin-Releasing-Hormon : CRH ) Sekretion von Kortisol ( Cs ) und ACTH im Rahmen der unilateralen Adrenalektomie beim Nierenzellkarzinom untersucht . Ziel der Studie war klinische oder laborchemische Zeichen , einer NNR-Insuffizienz auszuschliessen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	An 10 Patienten wurde die spontane und stimulierte ( Corticotropin-Releasing-Hormon : CRH ) Sekretion von Kortisol ( Cs ) und ACTH im Rahmen der unilateralen Adrenalektomie beim Nierenzellkarzinom untersucht . Ziel der Studie war klinische oder laborchemische Zeichen , einer NNR-Insuffizienz auszuschliessen .	[ "An", "10", "Patienten", "wurde", "die", "spontane", "und", "stimulierte", "(", "Corticotropin", "-", "Releasing", "-", "Hormon", ":", "CRH", ")", "Sekretion", "von", "Kortisol", "(", "Cs", ")", "und", "ACTH", "im", "Rahmen", "der", "unilateralen", "Adrenalektomie", "beim", "Nierenzellkarzinom", "untersucht", ".", "Ziel", "der", "Studie", "war", "klinische", "oder", "laborchemische", "Zeichen", ",", "einer", "NNR", "-", "Insuffizienz", "auszuschliessen", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Sekretion is an umlsterm, Kortisol is an umlsterm, ACTH is an umlsterm, Adrenalektomie is an umlsterm	DerAnaesthesist.70460303.ger.abstr_task1	Sentence: An 10 Patienten wurde die spontane und stimulierte ( Corticotropin-Releasing-Hormon : CRH ) Sekretion von Kortisol ( Cs ) und ACTH im Rahmen der unilateralen Adrenalektomie beim Nierenzellkarzinom untersucht . Ziel der Studie war klinische oder laborchemische Zeichen , einer NNR-Insuffizienz auszuschliessen . Instructions: please typing these entity words according to sentence: Patienten, Sekretion, Kortisol, ACTH, Adrenalektomie Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	An 10 Patienten wurde die spontane und stimulierte ( Corticotropin-Releasing-Hormon : CRH ) Sekretion von Kortisol ( Cs ) und ACTH im Rahmen der unilateralen Adrenalektomie beim Nierenzellkarzinom untersucht . Ziel der Studie war klinische oder laborchemische Zeichen , einer NNR-Insuffizienz auszuschliessen .	[ "An", "10", "Patienten", "wurde", "die", "spontane", "und", "stimulierte", "(", "Corticotropin", "-", "Releasing", "-", "Hormon", ":", "CRH", ")", "Sekretion", "von", "Kortisol", "(", "Cs", ")", "und", "ACTH", "im", "Rahmen", "der", "unilateralen", "Adrenalektomie", "beim", "Nierenzellkarzinom", "untersucht", ".", "Ziel", "der", "Studie", "war", "klinische", "oder", "laborchemische", "Zeichen", ",", "einer", "NNR", "-", "Insuffizienz", "auszuschliessen", "." ]	[ "umlsterm" ]
Patienten, Sekretion, Kortisol, ACTH, Adrenalektomie	DerAnaesthesist.70460303.ger.abstr_task2	Sentence: An 10 Patienten wurde die spontane und stimulierte ( Corticotropin-Releasing-Hormon : CRH ) Sekretion von Kortisol ( Cs ) und ACTH im Rahmen der unilateralen Adrenalektomie beim Nierenzellkarzinom untersucht . Ziel der Studie war klinische oder laborchemische Zeichen , einer NNR-Insuffizienz auszuschliessen . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	An 10 Patienten wurde die spontane und stimulierte ( Corticotropin-Releasing-Hormon : CRH ) Sekretion von Kortisol ( Cs ) und ACTH im Rahmen der unilateralen Adrenalektomie beim Nierenzellkarzinom untersucht . Ziel der Studie war klinische oder laborchemische Zeichen , einer NNR-Insuffizienz auszuschliessen .	[ "An", "10", "Patienten", "wurde", "die", "spontane", "und", "stimulierte", "(", "Corticotropin", "-", "Releasing", "-", "Hormon", ":", "CRH", ")", "Sekretion", "von", "Kortisol", "(", "Cs", ")", "und", "ACTH", "im", "Rahmen", "der", "unilateralen", "Adrenalektomie", "beim", "Nierenzellkarzinom", "untersucht", ".", "Ziel", "der", "Studie", "war", "klinische", "oder", "laborchemische", "Zeichen", ",", "einer", "NNR", "-", "Insuffizienz", "auszuschliessen", "." ]	[ "umlsterm" ]
alpha1H is a GENE-Y, T - type Ca2 + channel is a GENE-N	9670923_task0	Sentence: Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N	[ "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O" ]	Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family.	[ "Cloning", "and", "characterization", "of", "alpha1H", "from", "human", "heart", ",", "a", "member", "of", "the", "T", "-", "type", "Ca2", "+", "channel", "gene", "family", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
alpha1H is a GENE-Y, T - type Ca2 + channel is a GENE-N	9670923_task1	Sentence: Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family. Instructions: please typing these entity words according to sentence: alpha1H, T - type Ca2 + channel Options: GENE-Y, GENE-N	[ "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O" ]	Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family.	[ "Cloning", "and", "characterization", "of", "alpha1H", "from", "human", "heart", ",", "a", "member", "of", "the", "T", "-", "type", "Ca2", "+", "channel", "gene", "family", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
alpha1H, T - type Ca2 + channel	9670923_task2	Sentence: Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O" ]	Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family.	[ "Cloning", "and", "characterization", "of", "alpha1H", "from", "human", "heart", ",", "a", "member", "of", "the", "T", "-", "type", "Ca2", "+", "channel", "gene", "family", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Serotonin transporter is a GENE-Y, 5-HTTLPR is a GENE-Y, [ 3H]paroxetine is a CHEMICAL	10980326_task0	Sentence: Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.	[ "Serotonin", "transporter", "gene", "regulatory", "region", "polymorphism", "(", "5-HTTLPR", ")", ",", "[", "3H]paroxetine", "binding", "in", "healthy", "control", "subjects", "and", "alcohol", "-", "dependent", "patients", "and", "their", "relationships", "to", "impulsivity", "." ]	[ "GENE-Y", "CHEMICAL" ]
Serotonin transporter is a GENE-Y, 5-HTTLPR is a GENE-Y, [ 3H]paroxetine is a CHEMICAL	10980326_task1	Sentence: Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity. Instructions: please typing these entity words according to sentence: Serotonin transporter, 5-HTTLPR, [ 3H]paroxetine Options: GENE-Y, CHEMICAL	[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.	[ "Serotonin", "transporter", "gene", "regulatory", "region", "polymorphism", "(", "5-HTTLPR", ")", ",", "[", "3H]paroxetine", "binding", "in", "healthy", "control", "subjects", "and", "alcohol", "-", "dependent", "patients", "and", "their", "relationships", "to", "impulsivity", "." ]	[ "GENE-Y", "CHEMICAL" ]
Serotonin transporter, 5-HTTLPR, [ 3H]paroxetine	10980326_task2	Sentence: Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity. Instructions: please extract entity words from the input sentence	[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.	[ "Serotonin", "transporter", "gene", "regulatory", "region", "polymorphism", "(", "5-HTTLPR", ")", ",", "[", "3H]paroxetine", "binding", "in", "healthy", "control", "subjects", "and", "alcohol", "-", "dependent", "patients", "and", "their", "relationships", "to", "impulsivity", "." ]	[ "GENE-Y", "CHEMICAL" ]
insulin is a protein, glucose is a compound	DS.d1613_task0	Sentence: Association between insulin resistance, glucose intolerance, and hypertension in pregnancy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "B-protein", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O" ]	Association between insulin resistance, glucose intolerance, and hypertension in pregnancy.	[ "Association", "between", "insulin", "resistance", ",", "glucose", "intolerance", ",", "and", "hypertension", "in", "pregnancy", "." ]	[ "protein", "compound" ]
insulin is a protein, glucose is a compound	DS.d1613_task1	Sentence: Association between insulin resistance, glucose intolerance, and hypertension in pregnancy. Instructions: please typing these entity words according to sentence: insulin, glucose Options: compound, protein	[ "O", "O", "B-protein", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O" ]	Association between insulin resistance, glucose intolerance, and hypertension in pregnancy.	[ "Association", "between", "insulin", "resistance", ",", "glucose", "intolerance", ",", "and", "hypertension", "in", "pregnancy", "." ]	[ "protein", "compound" ]
insulin, glucose	DS.d1613_task2	Sentence: Association between insulin resistance, glucose intolerance, and hypertension in pregnancy. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-protein", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O" ]	Association between insulin resistance, glucose intolerance, and hypertension in pregnancy.	[ "Association", "between", "insulin", "resistance", ",", "glucose", "intolerance", ",", "and", "hypertension", "in", "pregnancy", "." ]	[ "protein", "compound" ]
Therapie is an umlsterm, Gesellschaft is an umlsterm, Haematologie is an umlsterm, Methode is an umlsterm, Therapiekonzept is an umlsterm, Chemotherapie is an umlsterm, bildgebender is an umlsterm, Diagnose is an umlsterm, Tumor is an umlsterm, Kinder is an umlsterm, Patienten is an umlsterm, Nephroblastom is an umlsterm, Chemotherapie is an umlsterm, Chemotherapie is an umlsterm, Therapiereduktion is an umlsterm	MonatsschriftKinderheilkunde.71450128.ger.abstr_task0	Sentence: Hintergrund : Die intensive Therapie der von der Gesellschaft fuer Paediatrische Onkologie und Haematologie ( GPOH ) ab 1980 durchgefuehrten Wilmstumorstudie sollte in der Folgestudie unter Wahrung der guten Ergebnisse reduziert werden . Methode 1989 : wurde das Therapiekonzept der International Society of Pediatric Oncology ( SIOP ) mit praeoperativer Chemotherapie nach bildgebender Diagnose uebernommen , wobei der Tumor durch die Vorbehandlung verkleinert wird , damit er bei einem Grossteil der Kinder vollstaendig entfernbar ist . Ergebnisse : Bei 505 in 5,25 Jahren aus 78 Kliniken gemeldeten Patienten hatten 486 ein Nephroblastom , 14 ein anderes Malignom und 5 eine benigne renale Laesion . Von 438 gemeldeten Nephroblastompatienten zwischen 0,5 und 16 Jahren erhielten 85,4 % praeoperativ eine Chemotherapie . Der Anteil bestrahlter Nephroblastompatienten ( 22,8 % ) und die kumulative Adriamycindosis bei hohen Stadien bzw. hoher Malignitaet wurden im Vergleich zur Vorstudie reduziert bei aehnlicher Ueberlebenswahrscheinlichkeit von 91 % nach 3 Jahren . Schlussfolgerung : Das Konzept einer generellen praeoperativen Chemotherapie zur Nephroblastombehandlung ist in der GPOH mit gutem Ergebnis und deutlicher Therapiereduktion im Vergleich zur Vorstudie durchzufuehren . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Hintergrund : Die intensive Therapie der von der Gesellschaft fuer Paediatrische Onkologie und Haematologie ( GPOH ) ab 1980 durchgefuehrten Wilmstumorstudie sollte in der Folgestudie unter Wahrung der guten Ergebnisse reduziert werden . Methode 1989 : wurde das Therapiekonzept der International Society of Pediatric Oncology ( SIOP ) mit praeoperativer Chemotherapie nach bildgebender Diagnose uebernommen , wobei der Tumor durch die Vorbehandlung verkleinert wird , damit er bei einem Grossteil der Kinder vollstaendig entfernbar ist . Ergebnisse : Bei 505 in 5,25 Jahren aus 78 Kliniken gemeldeten Patienten hatten 486 ein Nephroblastom , 14 ein anderes Malignom und 5 eine benigne renale Laesion . Von 438 gemeldeten Nephroblastompatienten zwischen 0,5 und 16 Jahren erhielten 85,4 % praeoperativ eine Chemotherapie . Der Anteil bestrahlter Nephroblastompatienten ( 22,8 % ) und die kumulative Adriamycindosis bei hohen Stadien bzw. hoher Malignitaet wurden im Vergleich zur Vorstudie reduziert bei aehnlicher Ueberlebenswahrscheinlichkeit von 91 % nach 3 Jahren . Schlussfolgerung : Das Konzept einer generellen praeoperativen Chemotherapie zur Nephroblastombehandlung ist in der GPOH mit gutem Ergebnis und deutlicher Therapiereduktion im Vergleich zur Vorstudie durchzufuehren .	[ "Hintergrund", ":", "Die", "intensive", "Therapie", "der", "von", "der", "Gesellschaft", "fuer", "Paediatrische", "Onkologie", "und", "Haematologie", "(", "GPOH", ")", "ab", "1980", "durchgefuehrten", "Wilmstumorstudie", "sollte", "in", "der", "Folgestudie", "unter", "Wahrung", "der", "guten", "Ergebnisse", "reduziert", "werden", ".", "Methode", "1989", ":", "wurde", "das", "Therapiekonzept", "der", "International", "Society", "of", "Pediatric", "Oncology", "(", "SIOP", ")", "mit", "praeoperativer", "Chemotherapie", "nach", "bildgebender", "Diagnose", "uebernommen", ",", "wobei", "der", "Tumor", "durch", "die", "Vorbehandlung", "verkleinert", "wird", ",", "damit", "er", "bei", "einem", "Grossteil", "der", "Kinder", "vollstaendig", "entfernbar", "ist", ".", "Ergebnisse", ":", "Bei", "505", "in", "5,25", "Jahren", "aus", "78", "Kliniken", "gemeldeten", "Patienten", "hatten", "486", "ein", "Nephroblastom", ",", "14", "ein", "anderes", "Malignom", "und", "5", "eine", "benigne", "renale", "Laesion", ".", "Von", "438", "gemeldeten", "Nephroblastompatienten", "zwischen", "0,5", "und", "16", "Jahren", "erhielten", "85,4", "%", "praeoperativ", "eine", "Chemotherapie", ".", "Der", "Anteil", "bestrahlter", "Nephroblastompatienten", "(", "22,8", "%", ")", "und", "die", "kumulative", "Adriamycindosis", "bei", "hohen", "Stadien", "bzw", ".", "hoher", "Malignitaet", "wurden", "im", "Vergleich", "zur", "Vorstudie", "reduziert", "bei", "aehnlicher", "Ueberlebenswahrscheinlichkeit", "von", "91", "%", "nach", "3", "Jahren", ".", "Schlussfolgerung", ":", "Das", "Konzept", "einer", "generellen", "praeoperativen", "Chemotherapie", "zur", "Nephroblastombehandlung", "ist", "in", "der", "GPOH", "mit", "gutem", "Ergebnis", "und", "deutlicher", "Therapiereduktion", "im", "Vergleich", "zur", "Vorstudie", "durchzufuehren", "." ]	[ "umlsterm" ]
Therapie is an umlsterm, Gesellschaft is an umlsterm, Haematologie is an umlsterm, Methode is an umlsterm, Therapiekonzept is an umlsterm, Chemotherapie is an umlsterm, bildgebender is an umlsterm, Diagnose is an umlsterm, Tumor is an umlsterm, Kinder is an umlsterm, Patienten is an umlsterm, Nephroblastom is an umlsterm, Chemotherapie is an umlsterm, Chemotherapie is an umlsterm, Therapiereduktion is an umlsterm	MonatsschriftKinderheilkunde.71450128.ger.abstr_task1	Sentence: Hintergrund : Die intensive Therapie der von der Gesellschaft fuer Paediatrische Onkologie und Haematologie ( GPOH ) ab 1980 durchgefuehrten Wilmstumorstudie sollte in der Folgestudie unter Wahrung der guten Ergebnisse reduziert werden . Methode 1989 : wurde das Therapiekonzept der International Society of Pediatric Oncology ( SIOP ) mit praeoperativer Chemotherapie nach bildgebender Diagnose uebernommen , wobei der Tumor durch die Vorbehandlung verkleinert wird , damit er bei einem Grossteil der Kinder vollstaendig entfernbar ist . Ergebnisse : Bei 505 in 5,25 Jahren aus 78 Kliniken gemeldeten Patienten hatten 486 ein Nephroblastom , 14 ein anderes Malignom und 5 eine benigne renale Laesion . Von 438 gemeldeten Nephroblastompatienten zwischen 0,5 und 16 Jahren erhielten 85,4 % praeoperativ eine Chemotherapie . Der Anteil bestrahlter Nephroblastompatienten ( 22,8 % ) und die kumulative Adriamycindosis bei hohen Stadien bzw. hoher Malignitaet wurden im Vergleich zur Vorstudie reduziert bei aehnlicher Ueberlebenswahrscheinlichkeit von 91 % nach 3 Jahren . Schlussfolgerung : Das Konzept einer generellen praeoperativen Chemotherapie zur Nephroblastombehandlung ist in der GPOH mit gutem Ergebnis und deutlicher Therapiereduktion im Vergleich zur Vorstudie durchzufuehren . Instructions: please typing these entity words according to sentence: Therapie, Gesellschaft, Haematologie, Methode, Therapiekonzept, Chemotherapie, bildgebender, Diagnose, Tumor, Kinder, Patienten, Nephroblastom, Chemotherapie, Chemotherapie, Therapiereduktion Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Hintergrund : Die intensive Therapie der von der Gesellschaft fuer Paediatrische Onkologie und Haematologie ( GPOH ) ab 1980 durchgefuehrten Wilmstumorstudie sollte in der Folgestudie unter Wahrung der guten Ergebnisse reduziert werden . Methode 1989 : wurde das Therapiekonzept der International Society of Pediatric Oncology ( SIOP ) mit praeoperativer Chemotherapie nach bildgebender Diagnose uebernommen , wobei der Tumor durch die Vorbehandlung verkleinert wird , damit er bei einem Grossteil der Kinder vollstaendig entfernbar ist . Ergebnisse : Bei 505 in 5,25 Jahren aus 78 Kliniken gemeldeten Patienten hatten 486 ein Nephroblastom , 14 ein anderes Malignom und 5 eine benigne renale Laesion . Von 438 gemeldeten Nephroblastompatienten zwischen 0,5 und 16 Jahren erhielten 85,4 % praeoperativ eine Chemotherapie . Der Anteil bestrahlter Nephroblastompatienten ( 22,8 % ) und die kumulative Adriamycindosis bei hohen Stadien bzw. hoher Malignitaet wurden im Vergleich zur Vorstudie reduziert bei aehnlicher Ueberlebenswahrscheinlichkeit von 91 % nach 3 Jahren . Schlussfolgerung : Das Konzept einer generellen praeoperativen Chemotherapie zur Nephroblastombehandlung ist in der GPOH mit gutem Ergebnis und deutlicher Therapiereduktion im Vergleich zur Vorstudie durchzufuehren .	[ "Hintergrund", ":", "Die", "intensive", "Therapie", "der", "von", "der", "Gesellschaft", "fuer", "Paediatrische", "Onkologie", "und", "Haematologie", "(", "GPOH", ")", "ab", "1980", "durchgefuehrten", "Wilmstumorstudie", "sollte", "in", "der", "Folgestudie", "unter", "Wahrung", "der", "guten", "Ergebnisse", "reduziert", "werden", ".", "Methode", "1989", ":", "wurde", "das", "Therapiekonzept", "der", "International", "Society", "of", "Pediatric", "Oncology", "(", "SIOP", ")", "mit", "praeoperativer", "Chemotherapie", "nach", "bildgebender", "Diagnose", "uebernommen", ",", "wobei", "der", "Tumor", "durch", "die", "Vorbehandlung", "verkleinert", "wird", ",", "damit", "er", "bei", "einem", "Grossteil", "der", "Kinder", "vollstaendig", "entfernbar", "ist", ".", "Ergebnisse", ":", "Bei", "505", "in", "5,25", "Jahren", "aus", "78", "Kliniken", "gemeldeten", "Patienten", "hatten", "486", "ein", "Nephroblastom", ",", "14", "ein", "anderes", "Malignom", "und", "5", "eine", "benigne", "renale", "Laesion", ".", "Von", "438", "gemeldeten", "Nephroblastompatienten", "zwischen", "0,5", "und", "16", "Jahren", "erhielten", "85,4", "%", "praeoperativ", "eine", "Chemotherapie", ".", "Der", "Anteil", "bestrahlter", "Nephroblastompatienten", "(", "22,8", "%", ")", "und", "die", "kumulative", "Adriamycindosis", "bei", "hohen", "Stadien", "bzw", ".", "hoher", "Malignitaet", "wurden", "im", "Vergleich", "zur", "Vorstudie", "reduziert", "bei", "aehnlicher", "Ueberlebenswahrscheinlichkeit", "von", "91", "%", "nach", "3", "Jahren", ".", "Schlussfolgerung", ":", "Das", "Konzept", "einer", "generellen", "praeoperativen", "Chemotherapie", "zur", "Nephroblastombehandlung", "ist", "in", "der", "GPOH", "mit", "gutem", "Ergebnis", "und", "deutlicher", "Therapiereduktion", "im", "Vergleich", "zur", "Vorstudie", "durchzufuehren", "." ]	[ "umlsterm" ]
Therapie, Gesellschaft, Haematologie, Methode, Therapiekonzept, Chemotherapie, bildgebender, Diagnose, Tumor, Kinder, Patienten, Nephroblastom, Chemotherapie, Chemotherapie, Therapiereduktion	MonatsschriftKinderheilkunde.71450128.ger.abstr_task2	Sentence: Hintergrund : Die intensive Therapie der von der Gesellschaft fuer Paediatrische Onkologie und Haematologie ( GPOH ) ab 1980 durchgefuehrten Wilmstumorstudie sollte in der Folgestudie unter Wahrung der guten Ergebnisse reduziert werden . Methode 1989 : wurde das Therapiekonzept der International Society of Pediatric Oncology ( SIOP ) mit praeoperativer Chemotherapie nach bildgebender Diagnose uebernommen , wobei der Tumor durch die Vorbehandlung verkleinert wird , damit er bei einem Grossteil der Kinder vollstaendig entfernbar ist . Ergebnisse : Bei 505 in 5,25 Jahren aus 78 Kliniken gemeldeten Patienten hatten 486 ein Nephroblastom , 14 ein anderes Malignom und 5 eine benigne renale Laesion . Von 438 gemeldeten Nephroblastompatienten zwischen 0,5 und 16 Jahren erhielten 85,4 % praeoperativ eine Chemotherapie . Der Anteil bestrahlter Nephroblastompatienten ( 22,8 % ) und die kumulative Adriamycindosis bei hohen Stadien bzw. hoher Malignitaet wurden im Vergleich zur Vorstudie reduziert bei aehnlicher Ueberlebenswahrscheinlichkeit von 91 % nach 3 Jahren . Schlussfolgerung : Das Konzept einer generellen praeoperativen Chemotherapie zur Nephroblastombehandlung ist in der GPOH mit gutem Ergebnis und deutlicher Therapiereduktion im Vergleich zur Vorstudie durchzufuehren . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Hintergrund : Die intensive Therapie der von der Gesellschaft fuer Paediatrische Onkologie und Haematologie ( GPOH ) ab 1980 durchgefuehrten Wilmstumorstudie sollte in der Folgestudie unter Wahrung der guten Ergebnisse reduziert werden . Methode 1989 : wurde das Therapiekonzept der International Society of Pediatric Oncology ( SIOP ) mit praeoperativer Chemotherapie nach bildgebender Diagnose uebernommen , wobei der Tumor durch die Vorbehandlung verkleinert wird , damit er bei einem Grossteil der Kinder vollstaendig entfernbar ist . Ergebnisse : Bei 505 in 5,25 Jahren aus 78 Kliniken gemeldeten Patienten hatten 486 ein Nephroblastom , 14 ein anderes Malignom und 5 eine benigne renale Laesion . Von 438 gemeldeten Nephroblastompatienten zwischen 0,5 und 16 Jahren erhielten 85,4 % praeoperativ eine Chemotherapie . Der Anteil bestrahlter Nephroblastompatienten ( 22,8 % ) und die kumulative Adriamycindosis bei hohen Stadien bzw. hoher Malignitaet wurden im Vergleich zur Vorstudie reduziert bei aehnlicher Ueberlebenswahrscheinlichkeit von 91 % nach 3 Jahren . Schlussfolgerung : Das Konzept einer generellen praeoperativen Chemotherapie zur Nephroblastombehandlung ist in der GPOH mit gutem Ergebnis und deutlicher Therapiereduktion im Vergleich zur Vorstudie durchzufuehren .	[ "Hintergrund", ":", "Die", "intensive", "Therapie", "der", "von", "der", "Gesellschaft", "fuer", "Paediatrische", "Onkologie", "und", "Haematologie", "(", "GPOH", ")", "ab", "1980", "durchgefuehrten", "Wilmstumorstudie", "sollte", "in", "der", "Folgestudie", "unter", "Wahrung", "der", "guten", "Ergebnisse", "reduziert", "werden", ".", "Methode", "1989", ":", "wurde", "das", "Therapiekonzept", "der", "International", "Society", "of", "Pediatric", "Oncology", "(", "SIOP", ")", "mit", "praeoperativer", "Chemotherapie", "nach", "bildgebender", "Diagnose", "uebernommen", ",", "wobei", "der", "Tumor", "durch", "die", "Vorbehandlung", "verkleinert", "wird", ",", "damit", "er", "bei", "einem", "Grossteil", "der", "Kinder", "vollstaendig", "entfernbar", "ist", ".", "Ergebnisse", ":", "Bei", "505", "in", "5,25", "Jahren", "aus", "78", "Kliniken", "gemeldeten", "Patienten", "hatten", "486", "ein", "Nephroblastom", ",", "14", "ein", "anderes", "Malignom", "und", "5", "eine", "benigne", "renale", "Laesion", ".", "Von", "438", "gemeldeten", "Nephroblastompatienten", "zwischen", "0,5", "und", "16", "Jahren", "erhielten", "85,4", "%", "praeoperativ", "eine", "Chemotherapie", ".", "Der", "Anteil", "bestrahlter", "Nephroblastompatienten", "(", "22,8", "%", ")", "und", "die", "kumulative", "Adriamycindosis", "bei", "hohen", "Stadien", "bzw", ".", "hoher", "Malignitaet", "wurden", "im", "Vergleich", "zur", "Vorstudie", "reduziert", "bei", "aehnlicher", "Ueberlebenswahrscheinlichkeit", "von", "91", "%", "nach", "3", "Jahren", ".", "Schlussfolgerung", ":", "Das", "Konzept", "einer", "generellen", "praeoperativen", "Chemotherapie", "zur", "Nephroblastombehandlung", "ist", "in", "der", "GPOH", "mit", "gutem", "Ergebnis", "und", "deutlicher", "Therapiereduktion", "im", "Vergleich", "zur", "Vorstudie", "durchzufuehren", "." ]	[ "umlsterm" ]
NOS is a protein, iNOS is a protein, nNOS is a protein, L - arginine methyl ester is a compound, aminoguanidine is a compound, 7-nitroindazole is a compound	DS.d251_task0	Sentence: Effects of inhibition of NOS, iNOS, and nNOS by N-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and 7-nitroindazole, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effects of inhibition of NOS, iNOS, and nNOS by N-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and 7-nitroindazole, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen.	[ "Effects", "of", "inhibition", "of", "NOS", ",", "iNOS", ",", "and", "nNOS", "by", "N", "-", "nitro", "-", "L", "-", "arginine", "methyl", "ester", "(", "L", "-", "NAME", ")", ",", "aminoguanidine", ",", "and", "7-nitroindazole", ",", "respectively", ",", "were", "determined", "on", "the", "antigen", "-", "induced", "systemic", "hypotension", "and", "portal", "hypertension", "in", "conscious", "Sprague", "-", "Dawley", "rats", "sensitized", "with", "the", "ovalbumin", "antigen", "." ]	[ "compound", "protein" ]
NOS is a protein, iNOS is a protein, nNOS is a protein, L - arginine methyl ester is a compound, aminoguanidine is a compound, 7-nitroindazole is a compound	DS.d251_task1	Sentence: Effects of inhibition of NOS, iNOS, and nNOS by N-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and 7-nitroindazole, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen. Instructions: please typing these entity words according to sentence: NOS, iNOS, nNOS, L - arginine methyl ester, aminoguanidine, 7-nitroindazole Options: compound, protein	[ "O", "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effects of inhibition of NOS, iNOS, and nNOS by N-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and 7-nitroindazole, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen.	[ "Effects", "of", "inhibition", "of", "NOS", ",", "iNOS", ",", "and", "nNOS", "by", "N", "-", "nitro", "-", "L", "-", "arginine", "methyl", "ester", "(", "L", "-", "NAME", ")", ",", "aminoguanidine", ",", "and", "7-nitroindazole", ",", "respectively", ",", "were", "determined", "on", "the", "antigen", "-", "induced", "systemic", "hypotension", "and", "portal", "hypertension", "in", "conscious", "Sprague", "-", "Dawley", "rats", "sensitized", "with", "the", "ovalbumin", "antigen", "." ]	[ "compound", "protein" ]
NOS, iNOS, nNOS, L - arginine methyl ester, aminoguanidine, 7-nitroindazole	DS.d251_task2	Sentence: Effects of inhibition of NOS, iNOS, and nNOS by N-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and 7-nitroindazole, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effects of inhibition of NOS, iNOS, and nNOS by N-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and 7-nitroindazole, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen.	[ "Effects", "of", "inhibition", "of", "NOS", ",", "iNOS", ",", "and", "nNOS", "by", "N", "-", "nitro", "-", "L", "-", "arginine", "methyl", "ester", "(", "L", "-", "NAME", ")", ",", "aminoguanidine", ",", "and", "7-nitroindazole", ",", "respectively", ",", "were", "determined", "on", "the", "antigen", "-", "induced", "systemic", "hypotension", "and", "portal", "hypertension", "in", "conscious", "Sprague", "-", "Dawley", "rats", "sensitized", "with", "the", "ovalbumin", "antigen", "." ]	[ "compound", "protein" ]
heart rate is an umlsterm, marker is an umlsterm, dysfunction is an umlsterm, prognosis is an umlsterm, critically ill is an umlsterm, patients is an umlsterm, dysfunction is an umlsterm, patients is an umlsterm, sepsis is an umlsterm, dysfunction is an umlsterm, syndrome is an umlsterm, MODS is an umlsterm	IntensiveMedizin.90360436.eng.abstr_task0	Sentence: Question : Reduced heart rate variability ( HRV ) as a marker of autonomic dysfunction indicates poor prognosis in critically ill patients . The question remains whether the autonomic dysfunction in these patients is primarily the result of sepsis or multiple organ dysfunction syndrome ( MODS ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Question : Reduced heart rate variability ( HRV ) as a marker of autonomic dysfunction indicates poor prognosis in critically ill patients . The question remains whether the autonomic dysfunction in these patients is primarily the result of sepsis or multiple organ dysfunction syndrome ( MODS ) .	[ "Question", ":", "Reduced", "heart", "rate", "variability", "(", "HRV", ")", "as", "a", "marker", "of", "autonomic", "dysfunction", "indicates", "poor", "prognosis", "in", "critically", "ill", "patients", ".", "The", "question", "remains", "whether", "the", "autonomic", "dysfunction", "in", "these", "patients", "is", "primarily", "the", "result", "of", "sepsis", "or", "multiple", "organ", "dysfunction", "syndrome", "(", "MODS", ")", "." ]	[ "umlsterm" ]
heart rate is an umlsterm, marker is an umlsterm, dysfunction is an umlsterm, prognosis is an umlsterm, critically ill is an umlsterm, patients is an umlsterm, dysfunction is an umlsterm, patients is an umlsterm, sepsis is an umlsterm, dysfunction is an umlsterm, syndrome is an umlsterm, MODS is an umlsterm	IntensiveMedizin.90360436.eng.abstr_task1	Sentence: Question : Reduced heart rate variability ( HRV ) as a marker of autonomic dysfunction indicates poor prognosis in critically ill patients . The question remains whether the autonomic dysfunction in these patients is primarily the result of sepsis or multiple organ dysfunction syndrome ( MODS ) . Instructions: please typing these entity words according to sentence: heart rate, marker, dysfunction, prognosis, critically ill, patients, dysfunction, patients, sepsis, dysfunction, syndrome, MODS Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Question : Reduced heart rate variability ( HRV ) as a marker of autonomic dysfunction indicates poor prognosis in critically ill patients . The question remains whether the autonomic dysfunction in these patients is primarily the result of sepsis or multiple organ dysfunction syndrome ( MODS ) .	[ "Question", ":", "Reduced", "heart", "rate", "variability", "(", "HRV", ")", "as", "a", "marker", "of", "autonomic", "dysfunction", "indicates", "poor", "prognosis", "in", "critically", "ill", "patients", ".", "The", "question", "remains", "whether", "the", "autonomic", "dysfunction", "in", "these", "patients", "is", "primarily", "the", "result", "of", "sepsis", "or", "multiple", "organ", "dysfunction", "syndrome", "(", "MODS", ")", "." ]	[ "umlsterm" ]
heart rate, marker, dysfunction, prognosis, critically ill, patients, dysfunction, patients, sepsis, dysfunction, syndrome, MODS	IntensiveMedizin.90360436.eng.abstr_task2	Sentence: Question : Reduced heart rate variability ( HRV ) as a marker of autonomic dysfunction indicates poor prognosis in critically ill patients . The question remains whether the autonomic dysfunction in these patients is primarily the result of sepsis or multiple organ dysfunction syndrome ( MODS ) . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Question : Reduced heart rate variability ( HRV ) as a marker of autonomic dysfunction indicates poor prognosis in critically ill patients . The question remains whether the autonomic dysfunction in these patients is primarily the result of sepsis or multiple organ dysfunction syndrome ( MODS ) .	[ "Question", ":", "Reduced", "heart", "rate", "variability", "(", "HRV", ")", "as", "a", "marker", "of", "autonomic", "dysfunction", "indicates", "poor", "prognosis", "in", "critically", "ill", "patients", ".", "The", "question", "remains", "whether", "the", "autonomic", "dysfunction", "in", "these", "patients", "is", "primarily", "the", "result", "of", "sepsis", "or", "multiple", "organ", "dysfunction", "syndrome", "(", "MODS", ")", "." ]	[ "umlsterm" ]
Analysen is an umlsterm, Amphetamin is an umlsterm, Maennern is an umlsterm, Frauen is an umlsterm, maennlichen is an umlsterm, Geschlechts is an umlsterm, Personen is an umlsterm, Cannabis is an umlsterm, Cannabis is an umlsterm, Alkohol is an umlsterm, Cannabis is an umlsterm, Kokain is an umlsterm, Opiat- is an umlsterm, Opiaten is an umlsterm, Cannabis is an umlsterm, Alkohol is an umlsterm, Kokain is an umlsterm	Rechtsmedizin.80080051.ger.abstr_task0	Sentence: Die Anzahl der chemisch-toxikologischen Analysen mit positivem Nachweis von Amphetaminderivaten und/oder Amphetamin im Koelner Untersuchungsgut der Jahre 1991-1996 zeigt eine deutliche Zunahme . Das Verhaeltnis von Maennern zu Frauen weist eine Ueberrepraesentanz des maennlichen Geschlechts auf , das Alter der untersuchten Personen ist mit um 25 Jahren im Vergleich zu anderen Drogenkonsumenten ohne Auffaelligkeiten . Der Anteil von zusaetzlich konsumierten Drogen stieg in den letzten Jahren auf ueber 90% , wobei die Kombinationen mit Cannabis , Cannabis und Alkohol sowie Cannabis und Kokain ueberwiegen . Der Anteil an Methylendioxyamphetaminderivaten steigt deutlich ab 1994. Die Amphetaminderivatkonsumenten wiesen - mit Ausnahme des Opiat- und Medikamentenkosums - kein wesentlich abweichendes Beikonsumverhalten im Vergleich zum reinen Amphetaminkonsum auf . Eine Verknuepfung der harten Drogenszene " " mit der " Amphetaminszene " im Sinne eines zunehmenden Amphetaminkonsums als Ersatzstoff anderer Drogen kann aus den Auswertungen nicht abgeleitet werden . Der Anteil an Opiaten ist im Vergleich zu Cannabis und Alkohol von geringer Bedeutung , der Anteil an Kokain als zusaetzlich konsumiertem Suchtstoff war in den letzten Jahren schwankend . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Anzahl der chemisch-toxikologischen Analysen mit positivem Nachweis von Amphetaminderivaten und/oder Amphetamin im Koelner Untersuchungsgut der Jahre 1991-1996 zeigt eine deutliche Zunahme . Das Verhaeltnis von Maennern zu Frauen weist eine Ueberrepraesentanz des maennlichen Geschlechts auf , das Alter der untersuchten Personen ist mit um 25 Jahren im Vergleich zu anderen Drogenkonsumenten ohne Auffaelligkeiten . Der Anteil von zusaetzlich konsumierten Drogen stieg in den letzten Jahren auf ueber 90% , wobei die Kombinationen mit Cannabis , Cannabis und Alkohol sowie Cannabis und Kokain ueberwiegen . Der Anteil an Methylendioxyamphetaminderivaten steigt deutlich ab 1994. Die Amphetaminderivatkonsumenten wiesen - mit Ausnahme des Opiat- und Medikamentenkosums - kein wesentlich abweichendes Beikonsumverhalten im Vergleich zum reinen Amphetaminkonsum auf . Eine Verknuepfung der harten Drogenszene " " mit der " Amphetaminszene " im Sinne eines zunehmenden Amphetaminkonsums als Ersatzstoff anderer Drogen kann aus den Auswertungen nicht abgeleitet werden . Der Anteil an Opiaten ist im Vergleich zu Cannabis und Alkohol von geringer Bedeutung , der Anteil an Kokain als zusaetzlich konsumiertem Suchtstoff war in den letzten Jahren schwankend .	[ "Die", "Anzahl", "der", "chemisch", "-", "toxikologischen", "Analysen", "mit", "positivem", "Nachweis", "von", "Amphetaminderivaten", "und", "/", "oder", "Amphetamin", "im", "Koelner", "Untersuchungsgut", "der", "Jahre", "1991", "-", "1996", "zeigt", "eine", "deutliche", "Zunahme", ".", "Das", "Verhaeltnis", "von", "Maennern", "zu", "Frauen", "weist", "eine", "Ueberrepraesentanz", "des", "maennlichen", "Geschlechts", "auf", ",", "das", "Alter", "der", "untersuchten", "Personen", "ist", "mit", "um", "25", "Jahren", "im", "Vergleich", "zu", "anderen", "Drogenkonsumenten", "ohne", "Auffaelligkeiten", ".", "Der", "Anteil", "von", "zusaetzlich", "konsumierten", "Drogen", "stieg", "in", "den", "letzten", "Jahren", "auf", "ueber", "90", "%", ",", "wobei", "die", "Kombinationen", "mit", "Cannabis", ",", "Cannabis", "und", "Alkohol", "sowie", "Cannabis", "und", "Kokain", "ueberwiegen", ".", "Der", "Anteil", "an", "Methylendioxyamphetaminderivaten", "steigt", "deutlich", "ab", "1994", ".", "Die", "Amphetaminderivatkonsumenten", "wiesen", "-", "mit", "Ausnahme", "des", "Opiat-", "und", "Medikamentenkosums", "-", "kein", "wesentlich", "abweichendes", "Beikonsumverhalten", "im", "Vergleich", "zum", "reinen", "Amphetaminkonsum", "auf", ".", "Eine", "Verknuepfung", "der", "harten", "Drogenszene", "\"", "\"", "mit", "der", "\"", "Amphetaminszene", "\"", "im", "Sinne", "eines", "zunehmenden", "Amphetaminkonsums", "als", "Ersatzstoff", "anderer", "Drogen", "kann", "aus", "den", "Auswertungen", "nicht", "abgeleitet", "werden", ".", "Der", "Anteil", "an", "Opiaten", "ist", "im", "Vergleich", "zu", "Cannabis", "und", "Alkohol", "von", "geringer", "Bedeutung", ",", "der", "Anteil", "an", "Kokain", "als", "zusaetzlich", "konsumiertem", "Suchtstoff", "war", "in", "den", "letzten", "Jahren", "schwankend", "." ]	[ "umlsterm" ]
Analysen is an umlsterm, Amphetamin is an umlsterm, Maennern is an umlsterm, Frauen is an umlsterm, maennlichen is an umlsterm, Geschlechts is an umlsterm, Personen is an umlsterm, Cannabis is an umlsterm, Cannabis is an umlsterm, Alkohol is an umlsterm, Cannabis is an umlsterm, Kokain is an umlsterm, Opiat- is an umlsterm, Opiaten is an umlsterm, Cannabis is an umlsterm, Alkohol is an umlsterm, Kokain is an umlsterm	Rechtsmedizin.80080051.ger.abstr_task1	Sentence: Die Anzahl der chemisch-toxikologischen Analysen mit positivem Nachweis von Amphetaminderivaten und/oder Amphetamin im Koelner Untersuchungsgut der Jahre 1991-1996 zeigt eine deutliche Zunahme . Das Verhaeltnis von Maennern zu Frauen weist eine Ueberrepraesentanz des maennlichen Geschlechts auf , das Alter der untersuchten Personen ist mit um 25 Jahren im Vergleich zu anderen Drogenkonsumenten ohne Auffaelligkeiten . Der Anteil von zusaetzlich konsumierten Drogen stieg in den letzten Jahren auf ueber 90% , wobei die Kombinationen mit Cannabis , Cannabis und Alkohol sowie Cannabis und Kokain ueberwiegen . Der Anteil an Methylendioxyamphetaminderivaten steigt deutlich ab 1994. Die Amphetaminderivatkonsumenten wiesen - mit Ausnahme des Opiat- und Medikamentenkosums - kein wesentlich abweichendes Beikonsumverhalten im Vergleich zum reinen Amphetaminkonsum auf . Eine Verknuepfung der harten Drogenszene " " mit der " Amphetaminszene " im Sinne eines zunehmenden Amphetaminkonsums als Ersatzstoff anderer Drogen kann aus den Auswertungen nicht abgeleitet werden . Der Anteil an Opiaten ist im Vergleich zu Cannabis und Alkohol von geringer Bedeutung , der Anteil an Kokain als zusaetzlich konsumiertem Suchtstoff war in den letzten Jahren schwankend . Instructions: please typing these entity words according to sentence: Analysen, Amphetamin, Maennern, Frauen, maennlichen, Geschlechts, Personen, Cannabis, Cannabis, Alkohol, Cannabis, Kokain, Opiat-, Opiaten, Cannabis, Alkohol, Kokain Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Anzahl der chemisch-toxikologischen Analysen mit positivem Nachweis von Amphetaminderivaten und/oder Amphetamin im Koelner Untersuchungsgut der Jahre 1991-1996 zeigt eine deutliche Zunahme . Das Verhaeltnis von Maennern zu Frauen weist eine Ueberrepraesentanz des maennlichen Geschlechts auf , das Alter der untersuchten Personen ist mit um 25 Jahren im Vergleich zu anderen Drogenkonsumenten ohne Auffaelligkeiten . Der Anteil von zusaetzlich konsumierten Drogen stieg in den letzten Jahren auf ueber 90% , wobei die Kombinationen mit Cannabis , Cannabis und Alkohol sowie Cannabis und Kokain ueberwiegen . Der Anteil an Methylendioxyamphetaminderivaten steigt deutlich ab 1994. Die Amphetaminderivatkonsumenten wiesen - mit Ausnahme des Opiat- und Medikamentenkosums - kein wesentlich abweichendes Beikonsumverhalten im Vergleich zum reinen Amphetaminkonsum auf . Eine Verknuepfung der harten Drogenszene " " mit der " Amphetaminszene " im Sinne eines zunehmenden Amphetaminkonsums als Ersatzstoff anderer Drogen kann aus den Auswertungen nicht abgeleitet werden . Der Anteil an Opiaten ist im Vergleich zu Cannabis und Alkohol von geringer Bedeutung , der Anteil an Kokain als zusaetzlich konsumiertem Suchtstoff war in den letzten Jahren schwankend .	[ "Die", "Anzahl", "der", "chemisch", "-", "toxikologischen", "Analysen", "mit", "positivem", "Nachweis", "von", "Amphetaminderivaten", "und", "/", "oder", "Amphetamin", "im", "Koelner", "Untersuchungsgut", "der", "Jahre", "1991", "-", "1996", "zeigt", "eine", "deutliche", "Zunahme", ".", "Das", "Verhaeltnis", "von", "Maennern", "zu", "Frauen", "weist", "eine", "Ueberrepraesentanz", "des", "maennlichen", "Geschlechts", "auf", ",", "das", "Alter", "der", "untersuchten", "Personen", "ist", "mit", "um", "25", "Jahren", "im", "Vergleich", "zu", "anderen", "Drogenkonsumenten", "ohne", "Auffaelligkeiten", ".", "Der", "Anteil", "von", "zusaetzlich", "konsumierten", "Drogen", "stieg", "in", "den", "letzten", "Jahren", "auf", "ueber", "90", "%", ",", "wobei", "die", "Kombinationen", "mit", "Cannabis", ",", "Cannabis", "und", "Alkohol", "sowie", "Cannabis", "und", "Kokain", "ueberwiegen", ".", "Der", "Anteil", "an", "Methylendioxyamphetaminderivaten", "steigt", "deutlich", "ab", "1994", ".", "Die", "Amphetaminderivatkonsumenten", "wiesen", "-", "mit", "Ausnahme", "des", "Opiat-", "und", "Medikamentenkosums", "-", "kein", "wesentlich", "abweichendes", "Beikonsumverhalten", "im", "Vergleich", "zum", "reinen", "Amphetaminkonsum", "auf", ".", "Eine", "Verknuepfung", "der", "harten", "Drogenszene", "\"", "\"", "mit", "der", "\"", "Amphetaminszene", "\"", "im", "Sinne", "eines", "zunehmenden", "Amphetaminkonsums", "als", "Ersatzstoff", "anderer", "Drogen", "kann", "aus", "den", "Auswertungen", "nicht", "abgeleitet", "werden", ".", "Der", "Anteil", "an", "Opiaten", "ist", "im", "Vergleich", "zu", "Cannabis", "und", "Alkohol", "von", "geringer", "Bedeutung", ",", "der", "Anteil", "an", "Kokain", "als", "zusaetzlich", "konsumiertem", "Suchtstoff", "war", "in", "den", "letzten", "Jahren", "schwankend", "." ]	[ "umlsterm" ]
Analysen, Amphetamin, Maennern, Frauen, maennlichen, Geschlechts, Personen, Cannabis, Cannabis, Alkohol, Cannabis, Kokain, Opiat-, Opiaten, Cannabis, Alkohol, Kokain	Rechtsmedizin.80080051.ger.abstr_task2	Sentence: Die Anzahl der chemisch-toxikologischen Analysen mit positivem Nachweis von Amphetaminderivaten und/oder Amphetamin im Koelner Untersuchungsgut der Jahre 1991-1996 zeigt eine deutliche Zunahme . Das Verhaeltnis von Maennern zu Frauen weist eine Ueberrepraesentanz des maennlichen Geschlechts auf , das Alter der untersuchten Personen ist mit um 25 Jahren im Vergleich zu anderen Drogenkonsumenten ohne Auffaelligkeiten . Der Anteil von zusaetzlich konsumierten Drogen stieg in den letzten Jahren auf ueber 90% , wobei die Kombinationen mit Cannabis , Cannabis und Alkohol sowie Cannabis und Kokain ueberwiegen . Der Anteil an Methylendioxyamphetaminderivaten steigt deutlich ab 1994. Die Amphetaminderivatkonsumenten wiesen - mit Ausnahme des Opiat- und Medikamentenkosums - kein wesentlich abweichendes Beikonsumverhalten im Vergleich zum reinen Amphetaminkonsum auf . Eine Verknuepfung der harten Drogenszene " " mit der " Amphetaminszene " im Sinne eines zunehmenden Amphetaminkonsums als Ersatzstoff anderer Drogen kann aus den Auswertungen nicht abgeleitet werden . Der Anteil an Opiaten ist im Vergleich zu Cannabis und Alkohol von geringer Bedeutung , der Anteil an Kokain als zusaetzlich konsumiertem Suchtstoff war in den letzten Jahren schwankend . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Anzahl der chemisch-toxikologischen Analysen mit positivem Nachweis von Amphetaminderivaten und/oder Amphetamin im Koelner Untersuchungsgut der Jahre 1991-1996 zeigt eine deutliche Zunahme . Das Verhaeltnis von Maennern zu Frauen weist eine Ueberrepraesentanz des maennlichen Geschlechts auf , das Alter der untersuchten Personen ist mit um 25 Jahren im Vergleich zu anderen Drogenkonsumenten ohne Auffaelligkeiten . Der Anteil von zusaetzlich konsumierten Drogen stieg in den letzten Jahren auf ueber 90% , wobei die Kombinationen mit Cannabis , Cannabis und Alkohol sowie Cannabis und Kokain ueberwiegen . Der Anteil an Methylendioxyamphetaminderivaten steigt deutlich ab 1994. Die Amphetaminderivatkonsumenten wiesen - mit Ausnahme des Opiat- und Medikamentenkosums - kein wesentlich abweichendes Beikonsumverhalten im Vergleich zum reinen Amphetaminkonsum auf . Eine Verknuepfung der harten Drogenszene " " mit der " Amphetaminszene " im Sinne eines zunehmenden Amphetaminkonsums als Ersatzstoff anderer Drogen kann aus den Auswertungen nicht abgeleitet werden . Der Anteil an Opiaten ist im Vergleich zu Cannabis und Alkohol von geringer Bedeutung , der Anteil an Kokain als zusaetzlich konsumiertem Suchtstoff war in den letzten Jahren schwankend .	[ "Die", "Anzahl", "der", "chemisch", "-", "toxikologischen", "Analysen", "mit", "positivem", "Nachweis", "von", "Amphetaminderivaten", "und", "/", "oder", "Amphetamin", "im", "Koelner", "Untersuchungsgut", "der", "Jahre", "1991", "-", "1996", "zeigt", "eine", "deutliche", "Zunahme", ".", "Das", "Verhaeltnis", "von", "Maennern", "zu", "Frauen", "weist", "eine", "Ueberrepraesentanz", "des", "maennlichen", "Geschlechts", "auf", ",", "das", "Alter", "der", "untersuchten", "Personen", "ist", "mit", "um", "25", "Jahren", "im", "Vergleich", "zu", "anderen", "Drogenkonsumenten", "ohne", "Auffaelligkeiten", ".", "Der", "Anteil", "von", "zusaetzlich", "konsumierten", "Drogen", "stieg", "in", "den", "letzten", "Jahren", "auf", "ueber", "90", "%", ",", "wobei", "die", "Kombinationen", "mit", "Cannabis", ",", "Cannabis", "und", "Alkohol", "sowie", "Cannabis", "und", "Kokain", "ueberwiegen", ".", "Der", "Anteil", "an", "Methylendioxyamphetaminderivaten", "steigt", "deutlich", "ab", "1994", ".", "Die", "Amphetaminderivatkonsumenten", "wiesen", "-", "mit", "Ausnahme", "des", "Opiat-", "und", "Medikamentenkosums", "-", "kein", "wesentlich", "abweichendes", "Beikonsumverhalten", "im", "Vergleich", "zum", "reinen", "Amphetaminkonsum", "auf", ".", "Eine", "Verknuepfung", "der", "harten", "Drogenszene", "\"", "\"", "mit", "der", "\"", "Amphetaminszene", "\"", "im", "Sinne", "eines", "zunehmenden", "Amphetaminkonsums", "als", "Ersatzstoff", "anderer", "Drogen", "kann", "aus", "den", "Auswertungen", "nicht", "abgeleitet", "werden", ".", "Der", "Anteil", "an", "Opiaten", "ist", "im", "Vergleich", "zu", "Cannabis", "und", "Alkohol", "von", "geringer", "Bedeutung", ",", "der", "Anteil", "an", "Kokain", "als", "zusaetzlich", "konsumiertem", "Suchtstoff", "war", "in", "den", "letzten", "Jahren", "schwankend", "." ]	[ "umlsterm" ]
PDGF receptor is a Individual_protein, PDGF - AB is a Individual_protein, mitogen - activated protein kinase is a Protein_family_or_group, ERK is a Gene/protein/RNA, AP-1 is a Gene/protein/RNA	482_task0	Sentence: In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA, Individual_protein, Protein_family_or_group	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O" ]	In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity.	[ "In", "vitro", "studies", "indicated", "that", "suramin", "completely", "blocked", "PDGF", "receptor", "activation", "or", "phosphorylation", "stimulated", "by", "PDGF", "-", "AB", ",", "inhibited", "activation", "of", "mitogen", "-", "activated", "protein", "kinase", "(", "ERK", ")", "kinases", "(", "MEK1/2", ")", "and", "ERK1/2", ",", "and", "abrogated", "transcription", "factor", "AP-1", "DNA", "-", "binding", "activity", "." ]	[ "Protein_family_or_group", "Individual_protein", "Gene/protein/RNA" ]
PDGF receptor is a Individual_protein, PDGF - AB is a Individual_protein, mitogen - activated protein kinase is a Protein_family_or_group, ERK is a Gene/protein/RNA, AP-1 is a Gene/protein/RNA	482_task1	Sentence: In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity. Instructions: please typing these entity words according to sentence: PDGF receptor, PDGF - AB, mitogen - activated protein kinase, ERK, AP-1 Options: Gene/protein/RNA, Individual_protein, Protein_family_or_group	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O" ]	In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity.	[ "In", "vitro", "studies", "indicated", "that", "suramin", "completely", "blocked", "PDGF", "receptor", "activation", "or", "phosphorylation", "stimulated", "by", "PDGF", "-", "AB", ",", "inhibited", "activation", "of", "mitogen", "-", "activated", "protein", "kinase", "(", "ERK", ")", "kinases", "(", "MEK1/2", ")", "and", "ERK1/2", ",", "and", "abrogated", "transcription", "factor", "AP-1", "DNA", "-", "binding", "activity", "." ]	[ "Protein_family_or_group", "Individual_protein", "Gene/protein/RNA" ]
PDGF receptor, PDGF - AB, mitogen - activated protein kinase, ERK, AP-1	482_task2	Sentence: In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O" ]	In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity.	[ "In", "vitro", "studies", "indicated", "that", "suramin", "completely", "blocked", "PDGF", "receptor", "activation", "or", "phosphorylation", "stimulated", "by", "PDGF", "-", "AB", ",", "inhibited", "activation", "of", "mitogen", "-", "activated", "protein", "kinase", "(", "ERK", ")", "kinases", "(", "MEK1/2", ")", "and", "ERK1/2", ",", "and", "abrogated", "transcription", "factor", "AP-1", "DNA", "-", "binding", "activity", "." ]	[ "Protein_family_or_group", "Individual_protein", "Gene/protein/RNA" ]
Farbstoffe is an umlsterm, Farbstoffe is an umlsterm, Quecksilberverbindungen is an umlsterm, Mann is an umlsterm, Entzuendung is an umlsterm, Haut is an umlsterm, Hauttestreaktion is an umlsterm, Farbstoff is an umlsterm, Patient is an umlsterm	DerHautarzt.70480666.ger.abstr_task0	Sentence: Allergische Reaktionen auf Farbstoffe in Taetowierungen sind vergleichsweise selten . In der Mehrzahl sind es Reaktionen auf die roten Farbstoffe . Waehrend frueher hauptsaechlich Quecksilberverbindungen ( Zinnober und Cadmiumsulfid ) dafuer verantwortlich waren , stehen heute die synthetischen anorganischen Azofarbstoffe im Vordergrund . Es wird ein 42jaehriger Mann mit allergischer Reaktion in seinen roten Taetowierungsanteilen vorgestellt . Histologisch imponierte eine chronisch verlaufende granulomatoese , teils fibrosierende Entzuendung mit transfollikulaerer Elimination von Pigmentgranula . Klinisch zeigte sich im Verlauf spontan eine partielle Rueckbildung der entzuendlichen Veraenderungen unter gleichzeitiger Depigmentierung und Vernarbung der Haut . Als Taetowierungsfarbstoff wurde ein aromatischer Azofarbstoff nachgewiesen . Neben der positiven Hauttestreaktion auf diesen Farbstoff zeigte der Patient zusaetzlich eine positive Testreaktion auf den Textilfarbstoffkoppler Napthol AS . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Allergische Reaktionen auf Farbstoffe in Taetowierungen sind vergleichsweise selten . In der Mehrzahl sind es Reaktionen auf die roten Farbstoffe . Waehrend frueher hauptsaechlich Quecksilberverbindungen ( Zinnober und Cadmiumsulfid ) dafuer verantwortlich waren , stehen heute die synthetischen anorganischen Azofarbstoffe im Vordergrund . Es wird ein 42jaehriger Mann mit allergischer Reaktion in seinen roten Taetowierungsanteilen vorgestellt . Histologisch imponierte eine chronisch verlaufende granulomatoese , teils fibrosierende Entzuendung mit transfollikulaerer Elimination von Pigmentgranula . Klinisch zeigte sich im Verlauf spontan eine partielle Rueckbildung der entzuendlichen Veraenderungen unter gleichzeitiger Depigmentierung und Vernarbung der Haut . Als Taetowierungsfarbstoff wurde ein aromatischer Azofarbstoff nachgewiesen . Neben der positiven Hauttestreaktion auf diesen Farbstoff zeigte der Patient zusaetzlich eine positive Testreaktion auf den Textilfarbstoffkoppler Napthol AS .	[ "Allergische", "Reaktionen", "auf", "Farbstoffe", "in", "Taetowierungen", "sind", "vergleichsweise", "selten", ".", "In", "der", "Mehrzahl", "sind", "es", "Reaktionen", "auf", "die", "roten", "Farbstoffe", ".", "Waehrend", "frueher", "hauptsaechlich", "Quecksilberverbindungen", "(", "Zinnober", "und", "Cadmiumsulfid", ")", "dafuer", "verantwortlich", "waren", ",", "stehen", "heute", "die", "synthetischen", "anorganischen", "Azofarbstoffe", "im", "Vordergrund", ".", "Es", "wird", "ein", "42jaehriger", "Mann", "mit", "allergischer", "Reaktion", "in", "seinen", "roten", "Taetowierungsanteilen", "vorgestellt", ".", "Histologisch", "imponierte", "eine", "chronisch", "verlaufende", "granulomatoese", ",", "teils", "fibrosierende", "Entzuendung", "mit", "transfollikulaerer", "Elimination", "von", "Pigmentgranula", ".", "Klinisch", "zeigte", "sich", "im", "Verlauf", "spontan", "eine", "partielle", "Rueckbildung", "der", "entzuendlichen", "Veraenderungen", "unter", "gleichzeitiger", "Depigmentierung", "und", "Vernarbung", "der", "Haut", ".", "Als", "Taetowierungsfarbstoff", "wurde", "ein", "aromatischer", "Azofarbstoff", "nachgewiesen", ".", "Neben", "der", "positiven", "Hauttestreaktion", "auf", "diesen", "Farbstoff", "zeigte", "der", "Patient", "zusaetzlich", "eine", "positive", "Testreaktion", "auf", "den", "Textilfarbstoffkoppler", "Napthol", "AS", "." ]	[ "umlsterm" ]
Farbstoffe is an umlsterm, Farbstoffe is an umlsterm, Quecksilberverbindungen is an umlsterm, Mann is an umlsterm, Entzuendung is an umlsterm, Haut is an umlsterm, Hauttestreaktion is an umlsterm, Farbstoff is an umlsterm, Patient is an umlsterm	DerHautarzt.70480666.ger.abstr_task1	Sentence: Allergische Reaktionen auf Farbstoffe in Taetowierungen sind vergleichsweise selten . In der Mehrzahl sind es Reaktionen auf die roten Farbstoffe . Waehrend frueher hauptsaechlich Quecksilberverbindungen ( Zinnober und Cadmiumsulfid ) dafuer verantwortlich waren , stehen heute die synthetischen anorganischen Azofarbstoffe im Vordergrund . Es wird ein 42jaehriger Mann mit allergischer Reaktion in seinen roten Taetowierungsanteilen vorgestellt . Histologisch imponierte eine chronisch verlaufende granulomatoese , teils fibrosierende Entzuendung mit transfollikulaerer Elimination von Pigmentgranula . Klinisch zeigte sich im Verlauf spontan eine partielle Rueckbildung der entzuendlichen Veraenderungen unter gleichzeitiger Depigmentierung und Vernarbung der Haut . Als Taetowierungsfarbstoff wurde ein aromatischer Azofarbstoff nachgewiesen . Neben der positiven Hauttestreaktion auf diesen Farbstoff zeigte der Patient zusaetzlich eine positive Testreaktion auf den Textilfarbstoffkoppler Napthol AS . Instructions: please typing these entity words according to sentence: Farbstoffe, Farbstoffe, Quecksilberverbindungen, Mann, Entzuendung, Haut, Hauttestreaktion, Farbstoff, Patient Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Allergische Reaktionen auf Farbstoffe in Taetowierungen sind vergleichsweise selten . In der Mehrzahl sind es Reaktionen auf die roten Farbstoffe . Waehrend frueher hauptsaechlich Quecksilberverbindungen ( Zinnober und Cadmiumsulfid ) dafuer verantwortlich waren , stehen heute die synthetischen anorganischen Azofarbstoffe im Vordergrund . Es wird ein 42jaehriger Mann mit allergischer Reaktion in seinen roten Taetowierungsanteilen vorgestellt . Histologisch imponierte eine chronisch verlaufende granulomatoese , teils fibrosierende Entzuendung mit transfollikulaerer Elimination von Pigmentgranula . Klinisch zeigte sich im Verlauf spontan eine partielle Rueckbildung der entzuendlichen Veraenderungen unter gleichzeitiger Depigmentierung und Vernarbung der Haut . Als Taetowierungsfarbstoff wurde ein aromatischer Azofarbstoff nachgewiesen . Neben der positiven Hauttestreaktion auf diesen Farbstoff zeigte der Patient zusaetzlich eine positive Testreaktion auf den Textilfarbstoffkoppler Napthol AS .	[ "Allergische", "Reaktionen", "auf", "Farbstoffe", "in", "Taetowierungen", "sind", "vergleichsweise", "selten", ".", "In", "der", "Mehrzahl", "sind", "es", "Reaktionen", "auf", "die", "roten", "Farbstoffe", ".", "Waehrend", "frueher", "hauptsaechlich", "Quecksilberverbindungen", "(", "Zinnober", "und", "Cadmiumsulfid", ")", "dafuer", "verantwortlich", "waren", ",", "stehen", "heute", "die", "synthetischen", "anorganischen", "Azofarbstoffe", "im", "Vordergrund", ".", "Es", "wird", "ein", "42jaehriger", "Mann", "mit", "allergischer", "Reaktion", "in", "seinen", "roten", "Taetowierungsanteilen", "vorgestellt", ".", "Histologisch", "imponierte", "eine", "chronisch", "verlaufende", "granulomatoese", ",", "teils", "fibrosierende", "Entzuendung", "mit", "transfollikulaerer", "Elimination", "von", "Pigmentgranula", ".", "Klinisch", "zeigte", "sich", "im", "Verlauf", "spontan", "eine", "partielle", "Rueckbildung", "der", "entzuendlichen", "Veraenderungen", "unter", "gleichzeitiger", "Depigmentierung", "und", "Vernarbung", "der", "Haut", ".", "Als", "Taetowierungsfarbstoff", "wurde", "ein", "aromatischer", "Azofarbstoff", "nachgewiesen", ".", "Neben", "der", "positiven", "Hauttestreaktion", "auf", "diesen", "Farbstoff", "zeigte", "der", "Patient", "zusaetzlich", "eine", "positive", "Testreaktion", "auf", "den", "Textilfarbstoffkoppler", "Napthol", "AS", "." ]	[ "umlsterm" ]
Farbstoffe, Farbstoffe, Quecksilberverbindungen, Mann, Entzuendung, Haut, Hauttestreaktion, Farbstoff, Patient	DerHautarzt.70480666.ger.abstr_task2	Sentence: Allergische Reaktionen auf Farbstoffe in Taetowierungen sind vergleichsweise selten . In der Mehrzahl sind es Reaktionen auf die roten Farbstoffe . Waehrend frueher hauptsaechlich Quecksilberverbindungen ( Zinnober und Cadmiumsulfid ) dafuer verantwortlich waren , stehen heute die synthetischen anorganischen Azofarbstoffe im Vordergrund . Es wird ein 42jaehriger Mann mit allergischer Reaktion in seinen roten Taetowierungsanteilen vorgestellt . Histologisch imponierte eine chronisch verlaufende granulomatoese , teils fibrosierende Entzuendung mit transfollikulaerer Elimination von Pigmentgranula . Klinisch zeigte sich im Verlauf spontan eine partielle Rueckbildung der entzuendlichen Veraenderungen unter gleichzeitiger Depigmentierung und Vernarbung der Haut . Als Taetowierungsfarbstoff wurde ein aromatischer Azofarbstoff nachgewiesen . Neben der positiven Hauttestreaktion auf diesen Farbstoff zeigte der Patient zusaetzlich eine positive Testreaktion auf den Textilfarbstoffkoppler Napthol AS . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Allergische Reaktionen auf Farbstoffe in Taetowierungen sind vergleichsweise selten . In der Mehrzahl sind es Reaktionen auf die roten Farbstoffe . Waehrend frueher hauptsaechlich Quecksilberverbindungen ( Zinnober und Cadmiumsulfid ) dafuer verantwortlich waren , stehen heute die synthetischen anorganischen Azofarbstoffe im Vordergrund . Es wird ein 42jaehriger Mann mit allergischer Reaktion in seinen roten Taetowierungsanteilen vorgestellt . Histologisch imponierte eine chronisch verlaufende granulomatoese , teils fibrosierende Entzuendung mit transfollikulaerer Elimination von Pigmentgranula . Klinisch zeigte sich im Verlauf spontan eine partielle Rueckbildung der entzuendlichen Veraenderungen unter gleichzeitiger Depigmentierung und Vernarbung der Haut . Als Taetowierungsfarbstoff wurde ein aromatischer Azofarbstoff nachgewiesen . Neben der positiven Hauttestreaktion auf diesen Farbstoff zeigte der Patient zusaetzlich eine positive Testreaktion auf den Textilfarbstoffkoppler Napthol AS .	[ "Allergische", "Reaktionen", "auf", "Farbstoffe", "in", "Taetowierungen", "sind", "vergleichsweise", "selten", ".", "In", "der", "Mehrzahl", "sind", "es", "Reaktionen", "auf", "die", "roten", "Farbstoffe", ".", "Waehrend", "frueher", "hauptsaechlich", "Quecksilberverbindungen", "(", "Zinnober", "und", "Cadmiumsulfid", ")", "dafuer", "verantwortlich", "waren", ",", "stehen", "heute", "die", "synthetischen", "anorganischen", "Azofarbstoffe", "im", "Vordergrund", ".", "Es", "wird", "ein", "42jaehriger", "Mann", "mit", "allergischer", "Reaktion", "in", "seinen", "roten", "Taetowierungsanteilen", "vorgestellt", ".", "Histologisch", "imponierte", "eine", "chronisch", "verlaufende", "granulomatoese", ",", "teils", "fibrosierende", "Entzuendung", "mit", "transfollikulaerer", "Elimination", "von", "Pigmentgranula", ".", "Klinisch", "zeigte", "sich", "im", "Verlauf", "spontan", "eine", "partielle", "Rueckbildung", "der", "entzuendlichen", "Veraenderungen", "unter", "gleichzeitiger", "Depigmentierung", "und", "Vernarbung", "der", "Haut", ".", "Als", "Taetowierungsfarbstoff", "wurde", "ein", "aromatischer", "Azofarbstoff", "nachgewiesen", ".", "Neben", "der", "positiven", "Hauttestreaktion", "auf", "diesen", "Farbstoff", "zeigte", "der", "Patient", "zusaetzlich", "eine", "positive", "Testreaktion", "auf", "den", "Textilfarbstoffkoppler", "Napthol", "AS", "." ]	[ "umlsterm" ]
Belastung is an umlsterm, diagnoseuebergreifende is an umlsterm, Instruments is an umlsterm	ZfuerGerontologie+Geriatrie.90320231.ger.abstr_task0	Sentence: Mit dem Grad Objektiver Gesundheitlicher Belastung ( OGB ) wird ein Expertenrating zur Erfassung der Beeintraechtigung durch koerperliche Erkrankungen vorgestellt , das unter Beruecksichtigung des Alters eine diagnoseuebergreifende klinische Schweregradeinschaetzung koerperlicher Erkrankungen ermoeglicht . Die fuenf Skalenstufen werden mit klinischen Ankerbeispielen belegt . Die Interrater-Reliabilitaet des OGB ist mit mindestens 0,74 zufriedenstellend . Externe Kriterien geben erste Hinweise auf die Validitaet des Instruments . Seine leichte Erlernbarkeit und Handhabbarkeit sprechen fuer einen breiten klinischen Einsatz sowohl im Rahmen des geriatrischen Basisassessments als auch unter Forschungsaspekten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mit dem Grad Objektiver Gesundheitlicher Belastung ( OGB ) wird ein Expertenrating zur Erfassung der Beeintraechtigung durch koerperliche Erkrankungen vorgestellt , das unter Beruecksichtigung des Alters eine diagnoseuebergreifende klinische Schweregradeinschaetzung koerperlicher Erkrankungen ermoeglicht . Die fuenf Skalenstufen werden mit klinischen Ankerbeispielen belegt . Die Interrater-Reliabilitaet des OGB ist mit mindestens 0,74 zufriedenstellend . Externe Kriterien geben erste Hinweise auf die Validitaet des Instruments . Seine leichte Erlernbarkeit und Handhabbarkeit sprechen fuer einen breiten klinischen Einsatz sowohl im Rahmen des geriatrischen Basisassessments als auch unter Forschungsaspekten .	[ "Mit", "dem", "Grad", "Objektiver", "Gesundheitlicher", "Belastung", "(", "OGB", ")", "wird", "ein", "Expertenrating", "zur", "Erfassung", "der", "Beeintraechtigung", "durch", "koerperliche", "Erkrankungen", "vorgestellt", ",", "das", "unter", "Beruecksichtigung", "des", "Alters", "eine", "diagnoseuebergreifende", "klinische", "Schweregradeinschaetzung", "koerperlicher", "Erkrankungen", "ermoeglicht", ".", "Die", "fuenf", "Skalenstufen", "werden", "mit", "klinischen", "Ankerbeispielen", "belegt", ".", "Die", "Interrater", "-", "Reliabilitaet", "des", "OGB", "ist", "mit", "mindestens", "0,74", "zufriedenstellend", ".", "Externe", "Kriterien", "geben", "erste", "Hinweise", "auf", "die", "Validitaet", "des", "Instruments", ".", "Seine", "leichte", "Erlernbarkeit", "und", "Handhabbarkeit", "sprechen", "fuer", "einen", "breiten", "klinischen", "Einsatz", "sowohl", "im", "Rahmen", "des", "geriatrischen", "Basisassessments", "als", "auch", "unter", "Forschungsaspekten", "." ]	[ "umlsterm" ]
Belastung is an umlsterm, diagnoseuebergreifende is an umlsterm, Instruments is an umlsterm	ZfuerGerontologie+Geriatrie.90320231.ger.abstr_task1	Sentence: Mit dem Grad Objektiver Gesundheitlicher Belastung ( OGB ) wird ein Expertenrating zur Erfassung der Beeintraechtigung durch koerperliche Erkrankungen vorgestellt , das unter Beruecksichtigung des Alters eine diagnoseuebergreifende klinische Schweregradeinschaetzung koerperlicher Erkrankungen ermoeglicht . Die fuenf Skalenstufen werden mit klinischen Ankerbeispielen belegt . Die Interrater-Reliabilitaet des OGB ist mit mindestens 0,74 zufriedenstellend . Externe Kriterien geben erste Hinweise auf die Validitaet des Instruments . Seine leichte Erlernbarkeit und Handhabbarkeit sprechen fuer einen breiten klinischen Einsatz sowohl im Rahmen des geriatrischen Basisassessments als auch unter Forschungsaspekten . Instructions: please typing these entity words according to sentence: Belastung, diagnoseuebergreifende, Instruments Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mit dem Grad Objektiver Gesundheitlicher Belastung ( OGB ) wird ein Expertenrating zur Erfassung der Beeintraechtigung durch koerperliche Erkrankungen vorgestellt , das unter Beruecksichtigung des Alters eine diagnoseuebergreifende klinische Schweregradeinschaetzung koerperlicher Erkrankungen ermoeglicht . Die fuenf Skalenstufen werden mit klinischen Ankerbeispielen belegt . Die Interrater-Reliabilitaet des OGB ist mit mindestens 0,74 zufriedenstellend . Externe Kriterien geben erste Hinweise auf die Validitaet des Instruments . Seine leichte Erlernbarkeit und Handhabbarkeit sprechen fuer einen breiten klinischen Einsatz sowohl im Rahmen des geriatrischen Basisassessments als auch unter Forschungsaspekten .	[ "Mit", "dem", "Grad", "Objektiver", "Gesundheitlicher", "Belastung", "(", "OGB", ")", "wird", "ein", "Expertenrating", "zur", "Erfassung", "der", "Beeintraechtigung", "durch", "koerperliche", "Erkrankungen", "vorgestellt", ",", "das", "unter", "Beruecksichtigung", "des", "Alters", "eine", "diagnoseuebergreifende", "klinische", "Schweregradeinschaetzung", "koerperlicher", "Erkrankungen", "ermoeglicht", ".", "Die", "fuenf", "Skalenstufen", "werden", "mit", "klinischen", "Ankerbeispielen", "belegt", ".", "Die", "Interrater", "-", "Reliabilitaet", "des", "OGB", "ist", "mit", "mindestens", "0,74", "zufriedenstellend", ".", "Externe", "Kriterien", "geben", "erste", "Hinweise", "auf", "die", "Validitaet", "des", "Instruments", ".", "Seine", "leichte", "Erlernbarkeit", "und", "Handhabbarkeit", "sprechen", "fuer", "einen", "breiten", "klinischen", "Einsatz", "sowohl", "im", "Rahmen", "des", "geriatrischen", "Basisassessments", "als", "auch", "unter", "Forschungsaspekten", "." ]	[ "umlsterm" ]
Belastung, diagnoseuebergreifende, Instruments	ZfuerGerontologie+Geriatrie.90320231.ger.abstr_task2	Sentence: Mit dem Grad Objektiver Gesundheitlicher Belastung ( OGB ) wird ein Expertenrating zur Erfassung der Beeintraechtigung durch koerperliche Erkrankungen vorgestellt , das unter Beruecksichtigung des Alters eine diagnoseuebergreifende klinische Schweregradeinschaetzung koerperlicher Erkrankungen ermoeglicht . Die fuenf Skalenstufen werden mit klinischen Ankerbeispielen belegt . Die Interrater-Reliabilitaet des OGB ist mit mindestens 0,74 zufriedenstellend . Externe Kriterien geben erste Hinweise auf die Validitaet des Instruments . Seine leichte Erlernbarkeit und Handhabbarkeit sprechen fuer einen breiten klinischen Einsatz sowohl im Rahmen des geriatrischen Basisassessments als auch unter Forschungsaspekten . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mit dem Grad Objektiver Gesundheitlicher Belastung ( OGB ) wird ein Expertenrating zur Erfassung der Beeintraechtigung durch koerperliche Erkrankungen vorgestellt , das unter Beruecksichtigung des Alters eine diagnoseuebergreifende klinische Schweregradeinschaetzung koerperlicher Erkrankungen ermoeglicht . Die fuenf Skalenstufen werden mit klinischen Ankerbeispielen belegt . Die Interrater-Reliabilitaet des OGB ist mit mindestens 0,74 zufriedenstellend . Externe Kriterien geben erste Hinweise auf die Validitaet des Instruments . Seine leichte Erlernbarkeit und Handhabbarkeit sprechen fuer einen breiten klinischen Einsatz sowohl im Rahmen des geriatrischen Basisassessments als auch unter Forschungsaspekten .	[ "Mit", "dem", "Grad", "Objektiver", "Gesundheitlicher", "Belastung", "(", "OGB", ")", "wird", "ein", "Expertenrating", "zur", "Erfassung", "der", "Beeintraechtigung", "durch", "koerperliche", "Erkrankungen", "vorgestellt", ",", "das", "unter", "Beruecksichtigung", "des", "Alters", "eine", "diagnoseuebergreifende", "klinische", "Schweregradeinschaetzung", "koerperlicher", "Erkrankungen", "ermoeglicht", ".", "Die", "fuenf", "Skalenstufen", "werden", "mit", "klinischen", "Ankerbeispielen", "belegt", ".", "Die", "Interrater", "-", "Reliabilitaet", "des", "OGB", "ist", "mit", "mindestens", "0,74", "zufriedenstellend", ".", "Externe", "Kriterien", "geben", "erste", "Hinweise", "auf", "die", "Validitaet", "des", "Instruments", ".", "Seine", "leichte", "Erlernbarkeit", "und", "Handhabbarkeit", "sprechen", "fuer", "einen", "breiten", "klinischen", "Einsatz", "sowohl", "im", "Rahmen", "des", "geriatrischen", "Basisassessments", "als", "auch", "unter", "Forschungsaspekten", "." ]	[ "umlsterm" ]
survivors of breast cancer : is a Participant_Condition, placebo - controlled is a Intervention_Control, bisphosphonate therapy is a Intervention_Pharmacological, breast cancer survivors . is a Participant_Condition, risedronate is a Intervention_Pharmacological, 12-month changes in spine and hip bone mineral density . is a Outcome_Physical, changes in markers of bone resorption ( urine N - telopeptide cross - linked collagen type I ) and formation ( osteocalcin , N - terminal propeptide of type I procollagen , and bone - specific alkaline phosphatase ) is a Outcome_Physical, Risedronate is a Intervention_Pharmacological, tolerated is a Outcome_Other, retention rate is a Outcome_Other	28357_task0	Sentence: Prevention of bone loss in survivors of breast cancer : A randomized , double-blind , placebo-controlled clinical trial . BACKGROUND Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors . OBJECTIVE Our objective was to determine whether risedronate , 35 mg weekly , is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause . DESIGN The study was a randomized , double-blind , placebo-controlled clinical trial over 12 months . SETTING AND PARTICIPANTS Participants included 87 newly postmenopausal women with status post chemotherapy , recruited from a breast cancer clinic in an academic medical center . INTERVENTION Participants were randomly assigned to receive risedronate 35 mg/wk or placebo . MAIN OUTCOME MEASURES The primary outcomes were the 12-month changes in spine and hip bone mineral density . Secondary outcomes included changes in markers of bone resorption ( urine N-telopeptide cross-linked collagen type I ) and formation ( osteocalcin , N-terminal propeptide of type I procollagen , and bone-specific alkaline phosphatase ) . RESULTS After 12 months , bone mineral density increased by 1.2 % at the spine and 1.3 % at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9 % at the spine and 0.8 % at the hip ( P < 0.01 , difference between groups ) . N-telopeptide cross-linked collagen type I , a marker of bone resorption , decreased by 19.3 % , and N-terminal propeptide of type I procollagen , a marker of bone formation , decreased by 26.6 % in participants on active therapy compared with increases in the control group . Risedronate was well tolerated , and the retention rate was 95 % at 1 yr . CONCLUSIONS Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy . Early measures to prevent bone loss should be considered in this cohort of breast cancer survivors . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other	[ "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Prevention of bone loss in survivors of breast cancer : A randomized , double-blind , placebo-controlled clinical trial . BACKGROUND Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors . OBJECTIVE Our objective was to determine whether risedronate , 35 mg weekly , is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause . DESIGN The study was a randomized , double-blind , placebo-controlled clinical trial over 12 months . SETTING AND PARTICIPANTS Participants included 87 newly postmenopausal women with status post chemotherapy , recruited from a breast cancer clinic in an academic medical center . INTERVENTION Participants were randomly assigned to receive risedronate 35 mg/wk or placebo . MAIN OUTCOME MEASURES The primary outcomes were the 12-month changes in spine and hip bone mineral density . Secondary outcomes included changes in markers of bone resorption ( urine N-telopeptide cross-linked collagen type I ) and formation ( osteocalcin , N-terminal propeptide of type I procollagen , and bone-specific alkaline phosphatase ) . RESULTS After 12 months , bone mineral density increased by 1.2 % at the spine and 1.3 % at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9 % at the spine and 0.8 % at the hip ( P < 0.01 , difference between groups ) . N-telopeptide cross-linked collagen type I , a marker of bone resorption , decreased by 19.3 % , and N-terminal propeptide of type I procollagen , a marker of bone formation , decreased by 26.6 % in participants on active therapy compared with increases in the control group . Risedronate was well tolerated , and the retention rate was 95 % at 1 yr . CONCLUSIONS Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy . Early measures to prevent bone loss should be considered in this cohort of breast cancer survivors .	[ "Prevention", "of", "bone", "loss", "in", "survivors", "of", "breast", "cancer", ":", "A", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "Few", "data", "are", "available", "on", "the", "safety", "and", "efficacy", "of", "once", "-", "weekly", "oral", "bisphosphonate", "therapy", "in", "breast", "cancer", "survivors", ".", "OBJECTIVE", "Our", "objective", "was", "to", "determine", "whether", "risedronate", ",", "35", "mg", "weekly", ",", "is", "efficacious", "and", "safe", "in", "preventing", "bone", "loss", "associated", "with", "chemotherapy", "-", "induced", "menopause", ".", "DESIGN", "The", "study", "was", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", "over", "12", "months", ".", "SETTING", "AND", "PARTICIPANTS", "Participants", "included", "87", "newly", "postmenopausal", "women", "with", "status", "post", "chemotherapy", ",", "recruited", "from", "a", "breast", "cancer", "clinic", "in", "an", "academic", "medical", "center", ".", "INTERVENTION", "Participants", "were", "randomly", "assigned", "to", "receive", "risedronate", "35", "mg", "/", "wk", "or", "placebo", ".", "MAIN", "OUTCOME", "MEASURES", "The", "primary", "outcomes", "were", "the", "12-month", "changes", "in", "spine", "and", "hip", "bone", "mineral", "density", ".", "Secondary", "outcomes", "included", "changes", "in", "markers", "of", "bone", "resorption", "(", "urine", "N", "-", "telopeptide", "cross", "-", "linked", "collagen", "type", "I", ")", "and", "formation", "(", "osteocalcin", ",", "N", "-", "terminal", "propeptide", "of", "type", "I", "procollagen", ",", "and", "bone", "-", "specific", "alkaline", "phosphatase", ")", ".", "RESULTS", "After", "12", "months", ",", "bone", "mineral", "density", "increased", "by", "1.2", "%", "at", "the", "spine", "and", "1.3", "%", "at", "the", "hip", "in", "women", "on", "risedronate", "vs", ".", "significant", "decreases", "for", "women", "in", "the", "placebo", "group", "of", "0.9", "%", "at", "the", "spine", "and", "0.8", "%", "at", "the", "hip", "(", "P", "<", "0.01", ",", "difference", "between", "groups", ")", ".", "N", "-", "telopeptide", "cross", "-", "linked", "collagen", "type", "I", ",", "a", "marker", "of", "bone", "resorption", ",", "decreased", "by", "19.3", "%", ",", "and", "N", "-", "terminal", "propeptide", "of", "type", "I", "procollagen", ",", "a", "marker", "of", "bone", "formation", ",", "decreased", "by", "26.6", "%", "in", "participants", "on", "active", "therapy", "compared", "with", "increases", "in", "the", "control", "group", ".", "Risedronate", "was", "well", "tolerated", ",", "and", "the", "retention", "rate", "was", "95", "%", "at", "1", "yr", ".", "CONCLUSIONS", "Risedronate", "once", "weekly", "prevented", "bone", "loss", "and", "reduced", "bone", "turnover", "in", "women", "with", "breast", "cancer", "treated", "with", "chemotherapy", ".", "Early", "measures", "to", "prevent", "bone", "loss", "should", "be", "considered", "in", "this", "cohort", "of", "breast", "cancer", "survivors", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Outcome_Other" ]
survivors of breast cancer : is a Participant_Condition, placebo - controlled is a Intervention_Control, bisphosphonate therapy is a Intervention_Pharmacological, breast cancer survivors . is a Participant_Condition, risedronate is a Intervention_Pharmacological, 12-month changes in spine and hip bone mineral density . is a Outcome_Physical, changes in markers of bone resorption ( urine N - telopeptide cross - linked collagen type I ) and formation ( osteocalcin , N - terminal propeptide of type I procollagen , and bone - specific alkaline phosphatase ) is a Outcome_Physical, Risedronate is a Intervention_Pharmacological, tolerated is a Outcome_Other, retention rate is a Outcome_Other	28357_task1	Sentence: Prevention of bone loss in survivors of breast cancer : A randomized , double-blind , placebo-controlled clinical trial . BACKGROUND Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors . OBJECTIVE Our objective was to determine whether risedronate , 35 mg weekly , is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause . DESIGN The study was a randomized , double-blind , placebo-controlled clinical trial over 12 months . SETTING AND PARTICIPANTS Participants included 87 newly postmenopausal women with status post chemotherapy , recruited from a breast cancer clinic in an academic medical center . INTERVENTION Participants were randomly assigned to receive risedronate 35 mg/wk or placebo . MAIN OUTCOME MEASURES The primary outcomes were the 12-month changes in spine and hip bone mineral density . Secondary outcomes included changes in markers of bone resorption ( urine N-telopeptide cross-linked collagen type I ) and formation ( osteocalcin , N-terminal propeptide of type I procollagen , and bone-specific alkaline phosphatase ) . RESULTS After 12 months , bone mineral density increased by 1.2 % at the spine and 1.3 % at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9 % at the spine and 0.8 % at the hip ( P < 0.01 , difference between groups ) . N-telopeptide cross-linked collagen type I , a marker of bone resorption , decreased by 19.3 % , and N-terminal propeptide of type I procollagen , a marker of bone formation , decreased by 26.6 % in participants on active therapy compared with increases in the control group . Risedronate was well tolerated , and the retention rate was 95 % at 1 yr . CONCLUSIONS Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy . Early measures to prevent bone loss should be considered in this cohort of breast cancer survivors . Instructions: please typing these entity words according to sentence: survivors of breast cancer :, placebo - controlled, bisphosphonate therapy, breast cancer survivors ., risedronate, 12-month changes in spine and hip bone mineral density ., changes in markers of bone resorption ( urine N - telopeptide cross - linked collagen type I ) and formation ( osteocalcin , N - terminal propeptide of type I procollagen , and bone - specific alkaline phosphatase ), Risedronate, tolerated, retention rate Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other	[ "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Prevention of bone loss in survivors of breast cancer : A randomized , double-blind , placebo-controlled clinical trial . BACKGROUND Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors . OBJECTIVE Our objective was to determine whether risedronate , 35 mg weekly , is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause . DESIGN The study was a randomized , double-blind , placebo-controlled clinical trial over 12 months . SETTING AND PARTICIPANTS Participants included 87 newly postmenopausal women with status post chemotherapy , recruited from a breast cancer clinic in an academic medical center . INTERVENTION Participants were randomly assigned to receive risedronate 35 mg/wk or placebo . MAIN OUTCOME MEASURES The primary outcomes were the 12-month changes in spine and hip bone mineral density . Secondary outcomes included changes in markers of bone resorption ( urine N-telopeptide cross-linked collagen type I ) and formation ( osteocalcin , N-terminal propeptide of type I procollagen , and bone-specific alkaline phosphatase ) . RESULTS After 12 months , bone mineral density increased by 1.2 % at the spine and 1.3 % at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9 % at the spine and 0.8 % at the hip ( P < 0.01 , difference between groups ) . N-telopeptide cross-linked collagen type I , a marker of bone resorption , decreased by 19.3 % , and N-terminal propeptide of type I procollagen , a marker of bone formation , decreased by 26.6 % in participants on active therapy compared with increases in the control group . Risedronate was well tolerated , and the retention rate was 95 % at 1 yr . CONCLUSIONS Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy . Early measures to prevent bone loss should be considered in this cohort of breast cancer survivors .	[ "Prevention", "of", "bone", "loss", "in", "survivors", "of", "breast", "cancer", ":", "A", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "Few", "data", "are", "available", "on", "the", "safety", "and", "efficacy", "of", "once", "-", "weekly", "oral", "bisphosphonate", "therapy", "in", "breast", "cancer", "survivors", ".", "OBJECTIVE", "Our", "objective", "was", "to", "determine", "whether", "risedronate", ",", "35", "mg", "weekly", ",", "is", "efficacious", "and", "safe", "in", "preventing", "bone", "loss", "associated", "with", "chemotherapy", "-", "induced", "menopause", ".", "DESIGN", "The", "study", "was", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", "over", "12", "months", ".", "SETTING", "AND", "PARTICIPANTS", "Participants", "included", "87", "newly", "postmenopausal", "women", "with", "status", "post", "chemotherapy", ",", "recruited", "from", "a", "breast", "cancer", "clinic", "in", "an", "academic", "medical", "center", ".", "INTERVENTION", "Participants", "were", "randomly", "assigned", "to", "receive", "risedronate", "35", "mg", "/", "wk", "or", "placebo", ".", "MAIN", "OUTCOME", "MEASURES", "The", "primary", "outcomes", "were", "the", "12-month", "changes", "in", "spine", "and", "hip", "bone", "mineral", "density", ".", "Secondary", "outcomes", "included", "changes", "in", "markers", "of", "bone", "resorption", "(", "urine", "N", "-", "telopeptide", "cross", "-", "linked", "collagen", "type", "I", ")", "and", "formation", "(", "osteocalcin", ",", "N", "-", "terminal", "propeptide", "of", "type", "I", "procollagen", ",", "and", "bone", "-", "specific", "alkaline", "phosphatase", ")", ".", "RESULTS", "After", "12", "months", ",", "bone", "mineral", "density", "increased", "by", "1.2", "%", "at", "the", "spine", "and", "1.3", "%", "at", "the", "hip", "in", "women", "on", "risedronate", "vs", ".", "significant", "decreases", "for", "women", "in", "the", "placebo", "group", "of", "0.9", "%", "at", "the", "spine", "and", "0.8", "%", "at", "the", "hip", "(", "P", "<", "0.01", ",", "difference", "between", "groups", ")", ".", "N", "-", "telopeptide", "cross", "-", "linked", "collagen", "type", "I", ",", "a", "marker", "of", "bone", "resorption", ",", "decreased", "by", "19.3", "%", ",", "and", "N", "-", "terminal", "propeptide", "of", "type", "I", "procollagen", ",", "a", "marker", "of", "bone", "formation", ",", "decreased", "by", "26.6", "%", "in", "participants", "on", "active", "therapy", "compared", "with", "increases", "in", "the", "control", "group", ".", "Risedronate", "was", "well", "tolerated", ",", "and", "the", "retention", "rate", "was", "95", "%", "at", "1", "yr", ".", "CONCLUSIONS", "Risedronate", "once", "weekly", "prevented", "bone", "loss", "and", "reduced", "bone", "turnover", "in", "women", "with", "breast", "cancer", "treated", "with", "chemotherapy", ".", "Early", "measures", "to", "prevent", "bone", "loss", "should", "be", "considered", "in", "this", "cohort", "of", "breast", "cancer", "survivors", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Outcome_Other" ]
survivors of breast cancer :, placebo - controlled, bisphosphonate therapy, breast cancer survivors ., risedronate, 12-month changes in spine and hip bone mineral density ., changes in markers of bone resorption ( urine N - telopeptide cross - linked collagen type I ) and formation ( osteocalcin , N - terminal propeptide of type I procollagen , and bone - specific alkaline phosphatase ), Risedronate, tolerated, retention rate	28357_task2	Sentence: Prevention of bone loss in survivors of breast cancer : A randomized , double-blind , placebo-controlled clinical trial . BACKGROUND Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors . OBJECTIVE Our objective was to determine whether risedronate , 35 mg weekly , is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause . DESIGN The study was a randomized , double-blind , placebo-controlled clinical trial over 12 months . SETTING AND PARTICIPANTS Participants included 87 newly postmenopausal women with status post chemotherapy , recruited from a breast cancer clinic in an academic medical center . INTERVENTION Participants were randomly assigned to receive risedronate 35 mg/wk or placebo . MAIN OUTCOME MEASURES The primary outcomes were the 12-month changes in spine and hip bone mineral density . Secondary outcomes included changes in markers of bone resorption ( urine N-telopeptide cross-linked collagen type I ) and formation ( osteocalcin , N-terminal propeptide of type I procollagen , and bone-specific alkaline phosphatase ) . RESULTS After 12 months , bone mineral density increased by 1.2 % at the spine and 1.3 % at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9 % at the spine and 0.8 % at the hip ( P < 0.01 , difference between groups ) . N-telopeptide cross-linked collagen type I , a marker of bone resorption , decreased by 19.3 % , and N-terminal propeptide of type I procollagen , a marker of bone formation , decreased by 26.6 % in participants on active therapy compared with increases in the control group . Risedronate was well tolerated , and the retention rate was 95 % at 1 yr . CONCLUSIONS Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy . Early measures to prevent bone loss should be considered in this cohort of breast cancer survivors . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Prevention of bone loss in survivors of breast cancer : A randomized , double-blind , placebo-controlled clinical trial . BACKGROUND Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors . OBJECTIVE Our objective was to determine whether risedronate , 35 mg weekly , is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause . DESIGN The study was a randomized , double-blind , placebo-controlled clinical trial over 12 months . SETTING AND PARTICIPANTS Participants included 87 newly postmenopausal women with status post chemotherapy , recruited from a breast cancer clinic in an academic medical center . INTERVENTION Participants were randomly assigned to receive risedronate 35 mg/wk or placebo . MAIN OUTCOME MEASURES The primary outcomes were the 12-month changes in spine and hip bone mineral density . Secondary outcomes included changes in markers of bone resorption ( urine N-telopeptide cross-linked collagen type I ) and formation ( osteocalcin , N-terminal propeptide of type I procollagen , and bone-specific alkaline phosphatase ) . RESULTS After 12 months , bone mineral density increased by 1.2 % at the spine and 1.3 % at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9 % at the spine and 0.8 % at the hip ( P < 0.01 , difference between groups ) . N-telopeptide cross-linked collagen type I , a marker of bone resorption , decreased by 19.3 % , and N-terminal propeptide of type I procollagen , a marker of bone formation , decreased by 26.6 % in participants on active therapy compared with increases in the control group . Risedronate was well tolerated , and the retention rate was 95 % at 1 yr . CONCLUSIONS Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy . Early measures to prevent bone loss should be considered in this cohort of breast cancer survivors .	[ "Prevention", "of", "bone", "loss", "in", "survivors", "of", "breast", "cancer", ":", "A", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "Few", "data", "are", "available", "on", "the", "safety", "and", "efficacy", "of", "once", "-", "weekly", "oral", "bisphosphonate", "therapy", "in", "breast", "cancer", "survivors", ".", "OBJECTIVE", "Our", "objective", "was", "to", "determine", "whether", "risedronate", ",", "35", "mg", "weekly", ",", "is", "efficacious", "and", "safe", "in", "preventing", "bone", "loss", "associated", "with", "chemotherapy", "-", "induced", "menopause", ".", "DESIGN", "The", "study", "was", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", "over", "12", "months", ".", "SETTING", "AND", "PARTICIPANTS", "Participants", "included", "87", "newly", "postmenopausal", "women", "with", "status", "post", "chemotherapy", ",", "recruited", "from", "a", "breast", "cancer", "clinic", "in", "an", "academic", "medical", "center", ".", "INTERVENTION", "Participants", "were", "randomly", "assigned", "to", "receive", "risedronate", "35", "mg", "/", "wk", "or", "placebo", ".", "MAIN", "OUTCOME", "MEASURES", "The", "primary", "outcomes", "were", "the", "12-month", "changes", "in", "spine", "and", "hip", "bone", "mineral", "density", ".", "Secondary", "outcomes", "included", "changes", "in", "markers", "of", "bone", "resorption", "(", "urine", "N", "-", "telopeptide", "cross", "-", "linked", "collagen", "type", "I", ")", "and", "formation", "(", "osteocalcin", ",", "N", "-", "terminal", "propeptide", "of", "type", "I", "procollagen", ",", "and", "bone", "-", "specific", "alkaline", "phosphatase", ")", ".", "RESULTS", "After", "12", "months", ",", "bone", "mineral", "density", "increased", "by", "1.2", "%", "at", "the", "spine", "and", "1.3", "%", "at", "the", "hip", "in", "women", "on", "risedronate", "vs", ".", "significant", "decreases", "for", "women", "in", "the", "placebo", "group", "of", "0.9", "%", "at", "the", "spine", "and", "0.8", "%", "at", "the", "hip", "(", "P", "<", "0.01", ",", "difference", "between", "groups", ")", ".", "N", "-", "telopeptide", "cross", "-", "linked", "collagen", "type", "I", ",", "a", "marker", "of", "bone", "resorption", ",", "decreased", "by", "19.3", "%", ",", "and", "N", "-", "terminal", "propeptide", "of", "type", "I", "procollagen", ",", "a", "marker", "of", "bone", "formation", ",", "decreased", "by", "26.6", "%", "in", "participants", "on", "active", "therapy", "compared", "with", "increases", "in", "the", "control", "group", ".", "Risedronate", "was", "well", "tolerated", ",", "and", "the", "retention", "rate", "was", "95", "%", "at", "1", "yr", ".", "CONCLUSIONS", "Risedronate", "once", "weekly", "prevented", "bone", "loss", "and", "reduced", "bone", "turnover", "in", "women", "with", "breast", "cancer", "treated", "with", "chemotherapy", ".", "Early", "measures", "to", "prevent", "bone", "loss", "should", "be", "considered", "in", "this", "cohort", "of", "breast", "cancer", "survivors", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Outcome_Other" ]
zoledronic acid is a Intervention_Pharmacological, women is a Participant_Sex, locally advanced breast cancer is a Participant_Condition, bisphosphonates is a Intervention_Pharmacological, disseminated tumour cells ( DTCs ) is a Outcome_Physical, neoadjuvant chemotherapy is a Participant_Condition, clinical stage II - III ( > or = T2 and / or > or = N1 ) newly diagnosed breast cancer is a Participant_Condition, 120 is a Participant_Sample-size, 4 mg zoledronic acid intravenously every is a Intervention_Pharmacological, no zoledronic acid is a Intervention_Pharmacological, four cycles of neoadjuvant epirubicin is a Intervention_Pharmacological, docetaxel is a Intervention_Pharmacological, and two cycles of adjuvant epirubicin plus docetaxel is a Intervention_Pharmacological, detectable DTCs is a Outcome_Physical, baseline bone marrow is a Participant_Condition, 109 is a Participant_Sample-size, bone - marrow samples is a Participant_Condition, osteonecrosis is a Outcome_Adverse-effects, Zoledronic acid is a Intervention_Pharmacological	45221_task0	Sentence: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer : an open label , randomised , phase 2 trial . BACKGROUND Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer . The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells ( DTCs ) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer . METHODS Patients were recruited for this open-label , phase 2 randomised trial between March 17 , 2003 , and May 19 , 2006 , at a single centre . Eligible patients had clinical stage II-III ( > or = T2 and/or > or = N1 ) newly diagnosed breast cancer , Eastern Cooperative Oncology Group performance status of 0 or 1 , and normal cardiac , renal , and liver function . 120 women were randomly assigned , using allocation concealment , to receive 4 mg zoledronic acid intravenously every 3 weeks ( n=60 ) , or no zoledronic acid ( n=60 ) , for 1 year concomitant with four cycles of neoadjuvant epirubicin ( 75 mg/m ( 2 ) ) plus docetaxel ( 75 mg/m ( 2 ) ) and two cycles of adjuvant epirubicin plus docetaxel . The primary endpoint was the number of patients with detectable DTCs at 3 months . Final analysis was done 1 year after the last patient was enrolled . Analyses were done for all patients with available data at 3 months . This study is registered with ClinicalTrials.gov , number NCT00242203 . FINDINGS Of the 120 patients initially enrolled , one withdrew after signing consent and one patient 's baseline bone marrow was not available . Both of these patients were in the control group . At 3 months , 109 bone-marrow samples were available for analysis . In the zoledronic acid group , bone marrow was not collected from one patient because of disease progression , one patient was taken off study because of severe diarrhoea , and two patients had not consented at the time of surgery . In the control group , bone marrow was not collected from two patients because of disease progression , one patient withdrew consent , and three patients were not consented at the time of surgery . At baseline , DTCs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the control group . At 3 months , 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs ( p=0.054 ) . The most common grade 3-4 toxicities were infection ( five of 60 patients in the zoledronic acid group and six of 59 in the control group ) and thrombosis ( five of 60 in the zoledronic acid and two of 59 in the control group ) . There was one documented case of osteonecrosis in the zoledronic acid group . INTERPRETATION Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery . Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs . FUNDING Novartis Pharmaceuticals and Pfizer Inc . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Participant_Sex, Outcome_Physical, Participant_Sample-size	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Sex", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer : an open label , randomised , phase 2 trial . BACKGROUND Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer . The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells ( DTCs ) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer . METHODS Patients were recruited for this open-label , phase 2 randomised trial between March 17 , 2003 , and May 19 , 2006 , at a single centre . Eligible patients had clinical stage II-III ( > or = T2 and/or > or = N1 ) newly diagnosed breast cancer , Eastern Cooperative Oncology Group performance status of 0 or 1 , and normal cardiac , renal , and liver function . 120 women were randomly assigned , using allocation concealment , to receive 4 mg zoledronic acid intravenously every 3 weeks ( n=60 ) , or no zoledronic acid ( n=60 ) , for 1 year concomitant with four cycles of neoadjuvant epirubicin ( 75 mg/m ( 2 ) ) plus docetaxel ( 75 mg/m ( 2 ) ) and two cycles of adjuvant epirubicin plus docetaxel . The primary endpoint was the number of patients with detectable DTCs at 3 months . Final analysis was done 1 year after the last patient was enrolled . Analyses were done for all patients with available data at 3 months . This study is registered with ClinicalTrials.gov , number NCT00242203 . FINDINGS Of the 120 patients initially enrolled , one withdrew after signing consent and one patient 's baseline bone marrow was not available . Both of these patients were in the control group . At 3 months , 109 bone-marrow samples were available for analysis . In the zoledronic acid group , bone marrow was not collected from one patient because of disease progression , one patient was taken off study because of severe diarrhoea , and two patients had not consented at the time of surgery . In the control group , bone marrow was not collected from two patients because of disease progression , one patient withdrew consent , and three patients were not consented at the time of surgery . At baseline , DTCs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the control group . At 3 months , 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs ( p=0.054 ) . The most common grade 3-4 toxicities were infection ( five of 60 patients in the zoledronic acid group and six of 59 in the control group ) and thrombosis ( five of 60 in the zoledronic acid and two of 59 in the control group ) . There was one documented case of osteonecrosis in the zoledronic acid group . INTERPRETATION Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery . Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs . FUNDING Novartis Pharmaceuticals and Pfizer Inc .	[ "Effect", "of", "zoledronic", "acid", "on", "disseminated", "tumour", "cells", "in", "women", "with", "locally", "advanced", "breast", "cancer", ":", "an", "open", "label", ",", "randomised", ",", "phase", "2", "trial", ".", "BACKGROUND", "Treatment", "with", "bisphosphonates", "decreases", "bone", "loss", "and", "can", "increase", "disease", "-", "free", "survival", "in", "patients", "with", "breast", "cancer", ".", "The", "aim", "of", "our", "study", "was", "to", "assess", "the", "effect", "of", "zoledronic", "acid", "on", "clearance", "of", "disseminated", "tumour", "cells", "(", "DTCs", ")", "from", "the", "bone", "marrow", "in", "women", "undergoing", "neoadjuvant", "chemotherapy", "for", "breast", "cancer", ".", "METHODS", "Patients", "were", "recruited", "for", "this", "open", "-", "label", ",", "phase", "2", "randomised", "trial", "between", "March", "17", ",", "2003", ",", "and", "May", "19", ",", "2006", ",", "at", "a", "single", "centre", ".", "Eligible", "patients", "had", "clinical", "stage", "II", "-", "III", "(", ">", "or", "=", "T2", "and", "/", "or", ">", "or", "=", "N1", ")", "newly", "diagnosed", "breast", "cancer", ",", "Eastern", "Cooperative", "Oncology", "Group", "performance", "status", "of", "0", "or", "1", ",", "and", "normal", "cardiac", ",", "renal", ",", "and", "liver", "function", ".", "120", "women", "were", "randomly", "assigned", ",", "using", "allocation", "concealment", ",", "to", "receive", "4", "mg", "zoledronic", "acid", "intravenously", "every", "3", "weeks", "(", "n=60", ")", ",", "or", "no", "zoledronic", "acid", "(", "n=60", ")", ",", "for", "1", "year", "concomitant", "with", "four", "cycles", "of", "neoadjuvant", "epirubicin", "(", "75", "mg", "/", "m", "(", "2", ")", ")", "plus", "docetaxel", "(", "75", "mg", "/", "m", "(", "2", ")", ")", "and", "two", "cycles", "of", "adjuvant", "epirubicin", "plus", "docetaxel", ".", "The", "primary", "endpoint", "was", "the", "number", "of", "patients", "with", "detectable", "DTCs", "at", "3", "months", ".", "Final", "analysis", "was", "done", "1", "year", "after", "the", "last", "patient", "was", "enrolled", ".", "Analyses", "were", "done", "for", "all", "patients", "with", "available", "data", "at", "3", "months", ".", "This", "study", "is", "registered", "with", "ClinicalTrials.gov", ",", "number", "NCT00242203", ".", "FINDINGS", "Of", "the", "120", "patients", "initially", "enrolled", ",", "one", "withdrew", "after", "signing", "consent", "and", "one", "patient", "'", "s", "baseline", "bone", "marrow", "was", "not", "available", ".", "Both", "of", "these", "patients", "were", "in", "the", "control", "group", ".", "At", "3", "months", ",", "109", "bone", "-", "marrow", "samples", "were", "available", "for", "analysis", ".", "In", "the", "zoledronic", "acid", "group", ",", "bone", "marrow", "was", "not", "collected", "from", "one", "patient", "because", "of", "disease", "progression", ",", "one", "patient", "was", "taken", "off", "study", "because", "of", "severe", "diarrhoea", ",", "and", "two", "patients", "had", "not", "consented", "at", "the", "time", "of", "surgery", ".", "In", "the", "control", "group", ",", "bone", "marrow", "was", "not", "collected", "from", "two", "patients", "because", "of", "disease", "progression", ",", "one", "patient", "withdrew", "consent", ",", "and", "three", "patients", "were", "not", "consented", "at", "the", "time", "of", "surgery", ".", "At", "baseline", ",", "DTCs", "were", "detected", "in", "26", "of", "60", "patients", "in", "the", "zoledronic", "acid", "group", "and", "28", "of", "58", "patients", "in", "the", "control", "group", ".", "At", "3", "months", ",", "17", "of", "56", "patients", "receiving", "zoledronic", "acid", "versus", "25", "of", "53", "patients", "who", "did", "not", "receive", "zoledronic", "acid", "had", "detectable", "DTCs", "(", "p=0.054", ")", ".", "The", "most", "common", "grade", "3", "-", "4", "toxicities", "were", "infection", "(", "five", "of", "60", "patients", "in", "the", "zoledronic", "acid", "group", "and", "six", "of", "59", "in", "the", "control", "group", ")", "and", "thrombosis", "(", "five", "of", "60", "in", "the", "zoledronic", "acid", "and", "two", "of", "59", "in", "the", "control", "group", ")", ".", "There", "was", "one", "documented", "case", "of", "osteonecrosis", "in", "the", "zoledronic", "acid", "group", ".", "INTERPRETATION", "Zoledronic", "acid", "administered", "with", "chemotherapy", "resulted", "in", "a", "decreased", "proportion", "of", "patients", "with", "DTCs", "detected", "in", "the", "bone", "marrow", "at", "the", "time", "of", "surgery", ".", "Our", "study", "supports", "the", "hypothesis", "that", "the", "antimetastatic", "effects", "of", "zoledronic", "acid", "may", "be", "through", "effects", "on", "DTCs", ".", "FUNDING", "Novartis", "Pharmaceuticals", "and", "Pfizer", "Inc", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Sex", "Participant_Sample-size" ]
zoledronic acid is a Intervention_Pharmacological, women is a Participant_Sex, locally advanced breast cancer is a Participant_Condition, bisphosphonates is a Intervention_Pharmacological, disseminated tumour cells ( DTCs ) is a Outcome_Physical, neoadjuvant chemotherapy is a Participant_Condition, clinical stage II - III ( > or = T2 and / or > or = N1 ) newly diagnosed breast cancer is a Participant_Condition, 120 is a Participant_Sample-size, 4 mg zoledronic acid intravenously every is a Intervention_Pharmacological, no zoledronic acid is a Intervention_Pharmacological, four cycles of neoadjuvant epirubicin is a Intervention_Pharmacological, docetaxel is a Intervention_Pharmacological, and two cycles of adjuvant epirubicin plus docetaxel is a Intervention_Pharmacological, detectable DTCs is a Outcome_Physical, baseline bone marrow is a Participant_Condition, 109 is a Participant_Sample-size, bone - marrow samples is a Participant_Condition, osteonecrosis is a Outcome_Adverse-effects, Zoledronic acid is a Intervention_Pharmacological	45221_task1	Sentence: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer : an open label , randomised , phase 2 trial . BACKGROUND Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer . The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells ( DTCs ) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer . METHODS Patients were recruited for this open-label , phase 2 randomised trial between March 17 , 2003 , and May 19 , 2006 , at a single centre . Eligible patients had clinical stage II-III ( > or = T2 and/or > or = N1 ) newly diagnosed breast cancer , Eastern Cooperative Oncology Group performance status of 0 or 1 , and normal cardiac , renal , and liver function . 120 women were randomly assigned , using allocation concealment , to receive 4 mg zoledronic acid intravenously every 3 weeks ( n=60 ) , or no zoledronic acid ( n=60 ) , for 1 year concomitant with four cycles of neoadjuvant epirubicin ( 75 mg/m ( 2 ) ) plus docetaxel ( 75 mg/m ( 2 ) ) and two cycles of adjuvant epirubicin plus docetaxel . The primary endpoint was the number of patients with detectable DTCs at 3 months . Final analysis was done 1 year after the last patient was enrolled . Analyses were done for all patients with available data at 3 months . This study is registered with ClinicalTrials.gov , number NCT00242203 . FINDINGS Of the 120 patients initially enrolled , one withdrew after signing consent and one patient 's baseline bone marrow was not available . Both of these patients were in the control group . At 3 months , 109 bone-marrow samples were available for analysis . In the zoledronic acid group , bone marrow was not collected from one patient because of disease progression , one patient was taken off study because of severe diarrhoea , and two patients had not consented at the time of surgery . In the control group , bone marrow was not collected from two patients because of disease progression , one patient withdrew consent , and three patients were not consented at the time of surgery . At baseline , DTCs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the control group . At 3 months , 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs ( p=0.054 ) . The most common grade 3-4 toxicities were infection ( five of 60 patients in the zoledronic acid group and six of 59 in the control group ) and thrombosis ( five of 60 in the zoledronic acid and two of 59 in the control group ) . There was one documented case of osteonecrosis in the zoledronic acid group . INTERPRETATION Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery . Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs . FUNDING Novartis Pharmaceuticals and Pfizer Inc . Instructions: please typing these entity words according to sentence: zoledronic acid, women, locally advanced breast cancer, bisphosphonates, disseminated tumour cells ( DTCs ), neoadjuvant chemotherapy, clinical stage II - III ( > or = T2 and / or > or = N1 ) newly diagnosed breast cancer, 120, 4 mg zoledronic acid intravenously every, no zoledronic acid, four cycles of neoadjuvant epirubicin, docetaxel, and two cycles of adjuvant epirubicin plus docetaxel, detectable DTCs, baseline bone marrow, 109, bone - marrow samples, osteonecrosis, Zoledronic acid Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Participant_Sex, Outcome_Physical, Participant_Sample-size	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Sex", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer : an open label , randomised , phase 2 trial . BACKGROUND Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer . The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells ( DTCs ) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer . METHODS Patients were recruited for this open-label , phase 2 randomised trial between March 17 , 2003 , and May 19 , 2006 , at a single centre . Eligible patients had clinical stage II-III ( > or = T2 and/or > or = N1 ) newly diagnosed breast cancer , Eastern Cooperative Oncology Group performance status of 0 or 1 , and normal cardiac , renal , and liver function . 120 women were randomly assigned , using allocation concealment , to receive 4 mg zoledronic acid intravenously every 3 weeks ( n=60 ) , or no zoledronic acid ( n=60 ) , for 1 year concomitant with four cycles of neoadjuvant epirubicin ( 75 mg/m ( 2 ) ) plus docetaxel ( 75 mg/m ( 2 ) ) and two cycles of adjuvant epirubicin plus docetaxel . The primary endpoint was the number of patients with detectable DTCs at 3 months . Final analysis was done 1 year after the last patient was enrolled . Analyses were done for all patients with available data at 3 months . This study is registered with ClinicalTrials.gov , number NCT00242203 . FINDINGS Of the 120 patients initially enrolled , one withdrew after signing consent and one patient 's baseline bone marrow was not available . Both of these patients were in the control group . At 3 months , 109 bone-marrow samples were available for analysis . In the zoledronic acid group , bone marrow was not collected from one patient because of disease progression , one patient was taken off study because of severe diarrhoea , and two patients had not consented at the time of surgery . In the control group , bone marrow was not collected from two patients because of disease progression , one patient withdrew consent , and three patients were not consented at the time of surgery . At baseline , DTCs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the control group . At 3 months , 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs ( p=0.054 ) . The most common grade 3-4 toxicities were infection ( five of 60 patients in the zoledronic acid group and six of 59 in the control group ) and thrombosis ( five of 60 in the zoledronic acid and two of 59 in the control group ) . There was one documented case of osteonecrosis in the zoledronic acid group . INTERPRETATION Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery . Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs . FUNDING Novartis Pharmaceuticals and Pfizer Inc .	[ "Effect", "of", "zoledronic", "acid", "on", "disseminated", "tumour", "cells", "in", "women", "with", "locally", "advanced", "breast", "cancer", ":", "an", "open", "label", ",", "randomised", ",", "phase", "2", "trial", ".", "BACKGROUND", "Treatment", "with", "bisphosphonates", "decreases", "bone", "loss", "and", "can", "increase", "disease", "-", "free", "survival", "in", "patients", "with", "breast", "cancer", ".", "The", "aim", "of", "our", "study", "was", "to", "assess", "the", "effect", "of", "zoledronic", "acid", "on", "clearance", "of", "disseminated", "tumour", "cells", "(", "DTCs", ")", "from", "the", "bone", "marrow", "in", "women", "undergoing", "neoadjuvant", "chemotherapy", "for", "breast", "cancer", ".", "METHODS", "Patients", "were", "recruited", "for", "this", "open", "-", "label", ",", "phase", "2", "randomised", "trial", "between", "March", "17", ",", "2003", ",", "and", "May", "19", ",", "2006", ",", "at", "a", "single", "centre", ".", "Eligible", "patients", "had", "clinical", "stage", "II", "-", "III", "(", ">", "or", "=", "T2", "and", "/", "or", ">", "or", "=", "N1", ")", "newly", "diagnosed", "breast", "cancer", ",", "Eastern", "Cooperative", "Oncology", "Group", "performance", "status", "of", "0", "or", "1", ",", "and", "normal", "cardiac", ",", "renal", ",", "and", "liver", "function", ".", "120", "women", "were", "randomly", "assigned", ",", "using", "allocation", "concealment", ",", "to", "receive", "4", "mg", "zoledronic", "acid", "intravenously", "every", "3", "weeks", "(", "n=60", ")", ",", "or", "no", "zoledronic", "acid", "(", "n=60", ")", ",", "for", "1", "year", "concomitant", "with", "four", "cycles", "of", "neoadjuvant", "epirubicin", "(", "75", "mg", "/", "m", "(", "2", ")", ")", "plus", "docetaxel", "(", "75", "mg", "/", "m", "(", "2", ")", ")", "and", "two", "cycles", "of", "adjuvant", "epirubicin", "plus", "docetaxel", ".", "The", "primary", "endpoint", "was", "the", "number", "of", "patients", "with", "detectable", "DTCs", "at", "3", "months", ".", "Final", "analysis", "was", "done", "1", "year", "after", "the", "last", "patient", "was", "enrolled", ".", "Analyses", "were", "done", "for", "all", "patients", "with", "available", "data", "at", "3", "months", ".", "This", "study", "is", "registered", "with", "ClinicalTrials.gov", ",", "number", "NCT00242203", ".", "FINDINGS", "Of", "the", "120", "patients", "initially", "enrolled", ",", "one", "withdrew", "after", "signing", "consent", "and", "one", "patient", "'", "s", "baseline", "bone", "marrow", "was", "not", "available", ".", "Both", "of", "these", "patients", "were", "in", "the", "control", "group", ".", "At", "3", "months", ",", "109", "bone", "-", "marrow", "samples", "were", "available", "for", "analysis", ".", "In", "the", "zoledronic", "acid", "group", ",", "bone", "marrow", "was", "not", "collected", "from", "one", "patient", "because", "of", "disease", "progression", ",", "one", "patient", "was", "taken", "off", "study", "because", "of", "severe", "diarrhoea", ",", "and", "two", "patients", "had", "not", "consented", "at", "the", "time", "of", "surgery", ".", "In", "the", "control", "group", ",", "bone", "marrow", "was", "not", "collected", "from", "two", "patients", "because", "of", "disease", "progression", ",", "one", "patient", "withdrew", "consent", ",", "and", "three", "patients", "were", "not", "consented", "at", "the", "time", "of", "surgery", ".", "At", "baseline", ",", "DTCs", "were", "detected", "in", "26", "of", "60", "patients", "in", "the", "zoledronic", "acid", "group", "and", "28", "of", "58", "patients", "in", "the", "control", "group", ".", "At", "3", "months", ",", "17", "of", "56", "patients", "receiving", "zoledronic", "acid", "versus", "25", "of", "53", "patients", "who", "did", "not", "receive", "zoledronic", "acid", "had", "detectable", "DTCs", "(", "p=0.054", ")", ".", "The", "most", "common", "grade", "3", "-", "4", "toxicities", "were", "infection", "(", "five", "of", "60", "patients", "in", "the", "zoledronic", "acid", "group", "and", "six", "of", "59", "in", "the", "control", "group", ")", "and", "thrombosis", "(", "five", "of", "60", "in", "the", "zoledronic", "acid", "and", "two", "of", "59", "in", "the", "control", "group", ")", ".", "There", "was", "one", "documented", "case", "of", "osteonecrosis", "in", "the", "zoledronic", "acid", "group", ".", "INTERPRETATION", "Zoledronic", "acid", "administered", "with", "chemotherapy", "resulted", "in", "a", "decreased", "proportion", "of", "patients", "with", "DTCs", "detected", "in", "the", "bone", "marrow", "at", "the", "time", "of", "surgery", ".", "Our", "study", "supports", "the", "hypothesis", "that", "the", "antimetastatic", "effects", "of", "zoledronic", "acid", "may", "be", "through", "effects", "on", "DTCs", ".", "FUNDING", "Novartis", "Pharmaceuticals", "and", "Pfizer", "Inc", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Sex", "Participant_Sample-size" ]
zoledronic acid, women, locally advanced breast cancer, bisphosphonates, disseminated tumour cells ( DTCs ), neoadjuvant chemotherapy, clinical stage II - III ( > or = T2 and / or > or = N1 ) newly diagnosed breast cancer, 120, 4 mg zoledronic acid intravenously every, no zoledronic acid, four cycles of neoadjuvant epirubicin, docetaxel, and two cycles of adjuvant epirubicin plus docetaxel, detectable DTCs, baseline bone marrow, 109, bone - marrow samples, osteonecrosis, Zoledronic acid	45221_task2	Sentence: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer : an open label , randomised , phase 2 trial . BACKGROUND Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer . The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells ( DTCs ) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer . METHODS Patients were recruited for this open-label , phase 2 randomised trial between March 17 , 2003 , and May 19 , 2006 , at a single centre . Eligible patients had clinical stage II-III ( > or = T2 and/or > or = N1 ) newly diagnosed breast cancer , Eastern Cooperative Oncology Group performance status of 0 or 1 , and normal cardiac , renal , and liver function . 120 women were randomly assigned , using allocation concealment , to receive 4 mg zoledronic acid intravenously every 3 weeks ( n=60 ) , or no zoledronic acid ( n=60 ) , for 1 year concomitant with four cycles of neoadjuvant epirubicin ( 75 mg/m ( 2 ) ) plus docetaxel ( 75 mg/m ( 2 ) ) and two cycles of adjuvant epirubicin plus docetaxel . The primary endpoint was the number of patients with detectable DTCs at 3 months . Final analysis was done 1 year after the last patient was enrolled . Analyses were done for all patients with available data at 3 months . This study is registered with ClinicalTrials.gov , number NCT00242203 . FINDINGS Of the 120 patients initially enrolled , one withdrew after signing consent and one patient 's baseline bone marrow was not available . Both of these patients were in the control group . At 3 months , 109 bone-marrow samples were available for analysis . In the zoledronic acid group , bone marrow was not collected from one patient because of disease progression , one patient was taken off study because of severe diarrhoea , and two patients had not consented at the time of surgery . In the control group , bone marrow was not collected from two patients because of disease progression , one patient withdrew consent , and three patients were not consented at the time of surgery . At baseline , DTCs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the control group . At 3 months , 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs ( p=0.054 ) . The most common grade 3-4 toxicities were infection ( five of 60 patients in the zoledronic acid group and six of 59 in the control group ) and thrombosis ( five of 60 in the zoledronic acid and two of 59 in the control group ) . There was one documented case of osteonecrosis in the zoledronic acid group . INTERPRETATION Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery . Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs . FUNDING Novartis Pharmaceuticals and Pfizer Inc . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Sex", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer : an open label , randomised , phase 2 trial . BACKGROUND Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer . The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells ( DTCs ) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer . METHODS Patients were recruited for this open-label , phase 2 randomised trial between March 17 , 2003 , and May 19 , 2006 , at a single centre . Eligible patients had clinical stage II-III ( > or = T2 and/or > or = N1 ) newly diagnosed breast cancer , Eastern Cooperative Oncology Group performance status of 0 or 1 , and normal cardiac , renal , and liver function . 120 women were randomly assigned , using allocation concealment , to receive 4 mg zoledronic acid intravenously every 3 weeks ( n=60 ) , or no zoledronic acid ( n=60 ) , for 1 year concomitant with four cycles of neoadjuvant epirubicin ( 75 mg/m ( 2 ) ) plus docetaxel ( 75 mg/m ( 2 ) ) and two cycles of adjuvant epirubicin plus docetaxel . The primary endpoint was the number of patients with detectable DTCs at 3 months . Final analysis was done 1 year after the last patient was enrolled . Analyses were done for all patients with available data at 3 months . This study is registered with ClinicalTrials.gov , number NCT00242203 . FINDINGS Of the 120 patients initially enrolled , one withdrew after signing consent and one patient 's baseline bone marrow was not available . Both of these patients were in the control group . At 3 months , 109 bone-marrow samples were available for analysis . In the zoledronic acid group , bone marrow was not collected from one patient because of disease progression , one patient was taken off study because of severe diarrhoea , and two patients had not consented at the time of surgery . In the control group , bone marrow was not collected from two patients because of disease progression , one patient withdrew consent , and three patients were not consented at the time of surgery . At baseline , DTCs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the control group . At 3 months , 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs ( p=0.054 ) . The most common grade 3-4 toxicities were infection ( five of 60 patients in the zoledronic acid group and six of 59 in the control group ) and thrombosis ( five of 60 in the zoledronic acid and two of 59 in the control group ) . There was one documented case of osteonecrosis in the zoledronic acid group . INTERPRETATION Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery . Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs . FUNDING Novartis Pharmaceuticals and Pfizer Inc .	[ "Effect", "of", "zoledronic", "acid", "on", "disseminated", "tumour", "cells", "in", "women", "with", "locally", "advanced", "breast", "cancer", ":", "an", "open", "label", ",", "randomised", ",", "phase", "2", "trial", ".", "BACKGROUND", "Treatment", "with", "bisphosphonates", "decreases", "bone", "loss", "and", "can", "increase", "disease", "-", "free", "survival", "in", "patients", "with", "breast", "cancer", ".", "The", "aim", "of", "our", "study", "was", "to", "assess", "the", "effect", "of", "zoledronic", "acid", "on", "clearance", "of", "disseminated", "tumour", "cells", "(", "DTCs", ")", "from", "the", "bone", "marrow", "in", "women", "undergoing", "neoadjuvant", "chemotherapy", "for", "breast", "cancer", ".", "METHODS", "Patients", "were", "recruited", "for", "this", "open", "-", "label", ",", "phase", "2", "randomised", "trial", "between", "March", "17", ",", "2003", ",", "and", "May", "19", ",", "2006", ",", "at", "a", "single", "centre", ".", "Eligible", "patients", "had", "clinical", "stage", "II", "-", "III", "(", ">", "or", "=", "T2", "and", "/", "or", ">", "or", "=", "N1", ")", "newly", "diagnosed", "breast", "cancer", ",", "Eastern", "Cooperative", "Oncology", "Group", "performance", "status", "of", "0", "or", "1", ",", "and", "normal", "cardiac", ",", "renal", ",", "and", "liver", "function", ".", "120", "women", "were", "randomly", "assigned", ",", "using", "allocation", "concealment", ",", "to", "receive", "4", "mg", "zoledronic", "acid", "intravenously", "every", "3", "weeks", "(", "n=60", ")", ",", "or", "no", "zoledronic", "acid", "(", "n=60", ")", ",", "for", "1", "year", "concomitant", "with", "four", "cycles", "of", "neoadjuvant", "epirubicin", "(", "75", "mg", "/", "m", "(", "2", ")", ")", "plus", "docetaxel", "(", "75", "mg", "/", "m", "(", "2", ")", ")", "and", "two", "cycles", "of", "adjuvant", "epirubicin", "plus", "docetaxel", ".", "The", "primary", "endpoint", "was", "the", "number", "of", "patients", "with", "detectable", "DTCs", "at", "3", "months", ".", "Final", "analysis", "was", "done", "1", "year", "after", "the", "last", "patient", "was", "enrolled", ".", "Analyses", "were", "done", "for", "all", "patients", "with", "available", "data", "at", "3", "months", ".", "This", "study", "is", "registered", "with", "ClinicalTrials.gov", ",", "number", "NCT00242203", ".", "FINDINGS", "Of", "the", "120", "patients", "initially", "enrolled", ",", "one", "withdrew", "after", "signing", "consent", "and", "one", "patient", "'", "s", "baseline", "bone", "marrow", "was", "not", "available", ".", "Both", "of", "these", "patients", "were", "in", "the", "control", "group", ".", "At", "3", "months", ",", "109", "bone", "-", "marrow", "samples", "were", "available", "for", "analysis", ".", "In", "the", "zoledronic", "acid", "group", ",", "bone", "marrow", "was", "not", "collected", "from", "one", "patient", "because", "of", "disease", "progression", ",", "one", "patient", "was", "taken", "off", "study", "because", "of", "severe", "diarrhoea", ",", "and", "two", "patients", "had", "not", "consented", "at", "the", "time", "of", "surgery", ".", "In", "the", "control", "group", ",", "bone", "marrow", "was", "not", "collected", "from", "two", "patients", "because", "of", "disease", "progression", ",", "one", "patient", "withdrew", "consent", ",", "and", "three", "patients", "were", "not", "consented", "at", "the", "time", "of", "surgery", ".", "At", "baseline", ",", "DTCs", "were", "detected", "in", "26", "of", "60", "patients", "in", "the", "zoledronic", "acid", "group", "and", "28", "of", "58", "patients", "in", "the", "control", "group", ".", "At", "3", "months", ",", "17", "of", "56", "patients", "receiving", "zoledronic", "acid", "versus", "25", "of", "53", "patients", "who", "did", "not", "receive", "zoledronic", "acid", "had", "detectable", "DTCs", "(", "p=0.054", ")", ".", "The", "most", "common", "grade", "3", "-", "4", "toxicities", "were", "infection", "(", "five", "of", "60", "patients", "in", "the", "zoledronic", "acid", "group", "and", "six", "of", "59", "in", "the", "control", "group", ")", "and", "thrombosis", "(", "five", "of", "60", "in", "the", "zoledronic", "acid", "and", "two", "of", "59", "in", "the", "control", "group", ")", ".", "There", "was", "one", "documented", "case", "of", "osteonecrosis", "in", "the", "zoledronic", "acid", "group", ".", "INTERPRETATION", "Zoledronic", "acid", "administered", "with", "chemotherapy", "resulted", "in", "a", "decreased", "proportion", "of", "patients", "with", "DTCs", "detected", "in", "the", "bone", "marrow", "at", "the", "time", "of", "surgery", ".", "Our", "study", "supports", "the", "hypothesis", "that", "the", "antimetastatic", "effects", "of", "zoledronic", "acid", "may", "be", "through", "effects", "on", "DTCs", ".", "FUNDING", "Novartis", "Pharmaceuticals", "and", "Pfizer", "Inc", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Sex", "Participant_Sample-size" ]
Previous is a Temporal, thoracic operation is a Procedure, same side is a Qualifier	NCT02469610_exc_task0	Sentence: Previous thoracic operation in the same side. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Procedure, Qualifier	[ "B-Temporal", "B-Procedure", "I-Procedure", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O" ]	Previous thoracic operation in the same side.	[ "Previous", "thoracic", "operation", "in", "the", "same", "side", ".", "\n" ]	[ "Procedure", "Qualifier", "Temporal" ]
Previous is a Temporal, thoracic operation is a Procedure, same side is a Qualifier	NCT02469610_exc_task1	Sentence: Previous thoracic operation in the same side. Instructions: please typing these entity words according to sentence: Previous, thoracic operation, same side Options: Temporal, Procedure, Qualifier	[ "B-Temporal", "B-Procedure", "I-Procedure", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O" ]	Previous thoracic operation in the same side.	[ "Previous", "thoracic", "operation", "in", "the", "same", "side", ".", "\n" ]	[ "Procedure", "Qualifier", "Temporal" ]
Previous, thoracic operation, same side	NCT02469610_exc_task2	Sentence: Previous thoracic operation in the same side. Instructions: please extract entity words from the input sentence	[ "B-Temporal", "B-Procedure", "I-Procedure", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O" ]	Previous thoracic operation in the same side.	[ "Previous", "thoracic", "operation", "in", "the", "same", "side", ".", "\n" ]	[ "Procedure", "Qualifier", "Temporal" ]
IgG is a PROTEINAS, IgA is a PROTEINAS, IgM is a PROTEINAS, C3 is a PROTEINAS, C1q is a PROTEINAS, fibrinógeno is a PROTEINAS, prednisona is a NORMALIZABLES, prednisona is a NORMALIZABLES, Azathioprina is a NORMALIZABLES, Omeprazol is a NORMALIZABLES, carbonato cálcico is a NORMALIZABLES, vitamina D4 is a NO_NORMALIZABLES, Nistatina is a NORMALIZABLES, prednisona is a NORMALIZABLES, Azathiproprina is a NORMALIZABLES	185_task0	Sentence: Paciente varón, de 47 años, casado, acude al departamento de Medicina Oral del Hospital de Clínicas de Porto Alegre y afirma tener lesiones dolorosas en la cavidad oral con aspecto de ampollas sangrantes que se rompen fácilmente y le dejan una superficie como ulcerada desde hace aproximadamente 4 meses. En la anamnesis el paciente declara no ser fumador y trabajar en un fábrica de baterías para coches, lo cual además le ha originado una intoxicación crónica (saturnismo). Dice poseer además una úlcera en la pierna derecha desde hace 20 años. En la exploración física se percibe la inflamación de los ganglios cervicales y submaxilares del lado izquierdo, así como varias lesiones de tipo ulceroso en la mucosa labial, el paladar, la mucosa yugal, el suelo de la boca y la laringe. Se confirma la lesión de la pierna derecha, así como lesiones de tipo erosivo recubiertas por una costra en las axilas y el tronco. Se practicó una biopsia parcial de una de las lesiones del labio inferior, en la cual se observó el signo de Nikolsky positivo en el momento de la toma y se vio que las características histopatológicas de la lesión eran ampollas con acantolisis suprabasal, lo cual es compatible con el pénfigo vulgar. Unos días después de la biopsia el paciente sufrió una exacerbación de las lesiones y tuvo que ser ingresado en el hospital con un cuadro consistente en: lesiones ampollosas en el tórax, la pierna derecha y la cavidad oral, que le impiden la alimentación. Se le hicieron nuevas biopsias de las lesiones del tronco y la boca y se le hizo además un examen de inmunofluorescencia, en el que se observaron depósito de IgG en las uniones intercelulares, IgA en las paredes de los vasos pequeños y ausencia de IgM, C3, C1q y de depósitos de fibrinógeno. Se comenzó el tratamiento con prednisona con dosis gradualmente crecientes hasta alcanzar los 100 mg diarios. El paciente respondió favorablemente al tratamiento y abandonó el hospital con una notable mejoría. Tras la hospitalización se estableció el tratamiento para el paciente a base de 140 mg diarios de prednisona asociados a 100 mg de Azathioprina, 40 mg de Omeprazol, 400 mg de carbonato cálcico, vitamina D4 y enjuagues de Nistatina, éstos últimos 4 veces al día. Tras un mes de tratamiento se observó una remisión casi total del cuadro y se redujo la dosis de prednisona a 120 mg durante 15 días y, posteriormente, a 100 mg. De igual modo, se decidió elevar la dosis de Azathiproprina a 150 mg diarios. El paciente se encuentra todavía bajo control médico. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, PROTEINAS, NO_NORMALIZABLES	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NO_NORMALIZABLES", "I-NO_NORMALIZABLES", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Paciente varón, de 47 años, casado, acude al departamento de Medicina Oral del Hospital de Clínicas de Porto Alegre y afirma tener lesiones dolorosas en la cavidad oral con aspecto de ampollas sangrantes que se rompen fácilmente y le dejan una superficie como ulcerada desde hace aproximadamente 4 meses. En la anamnesis el paciente declara no ser fumador y trabajar en un fábrica de baterías para coches, lo cual además le ha originado una intoxicación crónica (saturnismo). Dice poseer además una úlcera en la pierna derecha desde hace 20 años. En la exploración física se percibe la inflamación de los ganglios cervicales y submaxilares del lado izquierdo, así como varias lesiones de tipo ulceroso en la mucosa labial, el paladar, la mucosa yugal, el suelo de la boca y la laringe. Se confirma la lesión de la pierna derecha, así como lesiones de tipo erosivo recubiertas por una costra en las axilas y el tronco. Se practicó una biopsia parcial de una de las lesiones del labio inferior, en la cual se observó el signo de Nikolsky positivo en el momento de la toma y se vio que las características histopatológicas de la lesión eran ampollas con acantolisis suprabasal, lo cual es compatible con el pénfigo vulgar. Unos días después de la biopsia el paciente sufrió una exacerbación de las lesiones y tuvo que ser ingresado en el hospital con un cuadro consistente en: lesiones ampollosas en el tórax, la pierna derecha y la cavidad oral, que le impiden la alimentación. Se le hicieron nuevas biopsias de las lesiones del tronco y la boca y se le hizo además un examen de inmunofluorescencia, en el que se observaron depósito de IgG en las uniones intercelulares, IgA en las paredes de los vasos pequeños y ausencia de IgM, C3, C1q y de depósitos de fibrinógeno. Se comenzó el tratamiento con prednisona con dosis gradualmente crecientes hasta alcanzar los 100 mg diarios. El paciente respondió favorablemente al tratamiento y abandonó el hospital con una notable mejoría. Tras la hospitalización se estableció el tratamiento para el paciente a base de 140 mg diarios de prednisona asociados a 100 mg de Azathioprina, 40 mg de Omeprazol, 400 mg de carbonato cálcico, vitamina D4 y enjuagues de Nistatina, éstos últimos 4 veces al día. Tras un mes de tratamiento se observó una remisión casi total del cuadro y se redujo la dosis de prednisona a 120 mg durante 15 días y, posteriormente, a 100 mg. De igual modo, se decidió elevar la dosis de Azathiproprina a 150 mg diarios. El paciente se encuentra todavía bajo control médico.	[ "Paciente", "varón", ",", "de", "47", "años", ",", "casado", ",", "acude", "al", "departamento", "de", "Medicina", "Oral", "del", "Hospital", "de", "Clínicas", "de", "Porto", "Alegre", "y", "afirma", "tener", "lesiones", "dolorosas", "en", "la", "cavidad", "oral", "con", "aspecto", "de", "ampollas", "sangrantes", "que", "se", "rompen", "fácilmente", "y", "le", "dejan", "una", "superficie", "como", "ulcerada", "desde", "hace", "aproximadamente", "4", "meses", ".", "En", "la", "anamnesis", "el", "paciente", "declara", "no", "ser", "fumador", "y", "trabajar", "en", "un", "fábrica", "de", "baterías", "para", "coches", ",", "lo", "cual", "además", "le", "ha", "originado", "una", "intoxicación", "crónica", "(", "saturnismo", ")", ".", "Dice", "poseer", "además", "una", "úlcera", "en", "la", "pierna", "derecha", "desde", "hace", "20", "años", ".", "\n", "En", "la", "exploración", "física", "se", "percibe", "la", "inflamación", "de", "los", "ganglios", "cervicales", "y", "submaxilares", "del", "lado", "izquierdo", ",", "así", "como", "varias", "lesiones", "de", "tipo", "ulceroso", "en", "la", "mucosa", "labial", ",", "el", "paladar", ",", "la", "mucosa", "yugal", ",", "el", "suelo", "de", "la", "boca", "y", "la", "laringe", ".", "Se", "confirma", "la", "lesión", "de", "la", "pierna", "derecha", ",", "así", "como", "lesiones", "de", "tipo", "erosivo", "recubiertas", "por", "una", "costra", "en", "las", "axilas", "y", "el", "tronco", ".", "\n\n", "Se", "practicó", "una", "biopsia", "parcial", "de", "una", "de", "las", "lesiones", "del", "labio", "inferior", ",", "en", "la", "cual", "se", "observó", "el", "signo", "de", "Nikolsky", "positivo", "en", "el", "momento", "de", "la", "toma", "y", "se", "vio", "que", "las", "características", "histopatológicas", "de", "la", "lesión", "eran", "ampollas", "con", "acantolisis", "suprabasal", ",", "lo", "cual", "es", "compatible", "con", "el", "pénfigo", "vulgar", ".", "\n\n", "Unos", "días", "después", "de", "la", "biopsia", "el", "paciente", "sufrió", "una", "exacerbación", "de", "las", "lesiones", "y", "tuvo", "que", "ser", "ingresado", "en", "el", "hospital", "con", "un", "cuadro", "consistente", "en", ":", "lesiones", "ampollosas", "en", "el", "tórax", ",", "la", "pierna", "derecha", "y", "la", "cavidad", "oral", ",", "que", "le", "impiden", "la", "alimentación", ".", "Se", "le", "hicieron", "nuevas", "biopsias", "de", "las", "lesiones", "del", "tronco", "y", "la", "boca", "y", "se", "le", "hizo", "además", "un", "examen", "de", "inmunofluorescencia", ",", "en", "el", "que", "se", "observaron", "depósito", "de", "IgG", "en", "las", "uniones", "intercelulares", ",", "IgA", "en", "las", "paredes", "de", "los", "vasos", "pequeños", "y", "ausencia", "de", "IgM", ",", "C3", ",", "C1q", "y", "de", "depósitos", "de", "fibrinógeno", ".", "Se", "comenzó", "el", "tratamiento", "con", "prednisona", "con", "dosis", "gradualmente", "crecientes", "hasta", "alcanzar", "los", "100", "mg", "diarios", ".", "El", "paciente", "respondió", "favorablemente", "al", "tratamiento", "y", "abandonó", "el", "hospital", "con", "una", "notable", "mejoría", ".", "\n\n", "Tras", "la", "hospitalización", "se", "estableció", "el", "tratamiento", "para", "el", "paciente", "a", "base", "de", "140", "mg", "diarios", "de", "prednisona", "asociados", "a", "100", "mg", "de", "Azathioprina", ",", "40", "mg", "de", "Omeprazol", ",", "400", "mg", "de", "carbonato", "cálcico", ",", "vitamina", "D4", "y", "enjuagues", "de", "Nistatina", ",", "éstos", "últimos", "4", "veces", "al", "día", ".", "Tras", "un", "mes", "de", "tratamiento", "se", "observó", "una", "remisión", "casi", "total", "del", "cuadro", "y", "se", "redujo", "la", "dosis", "de", "prednisona", "a", "120", "mg", "durante", "15", "días", "y", ",", "posteriormente", ",", "a", "100", "mg", ".", "De", "igual", "modo", ",", "se", "decidió", "elevar", "la", "dosis", "de", "Azathiproprina", "a", "150", "mg", "diarios", ".", "El", "paciente", "se", "encuentra", "todavía", "bajo", "control", "médico", ".", "\n\n" ]	[ "NORMALIZABLES", "NO_NORMALIZABLES", "PROTEINAS" ]
IgG is a PROTEINAS, IgA is a PROTEINAS, IgM is a PROTEINAS, C3 is a PROTEINAS, C1q is a PROTEINAS, fibrinógeno is a PROTEINAS, prednisona is a NORMALIZABLES, prednisona is a NORMALIZABLES, Azathioprina is a NORMALIZABLES, Omeprazol is a NORMALIZABLES, carbonato cálcico is a NORMALIZABLES, vitamina D4 is a NO_NORMALIZABLES, Nistatina is a NORMALIZABLES, prednisona is a NORMALIZABLES, Azathiproprina is a NORMALIZABLES	185_task1	Sentence: Paciente varón, de 47 años, casado, acude al departamento de Medicina Oral del Hospital de Clínicas de Porto Alegre y afirma tener lesiones dolorosas en la cavidad oral con aspecto de ampollas sangrantes que se rompen fácilmente y le dejan una superficie como ulcerada desde hace aproximadamente 4 meses. En la anamnesis el paciente declara no ser fumador y trabajar en un fábrica de baterías para coches, lo cual además le ha originado una intoxicación crónica (saturnismo). Dice poseer además una úlcera en la pierna derecha desde hace 20 años. En la exploración física se percibe la inflamación de los ganglios cervicales y submaxilares del lado izquierdo, así como varias lesiones de tipo ulceroso en la mucosa labial, el paladar, la mucosa yugal, el suelo de la boca y la laringe. Se confirma la lesión de la pierna derecha, así como lesiones de tipo erosivo recubiertas por una costra en las axilas y el tronco. Se practicó una biopsia parcial de una de las lesiones del labio inferior, en la cual se observó el signo de Nikolsky positivo en el momento de la toma y se vio que las características histopatológicas de la lesión eran ampollas con acantolisis suprabasal, lo cual es compatible con el pénfigo vulgar. Unos días después de la biopsia el paciente sufrió una exacerbación de las lesiones y tuvo que ser ingresado en el hospital con un cuadro consistente en: lesiones ampollosas en el tórax, la pierna derecha y la cavidad oral, que le impiden la alimentación. Se le hicieron nuevas biopsias de las lesiones del tronco y la boca y se le hizo además un examen de inmunofluorescencia, en el que se observaron depósito de IgG en las uniones intercelulares, IgA en las paredes de los vasos pequeños y ausencia de IgM, C3, C1q y de depósitos de fibrinógeno. Se comenzó el tratamiento con prednisona con dosis gradualmente crecientes hasta alcanzar los 100 mg diarios. El paciente respondió favorablemente al tratamiento y abandonó el hospital con una notable mejoría. Tras la hospitalización se estableció el tratamiento para el paciente a base de 140 mg diarios de prednisona asociados a 100 mg de Azathioprina, 40 mg de Omeprazol, 400 mg de carbonato cálcico, vitamina D4 y enjuagues de Nistatina, éstos últimos 4 veces al día. Tras un mes de tratamiento se observó una remisión casi total del cuadro y se redujo la dosis de prednisona a 120 mg durante 15 días y, posteriormente, a 100 mg. De igual modo, se decidió elevar la dosis de Azathiproprina a 150 mg diarios. El paciente se encuentra todavía bajo control médico. Instructions: please typing these entity words according to sentence: IgG, IgA, IgM, C3, C1q, fibrinógeno, prednisona, prednisona, Azathioprina, Omeprazol, carbonato cálcico, vitamina D4, Nistatina, prednisona, Azathiproprina Options: NORMALIZABLES, PROTEINAS, NO_NORMALIZABLES	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NO_NORMALIZABLES", "I-NO_NORMALIZABLES", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Paciente varón, de 47 años, casado, acude al departamento de Medicina Oral del Hospital de Clínicas de Porto Alegre y afirma tener lesiones dolorosas en la cavidad oral con aspecto de ampollas sangrantes que se rompen fácilmente y le dejan una superficie como ulcerada desde hace aproximadamente 4 meses. En la anamnesis el paciente declara no ser fumador y trabajar en un fábrica de baterías para coches, lo cual además le ha originado una intoxicación crónica (saturnismo). Dice poseer además una úlcera en la pierna derecha desde hace 20 años. En la exploración física se percibe la inflamación de los ganglios cervicales y submaxilares del lado izquierdo, así como varias lesiones de tipo ulceroso en la mucosa labial, el paladar, la mucosa yugal, el suelo de la boca y la laringe. Se confirma la lesión de la pierna derecha, así como lesiones de tipo erosivo recubiertas por una costra en las axilas y el tronco. Se practicó una biopsia parcial de una de las lesiones del labio inferior, en la cual se observó el signo de Nikolsky positivo en el momento de la toma y se vio que las características histopatológicas de la lesión eran ampollas con acantolisis suprabasal, lo cual es compatible con el pénfigo vulgar. Unos días después de la biopsia el paciente sufrió una exacerbación de las lesiones y tuvo que ser ingresado en el hospital con un cuadro consistente en: lesiones ampollosas en el tórax, la pierna derecha y la cavidad oral, que le impiden la alimentación. Se le hicieron nuevas biopsias de las lesiones del tronco y la boca y se le hizo además un examen de inmunofluorescencia, en el que se observaron depósito de IgG en las uniones intercelulares, IgA en las paredes de los vasos pequeños y ausencia de IgM, C3, C1q y de depósitos de fibrinógeno. Se comenzó el tratamiento con prednisona con dosis gradualmente crecientes hasta alcanzar los 100 mg diarios. El paciente respondió favorablemente al tratamiento y abandonó el hospital con una notable mejoría. Tras la hospitalización se estableció el tratamiento para el paciente a base de 140 mg diarios de prednisona asociados a 100 mg de Azathioprina, 40 mg de Omeprazol, 400 mg de carbonato cálcico, vitamina D4 y enjuagues de Nistatina, éstos últimos 4 veces al día. Tras un mes de tratamiento se observó una remisión casi total del cuadro y se redujo la dosis de prednisona a 120 mg durante 15 días y, posteriormente, a 100 mg. De igual modo, se decidió elevar la dosis de Azathiproprina a 150 mg diarios. El paciente se encuentra todavía bajo control médico.	[ "Paciente", "varón", ",", "de", "47", "años", ",", "casado", ",", "acude", "al", "departamento", "de", "Medicina", "Oral", "del", "Hospital", "de", "Clínicas", "de", "Porto", "Alegre", "y", "afirma", "tener", "lesiones", "dolorosas", "en", "la", "cavidad", "oral", "con", "aspecto", "de", "ampollas", "sangrantes", "que", "se", "rompen", "fácilmente", "y", "le", "dejan", "una", "superficie", "como", "ulcerada", "desde", "hace", "aproximadamente", "4", "meses", ".", "En", "la", "anamnesis", "el", "paciente", "declara", "no", "ser", "fumador", "y", "trabajar", "en", "un", "fábrica", "de", "baterías", "para", "coches", ",", "lo", "cual", "además", "le", "ha", "originado", "una", "intoxicación", "crónica", "(", "saturnismo", ")", ".", "Dice", "poseer", "además", "una", "úlcera", "en", "la", "pierna", "derecha", "desde", "hace", "20", "años", ".", "\n", "En", "la", "exploración", "física", "se", "percibe", "la", "inflamación", "de", "los", "ganglios", "cervicales", "y", "submaxilares", "del", "lado", "izquierdo", ",", "así", "como", "varias", "lesiones", "de", "tipo", "ulceroso", "en", "la", "mucosa", "labial", ",", "el", "paladar", ",", "la", "mucosa", "yugal", ",", "el", "suelo", "de", "la", "boca", "y", "la", "laringe", ".", "Se", "confirma", "la", "lesión", "de", "la", "pierna", "derecha", ",", "así", "como", "lesiones", "de", "tipo", "erosivo", "recubiertas", "por", "una", "costra", "en", "las", "axilas", "y", "el", "tronco", ".", "\n\n", "Se", "practicó", "una", "biopsia", "parcial", "de", "una", "de", "las", "lesiones", "del", "labio", "inferior", ",", "en", "la", "cual", "se", "observó", "el", "signo", "de", "Nikolsky", "positivo", "en", "el", "momento", "de", "la", "toma", "y", "se", "vio", "que", "las", "características", "histopatológicas", "de", "la", "lesión", "eran", "ampollas", "con", "acantolisis", "suprabasal", ",", "lo", "cual", "es", "compatible", "con", "el", "pénfigo", "vulgar", ".", "\n\n", "Unos", "días", "después", "de", "la", "biopsia", "el", "paciente", "sufrió", "una", "exacerbación", "de", "las", "lesiones", "y", "tuvo", "que", "ser", "ingresado", "en", "el", "hospital", "con", "un", "cuadro", "consistente", "en", ":", "lesiones", "ampollosas", "en", "el", "tórax", ",", "la", "pierna", "derecha", "y", "la", "cavidad", "oral", ",", "que", "le", "impiden", "la", "alimentación", ".", "Se", "le", "hicieron", "nuevas", "biopsias", "de", "las", "lesiones", "del", "tronco", "y", "la", "boca", "y", "se", "le", "hizo", "además", "un", "examen", "de", "inmunofluorescencia", ",", "en", "el", "que", "se", "observaron", "depósito", "de", "IgG", "en", "las", "uniones", "intercelulares", ",", "IgA", "en", "las", "paredes", "de", "los", "vasos", "pequeños", "y", "ausencia", "de", "IgM", ",", "C3", ",", "C1q", "y", "de", "depósitos", "de", "fibrinógeno", ".", "Se", "comenzó", "el", "tratamiento", "con", "prednisona", "con", "dosis", "gradualmente", "crecientes", "hasta", "alcanzar", "los", "100", "mg", "diarios", ".", "El", "paciente", "respondió", "favorablemente", "al", "tratamiento", "y", "abandonó", "el", "hospital", "con", "una", "notable", "mejoría", ".", "\n\n", "Tras", "la", "hospitalización", "se", "estableció", "el", "tratamiento", "para", "el", "paciente", "a", "base", "de", "140", "mg", "diarios", "de", "prednisona", "asociados", "a", "100", "mg", "de", "Azathioprina", ",", "40", "mg", "de", "Omeprazol", ",", "400", "mg", "de", "carbonato", "cálcico", ",", "vitamina", "D4", "y", "enjuagues", "de", "Nistatina", ",", "éstos", "últimos", "4", "veces", "al", "día", ".", "Tras", "un", "mes", "de", "tratamiento", "se", "observó", "una", "remisión", "casi", "total", "del", "cuadro", "y", "se", "redujo", "la", "dosis", "de", "prednisona", "a", "120", "mg", "durante", "15", "días", "y", ",", "posteriormente", ",", "a", "100", "mg", ".", "De", "igual", "modo", ",", "se", "decidió", "elevar", "la", "dosis", "de", "Azathiproprina", "a", "150", "mg", "diarios", ".", "El", "paciente", "se", "encuentra", "todavía", "bajo", "control", "médico", ".", "\n\n" ]	[ "NORMALIZABLES", "NO_NORMALIZABLES", "PROTEINAS" ]
IgG, IgA, IgM, C3, C1q, fibrinógeno, prednisona, prednisona, Azathioprina, Omeprazol, carbonato cálcico, vitamina D4, Nistatina, prednisona, Azathiproprina	185_task2	Sentence: Paciente varón, de 47 años, casado, acude al departamento de Medicina Oral del Hospital de Clínicas de Porto Alegre y afirma tener lesiones dolorosas en la cavidad oral con aspecto de ampollas sangrantes que se rompen fácilmente y le dejan una superficie como ulcerada desde hace aproximadamente 4 meses. En la anamnesis el paciente declara no ser fumador y trabajar en un fábrica de baterías para coches, lo cual además le ha originado una intoxicación crónica (saturnismo). Dice poseer además una úlcera en la pierna derecha desde hace 20 años. En la exploración física se percibe la inflamación de los ganglios cervicales y submaxilares del lado izquierdo, así como varias lesiones de tipo ulceroso en la mucosa labial, el paladar, la mucosa yugal, el suelo de la boca y la laringe. Se confirma la lesión de la pierna derecha, así como lesiones de tipo erosivo recubiertas por una costra en las axilas y el tronco. Se practicó una biopsia parcial de una de las lesiones del labio inferior, en la cual se observó el signo de Nikolsky positivo en el momento de la toma y se vio que las características histopatológicas de la lesión eran ampollas con acantolisis suprabasal, lo cual es compatible con el pénfigo vulgar. Unos días después de la biopsia el paciente sufrió una exacerbación de las lesiones y tuvo que ser ingresado en el hospital con un cuadro consistente en: lesiones ampollosas en el tórax, la pierna derecha y la cavidad oral, que le impiden la alimentación. Se le hicieron nuevas biopsias de las lesiones del tronco y la boca y se le hizo además un examen de inmunofluorescencia, en el que se observaron depósito de IgG en las uniones intercelulares, IgA en las paredes de los vasos pequeños y ausencia de IgM, C3, C1q y de depósitos de fibrinógeno. Se comenzó el tratamiento con prednisona con dosis gradualmente crecientes hasta alcanzar los 100 mg diarios. El paciente respondió favorablemente al tratamiento y abandonó el hospital con una notable mejoría. Tras la hospitalización se estableció el tratamiento para el paciente a base de 140 mg diarios de prednisona asociados a 100 mg de Azathioprina, 40 mg de Omeprazol, 400 mg de carbonato cálcico, vitamina D4 y enjuagues de Nistatina, éstos últimos 4 veces al día. Tras un mes de tratamiento se observó una remisión casi total del cuadro y se redujo la dosis de prednisona a 120 mg durante 15 días y, posteriormente, a 100 mg. De igual modo, se decidió elevar la dosis de Azathiproprina a 150 mg diarios. El paciente se encuentra todavía bajo control médico. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NO_NORMALIZABLES", "I-NO_NORMALIZABLES", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Paciente varón, de 47 años, casado, acude al departamento de Medicina Oral del Hospital de Clínicas de Porto Alegre y afirma tener lesiones dolorosas en la cavidad oral con aspecto de ampollas sangrantes que se rompen fácilmente y le dejan una superficie como ulcerada desde hace aproximadamente 4 meses. En la anamnesis el paciente declara no ser fumador y trabajar en un fábrica de baterías para coches, lo cual además le ha originado una intoxicación crónica (saturnismo). Dice poseer además una úlcera en la pierna derecha desde hace 20 años. En la exploración física se percibe la inflamación de los ganglios cervicales y submaxilares del lado izquierdo, así como varias lesiones de tipo ulceroso en la mucosa labial, el paladar, la mucosa yugal, el suelo de la boca y la laringe. Se confirma la lesión de la pierna derecha, así como lesiones de tipo erosivo recubiertas por una costra en las axilas y el tronco. Se practicó una biopsia parcial de una de las lesiones del labio inferior, en la cual se observó el signo de Nikolsky positivo en el momento de la toma y se vio que las características histopatológicas de la lesión eran ampollas con acantolisis suprabasal, lo cual es compatible con el pénfigo vulgar. Unos días después de la biopsia el paciente sufrió una exacerbación de las lesiones y tuvo que ser ingresado en el hospital con un cuadro consistente en: lesiones ampollosas en el tórax, la pierna derecha y la cavidad oral, que le impiden la alimentación. Se le hicieron nuevas biopsias de las lesiones del tronco y la boca y se le hizo además un examen de inmunofluorescencia, en el que se observaron depósito de IgG en las uniones intercelulares, IgA en las paredes de los vasos pequeños y ausencia de IgM, C3, C1q y de depósitos de fibrinógeno. Se comenzó el tratamiento con prednisona con dosis gradualmente crecientes hasta alcanzar los 100 mg diarios. El paciente respondió favorablemente al tratamiento y abandonó el hospital con una notable mejoría. Tras la hospitalización se estableció el tratamiento para el paciente a base de 140 mg diarios de prednisona asociados a 100 mg de Azathioprina, 40 mg de Omeprazol, 400 mg de carbonato cálcico, vitamina D4 y enjuagues de Nistatina, éstos últimos 4 veces al día. Tras un mes de tratamiento se observó una remisión casi total del cuadro y se redujo la dosis de prednisona a 120 mg durante 15 días y, posteriormente, a 100 mg. De igual modo, se decidió elevar la dosis de Azathiproprina a 150 mg diarios. El paciente se encuentra todavía bajo control médico.	[ "Paciente", "varón", ",", "de", "47", "años", ",", "casado", ",", "acude", "al", "departamento", "de", "Medicina", "Oral", "del", "Hospital", "de", "Clínicas", "de", "Porto", "Alegre", "y", "afirma", "tener", "lesiones", "dolorosas", "en", "la", "cavidad", "oral", "con", "aspecto", "de", "ampollas", "sangrantes", "que", "se", "rompen", "fácilmente", "y", "le", "dejan", "una", "superficie", "como", "ulcerada", "desde", "hace", "aproximadamente", "4", "meses", ".", "En", "la", "anamnesis", "el", "paciente", "declara", "no", "ser", "fumador", "y", "trabajar", "en", "un", "fábrica", "de", "baterías", "para", "coches", ",", "lo", "cual", "además", "le", "ha", "originado", "una", "intoxicación", "crónica", "(", "saturnismo", ")", ".", "Dice", "poseer", "además", "una", "úlcera", "en", "la", "pierna", "derecha", "desde", "hace", "20", "años", ".", "\n", "En", "la", "exploración", "física", "se", "percibe", "la", "inflamación", "de", "los", "ganglios", "cervicales", "y", "submaxilares", "del", "lado", "izquierdo", ",", "así", "como", "varias", "lesiones", "de", "tipo", "ulceroso", "en", "la", "mucosa", "labial", ",", "el", "paladar", ",", "la", "mucosa", "yugal", ",", "el", "suelo", "de", "la", "boca", "y", "la", "laringe", ".", "Se", "confirma", "la", "lesión", "de", "la", "pierna", "derecha", ",", "así", "como", "lesiones", "de", "tipo", "erosivo", "recubiertas", "por", "una", "costra", "en", "las", "axilas", "y", "el", "tronco", ".", "\n\n", "Se", "practicó", "una", "biopsia", "parcial", "de", "una", "de", "las", "lesiones", "del", "labio", "inferior", ",", "en", "la", "cual", "se", "observó", "el", "signo", "de", "Nikolsky", "positivo", "en", "el", "momento", "de", "la", "toma", "y", "se", "vio", "que", "las", "características", "histopatológicas", "de", "la", "lesión", "eran", "ampollas", "con", "acantolisis", "suprabasal", ",", "lo", "cual", "es", "compatible", "con", "el", "pénfigo", "vulgar", ".", "\n\n", "Unos", "días", "después", "de", "la", "biopsia", "el", "paciente", "sufrió", "una", "exacerbación", "de", "las", "lesiones", "y", "tuvo", "que", "ser", "ingresado", "en", "el", "hospital", "con", "un", "cuadro", "consistente", "en", ":", "lesiones", "ampollosas", "en", "el", "tórax", ",", "la", "pierna", "derecha", "y", "la", "cavidad", "oral", ",", "que", "le", "impiden", "la", "alimentación", ".", "Se", "le", "hicieron", "nuevas", "biopsias", "de", "las", "lesiones", "del", "tronco", "y", "la", "boca", "y", "se", "le", "hizo", "además", "un", "examen", "de", "inmunofluorescencia", ",", "en", "el", "que", "se", "observaron", "depósito", "de", "IgG", "en", "las", "uniones", "intercelulares", ",", "IgA", "en", "las", "paredes", "de", "los", "vasos", "pequeños", "y", "ausencia", "de", "IgM", ",", "C3", ",", "C1q", "y", "de", "depósitos", "de", "fibrinógeno", ".", "Se", "comenzó", "el", "tratamiento", "con", "prednisona", "con", "dosis", "gradualmente", "crecientes", "hasta", "alcanzar", "los", "100", "mg", "diarios", ".", "El", "paciente", "respondió", "favorablemente", "al", "tratamiento", "y", "abandonó", "el", "hospital", "con", "una", "notable", "mejoría", ".", "\n\n", "Tras", "la", "hospitalización", "se", "estableció", "el", "tratamiento", "para", "el", "paciente", "a", "base", "de", "140", "mg", "diarios", "de", "prednisona", "asociados", "a", "100", "mg", "de", "Azathioprina", ",", "40", "mg", "de", "Omeprazol", ",", "400", "mg", "de", "carbonato", "cálcico", ",", "vitamina", "D4", "y", "enjuagues", "de", "Nistatina", ",", "éstos", "últimos", "4", "veces", "al", "día", ".", "Tras", "un", "mes", "de", "tratamiento", "se", "observó", "una", "remisión", "casi", "total", "del", "cuadro", "y", "se", "redujo", "la", "dosis", "de", "prednisona", "a", "120", "mg", "durante", "15", "días", "y", ",", "posteriormente", ",", "a", "100", "mg", ".", "De", "igual", "modo", ",", "se", "decidió", "elevar", "la", "dosis", "de", "Azathiproprina", "a", "150", "mg", "diarios", ".", "El", "paciente", "se", "encuentra", "todavía", "bajo", "control", "médico", ".", "\n\n" ]	[ "NORMALIZABLES", "NO_NORMALIZABLES", "PROTEINAS" ]
aim is an umlsterm, wound is an umlsterm, methods is an umlsterm, starter 's is an umlsterm, distances is an umlsterm, distance is an umlsterm, film is an umlsterm, computer is an umlsterm, wound is an umlsterm, distance is an umlsterm, black is an umlsterm, powder is an umlsterm, distance is an umlsterm, findings is an umlsterm, risk of is an umlsterm, injury is an umlsterm, injuries is an umlsterm, eye is an umlsterm, distance is an umlsterm, cornea is an umlsterm	Rechtsmedizin.90090210.eng.abstr_task0	Sentence: In order to describe the wounding capacity in standardized manner , gelatine was used to simulate biological targets in terminal ballistics . The aim was the investigation of blank cartridges with wound ballistic methods . Blank cartridges ( caliber 9 mm x 17 ) produced by RWS , SM , Wadie and Umarex were fired with starter's revolvers of . 380 caliber into 10% gelatine blocks . Shots were fired at 4 °C at distances ranging from close contact and from 1 up to 50 cm distance . The blocks of gelatine and their cross-sections were photographed using slide film which was digitized and analyzed by computer . Contact shots produced penetration from 21 to 63 mm in depth and the maximum diameter of the wound cavity measured from 7 to 42 mm . Up to a distance of 4 cm black powder blank cartridges produced tearing of more than 1 cm depth . Shots from a distance of 10 cm propelled many particles up to 13 mm deep into the gelatine . At a shooting range of 50 cm 13% of the particles penetrated deeper than 3 mm and some penetrated up to 7 mm . The experimental findings give evidence of the well known risk of fatal injury from contact shots . Up to a shooting range of 5 cm injuries of the eye bulb are to be expected and at a 50 cm distance severe lesions of the cornea . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	In order to describe the wounding capacity in standardized manner , gelatine was used to simulate biological targets in terminal ballistics . The aim was the investigation of blank cartridges with wound ballistic methods . Blank cartridges ( caliber 9 mm x 17 ) produced by RWS , SM , Wadie and Umarex were fired with starter's revolvers of . 380 caliber into 10% gelatine blocks . Shots were fired at 4 °C at distances ranging from close contact and from 1 up to 50 cm distance . The blocks of gelatine and their cross-sections were photographed using slide film which was digitized and analyzed by computer . Contact shots produced penetration from 21 to 63 mm in depth and the maximum diameter of the wound cavity measured from 7 to 42 mm . Up to a distance of 4 cm black powder blank cartridges produced tearing of more than 1 cm depth . Shots from a distance of 10 cm propelled many particles up to 13 mm deep into the gelatine . At a shooting range of 50 cm 13% of the particles penetrated deeper than 3 mm and some penetrated up to 7 mm . The experimental findings give evidence of the well known risk of fatal injury from contact shots . Up to a shooting range of 5 cm injuries of the eye bulb are to be expected and at a 50 cm distance severe lesions of the cornea .	[ "In", "order", "to", "describe", "the", "wounding", "capacity", "in", "standardized", "manner", ",", "gelatine", "was", "used", "to", "simulate", "biological", "targets", "in", "terminal", "ballistics", ".", "The", "aim", "was", "the", "investigation", "of", "blank", "cartridges", "with", "wound", "ballistic", "methods", ".", "Blank", "cartridges", "(", "caliber", "9", "mm", "x", "17", ")", "produced", "by", "RWS", ",", "SM", ",", "Wadie", "and", "Umarex", "were", "fired", "with", "starter", "'s", "revolvers", "of", ".", "380", "caliber", "into", "10", "%", "gelatine", "blocks", ".", "Shots", "were", "fired", "at", "4", "°", "C", "at", "distances", "ranging", "from", "close", "contact", "and", "from", "1", "up", "to", "50", "cm", "distance", ".", "The", "blocks", "of", "gelatine", "and", "their", "cross", "-", "sections", "were", "photographed", "using", "slide", "film", "which", "was", "digitized", "and", "analyzed", "by", "computer", ".", "Contact", "shots", "produced", "penetration", "from", "21", "to", "63", "mm", "in", "depth", "and", "the", "maximum", "diameter", "of", "the", "wound", "cavity", "measured", "from", "7", "to", "42", "mm", ".", "Up", "to", "a", "distance", "of", "4", "cm", "black", "powder", "blank", "cartridges", "produced", "tearing", "of", "more", "than", "1", "cm", "depth", ".", "Shots", "from", "a", "distance", "of", "10", "cm", "propelled", "many", "particles", "up", "to", "13", "mm", "deep", "into", "the", "gelatine", ".", "At", "a", "shooting", "range", "of", "50", "cm", "13", "%", "of", "the", "particles", "penetrated", "deeper", "than", "3", "mm", "and", "some", "penetrated", "up", "to", "7", "mm", ".", "The", "experimental", "findings", "give", "evidence", "of", "the", "well", "known", "risk", "of", "fatal", "injury", "from", "contact", "shots", ".", "Up", "to", "a", "shooting", "range", "of", "5", "cm", "injuries", "of", "the", "eye", "bulb", "are", "to", "be", "expected", "and", "at", "a", "50", "cm", "distance", "severe", "lesions", "of", "the", "cornea", "." ]	[ "umlsterm" ]
aim is an umlsterm, wound is an umlsterm, methods is an umlsterm, starter 's is an umlsterm, distances is an umlsterm, distance is an umlsterm, film is an umlsterm, computer is an umlsterm, wound is an umlsterm, distance is an umlsterm, black is an umlsterm, powder is an umlsterm, distance is an umlsterm, findings is an umlsterm, risk of is an umlsterm, injury is an umlsterm, injuries is an umlsterm, eye is an umlsterm, distance is an umlsterm, cornea is an umlsterm	Rechtsmedizin.90090210.eng.abstr_task1	Sentence: In order to describe the wounding capacity in standardized manner , gelatine was used to simulate biological targets in terminal ballistics . The aim was the investigation of blank cartridges with wound ballistic methods . Blank cartridges ( caliber 9 mm x 17 ) produced by RWS , SM , Wadie and Umarex were fired with starter's revolvers of . 380 caliber into 10% gelatine blocks . Shots were fired at 4 °C at distances ranging from close contact and from 1 up to 50 cm distance . The blocks of gelatine and their cross-sections were photographed using slide film which was digitized and analyzed by computer . Contact shots produced penetration from 21 to 63 mm in depth and the maximum diameter of the wound cavity measured from 7 to 42 mm . Up to a distance of 4 cm black powder blank cartridges produced tearing of more than 1 cm depth . Shots from a distance of 10 cm propelled many particles up to 13 mm deep into the gelatine . At a shooting range of 50 cm 13% of the particles penetrated deeper than 3 mm and some penetrated up to 7 mm . The experimental findings give evidence of the well known risk of fatal injury from contact shots . Up to a shooting range of 5 cm injuries of the eye bulb are to be expected and at a 50 cm distance severe lesions of the cornea . Instructions: please typing these entity words according to sentence: aim, wound, methods, starter 's, distances, distance, film, computer, wound, distance, black, powder, distance, findings, risk of, injury, injuries, eye, distance, cornea Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	In order to describe the wounding capacity in standardized manner , gelatine was used to simulate biological targets in terminal ballistics . The aim was the investigation of blank cartridges with wound ballistic methods . Blank cartridges ( caliber 9 mm x 17 ) produced by RWS , SM , Wadie and Umarex were fired with starter's revolvers of . 380 caliber into 10% gelatine blocks . Shots were fired at 4 °C at distances ranging from close contact and from 1 up to 50 cm distance . The blocks of gelatine and their cross-sections were photographed using slide film which was digitized and analyzed by computer . Contact shots produced penetration from 21 to 63 mm in depth and the maximum diameter of the wound cavity measured from 7 to 42 mm . Up to a distance of 4 cm black powder blank cartridges produced tearing of more than 1 cm depth . Shots from a distance of 10 cm propelled many particles up to 13 mm deep into the gelatine . At a shooting range of 50 cm 13% of the particles penetrated deeper than 3 mm and some penetrated up to 7 mm . The experimental findings give evidence of the well known risk of fatal injury from contact shots . Up to a shooting range of 5 cm injuries of the eye bulb are to be expected and at a 50 cm distance severe lesions of the cornea .	[ "In", "order", "to", "describe", "the", "wounding", "capacity", "in", "standardized", "manner", ",", "gelatine", "was", "used", "to", "simulate", "biological", "targets", "in", "terminal", "ballistics", ".", "The", "aim", "was", "the", "investigation", "of", "blank", "cartridges", "with", "wound", "ballistic", "methods", ".", "Blank", "cartridges", "(", "caliber", "9", "mm", "x", "17", ")", "produced", "by", "RWS", ",", "SM", ",", "Wadie", "and", "Umarex", "were", "fired", "with", "starter", "'s", "revolvers", "of", ".", "380", "caliber", "into", "10", "%", "gelatine", "blocks", ".", "Shots", "were", "fired", "at", "4", "°", "C", "at", "distances", "ranging", "from", "close", "contact", "and", "from", "1", "up", "to", "50", "cm", "distance", ".", "The", "blocks", "of", "gelatine", "and", "their", "cross", "-", "sections", "were", "photographed", "using", "slide", "film", "which", "was", "digitized", "and", "analyzed", "by", "computer", ".", "Contact", "shots", "produced", "penetration", "from", "21", "to", "63", "mm", "in", "depth", "and", "the", "maximum", "diameter", "of", "the", "wound", "cavity", "measured", "from", "7", "to", "42", "mm", ".", "Up", "to", "a", "distance", "of", "4", "cm", "black", "powder", "blank", "cartridges", "produced", "tearing", "of", "more", "than", "1", "cm", "depth", ".", "Shots", "from", "a", "distance", "of", "10", "cm", "propelled", "many", "particles", "up", "to", "13", "mm", "deep", "into", "the", "gelatine", ".", "At", "a", "shooting", "range", "of", "50", "cm", "13", "%", "of", "the", "particles", "penetrated", "deeper", "than", "3", "mm", "and", "some", "penetrated", "up", "to", "7", "mm", ".", "The", "experimental", "findings", "give", "evidence", "of", "the", "well", "known", "risk", "of", "fatal", "injury", "from", "contact", "shots", ".", "Up", "to", "a", "shooting", "range", "of", "5", "cm", "injuries", "of", "the", "eye", "bulb", "are", "to", "be", "expected", "and", "at", "a", "50", "cm", "distance", "severe", "lesions", "of", "the", "cornea", "." ]	[ "umlsterm" ]
aim, wound, methods, starter 's, distances, distance, film, computer, wound, distance, black, powder, distance, findings, risk of, injury, injuries, eye, distance, cornea	Rechtsmedizin.90090210.eng.abstr_task2	Sentence: In order to describe the wounding capacity in standardized manner , gelatine was used to simulate biological targets in terminal ballistics . The aim was the investigation of blank cartridges with wound ballistic methods . Blank cartridges ( caliber 9 mm x 17 ) produced by RWS , SM , Wadie and Umarex were fired with starter's revolvers of . 380 caliber into 10% gelatine blocks . Shots were fired at 4 °C at distances ranging from close contact and from 1 up to 50 cm distance . The blocks of gelatine and their cross-sections were photographed using slide film which was digitized and analyzed by computer . Contact shots produced penetration from 21 to 63 mm in depth and the maximum diameter of the wound cavity measured from 7 to 42 mm . Up to a distance of 4 cm black powder blank cartridges produced tearing of more than 1 cm depth . Shots from a distance of 10 cm propelled many particles up to 13 mm deep into the gelatine . At a shooting range of 50 cm 13% of the particles penetrated deeper than 3 mm and some penetrated up to 7 mm . The experimental findings give evidence of the well known risk of fatal injury from contact shots . Up to a shooting range of 5 cm injuries of the eye bulb are to be expected and at a 50 cm distance severe lesions of the cornea . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	In order to describe the wounding capacity in standardized manner , gelatine was used to simulate biological targets in terminal ballistics . The aim was the investigation of blank cartridges with wound ballistic methods . Blank cartridges ( caliber 9 mm x 17 ) produced by RWS , SM , Wadie and Umarex were fired with starter's revolvers of . 380 caliber into 10% gelatine blocks . Shots were fired at 4 °C at distances ranging from close contact and from 1 up to 50 cm distance . The blocks of gelatine and their cross-sections were photographed using slide film which was digitized and analyzed by computer . Contact shots produced penetration from 21 to 63 mm in depth and the maximum diameter of the wound cavity measured from 7 to 42 mm . Up to a distance of 4 cm black powder blank cartridges produced tearing of more than 1 cm depth . Shots from a distance of 10 cm propelled many particles up to 13 mm deep into the gelatine . At a shooting range of 50 cm 13% of the particles penetrated deeper than 3 mm and some penetrated up to 7 mm . The experimental findings give evidence of the well known risk of fatal injury from contact shots . Up to a shooting range of 5 cm injuries of the eye bulb are to be expected and at a 50 cm distance severe lesions of the cornea .	[ "In", "order", "to", "describe", "the", "wounding", "capacity", "in", "standardized", "manner", ",", "gelatine", "was", "used", "to", "simulate", "biological", "targets", "in", "terminal", "ballistics", ".", "The", "aim", "was", "the", "investigation", "of", "blank", "cartridges", "with", "wound", "ballistic", "methods", ".", "Blank", "cartridges", "(", "caliber", "9", "mm", "x", "17", ")", "produced", "by", "RWS", ",", "SM", ",", "Wadie", "and", "Umarex", "were", "fired", "with", "starter", "'s", "revolvers", "of", ".", "380", "caliber", "into", "10", "%", "gelatine", "blocks", ".", "Shots", "were", "fired", "at", "4", "°", "C", "at", "distances", "ranging", "from", "close", "contact", "and", "from", "1", "up", "to", "50", "cm", "distance", ".", "The", "blocks", "of", "gelatine", "and", "their", "cross", "-", "sections", "were", "photographed", "using", "slide", "film", "which", "was", "digitized", "and", "analyzed", "by", "computer", ".", "Contact", "shots", "produced", "penetration", "from", "21", "to", "63", "mm", "in", "depth", "and", "the", "maximum", "diameter", "of", "the", "wound", "cavity", "measured", "from", "7", "to", "42", "mm", ".", "Up", "to", "a", "distance", "of", "4", "cm", "black", "powder", "blank", "cartridges", "produced", "tearing", "of", "more", "than", "1", "cm", "depth", ".", "Shots", "from", "a", "distance", "of", "10", "cm", "propelled", "many", "particles", "up", "to", "13", "mm", "deep", "into", "the", "gelatine", ".", "At", "a", "shooting", "range", "of", "50", "cm", "13", "%", "of", "the", "particles", "penetrated", "deeper", "than", "3", "mm", "and", "some", "penetrated", "up", "to", "7", "mm", ".", "The", "experimental", "findings", "give", "evidence", "of", "the", "well", "known", "risk", "of", "fatal", "injury", "from", "contact", "shots", ".", "Up", "to", "a", "shooting", "range", "of", "5", "cm", "injuries", "of", "the", "eye", "bulb", "are", "to", "be", "expected", "and", "at", "a", "50", "cm", "distance", "severe", "lesions", "of", "the", "cornea", "." ]	[ "umlsterm" ]
Schaedel - Hirn - Verletzungen is an umlsterm, Verletzungen is an umlsterm, unfallchirurgischen is an umlsterm, Patienten is an umlsterm, Schaedel - Hirn - Trauma is an umlsterm, SHT is an umlsterm, Patienten is an umlsterm, Commotio cerebri is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Haematomausraeumung is an umlsterm, Blutungen is an umlsterm, Drainage is an umlsterm, Patienten is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Verletzungen is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, SHT is an umlsterm, Krankenhaeusern is an umlsterm, Roentgendiagnostik is an umlsterm, SHT is an umlsterm, Krankenhaus is an umlsterm, SHT is an umlsterm, lebensbedrohlichen is an umlsterm, Blutungen is an umlsterm, Druckentlastung is an umlsterm, Blutmassen is an umlsterm, Blutungen is an umlsterm, hinteren Schaedelgrube is an umlsterm, Hirnnervenverletzungen is an umlsterm, Schaedelbasisverletzungen is an umlsterm, Liquorfisteln is an umlsterm, Literatur is an umlsterm, Patienten is an umlsterm, SHT is an umlsterm	DerChirurg.60671107.ger.abstr_task0	Sentence: Zusammenfassung . Schaedel-Hirn-Verletzungen sind sowohl bei Polytraumen wie auch als isolierte Verletzungen sehr haeufig . In unserer Klinik der unfallchirurgischen Schwerpunktversorgung wurden in einem Zeitraum von 21 Monaten 489 Patienten mit einem Schaedel-Hirn-Trauma ( SHT ) behandelt . Dies entspricht 6,5 % aller stationaer behandelten Patienten . Waehrend bei Commotio cerebri ( CC 85,9 % , der Patienten ) immer eine konservative Therapie und komplikationsloser Verlauf festzustellen war , musste bei den 69 Patienten mit Contusio cerebri in 18 Faellen eine Craniotomie mit Haematomausraeumung bei sub- und epiduralen Blutungen und Drainage erfolgen . Bei zwei dieser Patienten war eine Revision wegen Nachblutung erforderlich . Eine Bildtelephonverbindung mit einem neurochirurgischen Zentrum wurde zweimal in Anspruch genommen . In vier Faellen mit Komplex-/Begleitverletzungen erfolgte die Verlegung in ein neurochirurgisches Zentrum . Die Letalitaet betrug 14,5 % . Es werden die Diagnostik und Therapie bei den einzelnen Verletzungen und die Voraussetzungen fuer die Behandlung von Patienten mit SHT in peripheren Krankenhaeusern dargestellt : Notarzt Notaufnahmemanagement , Neurologe , , Roentgendiagnostik mit CT , Operationsausstattung und qualifizierte Operateure . Falls diese Voraussetzungen gegeben sind , kann ein Grossteil auch schwerer SHT im peripheren Krankenhaus versorgt werden . Sind einige dieser Voraussetzungen nicht erfuellt , sollte bei jedem potentiell operationspflichtigen SHT die fruehzeitige Verlegung in ein Zentrum erfolgen . Nur bei akut lebensbedrohlichen Blutungen , bei denen aus zeitlichen Gruenden eine Verlegung nicht moeglich ist , muss auch in Kliniken der Grundversorgung ohne adaequate Voraussetzungen eine Craniotomie und Druckentlastung erfolgen . Bei Begleitverletzungen , wie intracerebrale Blutmassen , Ventrikeleinbruch , Blutungen in der hinteren Schaedelgrube , Hirnnervenverletzungen , Carotis- oder Sinus-cavernosus-Verletzung , Schaedelbasisverletzungen mit Liquorfisteln oder Pneumoencephalon sollen auch fuer Kliniken der Schwerpunktversorgung eine Indikation zur Verlegung in ein neurochirurgisches Zentrum sein . Diese Selektion ermoeglicht in peripheren Kliniken vergleichbare Behandlungsergebnisse , wie in der Literatur angegeben , und vermeidet die Ueberlastung neurochirurgischer Zentren mit Patienten nach SHT . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Zusammenfassung . Schaedel-Hirn-Verletzungen sind sowohl bei Polytraumen wie auch als isolierte Verletzungen sehr haeufig . In unserer Klinik der unfallchirurgischen Schwerpunktversorgung wurden in einem Zeitraum von 21 Monaten 489 Patienten mit einem Schaedel-Hirn-Trauma ( SHT ) behandelt . Dies entspricht 6,5 % aller stationaer behandelten Patienten . Waehrend bei Commotio cerebri ( CC 85,9 % , der Patienten ) immer eine konservative Therapie und komplikationsloser Verlauf festzustellen war , musste bei den 69 Patienten mit Contusio cerebri in 18 Faellen eine Craniotomie mit Haematomausraeumung bei sub- und epiduralen Blutungen und Drainage erfolgen . Bei zwei dieser Patienten war eine Revision wegen Nachblutung erforderlich . Eine Bildtelephonverbindung mit einem neurochirurgischen Zentrum wurde zweimal in Anspruch genommen . In vier Faellen mit Komplex-/Begleitverletzungen erfolgte die Verlegung in ein neurochirurgisches Zentrum . Die Letalitaet betrug 14,5 % . Es werden die Diagnostik und Therapie bei den einzelnen Verletzungen und die Voraussetzungen fuer die Behandlung von Patienten mit SHT in peripheren Krankenhaeusern dargestellt : Notarzt Notaufnahmemanagement , Neurologe , , Roentgendiagnostik mit CT , Operationsausstattung und qualifizierte Operateure . Falls diese Voraussetzungen gegeben sind , kann ein Grossteil auch schwerer SHT im peripheren Krankenhaus versorgt werden . Sind einige dieser Voraussetzungen nicht erfuellt , sollte bei jedem potentiell operationspflichtigen SHT die fruehzeitige Verlegung in ein Zentrum erfolgen . Nur bei akut lebensbedrohlichen Blutungen , bei denen aus zeitlichen Gruenden eine Verlegung nicht moeglich ist , muss auch in Kliniken der Grundversorgung ohne adaequate Voraussetzungen eine Craniotomie und Druckentlastung erfolgen . Bei Begleitverletzungen , wie intracerebrale Blutmassen , Ventrikeleinbruch , Blutungen in der hinteren Schaedelgrube , Hirnnervenverletzungen , Carotis- oder Sinus-cavernosus-Verletzung , Schaedelbasisverletzungen mit Liquorfisteln oder Pneumoencephalon sollen auch fuer Kliniken der Schwerpunktversorgung eine Indikation zur Verlegung in ein neurochirurgisches Zentrum sein . Diese Selektion ermoeglicht in peripheren Kliniken vergleichbare Behandlungsergebnisse , wie in der Literatur angegeben , und vermeidet die Ueberlastung neurochirurgischer Zentren mit Patienten nach SHT .	[ "Zusammenfassung", ".", "Schaedel", "-", "Hirn", "-", "Verletzungen", "sind", "sowohl", "bei", "Polytraumen", "wie", "auch", "als", "isolierte", "Verletzungen", "sehr", "haeufig", ".", "In", "unserer", "Klinik", "der", "unfallchirurgischen", "Schwerpunktversorgung", "wurden", "in", "einem", "Zeitraum", "von", "21", "Monaten", "489", "Patienten", "mit", "einem", "Schaedel", "-", "Hirn", "-", "Trauma", "(", "SHT", ")", "behandelt", ".", "Dies", "entspricht", "6,5", "%", "aller", "stationaer", "behandelten", "Patienten", ".", "Waehrend", "bei", "Commotio", "cerebri", "(", "CC", "85,9", "%", ",", "der", "Patienten", ")", "immer", "eine", "konservative", "Therapie", "und", "komplikationsloser", "Verlauf", "festzustellen", "war", ",", "musste", "bei", "den", "69", "Patienten", "mit", "Contusio", "cerebri", "in", "18", "Faellen", "eine", "Craniotomie", "mit", "Haematomausraeumung", "bei", "sub-", "und", "epiduralen", "Blutungen", "und", "Drainage", "erfolgen", ".", "Bei", "zwei", "dieser", "Patienten", "war", "eine", "Revision", "wegen", "Nachblutung", "erforderlich", ".", "Eine", "Bildtelephonverbindung", "mit", "einem", "neurochirurgischen", "Zentrum", "wurde", "zweimal", "in", "Anspruch", "genommen", ".", "In", "vier", "Faellen", "mit", "Komplex-/Begleitverletzungen", "erfolgte", "die", "Verlegung", "in", "ein", "neurochirurgisches", "Zentrum", ".", "Die", "Letalitaet", "betrug", "14,5", "%", ".", "Es", "werden", "die", "Diagnostik", "und", "Therapie", "bei", "den", "einzelnen", "Verletzungen", "und", "die", "Voraussetzungen", "fuer", "die", "Behandlung", "von", "Patienten", "mit", "SHT", "in", "peripheren", "Krankenhaeusern", "dargestellt", ":", "Notarzt", "Notaufnahmemanagement", ",", "Neurologe", ",", ",", "Roentgendiagnostik", "mit", "CT", ",", "Operationsausstattung", "und", "qualifizierte", "Operateure", ".", "Falls", "diese", "Voraussetzungen", "gegeben", "sind", ",", "kann", "ein", "Grossteil", "auch", "schwerer", "SHT", "im", "peripheren", "Krankenhaus", "versorgt", "werden", ".", "Sind", "einige", "dieser", "Voraussetzungen", "nicht", "erfuellt", ",", "sollte", "bei", "jedem", "potentiell", "operationspflichtigen", "SHT", "die", "fruehzeitige", "Verlegung", "in", "ein", "Zentrum", "erfolgen", ".", "Nur", "bei", "akut", "lebensbedrohlichen", "Blutungen", ",", "bei", "denen", "aus", "zeitlichen", "Gruenden", "eine", "Verlegung", "nicht", "moeglich", "ist", ",", "muss", "auch", "in", "Kliniken", "der", "Grundversorgung", "ohne", "adaequate", "Voraussetzungen", "eine", "Craniotomie", "und", "Druckentlastung", "erfolgen", ".", "Bei", "Begleitverletzungen", ",", "wie", "intracerebrale", "Blutmassen", ",", "Ventrikeleinbruch", ",", "Blutungen", "in", "der", "hinteren", "Schaedelgrube", ",", "Hirnnervenverletzungen", ",", "Carotis-", "oder", "Sinus", "-", "cavernosus", "-", "Verletzung", ",", "Schaedelbasisverletzungen", "mit", "Liquorfisteln", "oder", "Pneumoencephalon", "sollen", "auch", "fuer", "Kliniken", "der", "Schwerpunktversorgung", "eine", "Indikation", "zur", "Verlegung", "in", "ein", "neurochirurgisches", "Zentrum", "sein", ".", "Diese", "Selektion", "ermoeglicht", "in", "peripheren", "Kliniken", "vergleichbare", "Behandlungsergebnisse", ",", "wie", "in", "der", "Literatur", "angegeben", ",", "und", "vermeidet", "die", "Ueberlastung", "neurochirurgischer", "Zentren", "mit", "Patienten", "nach", "SHT", "." ]	[ "umlsterm" ]
Schaedel - Hirn - Verletzungen is an umlsterm, Verletzungen is an umlsterm, unfallchirurgischen is an umlsterm, Patienten is an umlsterm, Schaedel - Hirn - Trauma is an umlsterm, SHT is an umlsterm, Patienten is an umlsterm, Commotio cerebri is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Haematomausraeumung is an umlsterm, Blutungen is an umlsterm, Drainage is an umlsterm, Patienten is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Verletzungen is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, SHT is an umlsterm, Krankenhaeusern is an umlsterm, Roentgendiagnostik is an umlsterm, SHT is an umlsterm, Krankenhaus is an umlsterm, SHT is an umlsterm, lebensbedrohlichen is an umlsterm, Blutungen is an umlsterm, Druckentlastung is an umlsterm, Blutmassen is an umlsterm, Blutungen is an umlsterm, hinteren Schaedelgrube is an umlsterm, Hirnnervenverletzungen is an umlsterm, Schaedelbasisverletzungen is an umlsterm, Liquorfisteln is an umlsterm, Literatur is an umlsterm, Patienten is an umlsterm, SHT is an umlsterm	DerChirurg.60671107.ger.abstr_task1	Sentence: Zusammenfassung . Schaedel-Hirn-Verletzungen sind sowohl bei Polytraumen wie auch als isolierte Verletzungen sehr haeufig . In unserer Klinik der unfallchirurgischen Schwerpunktversorgung wurden in einem Zeitraum von 21 Monaten 489 Patienten mit einem Schaedel-Hirn-Trauma ( SHT ) behandelt . Dies entspricht 6,5 % aller stationaer behandelten Patienten . Waehrend bei Commotio cerebri ( CC 85,9 % , der Patienten ) immer eine konservative Therapie und komplikationsloser Verlauf festzustellen war , musste bei den 69 Patienten mit Contusio cerebri in 18 Faellen eine Craniotomie mit Haematomausraeumung bei sub- und epiduralen Blutungen und Drainage erfolgen . Bei zwei dieser Patienten war eine Revision wegen Nachblutung erforderlich . Eine Bildtelephonverbindung mit einem neurochirurgischen Zentrum wurde zweimal in Anspruch genommen . In vier Faellen mit Komplex-/Begleitverletzungen erfolgte die Verlegung in ein neurochirurgisches Zentrum . Die Letalitaet betrug 14,5 % . Es werden die Diagnostik und Therapie bei den einzelnen Verletzungen und die Voraussetzungen fuer die Behandlung von Patienten mit SHT in peripheren Krankenhaeusern dargestellt : Notarzt Notaufnahmemanagement , Neurologe , , Roentgendiagnostik mit CT , Operationsausstattung und qualifizierte Operateure . Falls diese Voraussetzungen gegeben sind , kann ein Grossteil auch schwerer SHT im peripheren Krankenhaus versorgt werden . Sind einige dieser Voraussetzungen nicht erfuellt , sollte bei jedem potentiell operationspflichtigen SHT die fruehzeitige Verlegung in ein Zentrum erfolgen . Nur bei akut lebensbedrohlichen Blutungen , bei denen aus zeitlichen Gruenden eine Verlegung nicht moeglich ist , muss auch in Kliniken der Grundversorgung ohne adaequate Voraussetzungen eine Craniotomie und Druckentlastung erfolgen . Bei Begleitverletzungen , wie intracerebrale Blutmassen , Ventrikeleinbruch , Blutungen in der hinteren Schaedelgrube , Hirnnervenverletzungen , Carotis- oder Sinus-cavernosus-Verletzung , Schaedelbasisverletzungen mit Liquorfisteln oder Pneumoencephalon sollen auch fuer Kliniken der Schwerpunktversorgung eine Indikation zur Verlegung in ein neurochirurgisches Zentrum sein . Diese Selektion ermoeglicht in peripheren Kliniken vergleichbare Behandlungsergebnisse , wie in der Literatur angegeben , und vermeidet die Ueberlastung neurochirurgischer Zentren mit Patienten nach SHT . Instructions: please typing these entity words according to sentence: Schaedel - Hirn - Verletzungen, Verletzungen, unfallchirurgischen, Patienten, Schaedel - Hirn - Trauma, SHT, Patienten, Commotio cerebri, Patienten, Therapie, Patienten, Haematomausraeumung, Blutungen, Drainage, Patienten, Diagnostik, Therapie, Verletzungen, Behandlung, Patienten, SHT, Krankenhaeusern, Roentgendiagnostik, SHT, Krankenhaus, SHT, lebensbedrohlichen, Blutungen, Druckentlastung, Blutmassen, Blutungen, hinteren Schaedelgrube, Hirnnervenverletzungen, Schaedelbasisverletzungen, Liquorfisteln, Literatur, Patienten, SHT Options: umlsterm	[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Zusammenfassung . Schaedel-Hirn-Verletzungen sind sowohl bei Polytraumen wie auch als isolierte Verletzungen sehr haeufig . In unserer Klinik der unfallchirurgischen Schwerpunktversorgung wurden in einem Zeitraum von 21 Monaten 489 Patienten mit einem Schaedel-Hirn-Trauma ( SHT ) behandelt . Dies entspricht 6,5 % aller stationaer behandelten Patienten . Waehrend bei Commotio cerebri ( CC 85,9 % , der Patienten ) immer eine konservative Therapie und komplikationsloser Verlauf festzustellen war , musste bei den 69 Patienten mit Contusio cerebri in 18 Faellen eine Craniotomie mit Haematomausraeumung bei sub- und epiduralen Blutungen und Drainage erfolgen . Bei zwei dieser Patienten war eine Revision wegen Nachblutung erforderlich . Eine Bildtelephonverbindung mit einem neurochirurgischen Zentrum wurde zweimal in Anspruch genommen . In vier Faellen mit Komplex-/Begleitverletzungen erfolgte die Verlegung in ein neurochirurgisches Zentrum . Die Letalitaet betrug 14,5 % . Es werden die Diagnostik und Therapie bei den einzelnen Verletzungen und die Voraussetzungen fuer die Behandlung von Patienten mit SHT in peripheren Krankenhaeusern dargestellt : Notarzt Notaufnahmemanagement , Neurologe , , Roentgendiagnostik mit CT , Operationsausstattung und qualifizierte Operateure . Falls diese Voraussetzungen gegeben sind , kann ein Grossteil auch schwerer SHT im peripheren Krankenhaus versorgt werden . Sind einige dieser Voraussetzungen nicht erfuellt , sollte bei jedem potentiell operationspflichtigen SHT die fruehzeitige Verlegung in ein Zentrum erfolgen . Nur bei akut lebensbedrohlichen Blutungen , bei denen aus zeitlichen Gruenden eine Verlegung nicht moeglich ist , muss auch in Kliniken der Grundversorgung ohne adaequate Voraussetzungen eine Craniotomie und Druckentlastung erfolgen . Bei Begleitverletzungen , wie intracerebrale Blutmassen , Ventrikeleinbruch , Blutungen in der hinteren Schaedelgrube , Hirnnervenverletzungen , Carotis- oder Sinus-cavernosus-Verletzung , Schaedelbasisverletzungen mit Liquorfisteln oder Pneumoencephalon sollen auch fuer Kliniken der Schwerpunktversorgung eine Indikation zur Verlegung in ein neurochirurgisches Zentrum sein . Diese Selektion ermoeglicht in peripheren Kliniken vergleichbare Behandlungsergebnisse , wie in der Literatur angegeben , und vermeidet die Ueberlastung neurochirurgischer Zentren mit Patienten nach SHT .	[ "Zusammenfassung", ".", "Schaedel", "-", "Hirn", "-", "Verletzungen", "sind", "sowohl", "bei", "Polytraumen", "wie", "auch", "als", "isolierte", "Verletzungen", "sehr", "haeufig", ".", "In", "unserer", "Klinik", "der", "unfallchirurgischen", "Schwerpunktversorgung", "wurden", "in", "einem", "Zeitraum", "von", "21", "Monaten", "489", "Patienten", "mit", "einem", "Schaedel", "-", "Hirn", "-", "Trauma", "(", "SHT", ")", "behandelt", ".", "Dies", "entspricht", "6,5", "%", "aller", "stationaer", "behandelten", "Patienten", ".", "Waehrend", "bei", "Commotio", "cerebri", "(", "CC", "85,9", "%", ",", "der", "Patienten", ")", "immer", "eine", "konservative", "Therapie", "und", "komplikationsloser", "Verlauf", "festzustellen", "war", ",", "musste", "bei", "den", "69", "Patienten", "mit", "Contusio", "cerebri", "in", "18", "Faellen", "eine", "Craniotomie", "mit", "Haematomausraeumung", "bei", "sub-", "und", "epiduralen", "Blutungen", "und", "Drainage", "erfolgen", ".", "Bei", "zwei", "dieser", "Patienten", "war", "eine", "Revision", "wegen", "Nachblutung", "erforderlich", ".", "Eine", "Bildtelephonverbindung", "mit", "einem", "neurochirurgischen", "Zentrum", "wurde", "zweimal", "in", "Anspruch", "genommen", ".", "In", "vier", "Faellen", "mit", "Komplex-/Begleitverletzungen", "erfolgte", "die", "Verlegung", "in", "ein", "neurochirurgisches", "Zentrum", ".", "Die", "Letalitaet", "betrug", "14,5", "%", ".", "Es", "werden", "die", "Diagnostik", "und", "Therapie", "bei", "den", "einzelnen", "Verletzungen", "und", "die", "Voraussetzungen", "fuer", "die", "Behandlung", "von", "Patienten", "mit", "SHT", "in", "peripheren", "Krankenhaeusern", "dargestellt", ":", "Notarzt", "Notaufnahmemanagement", ",", "Neurologe", ",", ",", "Roentgendiagnostik", "mit", "CT", ",", "Operationsausstattung", "und", "qualifizierte", "Operateure", ".", "Falls", "diese", "Voraussetzungen", "gegeben", "sind", ",", "kann", "ein", "Grossteil", "auch", "schwerer", "SHT", "im", "peripheren", "Krankenhaus", "versorgt", "werden", ".", "Sind", "einige", "dieser", "Voraussetzungen", "nicht", "erfuellt", ",", "sollte", "bei", "jedem", "potentiell", "operationspflichtigen", "SHT", "die", "fruehzeitige", "Verlegung", "in", "ein", "Zentrum", "erfolgen", ".", "Nur", "bei", "akut", "lebensbedrohlichen", "Blutungen", ",", "bei", "denen", "aus", "zeitlichen", "Gruenden", "eine", "Verlegung", "nicht", "moeglich", "ist", ",", "muss", "auch", "in", "Kliniken", "der", "Grundversorgung", "ohne", "adaequate", "Voraussetzungen", "eine", "Craniotomie", "und", "Druckentlastung", "erfolgen", ".", "Bei", "Begleitverletzungen", ",", "wie", "intracerebrale", "Blutmassen", ",", "Ventrikeleinbruch", ",", "Blutungen", "in", "der", "hinteren", "Schaedelgrube", ",", "Hirnnervenverletzungen", ",", "Carotis-", "oder", "Sinus", "-", "cavernosus", "-", "Verletzung", ",", "Schaedelbasisverletzungen", "mit", "Liquorfisteln", "oder", "Pneumoencephalon", "sollen", "auch", "fuer", "Kliniken", "der", "Schwerpunktversorgung", "eine", "Indikation", "zur", "Verlegung", "in", "ein", "neurochirurgisches", "Zentrum", "sein", ".", "Diese", "Selektion", "ermoeglicht", "in", "peripheren", "Kliniken", "vergleichbare", "Behandlungsergebnisse", ",", "wie", "in", "der", "Literatur", "angegeben", ",", "und", "vermeidet", "die", "Ueberlastung", "neurochirurgischer", "Zentren", "mit", "Patienten", "nach", "SHT", "." ]	[ "umlsterm" ]

telemedicine is an umlsterm, time is an umlsterm, time is an umlsterm, economic is an umlsterm, need is an umlsterm, all is an umlsterm

DerRadiologe.70370294.eng.abstr_task1

Sentence: The discussion about the implementation of telemedicine and teleresourcing and its consequences has been under way for some time now . The rate at which telemedical applications are being developed , leaves little time for consideration of the economic , scientific and social aspects . There is a need for integration of all the existing fragments into one coherent telemedical concept . Different aspects of telemedical concepts are discussed . Instructions: please typing these entity words according to sentence: telemedicine, time, time, economic, need, all Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The discussion about the implementation of telemedicine and teleresourcing and its consequences has been under way for some time now . The rate at which telemedical applications are being developed , leaves little time for consideration of the economic , scientific and social aspects . There is a need for integration of all the existing fragments into one coherent telemedical concept . Different aspects of telemedical concepts are discussed .

[ "The", "discussion", "about", "the", "implementation", "of", "telemedicine", "and", "teleresourcing", "and", "its", "consequences", "has", "been", "under", "way", "for", "some", "time", "now", ".", "The", "rate", "at", "which", "telemedical", "applications", "are", "being", "developed", ",", "leaves", "little", "time", "for", "consideration", "of", "the", "economic", ",", "scientific", "and", "social", "aspects", ".", "There", "is", "a", "need", "for", "integration", "of", "all", "the", "existing", "fragments", "into", "one", "coherent", "telemedical", "concept", ".", "Different", "aspects", "of", "telemedical", "concepts", "are", "discussed", "." ]

[ "umlsterm" ]

telemedicine, time, time, economic, need, all

DerRadiologe.70370294.eng.abstr_task2

Sentence: The discussion about the implementation of telemedicine and teleresourcing and its consequences has been under way for some time now . The rate at which telemedical applications are being developed , leaves little time for consideration of the economic , scientific and social aspects . There is a need for integration of all the existing fragments into one coherent telemedical concept . Different aspects of telemedical concepts are discussed . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The discussion about the implementation of telemedicine and teleresourcing and its consequences has been under way for some time now . The rate at which telemedical applications are being developed , leaves little time for consideration of the economic , scientific and social aspects . There is a need for integration of all the existing fragments into one coherent telemedical concept . Different aspects of telemedical concepts are discussed .

[ "The", "discussion", "about", "the", "implementation", "of", "telemedicine", "and", "teleresourcing", "and", "its", "consequences", "has", "been", "under", "way", "for", "some", "time", "now", ".", "The", "rate", "at", "which", "telemedical", "applications", "are", "being", "developed", ",", "leaves", "little", "time", "for", "consideration", "of", "the", "economic", ",", "scientific", "and", "social", "aspects", ".", "There", "is", "a", "need", "for", "integration", "of", "all", "the", "existing", "fragments", "into", "one", "coherent", "telemedical", "concept", ".", "Different", "aspects", "of", "telemedical", "concepts", "are", "discussed", "." ]

[ "umlsterm" ]

fatty acid is a CHEMICAL, GPCRs is a GENE-N

23409763_task0

Sentence: The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-N", "O" ]

The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs.

[ "The", "therapeutic", "potential", "of", "allosteric", "ligands", "for", "free", "fatty", "acid", "sensitive", "GPCRs", "." ]

[ "GENE-N", "CHEMICAL" ]

fatty acid is a CHEMICAL, GPCRs is a GENE-N

23409763_task1

Sentence: The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. Instructions: please typing these entity words according to sentence: fatty acid, GPCRs Options: GENE-N, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-N", "O" ]

The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs.

[ "The", "therapeutic", "potential", "of", "allosteric", "ligands", "for", "free", "fatty", "acid", "sensitive", "GPCRs", "." ]

[ "GENE-N", "CHEMICAL" ]

fatty acid, GPCRs

23409763_task2

Sentence: The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-N", "O" ]

The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs.

[ "The", "therapeutic", "potential", "of", "allosteric", "ligands", "for", "free", "fatty", "acid", "sensitive", "GPCRs", "." ]

[ "GENE-N", "CHEMICAL" ]

TNXB is a gene

27_task0

Sentence: TNXB locus may be a candidate gene predisposing to schizophrenia. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: gene

[ "B-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

TNXB locus may be a candidate gene predisposing to schizophrenia.

[ "TNXB", " ", "locus", "may", "be", "a", "candidate", "gene", "predisposing", "to", "schizophrenia", "." ]

[ "variant", "gene" ]

TNXB is a gene

27_task1

Sentence: TNXB locus may be a candidate gene predisposing to schizophrenia. Instructions: please typing these entity words according to sentence: TNXB Options: gene

[ "B-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

TNXB locus may be a candidate gene predisposing to schizophrenia.

[ "TNXB", " ", "locus", "may", "be", "a", "candidate", "gene", "predisposing", "to", "schizophrenia", "." ]

[ "variant", "gene" ]

TNXB

27_task2

Sentence: TNXB locus may be a candidate gene predisposing to schizophrenia. Instructions: please extract entity words from the input sentence

[ "B-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

TNXB locus may be a candidate gene predisposing to schizophrenia.

[ "TNXB", " ", "locus", "may", "be", "a", "candidate", "gene", "predisposing", "to", "schizophrenia", "." ]

[ "variant", "gene" ]

ATP - binding cassette transporter is a GENE-N, ABCB1 is a GENE-Y, BCRP is a GENE-Y, ABCG2 is a GENE-Y, Aβ is a GENE-Y, multidrug transporters is a GENE-N, ABCA1 is a GENE-Y, ABCA7 is a GENE-Y, ABCB1 is a GENE-Y, ABCC2 is a GENE-Y, ABCG2 is a GENE-Y, APOE4 is a GENE-Y, ABCA7 is a GENE-Y, ABCB1 is a GENE-Y, ABCB1 is a GENE-Y, 2677G > T is a GENE-N, ABCC2 is a GENE-Y, 3972C > T is a GENE-N, ABCB1 is a GENE-Y, ABC - transporters is a GENE-N, Aβ is a GENE-Y

33213_task0

Sentence: Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ. We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls. Materials & methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2. In addition, the APOE4 status was analyzed. Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study. Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females. This association of ABCB1 2677G>T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005). However, only ABCC2 3972C>T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants. Other transporters showed a lack of association. Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD. Original submitted 8 October 2012; Revision submitted 22 January 2013. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N

[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ. We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls. Materials & methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2. In addition, the APOE4 status was analyzed. Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study. Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females. This association of ABCB1 2677G>T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005). However, only ABCC2 3972C>T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants. Other transporters showed a lack of association. Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD. Original submitted 8 October 2012; Revision submitted 22 January 2013.

[ "Association", "of", "ATP", "-", "binding", "cassette", "transporter", "variants", "with", "the", "risk", "of", "Alzheimer", "'s", "disease", ".", "\n", "Aim", ":", "A", "number", "of", "studies", "have", "demonstrated", "that", "ABCB1", "and", "BCRP", "(", "ABCG2", ")", "actively", "transport", "Aβ", ".", "We", "aimed", "to", "investigate", "the", "association", "of", "genetic", "variants", "of", "selected", "multidrug", "transporters", "with", "Alzheimer", "'s", "disease", "(", "AD", ")", "in", "histopathologically", "confirmed", "AD", "cases", "and", "controls", ".", "Materials", "&", "methods", ":", "DNA", "from", "brain", "tissue", "of", "71", "AD", "cases", "with", "Consortium", "to", "Establish", "a", "Registry", "for", "Alzheimer", "'s", "Disease", "(", "CERAD", ")", "neuropathological", "stages", "B", "/", "C", "and", "81", "controls", "was", "genotyped", "for", "selected", "variants", "in", "ABCA1", ",", "ABCA7", ",", "ABCB1", ",", "ABCC2", "and", "ABCG2", ".", "In", "addition", ",", "the", "APOE4", "status", "was", "analyzed", ".", "Results", ":", "The", "novel", "ABCA7", "SNP", ",", "rs3752246", ",", "tended", "to", "be", "associated", "with", "AD", "in", "our", "study", ".", "Variants", "in", "ABCB1", "were", "significantly", "less", "frequent", "in", "AD", "cases", "older", "than", "65", "years", "of", "age", "and", "among", "females", ".", "This", "association", "of", "ABCB1", "2677G", ">", "T", "(", "rs2032582", ")", "was", "more", "pronounced", "in", "APOE4-negative", "cases", "(", "p", "=", "0.005", ")", ".", "However", ",", "only", "ABCC2", "3972C", ">", "T", "(", "rs3740066", ")", "was", "significantly", "associated", "with", "AD", "risk", "after", "logistic", "regression", "analysis", "including", "all", "variants", ".", "Other", "transporters", "showed", "a", "lack", "of", "association", ".", "Conclusion", ":", "Our", "results", "support", "the", "hypothesis", "that", "ABCB1", "and", "possibly", "other", "ABC", "-", "transporters", "are", "involved", "in", "the", "process", "of", "Aβ", "accumulation", "in", "the", "aging", "brain", "and", "may", "modulate", "the", "risk", "for", "AD", "in", "an", "allele", "-", "specific", "manner", ",", "and", "thus", "might", "represent", "a", "new", "target", "for", "prevention", "and", "treatment", "of", "AD", ".", "Original", "submitted", "8", "October", "2012", ";", "Revision", "submitted", "22", "January", "2013", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

ATP - binding cassette transporter is a GENE-N, ABCB1 is a GENE-Y, BCRP is a GENE-Y, ABCG2 is a GENE-Y, Aβ is a GENE-Y, multidrug transporters is a GENE-N, ABCA1 is a GENE-Y, ABCA7 is a GENE-Y, ABCB1 is a GENE-Y, ABCC2 is a GENE-Y, ABCG2 is a GENE-Y, APOE4 is a GENE-Y, ABCA7 is a GENE-Y, ABCB1 is a GENE-Y, ABCB1 is a GENE-Y, 2677G > T is a GENE-N, ABCC2 is a GENE-Y, 3972C > T is a GENE-N, ABCB1 is a GENE-Y, ABC - transporters is a GENE-N, Aβ is a GENE-Y

33213_task1

Sentence: Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ. We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls. Materials & methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2. In addition, the APOE4 status was analyzed. Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study. Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females. This association of ABCB1 2677G>T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005). However, only ABCC2 3972C>T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants. Other transporters showed a lack of association. Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD. Original submitted 8 October 2012; Revision submitted 22 January 2013. Instructions: please typing these entity words according to sentence: ATP - binding cassette transporter, ABCB1, BCRP, ABCG2, Aβ, multidrug transporters, ABCA1, ABCA7, ABCB1, ABCC2, ABCG2, APOE4, ABCA7, ABCB1, ABCB1, 2677G > T, ABCC2, 3972C > T, ABCB1, ABC - transporters, Aβ Options: GENE-Y, GENE-N

[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ. We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls. Materials & methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2. In addition, the APOE4 status was analyzed. Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study. Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females. This association of ABCB1 2677G>T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005). However, only ABCC2 3972C>T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants. Other transporters showed a lack of association. Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD. Original submitted 8 October 2012; Revision submitted 22 January 2013.

[ "Association", "of", "ATP", "-", "binding", "cassette", "transporter", "variants", "with", "the", "risk", "of", "Alzheimer", "'s", "disease", ".", "\n", "Aim", ":", "A", "number", "of", "studies", "have", "demonstrated", "that", "ABCB1", "and", "BCRP", "(", "ABCG2", ")", "actively", "transport", "Aβ", ".", "We", "aimed", "to", "investigate", "the", "association", "of", "genetic", "variants", "of", "selected", "multidrug", "transporters", "with", "Alzheimer", "'s", "disease", "(", "AD", ")", "in", "histopathologically", "confirmed", "AD", "cases", "and", "controls", ".", "Materials", "&", "methods", ":", "DNA", "from", "brain", "tissue", "of", "71", "AD", "cases", "with", "Consortium", "to", "Establish", "a", "Registry", "for", "Alzheimer", "'s", "Disease", "(", "CERAD", ")", "neuropathological", "stages", "B", "/", "C", "and", "81", "controls", "was", "genotyped", "for", "selected", "variants", "in", "ABCA1", ",", "ABCA7", ",", "ABCB1", ",", "ABCC2", "and", "ABCG2", ".", "In", "addition", ",", "the", "APOE4", "status", "was", "analyzed", ".", "Results", ":", "The", "novel", "ABCA7", "SNP", ",", "rs3752246", ",", "tended", "to", "be", "associated", "with", "AD", "in", "our", "study", ".", "Variants", "in", "ABCB1", "were", "significantly", "less", "frequent", "in", "AD", "cases", "older", "than", "65", "years", "of", "age", "and", "among", "females", ".", "This", "association", "of", "ABCB1", "2677G", ">", "T", "(", "rs2032582", ")", "was", "more", "pronounced", "in", "APOE4-negative", "cases", "(", "p", "=", "0.005", ")", ".", "However", ",", "only", "ABCC2", "3972C", ">", "T", "(", "rs3740066", ")", "was", "significantly", "associated", "with", "AD", "risk", "after", "logistic", "regression", "analysis", "including", "all", "variants", ".", "Other", "transporters", "showed", "a", "lack", "of", "association", ".", "Conclusion", ":", "Our", "results", "support", "the", "hypothesis", "that", "ABCB1", "and", "possibly", "other", "ABC", "-", "transporters", "are", "involved", "in", "the", "process", "of", "Aβ", "accumulation", "in", "the", "aging", "brain", "and", "may", "modulate", "the", "risk", "for", "AD", "in", "an", "allele", "-", "specific", "manner", ",", "and", "thus", "might", "represent", "a", "new", "target", "for", "prevention", "and", "treatment", "of", "AD", ".", "Original", "submitted", "8", "October", "2012", ";", "Revision", "submitted", "22", "January", "2013", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

ATP - binding cassette transporter, ABCB1, BCRP, ABCG2, Aβ, multidrug transporters, ABCA1, ABCA7, ABCB1, ABCC2, ABCG2, APOE4, ABCA7, ABCB1, ABCB1, 2677G > T, ABCC2, 3972C > T, ABCB1, ABC - transporters, Aβ

33213_task2

Sentence: Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ. We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls. Materials & methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2. In addition, the APOE4 status was analyzed. Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study. Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females. This association of ABCB1 2677G>T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005). However, only ABCC2 3972C>T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants. Other transporters showed a lack of association. Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD. Original submitted 8 October 2012; Revision submitted 22 January 2013. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Aim: A number of studies have demonstrated that ABCB1 and BCRP (ABCG2) actively transport Aβ. We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls. Materials & methods: DNA from brain tissue of 71 AD cases with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathological stages B/C and 81 controls was genotyped for selected variants in ABCA1, ABCA7, ABCB1, ABCC2 and ABCG2. In addition, the APOE4 status was analyzed. Results: The novel ABCA7 SNP, rs3752246, tended to be associated with AD in our study. Variants in ABCB1 were significantly less frequent in AD cases older than 65 years of age and among females. This association of ABCB1 2677G>T (rs2032582) was more pronounced in APOE4-negative cases (p = 0.005). However, only ABCC2 3972C>T (rs3740066) was significantly associated with AD risk after logistic regression analysis including all variants. Other transporters showed a lack of association. Conclusion: Our results support the hypothesis that ABCB1 and possibly other ABC-transporters are involved in the process of Aβ accumulation in the aging brain and may modulate the risk for AD in an allele-specific manner, and thus might represent a new target for prevention and treatment of AD. Original submitted 8 October 2012; Revision submitted 22 January 2013.

[ "Association", "of", "ATP", "-", "binding", "cassette", "transporter", "variants", "with", "the", "risk", "of", "Alzheimer", "'s", "disease", ".", "\n", "Aim", ":", "A", "number", "of", "studies", "have", "demonstrated", "that", "ABCB1", "and", "BCRP", "(", "ABCG2", ")", "actively", "transport", "Aβ", ".", "We", "aimed", "to", "investigate", "the", "association", "of", "genetic", "variants", "of", "selected", "multidrug", "transporters", "with", "Alzheimer", "'s", "disease", "(", "AD", ")", "in", "histopathologically", "confirmed", "AD", "cases", "and", "controls", ".", "Materials", "&", "methods", ":", "DNA", "from", "brain", "tissue", "of", "71", "AD", "cases", "with", "Consortium", "to", "Establish", "a", "Registry", "for", "Alzheimer", "'s", "Disease", "(", "CERAD", ")", "neuropathological", "stages", "B", "/", "C", "and", "81", "controls", "was", "genotyped", "for", "selected", "variants", "in", "ABCA1", ",", "ABCA7", ",", "ABCB1", ",", "ABCC2", "and", "ABCG2", ".", "In", "addition", ",", "the", "APOE4", "status", "was", "analyzed", ".", "Results", ":", "The", "novel", "ABCA7", "SNP", ",", "rs3752246", ",", "tended", "to", "be", "associated", "with", "AD", "in", "our", "study", ".", "Variants", "in", "ABCB1", "were", "significantly", "less", "frequent", "in", "AD", "cases", "older", "than", "65", "years", "of", "age", "and", "among", "females", ".", "This", "association", "of", "ABCB1", "2677G", ">", "T", "(", "rs2032582", ")", "was", "more", "pronounced", "in", "APOE4-negative", "cases", "(", "p", "=", "0.005", ")", ".", "However", ",", "only", "ABCC2", "3972C", ">", "T", "(", "rs3740066", ")", "was", "significantly", "associated", "with", "AD", "risk", "after", "logistic", "regression", "analysis", "including", "all", "variants", ".", "Other", "transporters", "showed", "a", "lack", "of", "association", ".", "Conclusion", ":", "Our", "results", "support", "the", "hypothesis", "that", "ABCB1", "and", "possibly", "other", "ABC", "-", "transporters", "are", "involved", "in", "the", "process", "of", "Aβ", "accumulation", "in", "the", "aging", "brain", "and", "may", "modulate", "the", "risk", "for", "AD", "in", "an", "allele", "-", "specific", "manner", ",", "and", "thus", "might", "represent", "a", "new", "target", "for", "prevention", "and", "treatment", "of", "AD", ".", "Original", "submitted", "8", "October", "2012", ";", "Revision", "submitted", "22", "January", "2013", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

AIDS is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Dokumentation is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Konzentration is an umlsterm, Beratungen is an umlsterm, Behandlungen is an umlsterm, Behandlung is an umlsterm, Therapieschemata is an umlsterm, HIV - Infektion is an umlsterm, Virusnachweis is an umlsterm, PCR is an umlsterm, Behandlung is an umlsterm, Krankenversicherung is an umlsterm, Behandlung is an umlsterm, Beratung is an umlsterm, Berater is an umlsterm

Bundesgesundheitsblatt.0043s045.ger.abstr_task0

Sentence: Innerhalb der letzten zwoelf Monate haben bundesweit 68 auf AIDS spezialisierte Einrichtungen mindestens in einem Fall eine Beratung und 19 eine Behandlung zur nicht-beruflichen HIV-Postexpositionsprophylaxe ( PEP ) durchgefuehrt . 531 Faellen einer Beratung stehen 143 Faelle gegenueber , in denen eine Behandlung empfohlen wurde . Die Dokumentation der Faelle erweist sich im Bereich der Beratung als lueckenhaft . Die Studie belegt 123 Faelle , in denen eine Behandlung erfolgte , von denen 67 durch die berichtenden Einrichtungen versorgt wurden ( davon 37 an nur zwei Einrichtungen ) . Sowohl bei Beratung als auch bei Behandlung zeigt sich eine Konzentration der Faelle auf einzelne Einrichtungen . Der Zeitpunkt der Beratungen und Behandlungen liegt bei 51,6% bzw. 91,1% innerhalb der fuer besonders wirksam erachteten 24 Stunden nach der Exposition . Die Behandlung erfolgt mit zehn unterschiedlichen Therapieschemata , die durch fuenf alternative Regimes ergaenzt werden . In der Mehrzahl der Faelle wird zum Nachweis oder Ausschluss einer HIV-Infektion neben dem HIV-Antikoerpertest und dem Western Blot ein Virusnachweis mittels bDNA oder PCR durchgefuehrt . Die Kosten der Behandlung traegt ueberwiegend die gesetzliche Krankenversicherung . Der Versuch eines Anrufers , sich im Bereich der klinischen und niedergelassenen aerztlichen Versorgung am Wochenende ueber die Moeglichkeit einer PEP zu informieren , scheitert in ueber der Haelfte der Faelle . Dabei ist vor allem der Bereich der aerztlichen Notrufzentralen offensichtlich nicht auf die entsprechenden Fragestellungen vorbereitet . In 25 von 33 Gespraechen sind die erreichten Ansprechpartner entweder nicht mit den Deutsch-Oesterreichischen Empfehlungen vertraut ( z.B. beziehen sich vier Faelle auf die alten Empfehlungen zur beruflichen PEP ) , erklaeren sich fuer nicht zustaendig oder bauen durch Beratungsstil und Einbestellung zu einem ungeeigneten Zeitpunkt Huerden auf , die einer angemessenen Behandlung entgegenstehen . Gleichwohl erhaelt der Anrufer in acht Faellen eine fachgerechte Beratung . Dies gelingt zum einen , weil durch mehrfache Anrufe oder Vermittlung letztlich ein kompetenter Gespraechspartner angetroffen werden kann . Zum anderen sind die Berater bereit , telefonisch darzulegen , warum und durch welche Vorgehensweise sie bereit sind , in diesem Fall eine HIV-PEP durchzufuehren . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Innerhalb der letzten zwoelf Monate haben bundesweit 68 auf AIDS spezialisierte Einrichtungen mindestens in einem Fall eine Beratung und 19 eine Behandlung zur nicht-beruflichen HIV-Postexpositionsprophylaxe ( PEP ) durchgefuehrt . 531 Faellen einer Beratung stehen 143 Faelle gegenueber , in denen eine Behandlung empfohlen wurde . Die Dokumentation der Faelle erweist sich im Bereich der Beratung als lueckenhaft . Die Studie belegt 123 Faelle , in denen eine Behandlung erfolgte , von denen 67 durch die berichtenden Einrichtungen versorgt wurden ( davon 37 an nur zwei Einrichtungen ) . Sowohl bei Beratung als auch bei Behandlung zeigt sich eine Konzentration der Faelle auf einzelne Einrichtungen . Der Zeitpunkt der Beratungen und Behandlungen liegt bei 51,6% bzw. 91,1% innerhalb der fuer besonders wirksam erachteten 24 Stunden nach der Exposition . Die Behandlung erfolgt mit zehn unterschiedlichen Therapieschemata , die durch fuenf alternative Regimes ergaenzt werden . In der Mehrzahl der Faelle wird zum Nachweis oder Ausschluss einer HIV-Infektion neben dem HIV-Antikoerpertest und dem Western Blot ein Virusnachweis mittels bDNA oder PCR durchgefuehrt . Die Kosten der Behandlung traegt ueberwiegend die gesetzliche Krankenversicherung . Der Versuch eines Anrufers , sich im Bereich der klinischen und niedergelassenen aerztlichen Versorgung am Wochenende ueber die Moeglichkeit einer PEP zu informieren , scheitert in ueber der Haelfte der Faelle . Dabei ist vor allem der Bereich der aerztlichen Notrufzentralen offensichtlich nicht auf die entsprechenden Fragestellungen vorbereitet . In 25 von 33 Gespraechen sind die erreichten Ansprechpartner entweder nicht mit den Deutsch-Oesterreichischen Empfehlungen vertraut ( z.B. beziehen sich vier Faelle auf die alten Empfehlungen zur beruflichen PEP ) , erklaeren sich fuer nicht zustaendig oder bauen durch Beratungsstil und Einbestellung zu einem ungeeigneten Zeitpunkt Huerden auf , die einer angemessenen Behandlung entgegenstehen . Gleichwohl erhaelt der Anrufer in acht Faellen eine fachgerechte Beratung . Dies gelingt zum einen , weil durch mehrfache Anrufe oder Vermittlung letztlich ein kompetenter Gespraechspartner angetroffen werden kann . Zum anderen sind die Berater bereit , telefonisch darzulegen , warum und durch welche Vorgehensweise sie bereit sind , in diesem Fall eine HIV-PEP durchzufuehren .

[ "Innerhalb", "der", "letzten", "zwoelf", "Monate", "haben", "bundesweit", "68", "auf", "AIDS", "spezialisierte", "Einrichtungen", "mindestens", "in", "einem", "Fall", "eine", "Beratung", "und", "19", "eine", "Behandlung", "zur", "nicht", "-", "beruflichen", "HIV", "-", "Postexpositionsprophylaxe", "(", "PEP", ")", "durchgefuehrt", ".", "531", "Faellen", "einer", "Beratung", "stehen", "143", "Faelle", "gegenueber", ",", "in", "denen", "eine", "Behandlung", "empfohlen", "wurde", ".", "Die", "Dokumentation", "der", "Faelle", "erweist", "sich", "im", "Bereich", "der", "Beratung", "als", "lueckenhaft", ".", "Die", "Studie", "belegt", "123", "Faelle", ",", "in", "denen", "eine", "Behandlung", "erfolgte", ",", "von", "denen", "67", "durch", "die", "berichtenden", "Einrichtungen", "versorgt", "wurden", "(", "davon", "37", "an", "nur", "zwei", "Einrichtungen", ")", ".", "Sowohl", "bei", "Beratung", "als", "auch", "bei", "Behandlung", "zeigt", "sich", "eine", "Konzentration", "der", "Faelle", "auf", "einzelne", "Einrichtungen", ".", "Der", "Zeitpunkt", "der", "Beratungen", "und", "Behandlungen", "liegt", "bei", "51,6", "%", "bzw", ".", "91,1", "%", "innerhalb", "der", "fuer", "besonders", "wirksam", "erachteten", "24", "Stunden", "nach", "der", "Exposition", ".", "Die", "Behandlung", "erfolgt", "mit", "zehn", "unterschiedlichen", "Therapieschemata", ",", "die", "durch", "fuenf", "alternative", "Regimes", "ergaenzt", "werden", ".", "In", "der", "Mehrzahl", "der", "Faelle", "wird", "zum", "Nachweis", "oder", "Ausschluss", "einer", "HIV", "-", "Infektion", "neben", "dem", "HIV", "-", "Antikoerpertest", "und", "dem", "Western", "Blot", "ein", "Virusnachweis", "mittels", "bDNA", "oder", "PCR", "durchgefuehrt", ".", "Die", "Kosten", "der", "Behandlung", "traegt", "ueberwiegend", "die", "gesetzliche", "Krankenversicherung", ".", "Der", "Versuch", "eines", "Anrufers", ",", "sich", "im", "Bereich", "der", "klinischen", "und", "niedergelassenen", "aerztlichen", "Versorgung", "am", "Wochenende", "ueber", "die", "Moeglichkeit", "einer", "PEP", "zu", "informieren", ",", "scheitert", "in", "ueber", "der", "Haelfte", "der", "Faelle", ".", "Dabei", "ist", "vor", "allem", "der", "Bereich", "der", "aerztlichen", "Notrufzentralen", "offensichtlich", "nicht", "auf", "die", "entsprechenden", "Fragestellungen", "vorbereitet", ".", "In", "25", "von", "33", "Gespraechen", "sind", "die", "erreichten", "Ansprechpartner", "entweder", "nicht", "mit", "den", "Deutsch", "-", "Oesterreichischen", "Empfehlungen", "vertraut", "(", "z.", "B.", "beziehen", "sich", "vier", "Faelle", "auf", "die", "alten", "Empfehlungen", "zur", "beruflichen", "PEP", ")", ",", "erklaeren", "sich", "fuer", "nicht", "zustaendig", "oder", "bauen", "durch", "Beratungsstil", "und", "Einbestellung", "zu", "einem", "ungeeigneten", "Zeitpunkt", "Huerden", "auf", ",", "die", "einer", "angemessenen", "Behandlung", "entgegenstehen", ".", "Gleichwohl", "erhaelt", "der", "Anrufer", "in", "acht", "Faellen", "eine", "fachgerechte", "Beratung", ".", "Dies", "gelingt", "zum", "einen", ",", "weil", "durch", "mehrfache", "Anrufe", "oder", "Vermittlung", "letztlich", "ein", "kompetenter", "Gespraechspartner", "angetroffen", "werden", "kann", ".", "Zum", "anderen", "sind", "die", "Berater", "bereit", ",", "telefonisch", "darzulegen", ",", "warum", "und", "durch", "welche", "Vorgehensweise", "sie", "bereit", "sind", ",", "in", "diesem", "Fall", "eine", "HIV", "-", "PEP", "durchzufuehren", "." ]

[ "umlsterm" ]

AIDS is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Dokumentation is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Beratung is an umlsterm, Behandlung is an umlsterm, Konzentration is an umlsterm, Beratungen is an umlsterm, Behandlungen is an umlsterm, Behandlung is an umlsterm, Therapieschemata is an umlsterm, HIV - Infektion is an umlsterm, Virusnachweis is an umlsterm, PCR is an umlsterm, Behandlung is an umlsterm, Krankenversicherung is an umlsterm, Behandlung is an umlsterm, Beratung is an umlsterm, Berater is an umlsterm

Bundesgesundheitsblatt.0043s045.ger.abstr_task1

Sentence: Innerhalb der letzten zwoelf Monate haben bundesweit 68 auf AIDS spezialisierte Einrichtungen mindestens in einem Fall eine Beratung und 19 eine Behandlung zur nicht-beruflichen HIV-Postexpositionsprophylaxe ( PEP ) durchgefuehrt . 531 Faellen einer Beratung stehen 143 Faelle gegenueber , in denen eine Behandlung empfohlen wurde . Die Dokumentation der Faelle erweist sich im Bereich der Beratung als lueckenhaft . Die Studie belegt 123 Faelle , in denen eine Behandlung erfolgte , von denen 67 durch die berichtenden Einrichtungen versorgt wurden ( davon 37 an nur zwei Einrichtungen ) . Sowohl bei Beratung als auch bei Behandlung zeigt sich eine Konzentration der Faelle auf einzelne Einrichtungen . Der Zeitpunkt der Beratungen und Behandlungen liegt bei 51,6% bzw. 91,1% innerhalb der fuer besonders wirksam erachteten 24 Stunden nach der Exposition . Die Behandlung erfolgt mit zehn unterschiedlichen Therapieschemata , die durch fuenf alternative Regimes ergaenzt werden . In der Mehrzahl der Faelle wird zum Nachweis oder Ausschluss einer HIV-Infektion neben dem HIV-Antikoerpertest und dem Western Blot ein Virusnachweis mittels bDNA oder PCR durchgefuehrt . Die Kosten der Behandlung traegt ueberwiegend die gesetzliche Krankenversicherung . Der Versuch eines Anrufers , sich im Bereich der klinischen und niedergelassenen aerztlichen Versorgung am Wochenende ueber die Moeglichkeit einer PEP zu informieren , scheitert in ueber der Haelfte der Faelle . Dabei ist vor allem der Bereich der aerztlichen Notrufzentralen offensichtlich nicht auf die entsprechenden Fragestellungen vorbereitet . In 25 von 33 Gespraechen sind die erreichten Ansprechpartner entweder nicht mit den Deutsch-Oesterreichischen Empfehlungen vertraut ( z.B. beziehen sich vier Faelle auf die alten Empfehlungen zur beruflichen PEP ) , erklaeren sich fuer nicht zustaendig oder bauen durch Beratungsstil und Einbestellung zu einem ungeeigneten Zeitpunkt Huerden auf , die einer angemessenen Behandlung entgegenstehen . Gleichwohl erhaelt der Anrufer in acht Faellen eine fachgerechte Beratung . Dies gelingt zum einen , weil durch mehrfache Anrufe oder Vermittlung letztlich ein kompetenter Gespraechspartner angetroffen werden kann . Zum anderen sind die Berater bereit , telefonisch darzulegen , warum und durch welche Vorgehensweise sie bereit sind , in diesem Fall eine HIV-PEP durchzufuehren . Instructions: please typing these entity words according to sentence: AIDS, Beratung, Behandlung, Beratung, Behandlung, Dokumentation, Beratung, Behandlung, Beratung, Behandlung, Konzentration, Beratungen, Behandlungen, Behandlung, Therapieschemata, HIV - Infektion, Virusnachweis, PCR, Behandlung, Krankenversicherung, Behandlung, Beratung, Berater Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Innerhalb der letzten zwoelf Monate haben bundesweit 68 auf AIDS spezialisierte Einrichtungen mindestens in einem Fall eine Beratung und 19 eine Behandlung zur nicht-beruflichen HIV-Postexpositionsprophylaxe ( PEP ) durchgefuehrt . 531 Faellen einer Beratung stehen 143 Faelle gegenueber , in denen eine Behandlung empfohlen wurde . Die Dokumentation der Faelle erweist sich im Bereich der Beratung als lueckenhaft . Die Studie belegt 123 Faelle , in denen eine Behandlung erfolgte , von denen 67 durch die berichtenden Einrichtungen versorgt wurden ( davon 37 an nur zwei Einrichtungen ) . Sowohl bei Beratung als auch bei Behandlung zeigt sich eine Konzentration der Faelle auf einzelne Einrichtungen . Der Zeitpunkt der Beratungen und Behandlungen liegt bei 51,6% bzw. 91,1% innerhalb der fuer besonders wirksam erachteten 24 Stunden nach der Exposition . Die Behandlung erfolgt mit zehn unterschiedlichen Therapieschemata , die durch fuenf alternative Regimes ergaenzt werden . In der Mehrzahl der Faelle wird zum Nachweis oder Ausschluss einer HIV-Infektion neben dem HIV-Antikoerpertest und dem Western Blot ein Virusnachweis mittels bDNA oder PCR durchgefuehrt . Die Kosten der Behandlung traegt ueberwiegend die gesetzliche Krankenversicherung . Der Versuch eines Anrufers , sich im Bereich der klinischen und niedergelassenen aerztlichen Versorgung am Wochenende ueber die Moeglichkeit einer PEP zu informieren , scheitert in ueber der Haelfte der Faelle . Dabei ist vor allem der Bereich der aerztlichen Notrufzentralen offensichtlich nicht auf die entsprechenden Fragestellungen vorbereitet . In 25 von 33 Gespraechen sind die erreichten Ansprechpartner entweder nicht mit den Deutsch-Oesterreichischen Empfehlungen vertraut ( z.B. beziehen sich vier Faelle auf die alten Empfehlungen zur beruflichen PEP ) , erklaeren sich fuer nicht zustaendig oder bauen durch Beratungsstil und Einbestellung zu einem ungeeigneten Zeitpunkt Huerden auf , die einer angemessenen Behandlung entgegenstehen . Gleichwohl erhaelt der Anrufer in acht Faellen eine fachgerechte Beratung . Dies gelingt zum einen , weil durch mehrfache Anrufe oder Vermittlung letztlich ein kompetenter Gespraechspartner angetroffen werden kann . Zum anderen sind die Berater bereit , telefonisch darzulegen , warum und durch welche Vorgehensweise sie bereit sind , in diesem Fall eine HIV-PEP durchzufuehren .

[ "Innerhalb", "der", "letzten", "zwoelf", "Monate", "haben", "bundesweit", "68", "auf", "AIDS", "spezialisierte", "Einrichtungen", "mindestens", "in", "einem", "Fall", "eine", "Beratung", "und", "19", "eine", "Behandlung", "zur", "nicht", "-", "beruflichen", "HIV", "-", "Postexpositionsprophylaxe", "(", "PEP", ")", "durchgefuehrt", ".", "531", "Faellen", "einer", "Beratung", "stehen", "143", "Faelle", "gegenueber", ",", "in", "denen", "eine", "Behandlung", "empfohlen", "wurde", ".", "Die", "Dokumentation", "der", "Faelle", "erweist", "sich", "im", "Bereich", "der", "Beratung", "als", "lueckenhaft", ".", "Die", "Studie", "belegt", "123", "Faelle", ",", "in", "denen", "eine", "Behandlung", "erfolgte", ",", "von", "denen", "67", "durch", "die", "berichtenden", "Einrichtungen", "versorgt", "wurden", "(", "davon", "37", "an", "nur", "zwei", "Einrichtungen", ")", ".", "Sowohl", "bei", "Beratung", "als", "auch", "bei", "Behandlung", "zeigt", "sich", "eine", "Konzentration", "der", "Faelle", "auf", "einzelne", "Einrichtungen", ".", "Der", "Zeitpunkt", "der", "Beratungen", "und", "Behandlungen", "liegt", "bei", "51,6", "%", "bzw", ".", "91,1", "%", "innerhalb", "der", "fuer", "besonders", "wirksam", "erachteten", "24", "Stunden", "nach", "der", "Exposition", ".", "Die", "Behandlung", "erfolgt", "mit", "zehn", "unterschiedlichen", "Therapieschemata", ",", "die", "durch", "fuenf", "alternative", "Regimes", "ergaenzt", "werden", ".", "In", "der", "Mehrzahl", "der", "Faelle", "wird", "zum", "Nachweis", "oder", "Ausschluss", "einer", "HIV", "-", "Infektion", "neben", "dem", "HIV", "-", "Antikoerpertest", "und", "dem", "Western", "Blot", "ein", "Virusnachweis", "mittels", "bDNA", "oder", "PCR", "durchgefuehrt", ".", "Die", "Kosten", "der", "Behandlung", "traegt", "ueberwiegend", "die", "gesetzliche", "Krankenversicherung", ".", "Der", "Versuch", "eines", "Anrufers", ",", "sich", "im", "Bereich", "der", "klinischen", "und", "niedergelassenen", "aerztlichen", "Versorgung", "am", "Wochenende", "ueber", "die", "Moeglichkeit", "einer", "PEP", "zu", "informieren", ",", "scheitert", "in", "ueber", "der", "Haelfte", "der", "Faelle", ".", "Dabei", "ist", "vor", "allem", "der", "Bereich", "der", "aerztlichen", "Notrufzentralen", "offensichtlich", "nicht", "auf", "die", "entsprechenden", "Fragestellungen", "vorbereitet", ".", "In", "25", "von", "33", "Gespraechen", "sind", "die", "erreichten", "Ansprechpartner", "entweder", "nicht", "mit", "den", "Deutsch", "-", "Oesterreichischen", "Empfehlungen", "vertraut", "(", "z.", "B.", "beziehen", "sich", "vier", "Faelle", "auf", "die", "alten", "Empfehlungen", "zur", "beruflichen", "PEP", ")", ",", "erklaeren", "sich", "fuer", "nicht", "zustaendig", "oder", "bauen", "durch", "Beratungsstil", "und", "Einbestellung", "zu", "einem", "ungeeigneten", "Zeitpunkt", "Huerden", "auf", ",", "die", "einer", "angemessenen", "Behandlung", "entgegenstehen", ".", "Gleichwohl", "erhaelt", "der", "Anrufer", "in", "acht", "Faellen", "eine", "fachgerechte", "Beratung", ".", "Dies", "gelingt", "zum", "einen", ",", "weil", "durch", "mehrfache", "Anrufe", "oder", "Vermittlung", "letztlich", "ein", "kompetenter", "Gespraechspartner", "angetroffen", "werden", "kann", ".", "Zum", "anderen", "sind", "die", "Berater", "bereit", ",", "telefonisch", "darzulegen", ",", "warum", "und", "durch", "welche", "Vorgehensweise", "sie", "bereit", "sind", ",", "in", "diesem", "Fall", "eine", "HIV", "-", "PEP", "durchzufuehren", "." ]

[ "umlsterm" ]

AIDS, Beratung, Behandlung, Beratung, Behandlung, Dokumentation, Beratung, Behandlung, Beratung, Behandlung, Konzentration, Beratungen, Behandlungen, Behandlung, Therapieschemata, HIV - Infektion, Virusnachweis, PCR, Behandlung, Krankenversicherung, Behandlung, Beratung, Berater

Bundesgesundheitsblatt.0043s045.ger.abstr_task2

Sentence: Innerhalb der letzten zwoelf Monate haben bundesweit 68 auf AIDS spezialisierte Einrichtungen mindestens in einem Fall eine Beratung und 19 eine Behandlung zur nicht-beruflichen HIV-Postexpositionsprophylaxe ( PEP ) durchgefuehrt . 531 Faellen einer Beratung stehen 143 Faelle gegenueber , in denen eine Behandlung empfohlen wurde . Die Dokumentation der Faelle erweist sich im Bereich der Beratung als lueckenhaft . Die Studie belegt 123 Faelle , in denen eine Behandlung erfolgte , von denen 67 durch die berichtenden Einrichtungen versorgt wurden ( davon 37 an nur zwei Einrichtungen ) . Sowohl bei Beratung als auch bei Behandlung zeigt sich eine Konzentration der Faelle auf einzelne Einrichtungen . Der Zeitpunkt der Beratungen und Behandlungen liegt bei 51,6% bzw. 91,1% innerhalb der fuer besonders wirksam erachteten 24 Stunden nach der Exposition . Die Behandlung erfolgt mit zehn unterschiedlichen Therapieschemata , die durch fuenf alternative Regimes ergaenzt werden . In der Mehrzahl der Faelle wird zum Nachweis oder Ausschluss einer HIV-Infektion neben dem HIV-Antikoerpertest und dem Western Blot ein Virusnachweis mittels bDNA oder PCR durchgefuehrt . Die Kosten der Behandlung traegt ueberwiegend die gesetzliche Krankenversicherung . Der Versuch eines Anrufers , sich im Bereich der klinischen und niedergelassenen aerztlichen Versorgung am Wochenende ueber die Moeglichkeit einer PEP zu informieren , scheitert in ueber der Haelfte der Faelle . Dabei ist vor allem der Bereich der aerztlichen Notrufzentralen offensichtlich nicht auf die entsprechenden Fragestellungen vorbereitet . In 25 von 33 Gespraechen sind die erreichten Ansprechpartner entweder nicht mit den Deutsch-Oesterreichischen Empfehlungen vertraut ( z.B. beziehen sich vier Faelle auf die alten Empfehlungen zur beruflichen PEP ) , erklaeren sich fuer nicht zustaendig oder bauen durch Beratungsstil und Einbestellung zu einem ungeeigneten Zeitpunkt Huerden auf , die einer angemessenen Behandlung entgegenstehen . Gleichwohl erhaelt der Anrufer in acht Faellen eine fachgerechte Beratung . Dies gelingt zum einen , weil durch mehrfache Anrufe oder Vermittlung letztlich ein kompetenter Gespraechspartner angetroffen werden kann . Zum anderen sind die Berater bereit , telefonisch darzulegen , warum und durch welche Vorgehensweise sie bereit sind , in diesem Fall eine HIV-PEP durchzufuehren . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Innerhalb der letzten zwoelf Monate haben bundesweit 68 auf AIDS spezialisierte Einrichtungen mindestens in einem Fall eine Beratung und 19 eine Behandlung zur nicht-beruflichen HIV-Postexpositionsprophylaxe ( PEP ) durchgefuehrt . 531 Faellen einer Beratung stehen 143 Faelle gegenueber , in denen eine Behandlung empfohlen wurde . Die Dokumentation der Faelle erweist sich im Bereich der Beratung als lueckenhaft . Die Studie belegt 123 Faelle , in denen eine Behandlung erfolgte , von denen 67 durch die berichtenden Einrichtungen versorgt wurden ( davon 37 an nur zwei Einrichtungen ) . Sowohl bei Beratung als auch bei Behandlung zeigt sich eine Konzentration der Faelle auf einzelne Einrichtungen . Der Zeitpunkt der Beratungen und Behandlungen liegt bei 51,6% bzw. 91,1% innerhalb der fuer besonders wirksam erachteten 24 Stunden nach der Exposition . Die Behandlung erfolgt mit zehn unterschiedlichen Therapieschemata , die durch fuenf alternative Regimes ergaenzt werden . In der Mehrzahl der Faelle wird zum Nachweis oder Ausschluss einer HIV-Infektion neben dem HIV-Antikoerpertest und dem Western Blot ein Virusnachweis mittels bDNA oder PCR durchgefuehrt . Die Kosten der Behandlung traegt ueberwiegend die gesetzliche Krankenversicherung . Der Versuch eines Anrufers , sich im Bereich der klinischen und niedergelassenen aerztlichen Versorgung am Wochenende ueber die Moeglichkeit einer PEP zu informieren , scheitert in ueber der Haelfte der Faelle . Dabei ist vor allem der Bereich der aerztlichen Notrufzentralen offensichtlich nicht auf die entsprechenden Fragestellungen vorbereitet . In 25 von 33 Gespraechen sind die erreichten Ansprechpartner entweder nicht mit den Deutsch-Oesterreichischen Empfehlungen vertraut ( z.B. beziehen sich vier Faelle auf die alten Empfehlungen zur beruflichen PEP ) , erklaeren sich fuer nicht zustaendig oder bauen durch Beratungsstil und Einbestellung zu einem ungeeigneten Zeitpunkt Huerden auf , die einer angemessenen Behandlung entgegenstehen . Gleichwohl erhaelt der Anrufer in acht Faellen eine fachgerechte Beratung . Dies gelingt zum einen , weil durch mehrfache Anrufe oder Vermittlung letztlich ein kompetenter Gespraechspartner angetroffen werden kann . Zum anderen sind die Berater bereit , telefonisch darzulegen , warum und durch welche Vorgehensweise sie bereit sind , in diesem Fall eine HIV-PEP durchzufuehren .

[ "Innerhalb", "der", "letzten", "zwoelf", "Monate", "haben", "bundesweit", "68", "auf", "AIDS", "spezialisierte", "Einrichtungen", "mindestens", "in", "einem", "Fall", "eine", "Beratung", "und", "19", "eine", "Behandlung", "zur", "nicht", "-", "beruflichen", "HIV", "-", "Postexpositionsprophylaxe", "(", "PEP", ")", "durchgefuehrt", ".", "531", "Faellen", "einer", "Beratung", "stehen", "143", "Faelle", "gegenueber", ",", "in", "denen", "eine", "Behandlung", "empfohlen", "wurde", ".", "Die", "Dokumentation", "der", "Faelle", "erweist", "sich", "im", "Bereich", "der", "Beratung", "als", "lueckenhaft", ".", "Die", "Studie", "belegt", "123", "Faelle", ",", "in", "denen", "eine", "Behandlung", "erfolgte", ",", "von", "denen", "67", "durch", "die", "berichtenden", "Einrichtungen", "versorgt", "wurden", "(", "davon", "37", "an", "nur", "zwei", "Einrichtungen", ")", ".", "Sowohl", "bei", "Beratung", "als", "auch", "bei", "Behandlung", "zeigt", "sich", "eine", "Konzentration", "der", "Faelle", "auf", "einzelne", "Einrichtungen", ".", "Der", "Zeitpunkt", "der", "Beratungen", "und", "Behandlungen", "liegt", "bei", "51,6", "%", "bzw", ".", "91,1", "%", "innerhalb", "der", "fuer", "besonders", "wirksam", "erachteten", "24", "Stunden", "nach", "der", "Exposition", ".", "Die", "Behandlung", "erfolgt", "mit", "zehn", "unterschiedlichen", "Therapieschemata", ",", "die", "durch", "fuenf", "alternative", "Regimes", "ergaenzt", "werden", ".", "In", "der", "Mehrzahl", "der", "Faelle", "wird", "zum", "Nachweis", "oder", "Ausschluss", "einer", "HIV", "-", "Infektion", "neben", "dem", "HIV", "-", "Antikoerpertest", "und", "dem", "Western", "Blot", "ein", "Virusnachweis", "mittels", "bDNA", "oder", "PCR", "durchgefuehrt", ".", "Die", "Kosten", "der", "Behandlung", "traegt", "ueberwiegend", "die", "gesetzliche", "Krankenversicherung", ".", "Der", "Versuch", "eines", "Anrufers", ",", "sich", "im", "Bereich", "der", "klinischen", "und", "niedergelassenen", "aerztlichen", "Versorgung", "am", "Wochenende", "ueber", "die", "Moeglichkeit", "einer", "PEP", "zu", "informieren", ",", "scheitert", "in", "ueber", "der", "Haelfte", "der", "Faelle", ".", "Dabei", "ist", "vor", "allem", "der", "Bereich", "der", "aerztlichen", "Notrufzentralen", "offensichtlich", "nicht", "auf", "die", "entsprechenden", "Fragestellungen", "vorbereitet", ".", "In", "25", "von", "33", "Gespraechen", "sind", "die", "erreichten", "Ansprechpartner", "entweder", "nicht", "mit", "den", "Deutsch", "-", "Oesterreichischen", "Empfehlungen", "vertraut", "(", "z.", "B.", "beziehen", "sich", "vier", "Faelle", "auf", "die", "alten", "Empfehlungen", "zur", "beruflichen", "PEP", ")", ",", "erklaeren", "sich", "fuer", "nicht", "zustaendig", "oder", "bauen", "durch", "Beratungsstil", "und", "Einbestellung", "zu", "einem", "ungeeigneten", "Zeitpunkt", "Huerden", "auf", ",", "die", "einer", "angemessenen", "Behandlung", "entgegenstehen", ".", "Gleichwohl", "erhaelt", "der", "Anrufer", "in", "acht", "Faellen", "eine", "fachgerechte", "Beratung", ".", "Dies", "gelingt", "zum", "einen", ",", "weil", "durch", "mehrfache", "Anrufe", "oder", "Vermittlung", "letztlich", "ein", "kompetenter", "Gespraechspartner", "angetroffen", "werden", "kann", ".", "Zum", "anderen", "sind", "die", "Berater", "bereit", ",", "telefonisch", "darzulegen", ",", "warum", "und", "durch", "welche", "Vorgehensweise", "sie", "bereit", "sind", ",", "in", "diesem", "Fall", "eine", "HIV", "-", "PEP", "durchzufuehren", "." ]

[ "umlsterm" ]

anthracene is a compound, DMBA is a compound, HER2 is a protein

DS.d1548_task0

Sentence: Because both TCDD and HFD are associated with increased breast cancer risk, we examined their effects on metabolic syndrome-associated phenotypes in three mouse models of breast cancer: 7,12-dimethylbenz(a) anthracene (DMBA), Tg(MMTV-Neu)202Mul/J (HER2), and TgN(MMTV-PyMT)634Mul/J (PyMT), all on an FVB/N genetic background. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Because both TCDD and HFD are associated with increased breast cancer risk, we examined their effects on metabolic syndrome-associated phenotypes in three mouse models of breast cancer: 7,12-dimethylbenz(a) anthracene (DMBA), Tg(MMTV-Neu)202Mul/J (HER2), and TgN(MMTV-PyMT)634Mul/J (PyMT), all on an FVB/N genetic background.

[ "Because", "both", "TCDD", "and", "HFD", "are", "associated", "with", "increased", "breast", "cancer", "risk", ",", "we", "examined", "their", "effects", "on", "metabolic", "syndrome", "-", "associated", "phenotypes", "in", "three", "mouse", "models", "of", "breast", "cancer", ":", "7,12-dimethylbenz(a", ")", "anthracene", "(", "DMBA", ")", ",", "Tg(MMTV", "-", "Neu)202Mul", "/", "J", "(", "HER2", ")", ",", "and", "TgN(MMTV", "-", "PyMT)634Mul", "/", "J", "(", "PyMT", ")", ",", "all", "on", "an", "FVB", "/", "N", "genetic", "background", "." ]

[ "compound", "protein" ]

anthracene is a compound, DMBA is a compound, HER2 is a protein

DS.d1548_task1

Sentence: Because both TCDD and HFD are associated with increased breast cancer risk, we examined their effects on metabolic syndrome-associated phenotypes in three mouse models of breast cancer: 7,12-dimethylbenz(a) anthracene (DMBA), Tg(MMTV-Neu)202Mul/J (HER2), and TgN(MMTV-PyMT)634Mul/J (PyMT), all on an FVB/N genetic background. Instructions: please typing these entity words according to sentence: anthracene, DMBA, HER2 Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Because both TCDD and HFD are associated with increased breast cancer risk, we examined their effects on metabolic syndrome-associated phenotypes in three mouse models of breast cancer: 7,12-dimethylbenz(a) anthracene (DMBA), Tg(MMTV-Neu)202Mul/J (HER2), and TgN(MMTV-PyMT)634Mul/J (PyMT), all on an FVB/N genetic background.

[ "Because", "both", "TCDD", "and", "HFD", "are", "associated", "with", "increased", "breast", "cancer", "risk", ",", "we", "examined", "their", "effects", "on", "metabolic", "syndrome", "-", "associated", "phenotypes", "in", "three", "mouse", "models", "of", "breast", "cancer", ":", "7,12-dimethylbenz(a", ")", "anthracene", "(", "DMBA", ")", ",", "Tg(MMTV", "-", "Neu)202Mul", "/", "J", "(", "HER2", ")", ",", "and", "TgN(MMTV", "-", "PyMT)634Mul", "/", "J", "(", "PyMT", ")", ",", "all", "on", "an", "FVB", "/", "N", "genetic", "background", "." ]

[ "compound", "protein" ]

anthracene, DMBA, HER2

DS.d1548_task2

Sentence: Because both TCDD and HFD are associated with increased breast cancer risk, we examined their effects on metabolic syndrome-associated phenotypes in three mouse models of breast cancer: 7,12-dimethylbenz(a) anthracene (DMBA), Tg(MMTV-Neu)202Mul/J (HER2), and TgN(MMTV-PyMT)634Mul/J (PyMT), all on an FVB/N genetic background. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Because both TCDD and HFD are associated with increased breast cancer risk, we examined their effects on metabolic syndrome-associated phenotypes in three mouse models of breast cancer: 7,12-dimethylbenz(a) anthracene (DMBA), Tg(MMTV-Neu)202Mul/J (HER2), and TgN(MMTV-PyMT)634Mul/J (PyMT), all on an FVB/N genetic background.

[ "Because", "both", "TCDD", "and", "HFD", "are", "associated", "with", "increased", "breast", "cancer", "risk", ",", "we", "examined", "their", "effects", "on", "metabolic", "syndrome", "-", "associated", "phenotypes", "in", "three", "mouse", "models", "of", "breast", "cancer", ":", "7,12-dimethylbenz(a", ")", "anthracene", "(", "DMBA", ")", ",", "Tg(MMTV", "-", "Neu)202Mul", "/", "J", "(", "HER2", ")", ",", "and", "TgN(MMTV", "-", "PyMT)634Mul", "/", "J", "(", "PyMT", ")", ",", "all", "on", "an", "FVB", "/", "N", "genetic", "background", "." ]

[ "compound", "protein" ]

cysG is a Protein, CysG is a Protein, CysG is a Protein, cysG is a Protein, CysG is a Protein, CysG is a Protein, CysG is a Protein, cysG is a Protein, CysG is a Protein, CysG is a Protein

541_task0

Sentence: Gene dissection demonstrates that the Escherichia coli cysG gene encodes a multifunctional protein. The C-terminus of the Escherichia coli CysG protein, consisting of amino acids 202-457, was expressed as a recombinant protein using gene dissection methodology. Analysis of the activity of this truncated protein, termed CysGA, revealed that it was able to methylate uroporphyrinogen III in the same S-adenosyl-L-methionine (SAM)-dependent manner as the complete CysG protein. However, this truncated protein was not able to complement E. coli cysG cells, thereby suggesting that the first 201 amino acids of the CysG protein had an enzymic activity associated with the conversion of dihydrosirohydrochlorin into sirohaem. Analysis of the N-terminus of the CysG protein revealed the presence of a putative pyridine dinucleotide binding site. When the purified CysG protein was incubated with NADP+, uroporphyrinogen III and SAM the enzyme was found to catalyse a coenzyme-mediated dehydrogenation to form sirohydrochlorin. The CysGA protein on the other hand showed no such coenzyme-dependent activity. Analysis of the porphyrinoid material isolated from strains harbouring plasmids containing the complete and truncated cysG genes suggested that the CysG protein was also involved in ferrochelation. The evidence presented in this paper suggests that the CysG protein is a multifunctional protein involved in SAM-dependent methylation, pyridine dinucleotide dependent dehydrogenation and ferrochelation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Gene dissection demonstrates that the Escherichia coli cysG gene encodes a multifunctional protein. The C-terminus of the Escherichia coli CysG protein, consisting of amino acids 202-457, was expressed as a recombinant protein using gene dissection methodology. Analysis of the activity of this truncated protein, termed CysGA, revealed that it was able to methylate uroporphyrinogen III in the same S-adenosyl-L-methionine (SAM)-dependent manner as the complete CysG protein. However, this truncated protein was not able to complement E. coli cysG cells, thereby suggesting that the first 201 amino acids of the CysG protein had an enzymic activity associated with the conversion of dihydrosirohydrochlorin into sirohaem. Analysis of the N-terminus of the CysG protein revealed the presence of a putative pyridine dinucleotide binding site. When the purified CysG protein was incubated with NADP+, uroporphyrinogen III and SAM the enzyme was found to catalyse a coenzyme-mediated dehydrogenation to form sirohydrochlorin. The CysGA protein on the other hand showed no such coenzyme-dependent activity. Analysis of the porphyrinoid material isolated from strains harbouring plasmids containing the complete and truncated cysG genes suggested that the CysG protein was also involved in ferrochelation. The evidence presented in this paper suggests that the CysG protein is a multifunctional protein involved in SAM-dependent methylation, pyridine dinucleotide dependent dehydrogenation and ferrochelation.

[ "Gene", "dissection", "demonstrates", "that", "the", "Escherichia", "coli", "cysG", "gene", "encodes", "a", "multifunctional", "protein", ".", "\n", "The", "C", "-", "terminus", "of", "the", "Escherichia", "coli", "CysG", "protein", ",", "consisting", "of", "amino", "acids", "202", "-", "457", ",", "was", "expressed", "as", "a", "recombinant", "protein", "using", "gene", "dissection", "methodology", ".", "Analysis", "of", "the", "activity", "of", "this", "truncated", "protein", ",", "termed", "CysGA", ",", "revealed", "that", "it", "was", "able", "to", "methylate", "uroporphyrinogen", "III", "in", "the", "same", "S", "-", "adenosyl", "-", "L", "-", "methionine", "(", "SAM)-dependent", "manner", "as", "the", "complete", "CysG", "protein", ".", "However", ",", "this", "truncated", "protein", "was", "not", "able", "to", "complement", "E.", "coli", "cysG", "cells", ",", "thereby", "suggesting", "that", "the", "first", "201", "amino", "acids", "of", "the", "CysG", "protein", "had", "an", "enzymic", "activity", "associated", "with", "the", "conversion", "of", "dihydrosirohydrochlorin", "into", "sirohaem", ".", "Analysis", "of", "the", "N", "-", "terminus", "of", "the", "CysG", "protein", "revealed", "the", "presence", "of", "a", "putative", "pyridine", "dinucleotide", "binding", "site", ".", "When", "the", "purified", "CysG", "protein", "was", "incubated", "with", "NADP+", ",", "uroporphyrinogen", "III", "and", "SAM", "the", "enzyme", "was", "found", "to", "catalyse", "a", "coenzyme", "-", "mediated", "dehydrogenation", "to", "form", "sirohydrochlorin", ".", "The", "CysGA", "protein", "on", "the", "other", "hand", "showed", "no", "such", "coenzyme", "-", "dependent", "activity", ".", "Analysis", "of", "the", "porphyrinoid", "material", "isolated", "from", "strains", "harbouring", "plasmids", "containing", "the", "complete", "and", "truncated", "cysG", "genes", "suggested", "that", "the", "CysG", "protein", "was", "also", "involved", "in", "ferrochelation", ".", "The", "evidence", "presented", "in", "this", "paper", "suggests", "that", "the", "CysG", "protein", "is", "a", "multifunctional", "protein", "involved", "in", "SAM", "-", "dependent", "methylation", ",", "pyridine", "dinucleotide", "dependent", "dehydrogenation", "and", "ferrochelation", ".", "\n" ]

[ "Protein" ]

cysG is a Protein, CysG is a Protein, CysG is a Protein, cysG is a Protein, CysG is a Protein, CysG is a Protein, CysG is a Protein, cysG is a Protein, CysG is a Protein, CysG is a Protein

541_task1

Sentence: Gene dissection demonstrates that the Escherichia coli cysG gene encodes a multifunctional protein. The C-terminus of the Escherichia coli CysG protein, consisting of amino acids 202-457, was expressed as a recombinant protein using gene dissection methodology. Analysis of the activity of this truncated protein, termed CysGA, revealed that it was able to methylate uroporphyrinogen III in the same S-adenosyl-L-methionine (SAM)-dependent manner as the complete CysG protein. However, this truncated protein was not able to complement E. coli cysG cells, thereby suggesting that the first 201 amino acids of the CysG protein had an enzymic activity associated with the conversion of dihydrosirohydrochlorin into sirohaem. Analysis of the N-terminus of the CysG protein revealed the presence of a putative pyridine dinucleotide binding site. When the purified CysG protein was incubated with NADP+, uroporphyrinogen III and SAM the enzyme was found to catalyse a coenzyme-mediated dehydrogenation to form sirohydrochlorin. The CysGA protein on the other hand showed no such coenzyme-dependent activity. Analysis of the porphyrinoid material isolated from strains harbouring plasmids containing the complete and truncated cysG genes suggested that the CysG protein was also involved in ferrochelation. The evidence presented in this paper suggests that the CysG protein is a multifunctional protein involved in SAM-dependent methylation, pyridine dinucleotide dependent dehydrogenation and ferrochelation. Instructions: please typing these entity words according to sentence: cysG, CysG, CysG, cysG, CysG, CysG, CysG, cysG, CysG, CysG Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Gene dissection demonstrates that the Escherichia coli cysG gene encodes a multifunctional protein. The C-terminus of the Escherichia coli CysG protein, consisting of amino acids 202-457, was expressed as a recombinant protein using gene dissection methodology. Analysis of the activity of this truncated protein, termed CysGA, revealed that it was able to methylate uroporphyrinogen III in the same S-adenosyl-L-methionine (SAM)-dependent manner as the complete CysG protein. However, this truncated protein was not able to complement E. coli cysG cells, thereby suggesting that the first 201 amino acids of the CysG protein had an enzymic activity associated with the conversion of dihydrosirohydrochlorin into sirohaem. Analysis of the N-terminus of the CysG protein revealed the presence of a putative pyridine dinucleotide binding site. When the purified CysG protein was incubated with NADP+, uroporphyrinogen III and SAM the enzyme was found to catalyse a coenzyme-mediated dehydrogenation to form sirohydrochlorin. The CysGA protein on the other hand showed no such coenzyme-dependent activity. Analysis of the porphyrinoid material isolated from strains harbouring plasmids containing the complete and truncated cysG genes suggested that the CysG protein was also involved in ferrochelation. The evidence presented in this paper suggests that the CysG protein is a multifunctional protein involved in SAM-dependent methylation, pyridine dinucleotide dependent dehydrogenation and ferrochelation.

[ "Gene", "dissection", "demonstrates", "that", "the", "Escherichia", "coli", "cysG", "gene", "encodes", "a", "multifunctional", "protein", ".", "\n", "The", "C", "-", "terminus", "of", "the", "Escherichia", "coli", "CysG", "protein", ",", "consisting", "of", "amino", "acids", "202", "-", "457", ",", "was", "expressed", "as", "a", "recombinant", "protein", "using", "gene", "dissection", "methodology", ".", "Analysis", "of", "the", "activity", "of", "this", "truncated", "protein", ",", "termed", "CysGA", ",", "revealed", "that", "it", "was", "able", "to", "methylate", "uroporphyrinogen", "III", "in", "the", "same", "S", "-", "adenosyl", "-", "L", "-", "methionine", "(", "SAM)-dependent", "manner", "as", "the", "complete", "CysG", "protein", ".", "However", ",", "this", "truncated", "protein", "was", "not", "able", "to", "complement", "E.", "coli", "cysG", "cells", ",", "thereby", "suggesting", "that", "the", "first", "201", "amino", "acids", "of", "the", "CysG", "protein", "had", "an", "enzymic", "activity", "associated", "with", "the", "conversion", "of", "dihydrosirohydrochlorin", "into", "sirohaem", ".", "Analysis", "of", "the", "N", "-", "terminus", "of", "the", "CysG", "protein", "revealed", "the", "presence", "of", "a", "putative", "pyridine", "dinucleotide", "binding", "site", ".", "When", "the", "purified", "CysG", "protein", "was", "incubated", "with", "NADP+", ",", "uroporphyrinogen", "III", "and", "SAM", "the", "enzyme", "was", "found", "to", "catalyse", "a", "coenzyme", "-", "mediated", "dehydrogenation", "to", "form", "sirohydrochlorin", ".", "The", "CysGA", "protein", "on", "the", "other", "hand", "showed", "no", "such", "coenzyme", "-", "dependent", "activity", ".", "Analysis", "of", "the", "porphyrinoid", "material", "isolated", "from", "strains", "harbouring", "plasmids", "containing", "the", "complete", "and", "truncated", "cysG", "genes", "suggested", "that", "the", "CysG", "protein", "was", "also", "involved", "in", "ferrochelation", ".", "The", "evidence", "presented", "in", "this", "paper", "suggests", "that", "the", "CysG", "protein", "is", "a", "multifunctional", "protein", "involved", "in", "SAM", "-", "dependent", "methylation", ",", "pyridine", "dinucleotide", "dependent", "dehydrogenation", "and", "ferrochelation", ".", "\n" ]

[ "Protein" ]

cysG, CysG, CysG, cysG, CysG, CysG, CysG, cysG, CysG, CysG

541_task2

Sentence: Gene dissection demonstrates that the Escherichia coli cysG gene encodes a multifunctional protein. The C-terminus of the Escherichia coli CysG protein, consisting of amino acids 202-457, was expressed as a recombinant protein using gene dissection methodology. Analysis of the activity of this truncated protein, termed CysGA, revealed that it was able to methylate uroporphyrinogen III in the same S-adenosyl-L-methionine (SAM)-dependent manner as the complete CysG protein. However, this truncated protein was not able to complement E. coli cysG cells, thereby suggesting that the first 201 amino acids of the CysG protein had an enzymic activity associated with the conversion of dihydrosirohydrochlorin into sirohaem. Analysis of the N-terminus of the CysG protein revealed the presence of a putative pyridine dinucleotide binding site. When the purified CysG protein was incubated with NADP+, uroporphyrinogen III and SAM the enzyme was found to catalyse a coenzyme-mediated dehydrogenation to form sirohydrochlorin. The CysGA protein on the other hand showed no such coenzyme-dependent activity. Analysis of the porphyrinoid material isolated from strains harbouring plasmids containing the complete and truncated cysG genes suggested that the CysG protein was also involved in ferrochelation. The evidence presented in this paper suggests that the CysG protein is a multifunctional protein involved in SAM-dependent methylation, pyridine dinucleotide dependent dehydrogenation and ferrochelation. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Gene dissection demonstrates that the Escherichia coli cysG gene encodes a multifunctional protein. The C-terminus of the Escherichia coli CysG protein, consisting of amino acids 202-457, was expressed as a recombinant protein using gene dissection methodology. Analysis of the activity of this truncated protein, termed CysGA, revealed that it was able to methylate uroporphyrinogen III in the same S-adenosyl-L-methionine (SAM)-dependent manner as the complete CysG protein. However, this truncated protein was not able to complement E. coli cysG cells, thereby suggesting that the first 201 amino acids of the CysG protein had an enzymic activity associated with the conversion of dihydrosirohydrochlorin into sirohaem. Analysis of the N-terminus of the CysG protein revealed the presence of a putative pyridine dinucleotide binding site. When the purified CysG protein was incubated with NADP+, uroporphyrinogen III and SAM the enzyme was found to catalyse a coenzyme-mediated dehydrogenation to form sirohydrochlorin. The CysGA protein on the other hand showed no such coenzyme-dependent activity. Analysis of the porphyrinoid material isolated from strains harbouring plasmids containing the complete and truncated cysG genes suggested that the CysG protein was also involved in ferrochelation. The evidence presented in this paper suggests that the CysG protein is a multifunctional protein involved in SAM-dependent methylation, pyridine dinucleotide dependent dehydrogenation and ferrochelation.

[ "Gene", "dissection", "demonstrates", "that", "the", "Escherichia", "coli", "cysG", "gene", "encodes", "a", "multifunctional", "protein", ".", "\n", "The", "C", "-", "terminus", "of", "the", "Escherichia", "coli", "CysG", "protein", ",", "consisting", "of", "amino", "acids", "202", "-", "457", ",", "was", "expressed", "as", "a", "recombinant", "protein", "using", "gene", "dissection", "methodology", ".", "Analysis", "of", "the", "activity", "of", "this", "truncated", "protein", ",", "termed", "CysGA", ",", "revealed", "that", "it", "was", "able", "to", "methylate", "uroporphyrinogen", "III", "in", "the", "same", "S", "-", "adenosyl", "-", "L", "-", "methionine", "(", "SAM)-dependent", "manner", "as", "the", "complete", "CysG", "protein", ".", "However", ",", "this", "truncated", "protein", "was", "not", "able", "to", "complement", "E.", "coli", "cysG", "cells", ",", "thereby", "suggesting", "that", "the", "first", "201", "amino", "acids", "of", "the", "CysG", "protein", "had", "an", "enzymic", "activity", "associated", "with", "the", "conversion", "of", "dihydrosirohydrochlorin", "into", "sirohaem", ".", "Analysis", "of", "the", "N", "-", "terminus", "of", "the", "CysG", "protein", "revealed", "the", "presence", "of", "a", "putative", "pyridine", "dinucleotide", "binding", "site", ".", "When", "the", "purified", "CysG", "protein", "was", "incubated", "with", "NADP+", ",", "uroporphyrinogen", "III", "and", "SAM", "the", "enzyme", "was", "found", "to", "catalyse", "a", "coenzyme", "-", "mediated", "dehydrogenation", "to", "form", "sirohydrochlorin", ".", "The", "CysGA", "protein", "on", "the", "other", "hand", "showed", "no", "such", "coenzyme", "-", "dependent", "activity", ".", "Analysis", "of", "the", "porphyrinoid", "material", "isolated", "from", "strains", "harbouring", "plasmids", "containing", "the", "complete", "and", "truncated", "cysG", "genes", "suggested", "that", "the", "CysG", "protein", "was", "also", "involved", "in", "ferrochelation", ".", "The", "evidence", "presented", "in", "this", "paper", "suggests", "that", "the", "CysG", "protein", "is", "a", "multifunctional", "protein", "involved", "in", "SAM", "-", "dependent", "methylation", ",", "pyridine", "dinucleotide", "dependent", "dehydrogenation", "and", "ferrochelation", ".", "\n" ]

[ "Protein" ]

observations is an umlsterm, persons is an umlsterm, sexually abused is an umlsterm, finding is an umlsterm, research is an umlsterm, occurrence is an umlsterm, persons is an umlsterm, role is an umlsterm, introjection is an umlsterm, masochism is an umlsterm, understanding is an umlsterm, behavior is an umlsterm, persons is an umlsterm, treatment is an umlsterm, persons is an umlsterm

Psychotherapeut.80430117.eng.abstr_task0

Sentence: Clinical observations consistently show that persons physically or sexually abused in infancy tend to become revictimized in subsequent relationships and , further , that these abusive relationships show a high degree of stability . One major finding of attachment research is the high occurrence of insecure attachment to primary attachment figures in abused persons . Among the typical patterns of relationship , role reversal ( parentification ) has been emphasized . From the psychoanalytic point of view , the theory of introjection of abusive relationships along with the newer theories on masochism have been making invaluable contributions to an understanding of the attachment behavior of abused persons . Finally , some consequences for the treatment of traumatized persons are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Clinical observations consistently show that persons physically or sexually abused in infancy tend to become revictimized in subsequent relationships and , further , that these abusive relationships show a high degree of stability . One major finding of attachment research is the high occurrence of insecure attachment to primary attachment figures in abused persons . Among the typical patterns of relationship , role reversal ( parentification ) has been emphasized . From the psychoanalytic point of view , the theory of introjection of abusive relationships along with the newer theories on masochism have been making invaluable contributions to an understanding of the attachment behavior of abused persons . Finally , some consequences for the treatment of traumatized persons are discussed .

[ "Clinical", "observations", "consistently", "show", "that", "persons", "physically", "or", "sexually", "abused", "in", "infancy", "tend", "to", "become", "revictimized", "in", "subsequent", "relationships", "and", ",", "further", ",", "that", "these", "abusive", "relationships", "show", "a", "high", "degree", "of", "stability", ".", "One", "major", "finding", "of", "attachment", "research", "is", "the", "high", "occurrence", "of", "insecure", "attachment", "to", "primary", "attachment", "figures", "in", "abused", "persons", ".", "Among", "the", "typical", "patterns", "of", "relationship", ",", "role", "reversal", "(", "parentification", ")", "has", "been", "emphasized", ".", "From", "the", "psychoanalytic", "point", "of", "view", ",", "the", "theory", "of", "introjection", "of", "abusive", "relationships", "along", "with", "the", "newer", "theories", "on", "masochism", "have", "been", "making", "invaluable", "contributions", "to", "an", "understanding", "of", "the", "attachment", "behavior", "of", "abused", "persons", ".", "Finally", ",", "some", "consequences", "for", "the", "treatment", "of", "traumatized", "persons", "are", "discussed", "." ]

[ "umlsterm" ]

observations is an umlsterm, persons is an umlsterm, sexually abused is an umlsterm, finding is an umlsterm, research is an umlsterm, occurrence is an umlsterm, persons is an umlsterm, role is an umlsterm, introjection is an umlsterm, masochism is an umlsterm, understanding is an umlsterm, behavior is an umlsterm, persons is an umlsterm, treatment is an umlsterm, persons is an umlsterm

Psychotherapeut.80430117.eng.abstr_task1

Sentence: Clinical observations consistently show that persons physically or sexually abused in infancy tend to become revictimized in subsequent relationships and , further , that these abusive relationships show a high degree of stability . One major finding of attachment research is the high occurrence of insecure attachment to primary attachment figures in abused persons . Among the typical patterns of relationship , role reversal ( parentification ) has been emphasized . From the psychoanalytic point of view , the theory of introjection of abusive relationships along with the newer theories on masochism have been making invaluable contributions to an understanding of the attachment behavior of abused persons . Finally , some consequences for the treatment of traumatized persons are discussed . Instructions: please typing these entity words according to sentence: observations, persons, sexually abused, finding, research, occurrence, persons, role, introjection, masochism, understanding, behavior, persons, treatment, persons Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Clinical observations consistently show that persons physically or sexually abused in infancy tend to become revictimized in subsequent relationships and , further , that these abusive relationships show a high degree of stability . One major finding of attachment research is the high occurrence of insecure attachment to primary attachment figures in abused persons . Among the typical patterns of relationship , role reversal ( parentification ) has been emphasized . From the psychoanalytic point of view , the theory of introjection of abusive relationships along with the newer theories on masochism have been making invaluable contributions to an understanding of the attachment behavior of abused persons . Finally , some consequences for the treatment of traumatized persons are discussed .

[ "Clinical", "observations", "consistently", "show", "that", "persons", "physically", "or", "sexually", "abused", "in", "infancy", "tend", "to", "become", "revictimized", "in", "subsequent", "relationships", "and", ",", "further", ",", "that", "these", "abusive", "relationships", "show", "a", "high", "degree", "of", "stability", ".", "One", "major", "finding", "of", "attachment", "research", "is", "the", "high", "occurrence", "of", "insecure", "attachment", "to", "primary", "attachment", "figures", "in", "abused", "persons", ".", "Among", "the", "typical", "patterns", "of", "relationship", ",", "role", "reversal", "(", "parentification", ")", "has", "been", "emphasized", ".", "From", "the", "psychoanalytic", "point", "of", "view", ",", "the", "theory", "of", "introjection", "of", "abusive", "relationships", "along", "with", "the", "newer", "theories", "on", "masochism", "have", "been", "making", "invaluable", "contributions", "to", "an", "understanding", "of", "the", "attachment", "behavior", "of", "abused", "persons", ".", "Finally", ",", "some", "consequences", "for", "the", "treatment", "of", "traumatized", "persons", "are", "discussed", "." ]

[ "umlsterm" ]

observations, persons, sexually abused, finding, research, occurrence, persons, role, introjection, masochism, understanding, behavior, persons, treatment, persons

Psychotherapeut.80430117.eng.abstr_task2

Sentence: Clinical observations consistently show that persons physically or sexually abused in infancy tend to become revictimized in subsequent relationships and , further , that these abusive relationships show a high degree of stability . One major finding of attachment research is the high occurrence of insecure attachment to primary attachment figures in abused persons . Among the typical patterns of relationship , role reversal ( parentification ) has been emphasized . From the psychoanalytic point of view , the theory of introjection of abusive relationships along with the newer theories on masochism have been making invaluable contributions to an understanding of the attachment behavior of abused persons . Finally , some consequences for the treatment of traumatized persons are discussed . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Clinical observations consistently show that persons physically or sexually abused in infancy tend to become revictimized in subsequent relationships and , further , that these abusive relationships show a high degree of stability . One major finding of attachment research is the high occurrence of insecure attachment to primary attachment figures in abused persons . Among the typical patterns of relationship , role reversal ( parentification ) has been emphasized . From the psychoanalytic point of view , the theory of introjection of abusive relationships along with the newer theories on masochism have been making invaluable contributions to an understanding of the attachment behavior of abused persons . Finally , some consequences for the treatment of traumatized persons are discussed .

[ "Clinical", "observations", "consistently", "show", "that", "persons", "physically", "or", "sexually", "abused", "in", "infancy", "tend", "to", "become", "revictimized", "in", "subsequent", "relationships", "and", ",", "further", ",", "that", "these", "abusive", "relationships", "show", "a", "high", "degree", "of", "stability", ".", "One", "major", "finding", "of", "attachment", "research", "is", "the", "high", "occurrence", "of", "insecure", "attachment", "to", "primary", "attachment", "figures", "in", "abused", "persons", ".", "Among", "the", "typical", "patterns", "of", "relationship", ",", "role", "reversal", "(", "parentification", ")", "has", "been", "emphasized", ".", "From", "the", "psychoanalytic", "point", "of", "view", ",", "the", "theory", "of", "introjection", "of", "abusive", "relationships", "along", "with", "the", "newer", "theories", "on", "masochism", "have", "been", "making", "invaluable", "contributions", "to", "an", "understanding", "of", "the", "attachment", "behavior", "of", "abused", "persons", ".", "Finally", ",", "some", "consequences", "for", "the", "treatment", "of", "traumatized", "persons", "are", "discussed", "." ]

[ "umlsterm" ]

patients is an umlsterm, pain is an umlsterm, postoperative period is an umlsterm, technologies is an umlsterm, drugs is an umlsterm, pain management is an umlsterm, incidence is an umlsterm, postoperative pain is an umlsterm, pain therapy is an umlsterm

DerAnaesthesist.7046s143.eng.abstr_task0

Sentence: Many patients still suffer from unnessesary pain in the postoperative period . Waiting for new technologies or drugs will not improve the status of acute pain management . The establishment of an acute service is needed to reduce the incidence of postoperative pain . Acute pain therapy is one of the great challenges we have to take up . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Many patients still suffer from unnessesary pain in the postoperative period . Waiting for new technologies or drugs will not improve the status of acute pain management . The establishment of an acute service is needed to reduce the incidence of postoperative pain . Acute pain therapy is one of the great challenges we have to take up .

[ "Many", "patients", "still", "suffer", "from", "unnessesary", "pain", "in", "the", "postoperative", "period", ".", "Waiting", "for", "new", "technologies", "or", "drugs", "will", "not", "improve", "the", "status", "of", "acute", "pain", "management", ".", "The", "establishment", "of", "an", "acute", "service", "is", "needed", "to", "reduce", "the", "incidence", "of", "postoperative", "pain", ".", "Acute", "pain", "therapy", "is", "one", "of", "the", "great", "challenges", "we", "have", "to", "take", "up", "." ]

[ "umlsterm" ]

patients is an umlsterm, pain is an umlsterm, postoperative period is an umlsterm, technologies is an umlsterm, drugs is an umlsterm, pain management is an umlsterm, incidence is an umlsterm, postoperative pain is an umlsterm, pain therapy is an umlsterm

DerAnaesthesist.7046s143.eng.abstr_task1

Sentence: Many patients still suffer from unnessesary pain in the postoperative period . Waiting for new technologies or drugs will not improve the status of acute pain management . The establishment of an acute service is needed to reduce the incidence of postoperative pain . Acute pain therapy is one of the great challenges we have to take up . Instructions: please typing these entity words according to sentence: patients, pain, postoperative period, technologies, drugs, pain management, incidence, postoperative pain, pain therapy Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Many patients still suffer from unnessesary pain in the postoperative period . Waiting for new technologies or drugs will not improve the status of acute pain management . The establishment of an acute service is needed to reduce the incidence of postoperative pain . Acute pain therapy is one of the great challenges we have to take up .

[ "Many", "patients", "still", "suffer", "from", "unnessesary", "pain", "in", "the", "postoperative", "period", ".", "Waiting", "for", "new", "technologies", "or", "drugs", "will", "not", "improve", "the", "status", "of", "acute", "pain", "management", ".", "The", "establishment", "of", "an", "acute", "service", "is", "needed", "to", "reduce", "the", "incidence", "of", "postoperative", "pain", ".", "Acute", "pain", "therapy", "is", "one", "of", "the", "great", "challenges", "we", "have", "to", "take", "up", "." ]

[ "umlsterm" ]

patients, pain, postoperative period, technologies, drugs, pain management, incidence, postoperative pain, pain therapy

DerAnaesthesist.7046s143.eng.abstr_task2

Sentence: Many patients still suffer from unnessesary pain in the postoperative period . Waiting for new technologies or drugs will not improve the status of acute pain management . The establishment of an acute service is needed to reduce the incidence of postoperative pain . Acute pain therapy is one of the great challenges we have to take up . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Many patients still suffer from unnessesary pain in the postoperative period . Waiting for new technologies or drugs will not improve the status of acute pain management . The establishment of an acute service is needed to reduce the incidence of postoperative pain . Acute pain therapy is one of the great challenges we have to take up .

[ "Many", "patients", "still", "suffer", "from", "unnessesary", "pain", "in", "the", "postoperative", "period", ".", "Waiting", "for", "new", "technologies", "or", "drugs", "will", "not", "improve", "the", "status", "of", "acute", "pain", "management", ".", "The", "establishment", "of", "an", "acute", "service", "is", "needed", "to", "reduce", "the", "incidence", "of", "postoperative", "pain", ".", "Acute", "pain", "therapy", "is", "one", "of", "the", "great", "challenges", "we", "have", "to", "take", "up", "." ]

[ "umlsterm" ]

Schmerzen is an umlsterm, Schmerzen is an umlsterm, Therapie is an umlsterm, Kompressionssyndrom is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Gewichtsabnahme is an umlsterm, Schmerzen is an umlsterm, medikamentoese Therapie is an umlsterm, farbkodierten is an umlsterm, Zwerchfells is an umlsterm, Verdachtsdiagnose is an umlsterm, Dokumentation is an umlsterm, Pankreasarkaden is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm, Kompressionssyndrom is an umlsterm, Gewichtsabnahme is an umlsterm, Leidensdruck is an umlsterm, Schmerzen is an umlsterm, Schmerzen is an umlsterm, Flussbeschleunigung is an umlsterm, Patienten is an umlsterm, Aorta is an umlsterm, Omentum minus is an umlsterm, Zwerchfellschenkels is an umlsterm, Plexus coeliacus is an umlsterm, Reststenose is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Kompressionssyndroms is an umlsterm, Stenose is an umlsterm, Schmerzen is an umlsterm, Schmerzen is an umlsterm, Gewichtsabnahme is an umlsterm, Tumorkompression is an umlsterm, Pankreatitis is an umlsterm

Gefaesschirurgie.90040028.ger.abstr_task0

Sentence: Epigastrische Schmerzen und postprandiale abdominelle Schmerzen sind haeufig , sprechen jedoch oft auf eine konventionelle Therapie nicht an . In wenigen Faellen kann ein Kompressionssyndrom des Truncus coeliacus vorliegen , das nur auf eine operative Therapie anspricht . Die Schwierigkeit besteht in der Festlegung der Kriterien , die zur Stellung der Operationsindikation fuehren . Aus diesem Grund wurden 61 Patienten mit Gewichtsabnahme und epigastrischen Schmerzen , bei denen andere Krankheitsbilder ausgeschlossen waren und die auf eine medikamentoese Therapie bzw. diaetetische Massnahme nicht ansprachen , einer farbkodierten Duplexsonographie des Abdomens unterzogen . Die Kriterien fuer den Verdacht des Vorliegens einer ligamentaeren Trunkusstenose waren eine maximale Flussgeschwindigkeit im Trunkus von ueber 200 cm/s , eine Fixation in In- und Exspirationsstellung des Zwerchfells und der sonographische Nachweis eines Stealeffekts mit Flussumkehr aus der A. mesenterica superior . Die Verdachtsdiagnose ligamentaere Trunkusstenose wurde angiographisch erhaertet mit der Dokumentation des Stealeffekts aus der A. mesenterica superior ueber Pankreasarkaden mit Darstellung des distalen Anteils des Truncus coeliacus . Bei 21 von 61 Patienten wurde die Diagnose " Kompressionssyndrom des Truncus coeliacus " gestellt . Bei Vorliegen der Kriterien Gewichtsabnahme mehr als 5 kg , erheblicher Leidensdruck durch epigastrische Schmerzen und postprandiale Schmerzen , Flussbeschleunigung im Truncus coeliacus ueber 200 cm/s und Fixation in Inspirationsstellung und eines Stealeffekts mit Flussumkehr in der A. mesenterica superior wurden die Patienten operiert n=10). ( Die Operation bestand in allen 10 Faellen in einer Freilegung der suprarenalen Aorta durch das Omentum minus und der Darstellung des Abgangs des Truncus coeliacus , in der Durchtrennung des Ligamentum arcuatum medianum und Einkerbung des rechten Zwerchfellschenkels sowie in der Resektion von Anteilen des Plexus coeliacus . Intraoperativ wurde die Reststenose nach Durchtrennung des Ligamentum arcuatum dilatiert und falls erforderlich , eine Gefaessrekonstruktion durchgefuehrt ; 80% der Patienten waren nach durchschnittlich 28 Monaten voellig beschwerdefrei , 10% waren gebessert und 1 Patient ohne Aenderung der praeoperativen Beschwerden . Schlussfolgerung : Voraussetzung fuer die erfolgreiche Operation des Kompressionssyndroms des Truncus coeliacus sind : 1. Der mittels farbcodierter Duplexsonographie gefuehrte Nachweis einer auch in Inspirationsstellung fixierten Stenose des Truncus . 2. Die Mesenteriko- und Zoeliakographie mit Nachweis des Stealeffekts . 3. Nahrungsabhaengige Symptomentrias : Epigastrische Schmerzen , postprandiale Schmerzen und Gewichtsabnahme . 4. Ausschluss anderer Ursachen , wie zum Beispiel Tumorkompression , chronische Pankreatitis u.a. . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Epigastrische Schmerzen und postprandiale abdominelle Schmerzen sind haeufig , sprechen jedoch oft auf eine konventionelle Therapie nicht an . In wenigen Faellen kann ein Kompressionssyndrom des Truncus coeliacus vorliegen , das nur auf eine operative Therapie anspricht . Die Schwierigkeit besteht in der Festlegung der Kriterien , die zur Stellung der Operationsindikation fuehren . Aus diesem Grund wurden 61 Patienten mit Gewichtsabnahme und epigastrischen Schmerzen , bei denen andere Krankheitsbilder ausgeschlossen waren und die auf eine medikamentoese Therapie bzw. diaetetische Massnahme nicht ansprachen , einer farbkodierten Duplexsonographie des Abdomens unterzogen . Die Kriterien fuer den Verdacht des Vorliegens einer ligamentaeren Trunkusstenose waren eine maximale Flussgeschwindigkeit im Trunkus von ueber 200 cm/s , eine Fixation in In- und Exspirationsstellung des Zwerchfells und der sonographische Nachweis eines Stealeffekts mit Flussumkehr aus der A. mesenterica superior . Die Verdachtsdiagnose ligamentaere Trunkusstenose wurde angiographisch erhaertet mit der Dokumentation des Stealeffekts aus der A. mesenterica superior ueber Pankreasarkaden mit Darstellung des distalen Anteils des Truncus coeliacus . Bei 21 von 61 Patienten wurde die Diagnose " Kompressionssyndrom des Truncus coeliacus " gestellt . Bei Vorliegen der Kriterien Gewichtsabnahme mehr als 5 kg , erheblicher Leidensdruck durch epigastrische Schmerzen und postprandiale Schmerzen , Flussbeschleunigung im Truncus coeliacus ueber 200 cm/s und Fixation in Inspirationsstellung und eines Stealeffekts mit Flussumkehr in der A. mesenterica superior wurden die Patienten operiert n=10). ( Die Operation bestand in allen 10 Faellen in einer Freilegung der suprarenalen Aorta durch das Omentum minus und der Darstellung des Abgangs des Truncus coeliacus , in der Durchtrennung des Ligamentum arcuatum medianum und Einkerbung des rechten Zwerchfellschenkels sowie in der Resektion von Anteilen des Plexus coeliacus . Intraoperativ wurde die Reststenose nach Durchtrennung des Ligamentum arcuatum dilatiert und falls erforderlich , eine Gefaessrekonstruktion durchgefuehrt ; 80% der Patienten waren nach durchschnittlich 28 Monaten voellig beschwerdefrei , 10% waren gebessert und 1 Patient ohne Aenderung der praeoperativen Beschwerden . Schlussfolgerung : Voraussetzung fuer die erfolgreiche Operation des Kompressionssyndroms des Truncus coeliacus sind : 1. Der mittels farbcodierter Duplexsonographie gefuehrte Nachweis einer auch in Inspirationsstellung fixierten Stenose des Truncus . 2. Die Mesenteriko- und Zoeliakographie mit Nachweis des Stealeffekts . 3. Nahrungsabhaengige Symptomentrias : Epigastrische Schmerzen , postprandiale Schmerzen und Gewichtsabnahme . 4. Ausschluss anderer Ursachen , wie zum Beispiel Tumorkompression , chronische Pankreatitis u.a. .

[ "Epigastrische", "Schmerzen", "und", "postprandiale", "abdominelle", "Schmerzen", "sind", "haeufig", ",", "sprechen", "jedoch", "oft", "auf", "eine", "konventionelle", "Therapie", "nicht", "an", ".", "In", "wenigen", "Faellen", "kann", "ein", "Kompressionssyndrom", "des", "Truncus", "coeliacus", "vorliegen", ",", "das", "nur", "auf", "eine", "operative", "Therapie", "anspricht", ".", "Die", "Schwierigkeit", "besteht", "in", "der", "Festlegung", "der", "Kriterien", ",", "die", "zur", "Stellung", "der", "Operationsindikation", "fuehren", ".", "Aus", "diesem", "Grund", "wurden", "61", "Patienten", "mit", "Gewichtsabnahme", "und", "epigastrischen", "Schmerzen", ",", "bei", "denen", "andere", "Krankheitsbilder", "ausgeschlossen", "waren", "und", "die", "auf", "eine", "medikamentoese", "Therapie", "bzw", ".", "diaetetische", "Massnahme", "nicht", "ansprachen", ",", "einer", "farbkodierten", "Duplexsonographie", "des", "Abdomens", "unterzogen", ".", "Die", "Kriterien", "fuer", "den", "Verdacht", "des", "Vorliegens", "einer", "ligamentaeren", "Trunkusstenose", "waren", "eine", "maximale", "Flussgeschwindigkeit", "im", "Trunkus", "von", "ueber", "200", "cm", "/", "s", ",", "eine", "Fixation", "in", "In-", "und", "Exspirationsstellung", "des", "Zwerchfells", "und", "der", "sonographische", "Nachweis", "eines", "Stealeffekts", "mit", "Flussumkehr", "aus", "der", "A.", "mesenterica", "superior", ".", "Die", "Verdachtsdiagnose", "ligamentaere", "Trunkusstenose", "wurde", "angiographisch", "erhaertet", "mit", "der", "Dokumentation", "des", "Stealeffekts", "aus", "der", "A.", "mesenterica", "superior", "ueber", "Pankreasarkaden", "mit", "Darstellung", "des", "distalen", "Anteils", "des", "Truncus", "coeliacus", ".", "Bei", "21", "von", "61", "Patienten", "wurde", "die", "Diagnose", "\"", "Kompressionssyndrom", "des", "Truncus", "coeliacus", "\"", "gestellt", ".", "Bei", "Vorliegen", "der", "Kriterien", "Gewichtsabnahme", "mehr", "als", "5", "kg", ",", "erheblicher", "Leidensdruck", "durch", "epigastrische", "Schmerzen", "und", "postprandiale", "Schmerzen", ",", "Flussbeschleunigung", "im", "Truncus", "coeliacus", "ueber", "200", "cm", "/", "s", "und", "Fixation", "in", "Inspirationsstellung", "und", "eines", "Stealeffekts", "mit", "Flussumkehr", "in", "der", "A.", "mesenterica", "superior", "wurden", "die", "Patienten", "operiert", "n=10", ")", ".", "(", "Die", "Operation", "bestand", "in", "allen", "10", "Faellen", "in", "einer", "Freilegung", "der", "suprarenalen", "Aorta", "durch", "das", "Omentum", "minus", "und", "der", "Darstellung", "des", "Abgangs", "des", "Truncus", "coeliacus", ",", "in", "der", "Durchtrennung", "des", "Ligamentum", "arcuatum", "medianum", "und", "Einkerbung", "des", "rechten", "Zwerchfellschenkels", "sowie", "in", "der", "Resektion", "von", "Anteilen", "des", "Plexus", "coeliacus", ".", "Intraoperativ", "wurde", "die", "Reststenose", "nach", "Durchtrennung", "des", "Ligamentum", "arcuatum", "dilatiert", "und", "falls", "erforderlich", ",", "eine", "Gefaessrekonstruktion", "durchgefuehrt", ";", "80", "%", "der", "Patienten", "waren", "nach", "durchschnittlich", "28", "Monaten", "voellig", "beschwerdefrei", ",", "10", "%", "waren", "gebessert", "und", "1", "Patient", "ohne", "Aenderung", "der", "praeoperativen", "Beschwerden", ".", "Schlussfolgerung", ":", "Voraussetzung", "fuer", "die", "erfolgreiche", "Operation", "des", "Kompressionssyndroms", "des", "Truncus", "coeliacus", "sind", ":", "1", ".", "Der", "mittels", "farbcodierter", "Duplexsonographie", "gefuehrte", "Nachweis", "einer", "auch", "in", "Inspirationsstellung", "fixierten", "Stenose", "des", "Truncus", ".", "2", ".", "Die", "Mesenteriko-", "und", "Zoeliakographie", "mit", "Nachweis", "des", "Stealeffekts", ".", "3", ".", "Nahrungsabhaengige", "Symptomentrias", ":", "Epigastrische", "Schmerzen", ",", "postprandiale", "Schmerzen", "und", "Gewichtsabnahme", ".", "4", ".", "Ausschluss", "anderer", "Ursachen", ",", "wie", "zum", "Beispiel", "Tumorkompression", ",", "chronische", "Pankreatitis", "u.a", ".", "." ]

[ "umlsterm" ]

Schmerzen is an umlsterm, Schmerzen is an umlsterm, Therapie is an umlsterm, Kompressionssyndrom is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Gewichtsabnahme is an umlsterm, Schmerzen is an umlsterm, medikamentoese Therapie is an umlsterm, farbkodierten is an umlsterm, Zwerchfells is an umlsterm, Verdachtsdiagnose is an umlsterm, Dokumentation is an umlsterm, Pankreasarkaden is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm, Kompressionssyndrom is an umlsterm, Gewichtsabnahme is an umlsterm, Leidensdruck is an umlsterm, Schmerzen is an umlsterm, Schmerzen is an umlsterm, Flussbeschleunigung is an umlsterm, Patienten is an umlsterm, Aorta is an umlsterm, Omentum minus is an umlsterm, Zwerchfellschenkels is an umlsterm, Plexus coeliacus is an umlsterm, Reststenose is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Kompressionssyndroms is an umlsterm, Stenose is an umlsterm, Schmerzen is an umlsterm, Schmerzen is an umlsterm, Gewichtsabnahme is an umlsterm, Tumorkompression is an umlsterm, Pankreatitis is an umlsterm

Gefaesschirurgie.90040028.ger.abstr_task1

Sentence: Epigastrische Schmerzen und postprandiale abdominelle Schmerzen sind haeufig , sprechen jedoch oft auf eine konventionelle Therapie nicht an . In wenigen Faellen kann ein Kompressionssyndrom des Truncus coeliacus vorliegen , das nur auf eine operative Therapie anspricht . Die Schwierigkeit besteht in der Festlegung der Kriterien , die zur Stellung der Operationsindikation fuehren . Aus diesem Grund wurden 61 Patienten mit Gewichtsabnahme und epigastrischen Schmerzen , bei denen andere Krankheitsbilder ausgeschlossen waren und die auf eine medikamentoese Therapie bzw. diaetetische Massnahme nicht ansprachen , einer farbkodierten Duplexsonographie des Abdomens unterzogen . Die Kriterien fuer den Verdacht des Vorliegens einer ligamentaeren Trunkusstenose waren eine maximale Flussgeschwindigkeit im Trunkus von ueber 200 cm/s , eine Fixation in In- und Exspirationsstellung des Zwerchfells und der sonographische Nachweis eines Stealeffekts mit Flussumkehr aus der A. mesenterica superior . Die Verdachtsdiagnose ligamentaere Trunkusstenose wurde angiographisch erhaertet mit der Dokumentation des Stealeffekts aus der A. mesenterica superior ueber Pankreasarkaden mit Darstellung des distalen Anteils des Truncus coeliacus . Bei 21 von 61 Patienten wurde die Diagnose " Kompressionssyndrom des Truncus coeliacus " gestellt . Bei Vorliegen der Kriterien Gewichtsabnahme mehr als 5 kg , erheblicher Leidensdruck durch epigastrische Schmerzen und postprandiale Schmerzen , Flussbeschleunigung im Truncus coeliacus ueber 200 cm/s und Fixation in Inspirationsstellung und eines Stealeffekts mit Flussumkehr in der A. mesenterica superior wurden die Patienten operiert n=10). ( Die Operation bestand in allen 10 Faellen in einer Freilegung der suprarenalen Aorta durch das Omentum minus und der Darstellung des Abgangs des Truncus coeliacus , in der Durchtrennung des Ligamentum arcuatum medianum und Einkerbung des rechten Zwerchfellschenkels sowie in der Resektion von Anteilen des Plexus coeliacus . Intraoperativ wurde die Reststenose nach Durchtrennung des Ligamentum arcuatum dilatiert und falls erforderlich , eine Gefaessrekonstruktion durchgefuehrt ; 80% der Patienten waren nach durchschnittlich 28 Monaten voellig beschwerdefrei , 10% waren gebessert und 1 Patient ohne Aenderung der praeoperativen Beschwerden . Schlussfolgerung : Voraussetzung fuer die erfolgreiche Operation des Kompressionssyndroms des Truncus coeliacus sind : 1. Der mittels farbcodierter Duplexsonographie gefuehrte Nachweis einer auch in Inspirationsstellung fixierten Stenose des Truncus . 2. Die Mesenteriko- und Zoeliakographie mit Nachweis des Stealeffekts . 3. Nahrungsabhaengige Symptomentrias : Epigastrische Schmerzen , postprandiale Schmerzen und Gewichtsabnahme . 4. Ausschluss anderer Ursachen , wie zum Beispiel Tumorkompression , chronische Pankreatitis u.a. . Instructions: please typing these entity words according to sentence: Schmerzen, Schmerzen, Therapie, Kompressionssyndrom, Therapie, Patienten, Gewichtsabnahme, Schmerzen, medikamentoese Therapie, farbkodierten, Zwerchfells, Verdachtsdiagnose, Dokumentation, Pankreasarkaden, Patienten, Diagnose, Kompressionssyndrom, Gewichtsabnahme, Leidensdruck, Schmerzen, Schmerzen, Flussbeschleunigung, Patienten, Aorta, Omentum minus, Zwerchfellschenkels, Plexus coeliacus, Reststenose, Patienten, Patient, Kompressionssyndroms, Stenose, Schmerzen, Schmerzen, Gewichtsabnahme, Tumorkompression, Pankreatitis Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Epigastrische Schmerzen und postprandiale abdominelle Schmerzen sind haeufig , sprechen jedoch oft auf eine konventionelle Therapie nicht an . In wenigen Faellen kann ein Kompressionssyndrom des Truncus coeliacus vorliegen , das nur auf eine operative Therapie anspricht . Die Schwierigkeit besteht in der Festlegung der Kriterien , die zur Stellung der Operationsindikation fuehren . Aus diesem Grund wurden 61 Patienten mit Gewichtsabnahme und epigastrischen Schmerzen , bei denen andere Krankheitsbilder ausgeschlossen waren und die auf eine medikamentoese Therapie bzw. diaetetische Massnahme nicht ansprachen , einer farbkodierten Duplexsonographie des Abdomens unterzogen . Die Kriterien fuer den Verdacht des Vorliegens einer ligamentaeren Trunkusstenose waren eine maximale Flussgeschwindigkeit im Trunkus von ueber 200 cm/s , eine Fixation in In- und Exspirationsstellung des Zwerchfells und der sonographische Nachweis eines Stealeffekts mit Flussumkehr aus der A. mesenterica superior . Die Verdachtsdiagnose ligamentaere Trunkusstenose wurde angiographisch erhaertet mit der Dokumentation des Stealeffekts aus der A. mesenterica superior ueber Pankreasarkaden mit Darstellung des distalen Anteils des Truncus coeliacus . Bei 21 von 61 Patienten wurde die Diagnose " Kompressionssyndrom des Truncus coeliacus " gestellt . Bei Vorliegen der Kriterien Gewichtsabnahme mehr als 5 kg , erheblicher Leidensdruck durch epigastrische Schmerzen und postprandiale Schmerzen , Flussbeschleunigung im Truncus coeliacus ueber 200 cm/s und Fixation in Inspirationsstellung und eines Stealeffekts mit Flussumkehr in der A. mesenterica superior wurden die Patienten operiert n=10). ( Die Operation bestand in allen 10 Faellen in einer Freilegung der suprarenalen Aorta durch das Omentum minus und der Darstellung des Abgangs des Truncus coeliacus , in der Durchtrennung des Ligamentum arcuatum medianum und Einkerbung des rechten Zwerchfellschenkels sowie in der Resektion von Anteilen des Plexus coeliacus . Intraoperativ wurde die Reststenose nach Durchtrennung des Ligamentum arcuatum dilatiert und falls erforderlich , eine Gefaessrekonstruktion durchgefuehrt ; 80% der Patienten waren nach durchschnittlich 28 Monaten voellig beschwerdefrei , 10% waren gebessert und 1 Patient ohne Aenderung der praeoperativen Beschwerden . Schlussfolgerung : Voraussetzung fuer die erfolgreiche Operation des Kompressionssyndroms des Truncus coeliacus sind : 1. Der mittels farbcodierter Duplexsonographie gefuehrte Nachweis einer auch in Inspirationsstellung fixierten Stenose des Truncus . 2. Die Mesenteriko- und Zoeliakographie mit Nachweis des Stealeffekts . 3. Nahrungsabhaengige Symptomentrias : Epigastrische Schmerzen , postprandiale Schmerzen und Gewichtsabnahme . 4. Ausschluss anderer Ursachen , wie zum Beispiel Tumorkompression , chronische Pankreatitis u.a. .

[ "Epigastrische", "Schmerzen", "und", "postprandiale", "abdominelle", "Schmerzen", "sind", "haeufig", ",", "sprechen", "jedoch", "oft", "auf", "eine", "konventionelle", "Therapie", "nicht", "an", ".", "In", "wenigen", "Faellen", "kann", "ein", "Kompressionssyndrom", "des", "Truncus", "coeliacus", "vorliegen", ",", "das", "nur", "auf", "eine", "operative", "Therapie", "anspricht", ".", "Die", "Schwierigkeit", "besteht", "in", "der", "Festlegung", "der", "Kriterien", ",", "die", "zur", "Stellung", "der", "Operationsindikation", "fuehren", ".", "Aus", "diesem", "Grund", "wurden", "61", "Patienten", "mit", "Gewichtsabnahme", "und", "epigastrischen", "Schmerzen", ",", "bei", "denen", "andere", "Krankheitsbilder", "ausgeschlossen", "waren", "und", "die", "auf", "eine", "medikamentoese", "Therapie", "bzw", ".", "diaetetische", "Massnahme", "nicht", "ansprachen", ",", "einer", "farbkodierten", "Duplexsonographie", "des", "Abdomens", "unterzogen", ".", "Die", "Kriterien", "fuer", "den", "Verdacht", "des", "Vorliegens", "einer", "ligamentaeren", "Trunkusstenose", "waren", "eine", "maximale", "Flussgeschwindigkeit", "im", "Trunkus", "von", "ueber", "200", "cm", "/", "s", ",", "eine", "Fixation", "in", "In-", "und", "Exspirationsstellung", "des", "Zwerchfells", "und", "der", "sonographische", "Nachweis", "eines", "Stealeffekts", "mit", "Flussumkehr", "aus", "der", "A.", "mesenterica", "superior", ".", "Die", "Verdachtsdiagnose", "ligamentaere", "Trunkusstenose", "wurde", "angiographisch", "erhaertet", "mit", "der", "Dokumentation", "des", "Stealeffekts", "aus", "der", "A.", "mesenterica", "superior", "ueber", "Pankreasarkaden", "mit", "Darstellung", "des", "distalen", "Anteils", "des", "Truncus", "coeliacus", ".", "Bei", "21", "von", "61", "Patienten", "wurde", "die", "Diagnose", "\"", "Kompressionssyndrom", "des", "Truncus", "coeliacus", "\"", "gestellt", ".", "Bei", "Vorliegen", "der", "Kriterien", "Gewichtsabnahme", "mehr", "als", "5", "kg", ",", "erheblicher", "Leidensdruck", "durch", "epigastrische", "Schmerzen", "und", "postprandiale", "Schmerzen", ",", "Flussbeschleunigung", "im", "Truncus", "coeliacus", "ueber", "200", "cm", "/", "s", "und", "Fixation", "in", "Inspirationsstellung", "und", "eines", "Stealeffekts", "mit", "Flussumkehr", "in", "der", "A.", "mesenterica", "superior", "wurden", "die", "Patienten", "operiert", "n=10", ")", ".", "(", "Die", "Operation", "bestand", "in", "allen", "10", "Faellen", "in", "einer", "Freilegung", "der", "suprarenalen", "Aorta", "durch", "das", "Omentum", "minus", "und", "der", "Darstellung", "des", "Abgangs", "des", "Truncus", "coeliacus", ",", "in", "der", "Durchtrennung", "des", "Ligamentum", "arcuatum", "medianum", "und", "Einkerbung", "des", "rechten", "Zwerchfellschenkels", "sowie", "in", "der", "Resektion", "von", "Anteilen", "des", "Plexus", "coeliacus", ".", "Intraoperativ", "wurde", "die", "Reststenose", "nach", "Durchtrennung", "des", "Ligamentum", "arcuatum", "dilatiert", "und", "falls", "erforderlich", ",", "eine", "Gefaessrekonstruktion", "durchgefuehrt", ";", "80", "%", "der", "Patienten", "waren", "nach", "durchschnittlich", "28", "Monaten", "voellig", "beschwerdefrei", ",", "10", "%", "waren", "gebessert", "und", "1", "Patient", "ohne", "Aenderung", "der", "praeoperativen", "Beschwerden", ".", "Schlussfolgerung", ":", "Voraussetzung", "fuer", "die", "erfolgreiche", "Operation", "des", "Kompressionssyndroms", "des", "Truncus", "coeliacus", "sind", ":", "1", ".", "Der", "mittels", "farbcodierter", "Duplexsonographie", "gefuehrte", "Nachweis", "einer", "auch", "in", "Inspirationsstellung", "fixierten", "Stenose", "des", "Truncus", ".", "2", ".", "Die", "Mesenteriko-", "und", "Zoeliakographie", "mit", "Nachweis", "des", "Stealeffekts", ".", "3", ".", "Nahrungsabhaengige", "Symptomentrias", ":", "Epigastrische", "Schmerzen", ",", "postprandiale", "Schmerzen", "und", "Gewichtsabnahme", ".", "4", ".", "Ausschluss", "anderer", "Ursachen", ",", "wie", "zum", "Beispiel", "Tumorkompression", ",", "chronische", "Pankreatitis", "u.a", ".", "." ]

[ "umlsterm" ]

Schmerzen, Schmerzen, Therapie, Kompressionssyndrom, Therapie, Patienten, Gewichtsabnahme, Schmerzen, medikamentoese Therapie, farbkodierten, Zwerchfells, Verdachtsdiagnose, Dokumentation, Pankreasarkaden, Patienten, Diagnose, Kompressionssyndrom, Gewichtsabnahme, Leidensdruck, Schmerzen, Schmerzen, Flussbeschleunigung, Patienten, Aorta, Omentum minus, Zwerchfellschenkels, Plexus coeliacus, Reststenose, Patienten, Patient, Kompressionssyndroms, Stenose, Schmerzen, Schmerzen, Gewichtsabnahme, Tumorkompression, Pankreatitis

Gefaesschirurgie.90040028.ger.abstr_task2

Sentence: Epigastrische Schmerzen und postprandiale abdominelle Schmerzen sind haeufig , sprechen jedoch oft auf eine konventionelle Therapie nicht an . In wenigen Faellen kann ein Kompressionssyndrom des Truncus coeliacus vorliegen , das nur auf eine operative Therapie anspricht . Die Schwierigkeit besteht in der Festlegung der Kriterien , die zur Stellung der Operationsindikation fuehren . Aus diesem Grund wurden 61 Patienten mit Gewichtsabnahme und epigastrischen Schmerzen , bei denen andere Krankheitsbilder ausgeschlossen waren und die auf eine medikamentoese Therapie bzw. diaetetische Massnahme nicht ansprachen , einer farbkodierten Duplexsonographie des Abdomens unterzogen . Die Kriterien fuer den Verdacht des Vorliegens einer ligamentaeren Trunkusstenose waren eine maximale Flussgeschwindigkeit im Trunkus von ueber 200 cm/s , eine Fixation in In- und Exspirationsstellung des Zwerchfells und der sonographische Nachweis eines Stealeffekts mit Flussumkehr aus der A. mesenterica superior . Die Verdachtsdiagnose ligamentaere Trunkusstenose wurde angiographisch erhaertet mit der Dokumentation des Stealeffekts aus der A. mesenterica superior ueber Pankreasarkaden mit Darstellung des distalen Anteils des Truncus coeliacus . Bei 21 von 61 Patienten wurde die Diagnose " Kompressionssyndrom des Truncus coeliacus " gestellt . Bei Vorliegen der Kriterien Gewichtsabnahme mehr als 5 kg , erheblicher Leidensdruck durch epigastrische Schmerzen und postprandiale Schmerzen , Flussbeschleunigung im Truncus coeliacus ueber 200 cm/s und Fixation in Inspirationsstellung und eines Stealeffekts mit Flussumkehr in der A. mesenterica superior wurden die Patienten operiert n=10). ( Die Operation bestand in allen 10 Faellen in einer Freilegung der suprarenalen Aorta durch das Omentum minus und der Darstellung des Abgangs des Truncus coeliacus , in der Durchtrennung des Ligamentum arcuatum medianum und Einkerbung des rechten Zwerchfellschenkels sowie in der Resektion von Anteilen des Plexus coeliacus . Intraoperativ wurde die Reststenose nach Durchtrennung des Ligamentum arcuatum dilatiert und falls erforderlich , eine Gefaessrekonstruktion durchgefuehrt ; 80% der Patienten waren nach durchschnittlich 28 Monaten voellig beschwerdefrei , 10% waren gebessert und 1 Patient ohne Aenderung der praeoperativen Beschwerden . Schlussfolgerung : Voraussetzung fuer die erfolgreiche Operation des Kompressionssyndroms des Truncus coeliacus sind : 1. Der mittels farbcodierter Duplexsonographie gefuehrte Nachweis einer auch in Inspirationsstellung fixierten Stenose des Truncus . 2. Die Mesenteriko- und Zoeliakographie mit Nachweis des Stealeffekts . 3. Nahrungsabhaengige Symptomentrias : Epigastrische Schmerzen , postprandiale Schmerzen und Gewichtsabnahme . 4. Ausschluss anderer Ursachen , wie zum Beispiel Tumorkompression , chronische Pankreatitis u.a. . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Epigastrische Schmerzen und postprandiale abdominelle Schmerzen sind haeufig , sprechen jedoch oft auf eine konventionelle Therapie nicht an . In wenigen Faellen kann ein Kompressionssyndrom des Truncus coeliacus vorliegen , das nur auf eine operative Therapie anspricht . Die Schwierigkeit besteht in der Festlegung der Kriterien , die zur Stellung der Operationsindikation fuehren . Aus diesem Grund wurden 61 Patienten mit Gewichtsabnahme und epigastrischen Schmerzen , bei denen andere Krankheitsbilder ausgeschlossen waren und die auf eine medikamentoese Therapie bzw. diaetetische Massnahme nicht ansprachen , einer farbkodierten Duplexsonographie des Abdomens unterzogen . Die Kriterien fuer den Verdacht des Vorliegens einer ligamentaeren Trunkusstenose waren eine maximale Flussgeschwindigkeit im Trunkus von ueber 200 cm/s , eine Fixation in In- und Exspirationsstellung des Zwerchfells und der sonographische Nachweis eines Stealeffekts mit Flussumkehr aus der A. mesenterica superior . Die Verdachtsdiagnose ligamentaere Trunkusstenose wurde angiographisch erhaertet mit der Dokumentation des Stealeffekts aus der A. mesenterica superior ueber Pankreasarkaden mit Darstellung des distalen Anteils des Truncus coeliacus . Bei 21 von 61 Patienten wurde die Diagnose " Kompressionssyndrom des Truncus coeliacus " gestellt . Bei Vorliegen der Kriterien Gewichtsabnahme mehr als 5 kg , erheblicher Leidensdruck durch epigastrische Schmerzen und postprandiale Schmerzen , Flussbeschleunigung im Truncus coeliacus ueber 200 cm/s und Fixation in Inspirationsstellung und eines Stealeffekts mit Flussumkehr in der A. mesenterica superior wurden die Patienten operiert n=10). ( Die Operation bestand in allen 10 Faellen in einer Freilegung der suprarenalen Aorta durch das Omentum minus und der Darstellung des Abgangs des Truncus coeliacus , in der Durchtrennung des Ligamentum arcuatum medianum und Einkerbung des rechten Zwerchfellschenkels sowie in der Resektion von Anteilen des Plexus coeliacus . Intraoperativ wurde die Reststenose nach Durchtrennung des Ligamentum arcuatum dilatiert und falls erforderlich , eine Gefaessrekonstruktion durchgefuehrt ; 80% der Patienten waren nach durchschnittlich 28 Monaten voellig beschwerdefrei , 10% waren gebessert und 1 Patient ohne Aenderung der praeoperativen Beschwerden . Schlussfolgerung : Voraussetzung fuer die erfolgreiche Operation des Kompressionssyndroms des Truncus coeliacus sind : 1. Der mittels farbcodierter Duplexsonographie gefuehrte Nachweis einer auch in Inspirationsstellung fixierten Stenose des Truncus . 2. Die Mesenteriko- und Zoeliakographie mit Nachweis des Stealeffekts . 3. Nahrungsabhaengige Symptomentrias : Epigastrische Schmerzen , postprandiale Schmerzen und Gewichtsabnahme . 4. Ausschluss anderer Ursachen , wie zum Beispiel Tumorkompression , chronische Pankreatitis u.a. .

[ "Epigastrische", "Schmerzen", "und", "postprandiale", "abdominelle", "Schmerzen", "sind", "haeufig", ",", "sprechen", "jedoch", "oft", "auf", "eine", "konventionelle", "Therapie", "nicht", "an", ".", "In", "wenigen", "Faellen", "kann", "ein", "Kompressionssyndrom", "des", "Truncus", "coeliacus", "vorliegen", ",", "das", "nur", "auf", "eine", "operative", "Therapie", "anspricht", ".", "Die", "Schwierigkeit", "besteht", "in", "der", "Festlegung", "der", "Kriterien", ",", "die", "zur", "Stellung", "der", "Operationsindikation", "fuehren", ".", "Aus", "diesem", "Grund", "wurden", "61", "Patienten", "mit", "Gewichtsabnahme", "und", "epigastrischen", "Schmerzen", ",", "bei", "denen", "andere", "Krankheitsbilder", "ausgeschlossen", "waren", "und", "die", "auf", "eine", "medikamentoese", "Therapie", "bzw", ".", "diaetetische", "Massnahme", "nicht", "ansprachen", ",", "einer", "farbkodierten", "Duplexsonographie", "des", "Abdomens", "unterzogen", ".", "Die", "Kriterien", "fuer", "den", "Verdacht", "des", "Vorliegens", "einer", "ligamentaeren", "Trunkusstenose", "waren", "eine", "maximale", "Flussgeschwindigkeit", "im", "Trunkus", "von", "ueber", "200", "cm", "/", "s", ",", "eine", "Fixation", "in", "In-", "und", "Exspirationsstellung", "des", "Zwerchfells", "und", "der", "sonographische", "Nachweis", "eines", "Stealeffekts", "mit", "Flussumkehr", "aus", "der", "A.", "mesenterica", "superior", ".", "Die", "Verdachtsdiagnose", "ligamentaere", "Trunkusstenose", "wurde", "angiographisch", "erhaertet", "mit", "der", "Dokumentation", "des", "Stealeffekts", "aus", "der", "A.", "mesenterica", "superior", "ueber", "Pankreasarkaden", "mit", "Darstellung", "des", "distalen", "Anteils", "des", "Truncus", "coeliacus", ".", "Bei", "21", "von", "61", "Patienten", "wurde", "die", "Diagnose", "\"", "Kompressionssyndrom", "des", "Truncus", "coeliacus", "\"", "gestellt", ".", "Bei", "Vorliegen", "der", "Kriterien", "Gewichtsabnahme", "mehr", "als", "5", "kg", ",", "erheblicher", "Leidensdruck", "durch", "epigastrische", "Schmerzen", "und", "postprandiale", "Schmerzen", ",", "Flussbeschleunigung", "im", "Truncus", "coeliacus", "ueber", "200", "cm", "/", "s", "und", "Fixation", "in", "Inspirationsstellung", "und", "eines", "Stealeffekts", "mit", "Flussumkehr", "in", "der", "A.", "mesenterica", "superior", "wurden", "die", "Patienten", "operiert", "n=10", ")", ".", "(", "Die", "Operation", "bestand", "in", "allen", "10", "Faellen", "in", "einer", "Freilegung", "der", "suprarenalen", "Aorta", "durch", "das", "Omentum", "minus", "und", "der", "Darstellung", "des", "Abgangs", "des", "Truncus", "coeliacus", ",", "in", "der", "Durchtrennung", "des", "Ligamentum", "arcuatum", "medianum", "und", "Einkerbung", "des", "rechten", "Zwerchfellschenkels", "sowie", "in", "der", "Resektion", "von", "Anteilen", "des", "Plexus", "coeliacus", ".", "Intraoperativ", "wurde", "die", "Reststenose", "nach", "Durchtrennung", "des", "Ligamentum", "arcuatum", "dilatiert", "und", "falls", "erforderlich", ",", "eine", "Gefaessrekonstruktion", "durchgefuehrt", ";", "80", "%", "der", "Patienten", "waren", "nach", "durchschnittlich", "28", "Monaten", "voellig", "beschwerdefrei", ",", "10", "%", "waren", "gebessert", "und", "1", "Patient", "ohne", "Aenderung", "der", "praeoperativen", "Beschwerden", ".", "Schlussfolgerung", ":", "Voraussetzung", "fuer", "die", "erfolgreiche", "Operation", "des", "Kompressionssyndroms", "des", "Truncus", "coeliacus", "sind", ":", "1", ".", "Der", "mittels", "farbcodierter", "Duplexsonographie", "gefuehrte", "Nachweis", "einer", "auch", "in", "Inspirationsstellung", "fixierten", "Stenose", "des", "Truncus", ".", "2", ".", "Die", "Mesenteriko-", "und", "Zoeliakographie", "mit", "Nachweis", "des", "Stealeffekts", ".", "3", ".", "Nahrungsabhaengige", "Symptomentrias", ":", "Epigastrische", "Schmerzen", ",", "postprandiale", "Schmerzen", "und", "Gewichtsabnahme", ".", "4", ".", "Ausschluss", "anderer", "Ursachen", ",", "wie", "zum", "Beispiel", "Tumorkompression", ",", "chronische", "Pankreatitis", "u.a", ".", "." ]

[ "umlsterm" ]

arformoterol is a CHEMICAL

17472819_task0

Sentence: Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.

[ "Nebulized", "arformoterol", "in", "patients", "with", "COPD", ":", "a", "12-week", ",", "multicenter", ",", "randomized", ",", "double", "-", "blind", ",", "double", "-", "dummy", ",", "placebo-", "and", "active", "-", "controlled", "trial", "." ]

[ "CHEMICAL", "GENE-Y" ]

arformoterol is a CHEMICAL

17472819_task1

Sentence: Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Instructions: please typing these entity words according to sentence: arformoterol Options: CHEMICAL

[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.

[ "Nebulized", "arformoterol", "in", "patients", "with", "COPD", ":", "a", "12-week", ",", "multicenter", ",", "randomized", ",", "double", "-", "blind", ",", "double", "-", "dummy", ",", "placebo-", "and", "active", "-", "controlled", "trial", "." ]

[ "CHEMICAL", "GENE-Y" ]

arformoterol

17472819_task2

Sentence: Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Instructions: please extract entity words from the input sentence

[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.

[ "Nebulized", "arformoterol", "in", "patients", "with", "COPD", ":", "a", "12-week", ",", "multicenter", ",", "randomized", ",", "double", "-", "blind", ",", "double", "-", "dummy", ",", "placebo-", "and", "active", "-", "controlled", "trial", "." ]

[ "CHEMICAL", "GENE-Y" ]

chemotherapy is an umlsterm, therapy is an umlsterm, head is an umlsterm, neck cancer is an umlsterm, survival rates is an umlsterm, All is an umlsterm, patients is an umlsterm, stage is an umlsterm, disease is an umlsterm, survival rates is an umlsterm, date is an umlsterm, chemotherapy is an umlsterm, disease is an umlsterm, patients is an umlsterm, disease is an umlsterm, stages is an umlsterm, Patients is an umlsterm, chemotherapy is an umlsterm, surgery is an umlsterm, radiotherapy is an umlsterm, arm is an umlsterm, standard is an umlsterm, treatment is an umlsterm, surgery is an umlsterm, radiotherapy is an umlsterm, arm is an umlsterm, Patients is an umlsterm, tumour is an umlsterm, neck is an umlsterm, disease is an umlsterm, chemotherapy is an umlsterm, patients is an umlsterm, head is an umlsterm, neck cancer is an umlsterm, overall is an umlsterm, survival is an umlsterm, arm is an umlsterm, arm is an umlsterm, Disease - free survival is an umlsterm, arm is an umlsterm, arm is an umlsterm, role is an umlsterm, chemotherapy is an umlsterm, patients is an umlsterm, carcinomas is an umlsterm, oral cavity is an umlsterm, tonsils is an umlsterm, stage is an umlsterm, disease is an umlsterm, surgery is an umlsterm

HNO.90470899.eng.abstr_task0

Sentence: Although induction chemotherapy administered prior to local therapy produces encouraging initial response rates in head and neck cancer , randomized studies have failed to demonstrate an improvement in survival rates . All randomized studies included only patients with advanced stage III and IV disease . In our opinion , this is the main reason for the low rate of complete responses demonstrated in the randomized trials ( maximum 18% ) . Frei et al. estimate that a 40%-50% complete response rate is necessary before improved survival rates are seen . To date , such complete response rates with induction chemotherapy have only been attainable in resectable T2-T3, N0-N2 disease . Therefore , we initiated a prospective randomized trial including only patients with the mentioned disease stages . Patients ( pts ) were randomized to receive either induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy ( arm A , 70 pts ) or standard treatment with surgery and radiotherapy ( arm B , 74 pts ) . Patients were classified according to primary tumour site and neck disease . The observed remission rate after chemotherapy confirmed the primary estimated rate for this subgroup of patients with head and neck cancer ( CR : 43% , PR : 37% , NR : 15% , PD : 5% ) . After a follow-up of 12-96 months overall survival was 58% in arm A and 45% in arm B ( n.s. ) . Disease-free survival in arm A ( 61% ) is statistically significantly better than in arm B ( 43% , P=0.03). Therefore , we recommend further controlled trials to investigate the role of induction chemotherapy in patients with primary resectable carcinomas of the oral cavity and tonsils and stage T2-T3 and N0-N2 disease prior to surgery . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Although induction chemotherapy administered prior to local therapy produces encouraging initial response rates in head and neck cancer , randomized studies have failed to demonstrate an improvement in survival rates . All randomized studies included only patients with advanced stage III and IV disease . In our opinion , this is the main reason for the low rate of complete responses demonstrated in the randomized trials ( maximum 18% ) . Frei et al. estimate that a 40%-50% complete response rate is necessary before improved survival rates are seen . To date , such complete response rates with induction chemotherapy have only been attainable in resectable T2-T3, N0-N2 disease . Therefore , we initiated a prospective randomized trial including only patients with the mentioned disease stages . Patients ( pts ) were randomized to receive either induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy ( arm A , 70 pts ) or standard treatment with surgery and radiotherapy ( arm B , 74 pts ) . Patients were classified according to primary tumour site and neck disease . The observed remission rate after chemotherapy confirmed the primary estimated rate for this subgroup of patients with head and neck cancer ( CR : 43% , PR : 37% , NR : 15% , PD : 5% ) . After a follow-up of 12-96 months overall survival was 58% in arm A and 45% in arm B ( n.s. ) . Disease-free survival in arm A ( 61% ) is statistically significantly better than in arm B ( 43% , P=0.03). Therefore , we recommend further controlled trials to investigate the role of induction chemotherapy in patients with primary resectable carcinomas of the oral cavity and tonsils and stage T2-T3 and N0-N2 disease prior to surgery .

[ "Although", "induction", "chemotherapy", "administered", "prior", "to", "local", "therapy", "produces", "encouraging", "initial", "response", "rates", "in", "head", "and", "neck", "cancer", ",", "randomized", "studies", "have", "failed", "to", "demonstrate", "an", "improvement", "in", "survival", "rates", ".", "All", "randomized", "studies", "included", "only", "patients", "with", "advanced", "stage", "III", "and", "IV", "disease", ".", "In", "our", "opinion", ",", "this", "is", "the", "main", "reason", "for", "the", "low", "rate", "of", "complete", "responses", "demonstrated", "in", "the", "randomized", "trials", "(", "maximum", "18", "%", ")", ".", "Frei", "et", "al", ".", "estimate", "that", "a", "40%-50", "%", "complete", "response", "rate", "is", "necessary", "before", "improved", "survival", "rates", "are", "seen", ".", "To", "date", ",", "such", "complete", "response", "rates", "with", "induction", "chemotherapy", "have", "only", "been", "attainable", "in", "resectable", "T2-T3", ",", "N0-N2", "disease", ".", "Therefore", ",", "we", "initiated", "a", "prospective", "randomized", "trial", "including", "only", "patients", "with", "the", "mentioned", "disease", "stages", ".", "Patients", "(", "pts", ")", "were", "randomized", "to", "receive", "either", "induction", "chemotherapy", "with", "three", "cycles", "of", "carboplatin/5-FU", "prior", "to", "surgery", "and", "radiotherapy", "(", "arm", "A", ",", "70", "pts", ")", "or", "standard", "treatment", "with", "surgery", "and", "radiotherapy", "(", "arm", "B", ",", "74", "pts", ")", ".", "Patients", "were", "classified", "according", "to", "primary", "tumour", "site", "and", "neck", "disease", ".", "The", "observed", "remission", "rate", "after", "chemotherapy", "confirmed", "the", "primary", "estimated", "rate", "for", "this", "subgroup", "of", "patients", "with", "head", "and", "neck", "cancer", "(", "CR", ":", "43", "%", ",", "PR", ":", "37", "%", ",", "NR", ":", "15", "%", ",", "PD", ":", "5", "%", ")", ".", "After", "a", "follow", "-", "up", "of", "12", "-", "96", "months", "overall", "survival", "was", "58", "%", "in", "arm", "A", "and", "45", "%", "in", "arm", "B", "(", "n.s", ".", ")", ".", "Disease", "-", "free", "survival", "in", "arm", "A", "(", "61", "%", ")", "is", "statistically", "significantly", "better", "than", "in", "arm", "B", "(", "43", "%", ",", "P=0.03", ")", ".", "Therefore", ",", "we", "recommend", "further", "controlled", "trials", "to", "investigate", "the", "role", "of", "induction", "chemotherapy", "in", "patients", "with", "primary", "resectable", "carcinomas", "of", "the", "oral", "cavity", "and", "tonsils", "and", "stage", "T2-T3", "and", "N0-N2", "disease", "prior", "to", "surgery", "." ]

[ "umlsterm" ]

chemotherapy is an umlsterm, therapy is an umlsterm, head is an umlsterm, neck cancer is an umlsterm, survival rates is an umlsterm, All is an umlsterm, patients is an umlsterm, stage is an umlsterm, disease is an umlsterm, survival rates is an umlsterm, date is an umlsterm, chemotherapy is an umlsterm, disease is an umlsterm, patients is an umlsterm, disease is an umlsterm, stages is an umlsterm, Patients is an umlsterm, chemotherapy is an umlsterm, surgery is an umlsterm, radiotherapy is an umlsterm, arm is an umlsterm, standard is an umlsterm, treatment is an umlsterm, surgery is an umlsterm, radiotherapy is an umlsterm, arm is an umlsterm, Patients is an umlsterm, tumour is an umlsterm, neck is an umlsterm, disease is an umlsterm, chemotherapy is an umlsterm, patients is an umlsterm, head is an umlsterm, neck cancer is an umlsterm, overall is an umlsterm, survival is an umlsterm, arm is an umlsterm, arm is an umlsterm, Disease - free survival is an umlsterm, arm is an umlsterm, arm is an umlsterm, role is an umlsterm, chemotherapy is an umlsterm, patients is an umlsterm, carcinomas is an umlsterm, oral cavity is an umlsterm, tonsils is an umlsterm, stage is an umlsterm, disease is an umlsterm, surgery is an umlsterm

HNO.90470899.eng.abstr_task1

Sentence: Although induction chemotherapy administered prior to local therapy produces encouraging initial response rates in head and neck cancer , randomized studies have failed to demonstrate an improvement in survival rates . All randomized studies included only patients with advanced stage III and IV disease . In our opinion , this is the main reason for the low rate of complete responses demonstrated in the randomized trials ( maximum 18% ) . Frei et al. estimate that a 40%-50% complete response rate is necessary before improved survival rates are seen . To date , such complete response rates with induction chemotherapy have only been attainable in resectable T2-T3, N0-N2 disease . Therefore , we initiated a prospective randomized trial including only patients with the mentioned disease stages . Patients ( pts ) were randomized to receive either induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy ( arm A , 70 pts ) or standard treatment with surgery and radiotherapy ( arm B , 74 pts ) . Patients were classified according to primary tumour site and neck disease . The observed remission rate after chemotherapy confirmed the primary estimated rate for this subgroup of patients with head and neck cancer ( CR : 43% , PR : 37% , NR : 15% , PD : 5% ) . After a follow-up of 12-96 months overall survival was 58% in arm A and 45% in arm B ( n.s. ) . Disease-free survival in arm A ( 61% ) is statistically significantly better than in arm B ( 43% , P=0.03). Therefore , we recommend further controlled trials to investigate the role of induction chemotherapy in patients with primary resectable carcinomas of the oral cavity and tonsils and stage T2-T3 and N0-N2 disease prior to surgery . Instructions: please typing these entity words according to sentence: chemotherapy, therapy, head, neck cancer, survival rates, All, patients, stage, disease, survival rates, date, chemotherapy, disease, patients, disease, stages, Patients, chemotherapy, surgery, radiotherapy, arm, standard, treatment, surgery, radiotherapy, arm, Patients, tumour, neck, disease, chemotherapy, patients, head, neck cancer, overall, survival, arm, arm, Disease - free survival, arm, arm, role, chemotherapy, patients, carcinomas, oral cavity, tonsils, stage, disease, surgery Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Although induction chemotherapy administered prior to local therapy produces encouraging initial response rates in head and neck cancer , randomized studies have failed to demonstrate an improvement in survival rates . All randomized studies included only patients with advanced stage III and IV disease . In our opinion , this is the main reason for the low rate of complete responses demonstrated in the randomized trials ( maximum 18% ) . Frei et al. estimate that a 40%-50% complete response rate is necessary before improved survival rates are seen . To date , such complete response rates with induction chemotherapy have only been attainable in resectable T2-T3, N0-N2 disease . Therefore , we initiated a prospective randomized trial including only patients with the mentioned disease stages . Patients ( pts ) were randomized to receive either induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy ( arm A , 70 pts ) or standard treatment with surgery and radiotherapy ( arm B , 74 pts ) . Patients were classified according to primary tumour site and neck disease . The observed remission rate after chemotherapy confirmed the primary estimated rate for this subgroup of patients with head and neck cancer ( CR : 43% , PR : 37% , NR : 15% , PD : 5% ) . After a follow-up of 12-96 months overall survival was 58% in arm A and 45% in arm B ( n.s. ) . Disease-free survival in arm A ( 61% ) is statistically significantly better than in arm B ( 43% , P=0.03). Therefore , we recommend further controlled trials to investigate the role of induction chemotherapy in patients with primary resectable carcinomas of the oral cavity and tonsils and stage T2-T3 and N0-N2 disease prior to surgery .

[ "Although", "induction", "chemotherapy", "administered", "prior", "to", "local", "therapy", "produces", "encouraging", "initial", "response", "rates", "in", "head", "and", "neck", "cancer", ",", "randomized", "studies", "have", "failed", "to", "demonstrate", "an", "improvement", "in", "survival", "rates", ".", "All", "randomized", "studies", "included", "only", "patients", "with", "advanced", "stage", "III", "and", "IV", "disease", ".", "In", "our", "opinion", ",", "this", "is", "the", "main", "reason", "for", "the", "low", "rate", "of", "complete", "responses", "demonstrated", "in", "the", "randomized", "trials", "(", "maximum", "18", "%", ")", ".", "Frei", "et", "al", ".", "estimate", "that", "a", "40%-50", "%", "complete", "response", "rate", "is", "necessary", "before", "improved", "survival", "rates", "are", "seen", ".", "To", "date", ",", "such", "complete", "response", "rates", "with", "induction", "chemotherapy", "have", "only", "been", "attainable", "in", "resectable", "T2-T3", ",", "N0-N2", "disease", ".", "Therefore", ",", "we", "initiated", "a", "prospective", "randomized", "trial", "including", "only", "patients", "with", "the", "mentioned", "disease", "stages", ".", "Patients", "(", "pts", ")", "were", "randomized", "to", "receive", "either", "induction", "chemotherapy", "with", "three", "cycles", "of", "carboplatin/5-FU", "prior", "to", "surgery", "and", "radiotherapy", "(", "arm", "A", ",", "70", "pts", ")", "or", "standard", "treatment", "with", "surgery", "and", "radiotherapy", "(", "arm", "B", ",", "74", "pts", ")", ".", "Patients", "were", "classified", "according", "to", "primary", "tumour", "site", "and", "neck", "disease", ".", "The", "observed", "remission", "rate", "after", "chemotherapy", "confirmed", "the", "primary", "estimated", "rate", "for", "this", "subgroup", "of", "patients", "with", "head", "and", "neck", "cancer", "(", "CR", ":", "43", "%", ",", "PR", ":", "37", "%", ",", "NR", ":", "15", "%", ",", "PD", ":", "5", "%", ")", ".", "After", "a", "follow", "-", "up", "of", "12", "-", "96", "months", "overall", "survival", "was", "58", "%", "in", "arm", "A", "and", "45", "%", "in", "arm", "B", "(", "n.s", ".", ")", ".", "Disease", "-", "free", "survival", "in", "arm", "A", "(", "61", "%", ")", "is", "statistically", "significantly", "better", "than", "in", "arm", "B", "(", "43", "%", ",", "P=0.03", ")", ".", "Therefore", ",", "we", "recommend", "further", "controlled", "trials", "to", "investigate", "the", "role", "of", "induction", "chemotherapy", "in", "patients", "with", "primary", "resectable", "carcinomas", "of", "the", "oral", "cavity", "and", "tonsils", "and", "stage", "T2-T3", "and", "N0-N2", "disease", "prior", "to", "surgery", "." ]

[ "umlsterm" ]

chemotherapy, therapy, head, neck cancer, survival rates, All, patients, stage, disease, survival rates, date, chemotherapy, disease, patients, disease, stages, Patients, chemotherapy, surgery, radiotherapy, arm, standard, treatment, surgery, radiotherapy, arm, Patients, tumour, neck, disease, chemotherapy, patients, head, neck cancer, overall, survival, arm, arm, Disease - free survival, arm, arm, role, chemotherapy, patients, carcinomas, oral cavity, tonsils, stage, disease, surgery

HNO.90470899.eng.abstr_task2

Sentence: Although induction chemotherapy administered prior to local therapy produces encouraging initial response rates in head and neck cancer , randomized studies have failed to demonstrate an improvement in survival rates . All randomized studies included only patients with advanced stage III and IV disease . In our opinion , this is the main reason for the low rate of complete responses demonstrated in the randomized trials ( maximum 18% ) . Frei et al. estimate that a 40%-50% complete response rate is necessary before improved survival rates are seen . To date , such complete response rates with induction chemotherapy have only been attainable in resectable T2-T3, N0-N2 disease . Therefore , we initiated a prospective randomized trial including only patients with the mentioned disease stages . Patients ( pts ) were randomized to receive either induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy ( arm A , 70 pts ) or standard treatment with surgery and radiotherapy ( arm B , 74 pts ) . Patients were classified according to primary tumour site and neck disease . The observed remission rate after chemotherapy confirmed the primary estimated rate for this subgroup of patients with head and neck cancer ( CR : 43% , PR : 37% , NR : 15% , PD : 5% ) . After a follow-up of 12-96 months overall survival was 58% in arm A and 45% in arm B ( n.s. ) . Disease-free survival in arm A ( 61% ) is statistically significantly better than in arm B ( 43% , P=0.03). Therefore , we recommend further controlled trials to investigate the role of induction chemotherapy in patients with primary resectable carcinomas of the oral cavity and tonsils and stage T2-T3 and N0-N2 disease prior to surgery . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Although induction chemotherapy administered prior to local therapy produces encouraging initial response rates in head and neck cancer , randomized studies have failed to demonstrate an improvement in survival rates . All randomized studies included only patients with advanced stage III and IV disease . In our opinion , this is the main reason for the low rate of complete responses demonstrated in the randomized trials ( maximum 18% ) . Frei et al. estimate that a 40%-50% complete response rate is necessary before improved survival rates are seen . To date , such complete response rates with induction chemotherapy have only been attainable in resectable T2-T3, N0-N2 disease . Therefore , we initiated a prospective randomized trial including only patients with the mentioned disease stages . Patients ( pts ) were randomized to receive either induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy ( arm A , 70 pts ) or standard treatment with surgery and radiotherapy ( arm B , 74 pts ) . Patients were classified according to primary tumour site and neck disease . The observed remission rate after chemotherapy confirmed the primary estimated rate for this subgroup of patients with head and neck cancer ( CR : 43% , PR : 37% , NR : 15% , PD : 5% ) . After a follow-up of 12-96 months overall survival was 58% in arm A and 45% in arm B ( n.s. ) . Disease-free survival in arm A ( 61% ) is statistically significantly better than in arm B ( 43% , P=0.03). Therefore , we recommend further controlled trials to investigate the role of induction chemotherapy in patients with primary resectable carcinomas of the oral cavity and tonsils and stage T2-T3 and N0-N2 disease prior to surgery .

[ "Although", "induction", "chemotherapy", "administered", "prior", "to", "local", "therapy", "produces", "encouraging", "initial", "response", "rates", "in", "head", "and", "neck", "cancer", ",", "randomized", "studies", "have", "failed", "to", "demonstrate", "an", "improvement", "in", "survival", "rates", ".", "All", "randomized", "studies", "included", "only", "patients", "with", "advanced", "stage", "III", "and", "IV", "disease", ".", "In", "our", "opinion", ",", "this", "is", "the", "main", "reason", "for", "the", "low", "rate", "of", "complete", "responses", "demonstrated", "in", "the", "randomized", "trials", "(", "maximum", "18", "%", ")", ".", "Frei", "et", "al", ".", "estimate", "that", "a", "40%-50", "%", "complete", "response", "rate", "is", "necessary", "before", "improved", "survival", "rates", "are", "seen", ".", "To", "date", ",", "such", "complete", "response", "rates", "with", "induction", "chemotherapy", "have", "only", "been", "attainable", "in", "resectable", "T2-T3", ",", "N0-N2", "disease", ".", "Therefore", ",", "we", "initiated", "a", "prospective", "randomized", "trial", "including", "only", "patients", "with", "the", "mentioned", "disease", "stages", ".", "Patients", "(", "pts", ")", "were", "randomized", "to", "receive", "either", "induction", "chemotherapy", "with", "three", "cycles", "of", "carboplatin/5-FU", "prior", "to", "surgery", "and", "radiotherapy", "(", "arm", "A", ",", "70", "pts", ")", "or", "standard", "treatment", "with", "surgery", "and", "radiotherapy", "(", "arm", "B", ",", "74", "pts", ")", ".", "Patients", "were", "classified", "according", "to", "primary", "tumour", "site", "and", "neck", "disease", ".", "The", "observed", "remission", "rate", "after", "chemotherapy", "confirmed", "the", "primary", "estimated", "rate", "for", "this", "subgroup", "of", "patients", "with", "head", "and", "neck", "cancer", "(", "CR", ":", "43", "%", ",", "PR", ":", "37", "%", ",", "NR", ":", "15", "%", ",", "PD", ":", "5", "%", ")", ".", "After", "a", "follow", "-", "up", "of", "12", "-", "96", "months", "overall", "survival", "was", "58", "%", "in", "arm", "A", "and", "45", "%", "in", "arm", "B", "(", "n.s", ".", ")", ".", "Disease", "-", "free", "survival", "in", "arm", "A", "(", "61", "%", ")", "is", "statistically", "significantly", "better", "than", "in", "arm", "B", "(", "43", "%", ",", "P=0.03", ")", ".", "Therefore", ",", "we", "recommend", "further", "controlled", "trials", "to", "investigate", "the", "role", "of", "induction", "chemotherapy", "in", "patients", "with", "primary", "resectable", "carcinomas", "of", "the", "oral", "cavity", "and", "tonsils", "and", "stage", "T2-T3", "and", "N0-N2", "disease", "prior", "to", "surgery", "." ]

[ "umlsterm" ]

ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, N - methyl - D - aspartate receptor is a GENE-N, Ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, N - methyl - D - aspartate receptors is a GENE-N, GluN1 is a GENE-Y, GluN2B is a GENE-Y, ifenprodil , is a CHEMICAL, zinc is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, amino is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, zinc is a CHEMICAL, GluN1 is a GENE-Y, GluN2A is a GENE-Y, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y

30398_task0

Sentence: Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Ifenprodil is an allosteric inhibitor of GluN1/GluN2B N-methyl-D-aspartate receptors. Despite its widespread use as a prototype for drug development and a subtype-selective tool for physiologic experiments, its precise effect on GluN1/GluN2B gating is yet to be fully understood. Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/GluN2B amino terminal domain dimer by an induced-fit mechanism. To delineate the effect of this unique binding on GluN1/GluN2B receptor gating, we recorded steady-state currents from cell-attached and outside-out patches. At pH 7.9 in cell-attached patches, ifenprodil increased the occupancy of the long-lived shut conformations, thereby reducing the open probability of the receptor with no change in the mean open time. In addition, ifenprodil selectively affected the area of shut time constants, but not the time constants themselves. Kinetic analyses suggested that ifenprodil prevents the transition of the receptor to an open state and increases its dwell time in an intrinsically occurring closed conformation or desensitized state. We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites. Our data also uncover the potential pH-dependent action of ifenprodil on gating. At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Ifenprodil is an allosteric inhibitor of GluN1/GluN2B N-methyl-D-aspartate receptors. Despite its widespread use as a prototype for drug development and a subtype-selective tool for physiologic experiments, its precise effect on GluN1/GluN2B gating is yet to be fully understood. Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/GluN2B amino terminal domain dimer by an induced-fit mechanism. To delineate the effect of this unique binding on GluN1/GluN2B receptor gating, we recorded steady-state currents from cell-attached and outside-out patches. At pH 7.9 in cell-attached patches, ifenprodil increased the occupancy of the long-lived shut conformations, thereby reducing the open probability of the receptor with no change in the mean open time. In addition, ifenprodil selectively affected the area of shut time constants, but not the time constants themselves. Kinetic analyses suggested that ifenprodil prevents the transition of the receptor to an open state and increases its dwell time in an intrinsically occurring closed conformation or desensitized state. We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites. Our data also uncover the potential pH-dependent action of ifenprodil on gating. At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.

[ "Effect", "of", "ifenprodil", "on", "GluN1", "/", "GluN2B", "N", "-", "methyl", "-", "D", "-", "aspartate", "receptor", "gating", ".", "\n", "Ifenprodil", "is", "an", "allosteric", "inhibitor", "of", "GluN1", "/", "GluN2B", "N", "-", "methyl", "-", "D", "-", "aspartate", "receptors", ".", "Despite", "its", "widespread", "use", "as", "a", "prototype", "for", "drug", "development", "and", "a", "subtype", "-", "selective", "tool", "for", "physiologic", "experiments", ",", "its", "precise", "effect", "on", "GluN1", "/", "GluN2B", "gating", "is", "yet", "to", "be", "fully", "understood", ".", "Interestingly", ",", "recent", "crystallographic", "evidence", "identified", "that", "ifenprodil", ",", "unlike", "zinc", ",", "binds", "at", "the", "interface", "of", "the", "GluN1", "/", "GluN2B", "amino", "terminal", "domain", "dimer", "by", "an", "induced", "-", "fit", "mechanism", ".", "To", "delineate", "the", "effect", "of", "this", "unique", "binding", "on", "GluN1", "/", "GluN2B", "receptor", "gating", ",", "we", "recorded", "steady", "-", "state", "currents", "from", "cell", "-", "attached", "and", "outside", "-", "out", "patches", ".", "At", "pH", "7.9", "in", "cell", "-", "attached", "patches", ",", "ifenprodil", "increased", "the", "occupancy", "of", "the", "long", "-", "lived", "shut", "conformations", ",", "thereby", "reducing", "the", "open", "probability", "of", "the", "receptor", "with", "no", "change", "in", "the", "mean", "open", "time", ".", "In", "addition", ",", "ifenprodil", "selectively", "affected", "the", "area", "of", "shut", "time", "constants", ",", "but", "not", "the", "time", "constants", "themselves", ".", "Kinetic", "analyses", "suggested", "that", "ifenprodil", "prevents", "the", "transition", "of", "the", "receptor", "to", "an", "open", "state", "and", "increases", "its", "dwell", "time", "in", "an", "intrinsically", "occurring", "closed", "conformation", "or", "desensitized", "state", ".", "We", "found", "distinct", "differences", "in", "the", "action", "of", "ifenprodil", "at", "GluN1", "/", "GluN2B", "in", "comparison", "with", "previous", "studies", "on", "the", "effect", "of", "zinc", "on", "GluN1", "/", "GluN2A", "gating", ",", "which", "may", "arise", "due", "to", "their", "unique", "binding", "sites", ".", "Our", "data", "also", "uncover", "the", "potential", "pH", "-", "dependent", "action", "of", "ifenprodil", "on", "gating", ".", "At", "a", "low", "pH", "(", "pH", "7.4", ")", ",", "but", "not", "pH", "7.9", ",", "ifenprodil", "reduces", "the", "mean", "open", "time", "of", "GluN1", "/", "GluN2B", "receptors", ",", "which", "may", "be", "responsible", "for", "its", "usefulness", "as", "a", "context", "-", "dependent", "inhibitor", "in", "conditions", "like", "ischemia", "and", "stroke", ",", "when", "the", "pH", "of", "the", "extracellular", "milieu", "becomes", "acidic", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, N - methyl - D - aspartate receptor is a GENE-N, Ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, N - methyl - D - aspartate receptors is a GENE-N, GluN1 is a GENE-Y, GluN2B is a GENE-Y, ifenprodil , is a CHEMICAL, zinc is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, amino is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, zinc is a CHEMICAL, GluN1 is a GENE-Y, GluN2A is a GENE-Y, ifenprodil is a CHEMICAL, ifenprodil is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y

30398_task1

Sentence: Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Ifenprodil is an allosteric inhibitor of GluN1/GluN2B N-methyl-D-aspartate receptors. Despite its widespread use as a prototype for drug development and a subtype-selective tool for physiologic experiments, its precise effect on GluN1/GluN2B gating is yet to be fully understood. Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/GluN2B amino terminal domain dimer by an induced-fit mechanism. To delineate the effect of this unique binding on GluN1/GluN2B receptor gating, we recorded steady-state currents from cell-attached and outside-out patches. At pH 7.9 in cell-attached patches, ifenprodil increased the occupancy of the long-lived shut conformations, thereby reducing the open probability of the receptor with no change in the mean open time. In addition, ifenprodil selectively affected the area of shut time constants, but not the time constants themselves. Kinetic analyses suggested that ifenprodil prevents the transition of the receptor to an open state and increases its dwell time in an intrinsically occurring closed conformation or desensitized state. We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites. Our data also uncover the potential pH-dependent action of ifenprodil on gating. At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic. Instructions: please typing these entity words according to sentence: ifenprodil, GluN1, GluN2B, N - methyl - D - aspartate receptor, Ifenprodil, GluN1, GluN2B, N - methyl - D - aspartate receptors, GluN1, GluN2B, ifenprodil ,, zinc, GluN1, GluN2B, amino, GluN1, GluN2B, ifenprodil, ifenprodil, ifenprodil, ifenprodil, GluN1, GluN2B, zinc, GluN1, GluN2A, ifenprodil, ifenprodil, GluN1, GluN2B Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Ifenprodil is an allosteric inhibitor of GluN1/GluN2B N-methyl-D-aspartate receptors. Despite its widespread use as a prototype for drug development and a subtype-selective tool for physiologic experiments, its precise effect on GluN1/GluN2B gating is yet to be fully understood. Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/GluN2B amino terminal domain dimer by an induced-fit mechanism. To delineate the effect of this unique binding on GluN1/GluN2B receptor gating, we recorded steady-state currents from cell-attached and outside-out patches. At pH 7.9 in cell-attached patches, ifenprodil increased the occupancy of the long-lived shut conformations, thereby reducing the open probability of the receptor with no change in the mean open time. In addition, ifenprodil selectively affected the area of shut time constants, but not the time constants themselves. Kinetic analyses suggested that ifenprodil prevents the transition of the receptor to an open state and increases its dwell time in an intrinsically occurring closed conformation or desensitized state. We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites. Our data also uncover the potential pH-dependent action of ifenprodil on gating. At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.

[ "Effect", "of", "ifenprodil", "on", "GluN1", "/", "GluN2B", "N", "-", "methyl", "-", "D", "-", "aspartate", "receptor", "gating", ".", "\n", "Ifenprodil", "is", "an", "allosteric", "inhibitor", "of", "GluN1", "/", "GluN2B", "N", "-", "methyl", "-", "D", "-", "aspartate", "receptors", ".", "Despite", "its", "widespread", "use", "as", "a", "prototype", "for", "drug", "development", "and", "a", "subtype", "-", "selective", "tool", "for", "physiologic", "experiments", ",", "its", "precise", "effect", "on", "GluN1", "/", "GluN2B", "gating", "is", "yet", "to", "be", "fully", "understood", ".", "Interestingly", ",", "recent", "crystallographic", "evidence", "identified", "that", "ifenprodil", ",", "unlike", "zinc", ",", "binds", "at", "the", "interface", "of", "the", "GluN1", "/", "GluN2B", "amino", "terminal", "domain", "dimer", "by", "an", "induced", "-", "fit", "mechanism", ".", "To", "delineate", "the", "effect", "of", "this", "unique", "binding", "on", "GluN1", "/", "GluN2B", "receptor", "gating", ",", "we", "recorded", "steady", "-", "state", "currents", "from", "cell", "-", "attached", "and", "outside", "-", "out", "patches", ".", "At", "pH", "7.9", "in", "cell", "-", "attached", "patches", ",", "ifenprodil", "increased", "the", "occupancy", "of", "the", "long", "-", "lived", "shut", "conformations", ",", "thereby", "reducing", "the", "open", "probability", "of", "the", "receptor", "with", "no", "change", "in", "the", "mean", "open", "time", ".", "In", "addition", ",", "ifenprodil", "selectively", "affected", "the", "area", "of", "shut", "time", "constants", ",", "but", "not", "the", "time", "constants", "themselves", ".", "Kinetic", "analyses", "suggested", "that", "ifenprodil", "prevents", "the", "transition", "of", "the", "receptor", "to", "an", "open", "state", "and", "increases", "its", "dwell", "time", "in", "an", "intrinsically", "occurring", "closed", "conformation", "or", "desensitized", "state", ".", "We", "found", "distinct", "differences", "in", "the", "action", "of", "ifenprodil", "at", "GluN1", "/", "GluN2B", "in", "comparison", "with", "previous", "studies", "on", "the", "effect", "of", "zinc", "on", "GluN1", "/", "GluN2A", "gating", ",", "which", "may", "arise", "due", "to", "their", "unique", "binding", "sites", ".", "Our", "data", "also", "uncover", "the", "potential", "pH", "-", "dependent", "action", "of", "ifenprodil", "on", "gating", ".", "At", "a", "low", "pH", "(", "pH", "7.4", ")", ",", "but", "not", "pH", "7.9", ",", "ifenprodil", "reduces", "the", "mean", "open", "time", "of", "GluN1", "/", "GluN2B", "receptors", ",", "which", "may", "be", "responsible", "for", "its", "usefulness", "as", "a", "context", "-", "dependent", "inhibitor", "in", "conditions", "like", "ischemia", "and", "stroke", ",", "when", "the", "pH", "of", "the", "extracellular", "milieu", "becomes", "acidic", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

ifenprodil, GluN1, GluN2B, N - methyl - D - aspartate receptor, Ifenprodil, GluN1, GluN2B, N - methyl - D - aspartate receptors, GluN1, GluN2B, ifenprodil ,, zinc, GluN1, GluN2B, amino, GluN1, GluN2B, ifenprodil, ifenprodil, ifenprodil, ifenprodil, GluN1, GluN2B, zinc, GluN1, GluN2A, ifenprodil, ifenprodil, GluN1, GluN2B

30398_task2

Sentence: Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Ifenprodil is an allosteric inhibitor of GluN1/GluN2B N-methyl-D-aspartate receptors. Despite its widespread use as a prototype for drug development and a subtype-selective tool for physiologic experiments, its precise effect on GluN1/GluN2B gating is yet to be fully understood. Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/GluN2B amino terminal domain dimer by an induced-fit mechanism. To delineate the effect of this unique binding on GluN1/GluN2B receptor gating, we recorded steady-state currents from cell-attached and outside-out patches. At pH 7.9 in cell-attached patches, ifenprodil increased the occupancy of the long-lived shut conformations, thereby reducing the open probability of the receptor with no change in the mean open time. In addition, ifenprodil selectively affected the area of shut time constants, but not the time constants themselves. Kinetic analyses suggested that ifenprodil prevents the transition of the receptor to an open state and increases its dwell time in an intrinsically occurring closed conformation or desensitized state. We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites. Our data also uncover the potential pH-dependent action of ifenprodil on gating. At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Ifenprodil is an allosteric inhibitor of GluN1/GluN2B N-methyl-D-aspartate receptors. Despite its widespread use as a prototype for drug development and a subtype-selective tool for physiologic experiments, its precise effect on GluN1/GluN2B gating is yet to be fully understood. Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/GluN2B amino terminal domain dimer by an induced-fit mechanism. To delineate the effect of this unique binding on GluN1/GluN2B receptor gating, we recorded steady-state currents from cell-attached and outside-out patches. At pH 7.9 in cell-attached patches, ifenprodil increased the occupancy of the long-lived shut conformations, thereby reducing the open probability of the receptor with no change in the mean open time. In addition, ifenprodil selectively affected the area of shut time constants, but not the time constants themselves. Kinetic analyses suggested that ifenprodil prevents the transition of the receptor to an open state and increases its dwell time in an intrinsically occurring closed conformation or desensitized state. We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites. Our data also uncover the potential pH-dependent action of ifenprodil on gating. At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.

[ "Effect", "of", "ifenprodil", "on", "GluN1", "/", "GluN2B", "N", "-", "methyl", "-", "D", "-", "aspartate", "receptor", "gating", ".", "\n", "Ifenprodil", "is", "an", "allosteric", "inhibitor", "of", "GluN1", "/", "GluN2B", "N", "-", "methyl", "-", "D", "-", "aspartate", "receptors", ".", "Despite", "its", "widespread", "use", "as", "a", "prototype", "for", "drug", "development", "and", "a", "subtype", "-", "selective", "tool", "for", "physiologic", "experiments", ",", "its", "precise", "effect", "on", "GluN1", "/", "GluN2B", "gating", "is", "yet", "to", "be", "fully", "understood", ".", "Interestingly", ",", "recent", "crystallographic", "evidence", "identified", "that", "ifenprodil", ",", "unlike", "zinc", ",", "binds", "at", "the", "interface", "of", "the", "GluN1", "/", "GluN2B", "amino", "terminal", "domain", "dimer", "by", "an", "induced", "-", "fit", "mechanism", ".", "To", "delineate", "the", "effect", "of", "this", "unique", "binding", "on", "GluN1", "/", "GluN2B", "receptor", "gating", ",", "we", "recorded", "steady", "-", "state", "currents", "from", "cell", "-", "attached", "and", "outside", "-", "out", "patches", ".", "At", "pH", "7.9", "in", "cell", "-", "attached", "patches", ",", "ifenprodil", "increased", "the", "occupancy", "of", "the", "long", "-", "lived", "shut", "conformations", ",", "thereby", "reducing", "the", "open", "probability", "of", "the", "receptor", "with", "no", "change", "in", "the", "mean", "open", "time", ".", "In", "addition", ",", "ifenprodil", "selectively", "affected", "the", "area", "of", "shut", "time", "constants", ",", "but", "not", "the", "time", "constants", "themselves", ".", "Kinetic", "analyses", "suggested", "that", "ifenprodil", "prevents", "the", "transition", "of", "the", "receptor", "to", "an", "open", "state", "and", "increases", "its", "dwell", "time", "in", "an", "intrinsically", "occurring", "closed", "conformation", "or", "desensitized", "state", ".", "We", "found", "distinct", "differences", "in", "the", "action", "of", "ifenprodil", "at", "GluN1", "/", "GluN2B", "in", "comparison", "with", "previous", "studies", "on", "the", "effect", "of", "zinc", "on", "GluN1", "/", "GluN2A", "gating", ",", "which", "may", "arise", "due", "to", "their", "unique", "binding", "sites", ".", "Our", "data", "also", "uncover", "the", "potential", "pH", "-", "dependent", "action", "of", "ifenprodil", "on", "gating", ".", "At", "a", "low", "pH", "(", "pH", "7.4", ")", ",", "but", "not", "pH", "7.9", ",", "ifenprodil", "reduces", "the", "mean", "open", "time", "of", "GluN1", "/", "GluN2B", "receptors", ",", "which", "may", "be", "responsible", "for", "its", "usefulness", "as", "a", "context", "-", "dependent", "inhibitor", "in", "conditions", "like", "ischemia", "and", "stroke", ",", "when", "the", "pH", "of", "the", "extracellular", "milieu", "becomes", "acidic", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

IgE is a gene

9_task0

Sentence: Association of tumor necrosis factor polymorphisms with asthma and serum total IgE . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: gene

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O" ]

Association of tumor necrosis factor polymorphisms with asthma and serum total IgE .

[ "Association", "of", "tumor", "necrosis", "factor", "polymorphisms", "with", "asthma", "and", "serum", "total", " ", "IgE", "." ]

[ "gene" ]

IgE is a gene

9_task1

Sentence: Association of tumor necrosis factor polymorphisms with asthma and serum total IgE . Instructions: please typing these entity words according to sentence: IgE Options: gene

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O" ]

Association of tumor necrosis factor polymorphisms with asthma and serum total IgE .

[ "Association", "of", "tumor", "necrosis", "factor", "polymorphisms", "with", "asthma", "and", "serum", "total", " ", "IgE", "." ]

[ "gene" ]

IgE

9_task2

Sentence: Association of tumor necrosis factor polymorphisms with asthma and serum total IgE . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O" ]

Association of tumor necrosis factor polymorphisms with asthma and serum total IgE .

[ "Association", "of", "tumor", "necrosis", "factor", "polymorphisms", "with", "asthma", "and", "serum", "total", " ", "IgE", "." ]

[ "gene" ]

vivo protein - DNA interactions is an other_name, human beta - globin locus is a DNA_domain_or_region, erythroid cells is a cell_type, fetal or the adult globin gene program is a (OR other_name other_name)

30930_task0

Sentence: Globin gene switching. In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, DNA_domain_or_region, (OR other_name other_name), other_name

[ "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "O", "O", "B-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "O" ]

Globin gene switching. In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program.

[ "Globin", "gene", "switching", ".", "In", "vivo", "protein", "-", "DNA", "interactions", "of", "the", "human", "beta", "-", "globin", "locus", "in", "erythroid", "cells", "expressing", "the", "fetal", "or", "the", "adult", "globin", "gene", "program", "." ]

[ "(OR other_name other_name)", "other_name", "(AND DNA_domain_or_region DNA_domain_or_region)", "(OR DNA_domain_or_region DNA_domain_or_region)", "cell_type", "", "DNA_family_or_group", "DNA_domain_or_region", "protein_complex", "protein_molecule" ]

vivo protein - DNA interactions is an other_name, human beta - globin locus is a DNA_domain_or_region, erythroid cells is a cell_type, fetal or the adult globin gene program is a (OR other_name other_name)

30930_task1

Sentence: Globin gene switching. In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program. Instructions: please typing these entity words according to sentence: vivo protein - DNA interactions, human beta - globin locus, erythroid cells, fetal or the adult globin gene program Options: cell_type, DNA_domain_or_region, (OR other_name other_name), other_name

[ "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "O", "O", "B-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "O" ]

Globin gene switching. In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program.

[ "Globin", "gene", "switching", ".", "In", "vivo", "protein", "-", "DNA", "interactions", "of", "the", "human", "beta", "-", "globin", "locus", "in", "erythroid", "cells", "expressing", "the", "fetal", "or", "the", "adult", "globin", "gene", "program", "." ]

[ "(OR other_name other_name)", "other_name", "(AND DNA_domain_or_region DNA_domain_or_region)", "(OR DNA_domain_or_region DNA_domain_or_region)", "cell_type", "", "DNA_family_or_group", "DNA_domain_or_region", "protein_complex", "protein_molecule" ]

vivo protein - DNA interactions, human beta - globin locus, erythroid cells, fetal or the adult globin gene program

30930_task2

Sentence: Globin gene switching. In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "O", "O", "B-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "I-(OR other_name other_name)", "O" ]

Globin gene switching. In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program.

[ "Globin", "gene", "switching", ".", "In", "vivo", "protein", "-", "DNA", "interactions", "of", "the", "human", "beta", "-", "globin", "locus", "in", "erythroid", "cells", "expressing", "the", "fetal", "or", "the", "adult", "globin", "gene", "program", "." ]

[ "(OR other_name other_name)", "other_name", "(AND DNA_domain_or_region DNA_domain_or_region)", "(OR DNA_domain_or_region DNA_domain_or_region)", "cell_type", "", "DNA_family_or_group", "DNA_domain_or_region", "protein_complex", "protein_molecule" ]

inhaled budesonide is a Intervention_Pharmacological, fluticasone propionate is a Intervention_Pharmacological, normal subjects . is a Participant_Condition, nine healthy subjects is a Participant_Condition, 800 micrograms day-1 of budesonide Turbohaler ( B800 ) is a Intervention_Pharmacological, fluticasone Diskhaler 750 micrograms day-1 is a Intervention_Pharmacological, hypothalmic - pituitary adrenal ( HPA ) axis activity is a Outcome_Physical, bone metabolism is a Outcome_Physical, post tetracosactrin serum cortisol is a Outcome_Physical, dose - response effect is a Outcome_Other, difference is a Outcome_Other

82818_task0

Sentence: A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects . 1 . The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices . 2 . A randomised , single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler ( B800 ) for 1 week , followed by 1 week of 1600 micrograms day-1 ( B1600 ) , or fluticasone Diskhaler 750 micrograms day-1 ( F750 ) for 1 week followed by 1 week of 1500 micrograms day-1 ( F1500 ) . There was a 1 week washout between treatments with fluticasone or budesonide . A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects . 3 . Parameters of hypothalmic-pituitary adrenal ( HPA ) axis activity and bone metabolism were measured at baseline ( B0/F0 ) , at the end of each week of treatment and after the 1 week washout ( F0 or B0 ) . 4 . Both fluticasone and budesonide significantly ( P < 0.05 ) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged . No dose-response effect was observed with either drug , and there was no significant difference between treatment with fluticasone or budesonide . 5 . Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin , although the higher doses of both drugs significantly reduced fasting urinary calcium levels . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects . 1 . The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices . 2 . A randomised , single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler ( B800 ) for 1 week , followed by 1 week of 1600 micrograms day-1 ( B1600 ) , or fluticasone Diskhaler 750 micrograms day-1 ( F750 ) for 1 week followed by 1 week of 1500 micrograms day-1 ( F1500 ) . There was a 1 week washout between treatments with fluticasone or budesonide . A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects . 3 . Parameters of hypothalmic-pituitary adrenal ( HPA ) axis activity and bone metabolism were measured at baseline ( B0/F0 ) , at the end of each week of treatment and after the 1 week washout ( F0 or B0 ) . 4 . Both fluticasone and budesonide significantly ( P < 0.05 ) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged . No dose-response effect was observed with either drug , and there was no significant difference between treatment with fluticasone or budesonide . 5 . Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin , although the higher doses of both drugs significantly reduced fasting urinary calcium levels . ( ABSTRACT TRUNCATED AT 250 WORDS )

[ "A", "comparison", "of", "the", "systemic", "bioactivity", "of", "inhaled", "budesonide", "and", "fluticasone", "propionate", "in", "normal", "subjects", ".", "1", ".", "The", "aim", "of", "this", "study", "was", "to", "compare", "the", "systemic", "bioactivity", "of", "low", "and", "high", "doses", "of", "inhaled", "budesonide", "and", "fluticasone", "propionate", "given", "by", "respective", "dry", "powder", "inhaler", "devices", ".", "2", ".", "A", "randomised", ",", "single", "blind", "cross", "-", "over", "design", "was", "used", "in", "nine", "healthy", "subjects", "who", "were", "given", "800", "micrograms", "day-1", "of", "budesonide", "Turbohaler", "(", "B800", ")", "for", "1", "week", ",", "followed", "by", "1", "week", "of", "1600", "micrograms", "day-1", "(", "B1600", ")", ",", "or", "fluticasone", "Diskhaler", "750", "micrograms", "day-1", "(", "F750", ")", "for", "1", "week", "followed", "by", "1", "week", "of", "1500", "micrograms", "day-1", "(", "F1500", ")", ".", "There", "was", "a", "1", "week", "washout", "between", "treatments", "with", "fluticasone", "or", "budesonide", ".", "A", "twice", "daily", "dosing", "regime", "was", "used", "and", "mouth", "-", "rinsing", "was", "employed", "to", "reduce", "gut", "bioavailability", "as", "well", "as", "to", "obviate", "local", "adverse", "effects", ".", "3", ".", "Parameters", "of", "hypothalmic", "-", "pituitary", "adrenal", "(", "HPA", ")", "axis", "activity", "and", "bone", "metabolism", "were", "measured", "at", "baseline", "(", "B0", "/", "F0", ")", ",", "at", "the", "end", "of", "each", "week", "of", "treatment", "and", "after", "the", "1", "week", "washout", "(", "F0", "or", "B0", ")", ".", "4", ".", "Both", "fluticasone", "and", "budesonide", "significantly", "(", "P", "<", "0.05", ")", "attenuated", "the", "post", "tetracosactrin", "serum", "cortisol", "at", "low", "and", "high", "doses", "whilst", "early", "morning", "cortisol", "was", "unchanged", ".", "No", "dose", "-", "response", "effect", "was", "observed", "with", "either", "drug", ",", "and", "there", "was", "no", "significant", "difference", "between", "treatment", "with", "fluticasone", "or", "budesonide", ".", "5", ".", "Neither", "budesonide", "nor", "fluticasone", "produced", "significant", "suppression", "of", "plasma", "osteocalcin", ",", "although", "the", "higher", "doses", "of", "both", "drugs", "significantly", "reduced", "fasting", "urinary", "calcium", "levels", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Outcome_Other" ]

inhaled budesonide is a Intervention_Pharmacological, fluticasone propionate is a Intervention_Pharmacological, normal subjects . is a Participant_Condition, nine healthy subjects is a Participant_Condition, 800 micrograms day-1 of budesonide Turbohaler ( B800 ) is a Intervention_Pharmacological, fluticasone Diskhaler 750 micrograms day-1 is a Intervention_Pharmacological, hypothalmic - pituitary adrenal ( HPA ) axis activity is a Outcome_Physical, bone metabolism is a Outcome_Physical, post tetracosactrin serum cortisol is a Outcome_Physical, dose - response effect is a Outcome_Other, difference is a Outcome_Other

82818_task1

Sentence: A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects . 1 . The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices . 2 . A randomised , single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler ( B800 ) for 1 week , followed by 1 week of 1600 micrograms day-1 ( B1600 ) , or fluticasone Diskhaler 750 micrograms day-1 ( F750 ) for 1 week followed by 1 week of 1500 micrograms day-1 ( F1500 ) . There was a 1 week washout between treatments with fluticasone or budesonide . A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects . 3 . Parameters of hypothalmic-pituitary adrenal ( HPA ) axis activity and bone metabolism were measured at baseline ( B0/F0 ) , at the end of each week of treatment and after the 1 week washout ( F0 or B0 ) . 4 . Both fluticasone and budesonide significantly ( P < 0.05 ) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged . No dose-response effect was observed with either drug , and there was no significant difference between treatment with fluticasone or budesonide . 5 . Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin , although the higher doses of both drugs significantly reduced fasting urinary calcium levels . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please typing these entity words according to sentence: inhaled budesonide, fluticasone propionate, normal subjects ., nine healthy subjects, 800 micrograms day-1 of budesonide Turbohaler ( B800 ), fluticasone Diskhaler 750 micrograms day-1, hypothalmic - pituitary adrenal ( HPA ) axis activity, bone metabolism, post tetracosactrin serum cortisol, dose - response effect, difference Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects . 1 . The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices . 2 . A randomised , single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler ( B800 ) for 1 week , followed by 1 week of 1600 micrograms day-1 ( B1600 ) , or fluticasone Diskhaler 750 micrograms day-1 ( F750 ) for 1 week followed by 1 week of 1500 micrograms day-1 ( F1500 ) . There was a 1 week washout between treatments with fluticasone or budesonide . A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects . 3 . Parameters of hypothalmic-pituitary adrenal ( HPA ) axis activity and bone metabolism were measured at baseline ( B0/F0 ) , at the end of each week of treatment and after the 1 week washout ( F0 or B0 ) . 4 . Both fluticasone and budesonide significantly ( P < 0.05 ) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged . No dose-response effect was observed with either drug , and there was no significant difference between treatment with fluticasone or budesonide . 5 . Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin , although the higher doses of both drugs significantly reduced fasting urinary calcium levels . ( ABSTRACT TRUNCATED AT 250 WORDS )

[ "A", "comparison", "of", "the", "systemic", "bioactivity", "of", "inhaled", "budesonide", "and", "fluticasone", "propionate", "in", "normal", "subjects", ".", "1", ".", "The", "aim", "of", "this", "study", "was", "to", "compare", "the", "systemic", "bioactivity", "of", "low", "and", "high", "doses", "of", "inhaled", "budesonide", "and", "fluticasone", "propionate", "given", "by", "respective", "dry", "powder", "inhaler", "devices", ".", "2", ".", "A", "randomised", ",", "single", "blind", "cross", "-", "over", "design", "was", "used", "in", "nine", "healthy", "subjects", "who", "were", "given", "800", "micrograms", "day-1", "of", "budesonide", "Turbohaler", "(", "B800", ")", "for", "1", "week", ",", "followed", "by", "1", "week", "of", "1600", "micrograms", "day-1", "(", "B1600", ")", ",", "or", "fluticasone", "Diskhaler", "750", "micrograms", "day-1", "(", "F750", ")", "for", "1", "week", "followed", "by", "1", "week", "of", "1500", "micrograms", "day-1", "(", "F1500", ")", ".", "There", "was", "a", "1", "week", "washout", "between", "treatments", "with", "fluticasone", "or", "budesonide", ".", "A", "twice", "daily", "dosing", "regime", "was", "used", "and", "mouth", "-", "rinsing", "was", "employed", "to", "reduce", "gut", "bioavailability", "as", "well", "as", "to", "obviate", "local", "adverse", "effects", ".", "3", ".", "Parameters", "of", "hypothalmic", "-", "pituitary", "adrenal", "(", "HPA", ")", "axis", "activity", "and", "bone", "metabolism", "were", "measured", "at", "baseline", "(", "B0", "/", "F0", ")", ",", "at", "the", "end", "of", "each", "week", "of", "treatment", "and", "after", "the", "1", "week", "washout", "(", "F0", "or", "B0", ")", ".", "4", ".", "Both", "fluticasone", "and", "budesonide", "significantly", "(", "P", "<", "0.05", ")", "attenuated", "the", "post", "tetracosactrin", "serum", "cortisol", "at", "low", "and", "high", "doses", "whilst", "early", "morning", "cortisol", "was", "unchanged", ".", "No", "dose", "-", "response", "effect", "was", "observed", "with", "either", "drug", ",", "and", "there", "was", "no", "significant", "difference", "between", "treatment", "with", "fluticasone", "or", "budesonide", ".", "5", ".", "Neither", "budesonide", "nor", "fluticasone", "produced", "significant", "suppression", "of", "plasma", "osteocalcin", ",", "although", "the", "higher", "doses", "of", "both", "drugs", "significantly", "reduced", "fasting", "urinary", "calcium", "levels", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Outcome_Other" ]

inhaled budesonide, fluticasone propionate, normal subjects ., nine healthy subjects, 800 micrograms day-1 of budesonide Turbohaler ( B800 ), fluticasone Diskhaler 750 micrograms day-1, hypothalmic - pituitary adrenal ( HPA ) axis activity, bone metabolism, post tetracosactrin serum cortisol, dose - response effect, difference

82818_task2

Sentence: A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects . 1 . The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices . 2 . A randomised , single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler ( B800 ) for 1 week , followed by 1 week of 1600 micrograms day-1 ( B1600 ) , or fluticasone Diskhaler 750 micrograms day-1 ( F750 ) for 1 week followed by 1 week of 1500 micrograms day-1 ( F1500 ) . There was a 1 week washout between treatments with fluticasone or budesonide . A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects . 3 . Parameters of hypothalmic-pituitary adrenal ( HPA ) axis activity and bone metabolism were measured at baseline ( B0/F0 ) , at the end of each week of treatment and after the 1 week washout ( F0 or B0 ) . 4 . Both fluticasone and budesonide significantly ( P < 0.05 ) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged . No dose-response effect was observed with either drug , and there was no significant difference between treatment with fluticasone or budesonide . 5 . Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin , although the higher doses of both drugs significantly reduced fasting urinary calcium levels . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects . 1 . The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices . 2 . A randomised , single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler ( B800 ) for 1 week , followed by 1 week of 1600 micrograms day-1 ( B1600 ) , or fluticasone Diskhaler 750 micrograms day-1 ( F750 ) for 1 week followed by 1 week of 1500 micrograms day-1 ( F1500 ) . There was a 1 week washout between treatments with fluticasone or budesonide . A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects . 3 . Parameters of hypothalmic-pituitary adrenal ( HPA ) axis activity and bone metabolism were measured at baseline ( B0/F0 ) , at the end of each week of treatment and after the 1 week washout ( F0 or B0 ) . 4 . Both fluticasone and budesonide significantly ( P < 0.05 ) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged . No dose-response effect was observed with either drug , and there was no significant difference between treatment with fluticasone or budesonide . 5 . Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin , although the higher doses of both drugs significantly reduced fasting urinary calcium levels . ( ABSTRACT TRUNCATED AT 250 WORDS )

[ "A", "comparison", "of", "the", "systemic", "bioactivity", "of", "inhaled", "budesonide", "and", "fluticasone", "propionate", "in", "normal", "subjects", ".", "1", ".", "The", "aim", "of", "this", "study", "was", "to", "compare", "the", "systemic", "bioactivity", "of", "low", "and", "high", "doses", "of", "inhaled", "budesonide", "and", "fluticasone", "propionate", "given", "by", "respective", "dry", "powder", "inhaler", "devices", ".", "2", ".", "A", "randomised", ",", "single", "blind", "cross", "-", "over", "design", "was", "used", "in", "nine", "healthy", "subjects", "who", "were", "given", "800", "micrograms", "day-1", "of", "budesonide", "Turbohaler", "(", "B800", ")", "for", "1", "week", ",", "followed", "by", "1", "week", "of", "1600", "micrograms", "day-1", "(", "B1600", ")", ",", "or", "fluticasone", "Diskhaler", "750", "micrograms", "day-1", "(", "F750", ")", "for", "1", "week", "followed", "by", "1", "week", "of", "1500", "micrograms", "day-1", "(", "F1500", ")", ".", "There", "was", "a", "1", "week", "washout", "between", "treatments", "with", "fluticasone", "or", "budesonide", ".", "A", "twice", "daily", "dosing", "regime", "was", "used", "and", "mouth", "-", "rinsing", "was", "employed", "to", "reduce", "gut", "bioavailability", "as", "well", "as", "to", "obviate", "local", "adverse", "effects", ".", "3", ".", "Parameters", "of", "hypothalmic", "-", "pituitary", "adrenal", "(", "HPA", ")", "axis", "activity", "and", "bone", "metabolism", "were", "measured", "at", "baseline", "(", "B0", "/", "F0", ")", ",", "at", "the", "end", "of", "each", "week", "of", "treatment", "and", "after", "the", "1", "week", "washout", "(", "F0", "or", "B0", ")", ".", "4", ".", "Both", "fluticasone", "and", "budesonide", "significantly", "(", "P", "<", "0.05", ")", "attenuated", "the", "post", "tetracosactrin", "serum", "cortisol", "at", "low", "and", "high", "doses", "whilst", "early", "morning", "cortisol", "was", "unchanged", ".", "No", "dose", "-", "response", "effect", "was", "observed", "with", "either", "drug", ",", "and", "there", "was", "no", "significant", "difference", "between", "treatment", "with", "fluticasone", "or", "budesonide", ".", "5", ".", "Neither", "budesonide", "nor", "fluticasone", "produced", "significant", "suppression", "of", "plasma", "osteocalcin", ",", "although", "the", "higher", "doses", "of", "both", "drugs", "significantly", "reduced", "fasting", "urinary", "calcium", "levels", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Outcome_Other" ]

Latent Membrane Protein 1 is a Protein, Akt is a Protein, Stat3 is a Protein, Latent membrane protein 1 is a Protein, LMP1 is a Protein, LMP1 is a Protein, Akt is a Protein, Stat3 is a Protein, LMP1 is a Protein, IL4 is a Protein, Stat6 is a Protein, Stat3 is a Protein, Akt is a Protein, Stat3 is a Protein, Latent membrane protein 1 is a Protein, LMP1 is a Protein, LMP1 is a Protein, Akt is a Protein, Stat3 is a Protein, Stat3 is a Protein, Akt is a Protein, LMP1 is a Protein

38_task0

Sentence: EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B Cell Lymphomas Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated cell cycle markers, and inhibitors of Akt, NFkappaB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas. Author Summary Epstein-Barr virus (EBV) is linked to the development of multiple cancers, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is expressed in many EBV-associated cancers and is responsible for most of the altered cellular growth properties that are induced by EBV infection. This study reveals that LMP1 induces lymphomas in B-1a lymphocytes, a cell type that is susceptible to transformation in aged mice. The lymphomas require Akt, NFkappaB, and Stat3 signaling for enhanced growth and survival. The activation of the Stat3, Akt, and NFkappaB signaling pathways likely underlies the ability of LMP1 to promote malignant transformation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B Cell Lymphomas Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated cell cycle markers, and inhibitors of Akt, NFkappaB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas. Author Summary Epstein-Barr virus (EBV) is linked to the development of multiple cancers, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is expressed in many EBV-associated cancers and is responsible for most of the altered cellular growth properties that are induced by EBV infection. This study reveals that LMP1 induces lymphomas in B-1a lymphocytes, a cell type that is susceptible to transformation in aged mice. The lymphomas require Akt, NFkappaB, and Stat3 signaling for enhanced growth and survival. The activation of the Stat3, Akt, and NFkappaB signaling pathways likely underlies the ability of LMP1 to promote malignant transformation.

[ "EBV", "Latent", "Membrane", "Protein", "1", "Activates", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "in", "B", "Cell", "Lymphomas", "\n", "Latent", "membrane", "protein", "1", "(", "LMP1", ")", "is", "the", "major", "oncoprotein", "of", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", ".", "In", "transgenic", "mice", ",", "LMP1", "promotes", "increased", "lymphoma", "development", "by", "12", "mo", "of", "age", ".", "This", "study", "reveals", "that", "lymphoma", "develops", "in", "B-1a", "lymphocytes", ",", "a", "population", "that", "is", "associated", "with", "transformation", "in", "older", "mice", ".", "The", "lymphoma", "cells", "have", "deregulated", "cell", "cycle", "markers", ",", "and", "inhibitors", "of", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "block", "the", "enhanced", "viability", "of", "LMP1", "transgenic", "lymphocytes", "and", "lymphoma", "cells", "in", "vitro", ".", "Lymphoma", "cells", "are", "independent", "of", "IL4", "/", "Stat6", "signaling", "for", "survival", "and", "proliferation", ",", "but", "have", "constitutively", "activated", "Stat3", "signaling", ".", "These", "same", "targets", "are", "also", "deregulated", "in", "wild", "-", "type", "B-1a", "lymphomas", "that", "arise", "spontaneously", "through", "age", "predisposition", ".", "These", "results", "suggest", "that", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "pathways", "may", "serve", "as", "effective", "targets", "in", "the", "treatment", "of", "EBV", "-", "associated", "B", "cell", "lymphomas", ".", "\n", "Author", "Summary", "\n", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "is", "linked", "to", "the", "development", "of", "multiple", "cancers", ",", "including", "post", "-", "transplant", "lymphoma", ",", "Hodgkin", "disease", ",", "and", "nasopharyngeal", "carcinoma", ".", "Latent", "membrane", "protein", "1", "(", "LMP1", ")", "is", "expressed", "in", "many", "EBV", "-", "associated", "cancers", "and", "is", "responsible", "for", "most", "of", "the", "altered", "cellular", "growth", "properties", "that", "are", "induced", "by", "EBV", "infection", ".", "This", "study", "reveals", "that", "LMP1", "induces", "lymphomas", "in", "B-1a", "lymphocytes", ",", "a", "cell", "type", "that", "is", "susceptible", "to", "transformation", "in", "aged", "mice", ".", "The", "lymphomas", "require", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "signaling", "for", "enhanced", "growth", "and", "survival", ".", "The", "activation", "of", "the", "Stat3", ",", "Akt", ",", "and", "NFkappaB", "signaling", "pathways", "likely", "underlies", "the", "ability", "of", "LMP1", "to", "promote", "malignant", "transformation", ".", "\n" ]

[ "Protein" ]

Latent Membrane Protein 1 is a Protein, Akt is a Protein, Stat3 is a Protein, Latent membrane protein 1 is a Protein, LMP1 is a Protein, LMP1 is a Protein, Akt is a Protein, Stat3 is a Protein, LMP1 is a Protein, IL4 is a Protein, Stat6 is a Protein, Stat3 is a Protein, Akt is a Protein, Stat3 is a Protein, Latent membrane protein 1 is a Protein, LMP1 is a Protein, LMP1 is a Protein, Akt is a Protein, Stat3 is a Protein, Stat3 is a Protein, Akt is a Protein, LMP1 is a Protein

38_task1

Sentence: EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B Cell Lymphomas Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated cell cycle markers, and inhibitors of Akt, NFkappaB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas. Author Summary Epstein-Barr virus (EBV) is linked to the development of multiple cancers, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is expressed in many EBV-associated cancers and is responsible for most of the altered cellular growth properties that are induced by EBV infection. This study reveals that LMP1 induces lymphomas in B-1a lymphocytes, a cell type that is susceptible to transformation in aged mice. The lymphomas require Akt, NFkappaB, and Stat3 signaling for enhanced growth and survival. The activation of the Stat3, Akt, and NFkappaB signaling pathways likely underlies the ability of LMP1 to promote malignant transformation. Instructions: please typing these entity words according to sentence: Latent Membrane Protein 1, Akt, Stat3, Latent membrane protein 1, LMP1, LMP1, Akt, Stat3, LMP1, IL4, Stat6, Stat3, Akt, Stat3, Latent membrane protein 1, LMP1, LMP1, Akt, Stat3, Stat3, Akt, LMP1 Options: Protein

[ "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B Cell Lymphomas Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated cell cycle markers, and inhibitors of Akt, NFkappaB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas. Author Summary Epstein-Barr virus (EBV) is linked to the development of multiple cancers, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is expressed in many EBV-associated cancers and is responsible for most of the altered cellular growth properties that are induced by EBV infection. This study reveals that LMP1 induces lymphomas in B-1a lymphocytes, a cell type that is susceptible to transformation in aged mice. The lymphomas require Akt, NFkappaB, and Stat3 signaling for enhanced growth and survival. The activation of the Stat3, Akt, and NFkappaB signaling pathways likely underlies the ability of LMP1 to promote malignant transformation.

[ "EBV", "Latent", "Membrane", "Protein", "1", "Activates", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "in", "B", "Cell", "Lymphomas", "\n", "Latent", "membrane", "protein", "1", "(", "LMP1", ")", "is", "the", "major", "oncoprotein", "of", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", ".", "In", "transgenic", "mice", ",", "LMP1", "promotes", "increased", "lymphoma", "development", "by", "12", "mo", "of", "age", ".", "This", "study", "reveals", "that", "lymphoma", "develops", "in", "B-1a", "lymphocytes", ",", "a", "population", "that", "is", "associated", "with", "transformation", "in", "older", "mice", ".", "The", "lymphoma", "cells", "have", "deregulated", "cell", "cycle", "markers", ",", "and", "inhibitors", "of", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "block", "the", "enhanced", "viability", "of", "LMP1", "transgenic", "lymphocytes", "and", "lymphoma", "cells", "in", "vitro", ".", "Lymphoma", "cells", "are", "independent", "of", "IL4", "/", "Stat6", "signaling", "for", "survival", "and", "proliferation", ",", "but", "have", "constitutively", "activated", "Stat3", "signaling", ".", "These", "same", "targets", "are", "also", "deregulated", "in", "wild", "-", "type", "B-1a", "lymphomas", "that", "arise", "spontaneously", "through", "age", "predisposition", ".", "These", "results", "suggest", "that", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "pathways", "may", "serve", "as", "effective", "targets", "in", "the", "treatment", "of", "EBV", "-", "associated", "B", "cell", "lymphomas", ".", "\n", "Author", "Summary", "\n", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "is", "linked", "to", "the", "development", "of", "multiple", "cancers", ",", "including", "post", "-", "transplant", "lymphoma", ",", "Hodgkin", "disease", ",", "and", "nasopharyngeal", "carcinoma", ".", "Latent", "membrane", "protein", "1", "(", "LMP1", ")", "is", "expressed", "in", "many", "EBV", "-", "associated", "cancers", "and", "is", "responsible", "for", "most", "of", "the", "altered", "cellular", "growth", "properties", "that", "are", "induced", "by", "EBV", "infection", ".", "This", "study", "reveals", "that", "LMP1", "induces", "lymphomas", "in", "B-1a", "lymphocytes", ",", "a", "cell", "type", "that", "is", "susceptible", "to", "transformation", "in", "aged", "mice", ".", "The", "lymphomas", "require", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "signaling", "for", "enhanced", "growth", "and", "survival", ".", "The", "activation", "of", "the", "Stat3", ",", "Akt", ",", "and", "NFkappaB", "signaling", "pathways", "likely", "underlies", "the", "ability", "of", "LMP1", "to", "promote", "malignant", "transformation", ".", "\n" ]

[ "Protein" ]

Latent Membrane Protein 1, Akt, Stat3, Latent membrane protein 1, LMP1, LMP1, Akt, Stat3, LMP1, IL4, Stat6, Stat3, Akt, Stat3, Latent membrane protein 1, LMP1, LMP1, Akt, Stat3, Stat3, Akt, LMP1

38_task2

Sentence: EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B Cell Lymphomas Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated cell cycle markers, and inhibitors of Akt, NFkappaB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas. Author Summary Epstein-Barr virus (EBV) is linked to the development of multiple cancers, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is expressed in many EBV-associated cancers and is responsible for most of the altered cellular growth properties that are induced by EBV infection. This study reveals that LMP1 induces lymphomas in B-1a lymphocytes, a cell type that is susceptible to transformation in aged mice. The lymphomas require Akt, NFkappaB, and Stat3 signaling for enhanced growth and survival. The activation of the Stat3, Akt, and NFkappaB signaling pathways likely underlies the ability of LMP1 to promote malignant transformation. Instructions: please extract entity words from the input sentence

[ "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B Cell Lymphomas Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated cell cycle markers, and inhibitors of Akt, NFkappaB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas. Author Summary Epstein-Barr virus (EBV) is linked to the development of multiple cancers, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is expressed in many EBV-associated cancers and is responsible for most of the altered cellular growth properties that are induced by EBV infection. This study reveals that LMP1 induces lymphomas in B-1a lymphocytes, a cell type that is susceptible to transformation in aged mice. The lymphomas require Akt, NFkappaB, and Stat3 signaling for enhanced growth and survival. The activation of the Stat3, Akt, and NFkappaB signaling pathways likely underlies the ability of LMP1 to promote malignant transformation.

[ "EBV", "Latent", "Membrane", "Protein", "1", "Activates", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "in", "B", "Cell", "Lymphomas", "\n", "Latent", "membrane", "protein", "1", "(", "LMP1", ")", "is", "the", "major", "oncoprotein", "of", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", ".", "In", "transgenic", "mice", ",", "LMP1", "promotes", "increased", "lymphoma", "development", "by", "12", "mo", "of", "age", ".", "This", "study", "reveals", "that", "lymphoma", "develops", "in", "B-1a", "lymphocytes", ",", "a", "population", "that", "is", "associated", "with", "transformation", "in", "older", "mice", ".", "The", "lymphoma", "cells", "have", "deregulated", "cell", "cycle", "markers", ",", "and", "inhibitors", "of", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "block", "the", "enhanced", "viability", "of", "LMP1", "transgenic", "lymphocytes", "and", "lymphoma", "cells", "in", "vitro", ".", "Lymphoma", "cells", "are", "independent", "of", "IL4", "/", "Stat6", "signaling", "for", "survival", "and", "proliferation", ",", "but", "have", "constitutively", "activated", "Stat3", "signaling", ".", "These", "same", "targets", "are", "also", "deregulated", "in", "wild", "-", "type", "B-1a", "lymphomas", "that", "arise", "spontaneously", "through", "age", "predisposition", ".", "These", "results", "suggest", "that", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "pathways", "may", "serve", "as", "effective", "targets", "in", "the", "treatment", "of", "EBV", "-", "associated", "B", "cell", "lymphomas", ".", "\n", "Author", "Summary", "\n", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "is", "linked", "to", "the", "development", "of", "multiple", "cancers", ",", "including", "post", "-", "transplant", "lymphoma", ",", "Hodgkin", "disease", ",", "and", "nasopharyngeal", "carcinoma", ".", "Latent", "membrane", "protein", "1", "(", "LMP1", ")", "is", "expressed", "in", "many", "EBV", "-", "associated", "cancers", "and", "is", "responsible", "for", "most", "of", "the", "altered", "cellular", "growth", "properties", "that", "are", "induced", "by", "EBV", "infection", ".", "This", "study", "reveals", "that", "LMP1", "induces", "lymphomas", "in", "B-1a", "lymphocytes", ",", "a", "cell", "type", "that", "is", "susceptible", "to", "transformation", "in", "aged", "mice", ".", "The", "lymphomas", "require", "Akt", ",", "NFkappaB", ",", "and", "Stat3", "signaling", "for", "enhanced", "growth", "and", "survival", ".", "The", "activation", "of", "the", "Stat3", ",", "Akt", ",", "and", "NFkappaB", "signaling", "pathways", "likely", "underlies", "the", "ability", "of", "LMP1", "to", "promote", "malignant", "transformation", ".", "\n" ]

[ "Protein" ]

Patienten is an umlsterm, Sekretion is an umlsterm, Kortisol is an umlsterm, ACTH is an umlsterm, Adrenalektomie is an umlsterm

DerAnaesthesist.70460303.ger.abstr_task0

Sentence: An 10 Patienten wurde die spontane und stimulierte ( Corticotropin-Releasing-Hormon : CRH ) Sekretion von Kortisol ( Cs ) und ACTH im Rahmen der unilateralen Adrenalektomie beim Nierenzellkarzinom untersucht . Ziel der Studie war klinische oder laborchemische Zeichen , einer NNR-Insuffizienz auszuschliessen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

An 10 Patienten wurde die spontane und stimulierte ( Corticotropin-Releasing-Hormon : CRH ) Sekretion von Kortisol ( Cs ) und ACTH im Rahmen der unilateralen Adrenalektomie beim Nierenzellkarzinom untersucht . Ziel der Studie war klinische oder laborchemische Zeichen , einer NNR-Insuffizienz auszuschliessen .

[ "An", "10", "Patienten", "wurde", "die", "spontane", "und", "stimulierte", "(", "Corticotropin", "-", "Releasing", "-", "Hormon", ":", "CRH", ")", "Sekretion", "von", "Kortisol", "(", "Cs", ")", "und", "ACTH", "im", "Rahmen", "der", "unilateralen", "Adrenalektomie", "beim", "Nierenzellkarzinom", "untersucht", ".", "Ziel", "der", "Studie", "war", "klinische", "oder", "laborchemische", "Zeichen", ",", "einer", "NNR", "-", "Insuffizienz", "auszuschliessen", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Sekretion is an umlsterm, Kortisol is an umlsterm, ACTH is an umlsterm, Adrenalektomie is an umlsterm

DerAnaesthesist.70460303.ger.abstr_task1

Sentence: An 10 Patienten wurde die spontane und stimulierte ( Corticotropin-Releasing-Hormon : CRH ) Sekretion von Kortisol ( Cs ) und ACTH im Rahmen der unilateralen Adrenalektomie beim Nierenzellkarzinom untersucht . Ziel der Studie war klinische oder laborchemische Zeichen , einer NNR-Insuffizienz auszuschliessen . Instructions: please typing these entity words according to sentence: Patienten, Sekretion, Kortisol, ACTH, Adrenalektomie Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

An 10 Patienten wurde die spontane und stimulierte ( Corticotropin-Releasing-Hormon : CRH ) Sekretion von Kortisol ( Cs ) und ACTH im Rahmen der unilateralen Adrenalektomie beim Nierenzellkarzinom untersucht . Ziel der Studie war klinische oder laborchemische Zeichen , einer NNR-Insuffizienz auszuschliessen .

[ "An", "10", "Patienten", "wurde", "die", "spontane", "und", "stimulierte", "(", "Corticotropin", "-", "Releasing", "-", "Hormon", ":", "CRH", ")", "Sekretion", "von", "Kortisol", "(", "Cs", ")", "und", "ACTH", "im", "Rahmen", "der", "unilateralen", "Adrenalektomie", "beim", "Nierenzellkarzinom", "untersucht", ".", "Ziel", "der", "Studie", "war", "klinische", "oder", "laborchemische", "Zeichen", ",", "einer", "NNR", "-", "Insuffizienz", "auszuschliessen", "." ]

[ "umlsterm" ]

Patienten, Sekretion, Kortisol, ACTH, Adrenalektomie

DerAnaesthesist.70460303.ger.abstr_task2

Sentence: An 10 Patienten wurde die spontane und stimulierte ( Corticotropin-Releasing-Hormon : CRH ) Sekretion von Kortisol ( Cs ) und ACTH im Rahmen der unilateralen Adrenalektomie beim Nierenzellkarzinom untersucht . Ziel der Studie war klinische oder laborchemische Zeichen , einer NNR-Insuffizienz auszuschliessen . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

An 10 Patienten wurde die spontane und stimulierte ( Corticotropin-Releasing-Hormon : CRH ) Sekretion von Kortisol ( Cs ) und ACTH im Rahmen der unilateralen Adrenalektomie beim Nierenzellkarzinom untersucht . Ziel der Studie war klinische oder laborchemische Zeichen , einer NNR-Insuffizienz auszuschliessen .

[ "An", "10", "Patienten", "wurde", "die", "spontane", "und", "stimulierte", "(", "Corticotropin", "-", "Releasing", "-", "Hormon", ":", "CRH", ")", "Sekretion", "von", "Kortisol", "(", "Cs", ")", "und", "ACTH", "im", "Rahmen", "der", "unilateralen", "Adrenalektomie", "beim", "Nierenzellkarzinom", "untersucht", ".", "Ziel", "der", "Studie", "war", "klinische", "oder", "laborchemische", "Zeichen", ",", "einer", "NNR", "-", "Insuffizienz", "auszuschliessen", "." ]

[ "umlsterm" ]

alpha1H is a GENE-Y, T - type Ca2 + channel is a GENE-N

9670923_task0

Sentence: Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N

[ "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O" ]

Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family.

[ "Cloning", "and", "characterization", "of", "alpha1H", "from", "human", "heart", ",", "a", "member", "of", "the", "T", "-", "type", "Ca2", "+", "channel", "gene", "family", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

alpha1H is a GENE-Y, T - type Ca2 + channel is a GENE-N

9670923_task1

Sentence: Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family. Instructions: please typing these entity words according to sentence: alpha1H, T - type Ca2 + channel Options: GENE-Y, GENE-N

[ "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O" ]

Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family.

[ "Cloning", "and", "characterization", "of", "alpha1H", "from", "human", "heart", ",", "a", "member", "of", "the", "T", "-", "type", "Ca2", "+", "channel", "gene", "family", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

alpha1H, T - type Ca2 + channel

9670923_task2

Sentence: Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O" ]

Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family.

[ "Cloning", "and", "characterization", "of", "alpha1H", "from", "human", "heart", ",", "a", "member", "of", "the", "T", "-", "type", "Ca2", "+", "channel", "gene", "family", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Serotonin transporter is a GENE-Y, 5-HTTLPR is a GENE-Y, [ 3H]paroxetine is a CHEMICAL

10980326_task0

Sentence: Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.

[ "Serotonin", "transporter", "gene", "regulatory", "region", "polymorphism", "(", "5-HTTLPR", ")", ",", "[", "3H]paroxetine", "binding", "in", "healthy", "control", "subjects", "and", "alcohol", "-", "dependent", "patients", "and", "their", "relationships", "to", "impulsivity", "." ]

[ "GENE-Y", "CHEMICAL" ]

Serotonin transporter is a GENE-Y, 5-HTTLPR is a GENE-Y, [ 3H]paroxetine is a CHEMICAL

10980326_task1

Sentence: Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity. Instructions: please typing these entity words according to sentence: Serotonin transporter, 5-HTTLPR, [ 3H]paroxetine Options: GENE-Y, CHEMICAL

[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.

[ "Serotonin", "transporter", "gene", "regulatory", "region", "polymorphism", "(", "5-HTTLPR", ")", ",", "[", "3H]paroxetine", "binding", "in", "healthy", "control", "subjects", "and", "alcohol", "-", "dependent", "patients", "and", "their", "relationships", "to", "impulsivity", "." ]

[ "GENE-Y", "CHEMICAL" ]

Serotonin transporter, 5-HTTLPR, [ 3H]paroxetine

10980326_task2

Sentence: Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity. Instructions: please extract entity words from the input sentence

[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.

[ "Serotonin", "transporter", "gene", "regulatory", "region", "polymorphism", "(", "5-HTTLPR", ")", ",", "[", "3H]paroxetine", "binding", "in", "healthy", "control", "subjects", "and", "alcohol", "-", "dependent", "patients", "and", "their", "relationships", "to", "impulsivity", "." ]

[ "GENE-Y", "CHEMICAL" ]

insulin is a protein, glucose is a compound

DS.d1613_task0

Sentence: Association between insulin resistance, glucose intolerance, and hypertension in pregnancy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "B-protein", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O" ]

Association between insulin resistance, glucose intolerance, and hypertension in pregnancy.

[ "Association", "between", "insulin", "resistance", ",", "glucose", "intolerance", ",", "and", "hypertension", "in", "pregnancy", "." ]

[ "protein", "compound" ]

insulin is a protein, glucose is a compound

DS.d1613_task1

Sentence: Association between insulin resistance, glucose intolerance, and hypertension in pregnancy. Instructions: please typing these entity words according to sentence: insulin, glucose Options: compound, protein

[ "O", "O", "B-protein", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O" ]

Association between insulin resistance, glucose intolerance, and hypertension in pregnancy.

[ "Association", "between", "insulin", "resistance", ",", "glucose", "intolerance", ",", "and", "hypertension", "in", "pregnancy", "." ]

[ "protein", "compound" ]

insulin, glucose

DS.d1613_task2

Sentence: Association between insulin resistance, glucose intolerance, and hypertension in pregnancy. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-protein", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O" ]

Association between insulin resistance, glucose intolerance, and hypertension in pregnancy.

[ "Association", "between", "insulin", "resistance", ",", "glucose", "intolerance", ",", "and", "hypertension", "in", "pregnancy", "." ]

[ "protein", "compound" ]

Therapie is an umlsterm, Gesellschaft is an umlsterm, Haematologie is an umlsterm, Methode is an umlsterm, Therapiekonzept is an umlsterm, Chemotherapie is an umlsterm, bildgebender is an umlsterm, Diagnose is an umlsterm, Tumor is an umlsterm, Kinder is an umlsterm, Patienten is an umlsterm, Nephroblastom is an umlsterm, Chemotherapie is an umlsterm, Chemotherapie is an umlsterm, Therapiereduktion is an umlsterm

MonatsschriftKinderheilkunde.71450128.ger.abstr_task0

Sentence: Hintergrund : Die intensive Therapie der von der Gesellschaft fuer Paediatrische Onkologie und Haematologie ( GPOH ) ab 1980 durchgefuehrten Wilmstumorstudie sollte in der Folgestudie unter Wahrung der guten Ergebnisse reduziert werden . Methode 1989 : wurde das Therapiekonzept der International Society of Pediatric Oncology ( SIOP ) mit praeoperativer Chemotherapie nach bildgebender Diagnose uebernommen , wobei der Tumor durch die Vorbehandlung verkleinert wird , damit er bei einem Grossteil der Kinder vollstaendig entfernbar ist . Ergebnisse : Bei 505 in 5,25 Jahren aus 78 Kliniken gemeldeten Patienten hatten 486 ein Nephroblastom , 14 ein anderes Malignom und 5 eine benigne renale Laesion . Von 438 gemeldeten Nephroblastompatienten zwischen 0,5 und 16 Jahren erhielten 85,4 % praeoperativ eine Chemotherapie . Der Anteil bestrahlter Nephroblastompatienten ( 22,8 % ) und die kumulative Adriamycindosis bei hohen Stadien bzw. hoher Malignitaet wurden im Vergleich zur Vorstudie reduziert bei aehnlicher Ueberlebenswahrscheinlichkeit von 91 % nach 3 Jahren . Schlussfolgerung : Das Konzept einer generellen praeoperativen Chemotherapie zur Nephroblastombehandlung ist in der GPOH mit gutem Ergebnis und deutlicher Therapiereduktion im Vergleich zur Vorstudie durchzufuehren . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Hintergrund : Die intensive Therapie der von der Gesellschaft fuer Paediatrische Onkologie und Haematologie ( GPOH ) ab 1980 durchgefuehrten Wilmstumorstudie sollte in der Folgestudie unter Wahrung der guten Ergebnisse reduziert werden . Methode 1989 : wurde das Therapiekonzept der International Society of Pediatric Oncology ( SIOP ) mit praeoperativer Chemotherapie nach bildgebender Diagnose uebernommen , wobei der Tumor durch die Vorbehandlung verkleinert wird , damit er bei einem Grossteil der Kinder vollstaendig entfernbar ist . Ergebnisse : Bei 505 in 5,25 Jahren aus 78 Kliniken gemeldeten Patienten hatten 486 ein Nephroblastom , 14 ein anderes Malignom und 5 eine benigne renale Laesion . Von 438 gemeldeten Nephroblastompatienten zwischen 0,5 und 16 Jahren erhielten 85,4 % praeoperativ eine Chemotherapie . Der Anteil bestrahlter Nephroblastompatienten ( 22,8 % ) und die kumulative Adriamycindosis bei hohen Stadien bzw. hoher Malignitaet wurden im Vergleich zur Vorstudie reduziert bei aehnlicher Ueberlebenswahrscheinlichkeit von 91 % nach 3 Jahren . Schlussfolgerung : Das Konzept einer generellen praeoperativen Chemotherapie zur Nephroblastombehandlung ist in der GPOH mit gutem Ergebnis und deutlicher Therapiereduktion im Vergleich zur Vorstudie durchzufuehren .

[ "Hintergrund", ":", "Die", "intensive", "Therapie", "der", "von", "der", "Gesellschaft", "fuer", "Paediatrische", "Onkologie", "und", "Haematologie", "(", "GPOH", ")", "ab", "1980", "durchgefuehrten", "Wilmstumorstudie", "sollte", "in", "der", "Folgestudie", "unter", "Wahrung", "der", "guten", "Ergebnisse", "reduziert", "werden", ".", "Methode", "1989", ":", "wurde", "das", "Therapiekonzept", "der", "International", "Society", "of", "Pediatric", "Oncology", "(", "SIOP", ")", "mit", "praeoperativer", "Chemotherapie", "nach", "bildgebender", "Diagnose", "uebernommen", ",", "wobei", "der", "Tumor", "durch", "die", "Vorbehandlung", "verkleinert", "wird", ",", "damit", "er", "bei", "einem", "Grossteil", "der", "Kinder", "vollstaendig", "entfernbar", "ist", ".", "Ergebnisse", ":", "Bei", "505", "in", "5,25", "Jahren", "aus", "78", "Kliniken", "gemeldeten", "Patienten", "hatten", "486", "ein", "Nephroblastom", ",", "14", "ein", "anderes", "Malignom", "und", "5", "eine", "benigne", "renale", "Laesion", ".", "Von", "438", "gemeldeten", "Nephroblastompatienten", "zwischen", "0,5", "und", "16", "Jahren", "erhielten", "85,4", "%", "praeoperativ", "eine", "Chemotherapie", ".", "Der", "Anteil", "bestrahlter", "Nephroblastompatienten", "(", "22,8", "%", ")", "und", "die", "kumulative", "Adriamycindosis", "bei", "hohen", "Stadien", "bzw", ".", "hoher", "Malignitaet", "wurden", "im", "Vergleich", "zur", "Vorstudie", "reduziert", "bei", "aehnlicher", "Ueberlebenswahrscheinlichkeit", "von", "91", "%", "nach", "3", "Jahren", ".", "Schlussfolgerung", ":", "Das", "Konzept", "einer", "generellen", "praeoperativen", "Chemotherapie", "zur", "Nephroblastombehandlung", "ist", "in", "der", "GPOH", "mit", "gutem", "Ergebnis", "und", "deutlicher", "Therapiereduktion", "im", "Vergleich", "zur", "Vorstudie", "durchzufuehren", "." ]

[ "umlsterm" ]

Therapie is an umlsterm, Gesellschaft is an umlsterm, Haematologie is an umlsterm, Methode is an umlsterm, Therapiekonzept is an umlsterm, Chemotherapie is an umlsterm, bildgebender is an umlsterm, Diagnose is an umlsterm, Tumor is an umlsterm, Kinder is an umlsterm, Patienten is an umlsterm, Nephroblastom is an umlsterm, Chemotherapie is an umlsterm, Chemotherapie is an umlsterm, Therapiereduktion is an umlsterm

MonatsschriftKinderheilkunde.71450128.ger.abstr_task1

Sentence: Hintergrund : Die intensive Therapie der von der Gesellschaft fuer Paediatrische Onkologie und Haematologie ( GPOH ) ab 1980 durchgefuehrten Wilmstumorstudie sollte in der Folgestudie unter Wahrung der guten Ergebnisse reduziert werden . Methode 1989 : wurde das Therapiekonzept der International Society of Pediatric Oncology ( SIOP ) mit praeoperativer Chemotherapie nach bildgebender Diagnose uebernommen , wobei der Tumor durch die Vorbehandlung verkleinert wird , damit er bei einem Grossteil der Kinder vollstaendig entfernbar ist . Ergebnisse : Bei 505 in 5,25 Jahren aus 78 Kliniken gemeldeten Patienten hatten 486 ein Nephroblastom , 14 ein anderes Malignom und 5 eine benigne renale Laesion . Von 438 gemeldeten Nephroblastompatienten zwischen 0,5 und 16 Jahren erhielten 85,4 % praeoperativ eine Chemotherapie . Der Anteil bestrahlter Nephroblastompatienten ( 22,8 % ) und die kumulative Adriamycindosis bei hohen Stadien bzw. hoher Malignitaet wurden im Vergleich zur Vorstudie reduziert bei aehnlicher Ueberlebenswahrscheinlichkeit von 91 % nach 3 Jahren . Schlussfolgerung : Das Konzept einer generellen praeoperativen Chemotherapie zur Nephroblastombehandlung ist in der GPOH mit gutem Ergebnis und deutlicher Therapiereduktion im Vergleich zur Vorstudie durchzufuehren . Instructions: please typing these entity words according to sentence: Therapie, Gesellschaft, Haematologie, Methode, Therapiekonzept, Chemotherapie, bildgebender, Diagnose, Tumor, Kinder, Patienten, Nephroblastom, Chemotherapie, Chemotherapie, Therapiereduktion Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Hintergrund : Die intensive Therapie der von der Gesellschaft fuer Paediatrische Onkologie und Haematologie ( GPOH ) ab 1980 durchgefuehrten Wilmstumorstudie sollte in der Folgestudie unter Wahrung der guten Ergebnisse reduziert werden . Methode 1989 : wurde das Therapiekonzept der International Society of Pediatric Oncology ( SIOP ) mit praeoperativer Chemotherapie nach bildgebender Diagnose uebernommen , wobei der Tumor durch die Vorbehandlung verkleinert wird , damit er bei einem Grossteil der Kinder vollstaendig entfernbar ist . Ergebnisse : Bei 505 in 5,25 Jahren aus 78 Kliniken gemeldeten Patienten hatten 486 ein Nephroblastom , 14 ein anderes Malignom und 5 eine benigne renale Laesion . Von 438 gemeldeten Nephroblastompatienten zwischen 0,5 und 16 Jahren erhielten 85,4 % praeoperativ eine Chemotherapie . Der Anteil bestrahlter Nephroblastompatienten ( 22,8 % ) und die kumulative Adriamycindosis bei hohen Stadien bzw. hoher Malignitaet wurden im Vergleich zur Vorstudie reduziert bei aehnlicher Ueberlebenswahrscheinlichkeit von 91 % nach 3 Jahren . Schlussfolgerung : Das Konzept einer generellen praeoperativen Chemotherapie zur Nephroblastombehandlung ist in der GPOH mit gutem Ergebnis und deutlicher Therapiereduktion im Vergleich zur Vorstudie durchzufuehren .

[ "Hintergrund", ":", "Die", "intensive", "Therapie", "der", "von", "der", "Gesellschaft", "fuer", "Paediatrische", "Onkologie", "und", "Haematologie", "(", "GPOH", ")", "ab", "1980", "durchgefuehrten", "Wilmstumorstudie", "sollte", "in", "der", "Folgestudie", "unter", "Wahrung", "der", "guten", "Ergebnisse", "reduziert", "werden", ".", "Methode", "1989", ":", "wurde", "das", "Therapiekonzept", "der", "International", "Society", "of", "Pediatric", "Oncology", "(", "SIOP", ")", "mit", "praeoperativer", "Chemotherapie", "nach", "bildgebender", "Diagnose", "uebernommen", ",", "wobei", "der", "Tumor", "durch", "die", "Vorbehandlung", "verkleinert", "wird", ",", "damit", "er", "bei", "einem", "Grossteil", "der", "Kinder", "vollstaendig", "entfernbar", "ist", ".", "Ergebnisse", ":", "Bei", "505", "in", "5,25", "Jahren", "aus", "78", "Kliniken", "gemeldeten", "Patienten", "hatten", "486", "ein", "Nephroblastom", ",", "14", "ein", "anderes", "Malignom", "und", "5", "eine", "benigne", "renale", "Laesion", ".", "Von", "438", "gemeldeten", "Nephroblastompatienten", "zwischen", "0,5", "und", "16", "Jahren", "erhielten", "85,4", "%", "praeoperativ", "eine", "Chemotherapie", ".", "Der", "Anteil", "bestrahlter", "Nephroblastompatienten", "(", "22,8", "%", ")", "und", "die", "kumulative", "Adriamycindosis", "bei", "hohen", "Stadien", "bzw", ".", "hoher", "Malignitaet", "wurden", "im", "Vergleich", "zur", "Vorstudie", "reduziert", "bei", "aehnlicher", "Ueberlebenswahrscheinlichkeit", "von", "91", "%", "nach", "3", "Jahren", ".", "Schlussfolgerung", ":", "Das", "Konzept", "einer", "generellen", "praeoperativen", "Chemotherapie", "zur", "Nephroblastombehandlung", "ist", "in", "der", "GPOH", "mit", "gutem", "Ergebnis", "und", "deutlicher", "Therapiereduktion", "im", "Vergleich", "zur", "Vorstudie", "durchzufuehren", "." ]

[ "umlsterm" ]

Therapie, Gesellschaft, Haematologie, Methode, Therapiekonzept, Chemotherapie, bildgebender, Diagnose, Tumor, Kinder, Patienten, Nephroblastom, Chemotherapie, Chemotherapie, Therapiereduktion

MonatsschriftKinderheilkunde.71450128.ger.abstr_task2

Sentence: Hintergrund : Die intensive Therapie der von der Gesellschaft fuer Paediatrische Onkologie und Haematologie ( GPOH ) ab 1980 durchgefuehrten Wilmstumorstudie sollte in der Folgestudie unter Wahrung der guten Ergebnisse reduziert werden . Methode 1989 : wurde das Therapiekonzept der International Society of Pediatric Oncology ( SIOP ) mit praeoperativer Chemotherapie nach bildgebender Diagnose uebernommen , wobei der Tumor durch die Vorbehandlung verkleinert wird , damit er bei einem Grossteil der Kinder vollstaendig entfernbar ist . Ergebnisse : Bei 505 in 5,25 Jahren aus 78 Kliniken gemeldeten Patienten hatten 486 ein Nephroblastom , 14 ein anderes Malignom und 5 eine benigne renale Laesion . Von 438 gemeldeten Nephroblastompatienten zwischen 0,5 und 16 Jahren erhielten 85,4 % praeoperativ eine Chemotherapie . Der Anteil bestrahlter Nephroblastompatienten ( 22,8 % ) und die kumulative Adriamycindosis bei hohen Stadien bzw. hoher Malignitaet wurden im Vergleich zur Vorstudie reduziert bei aehnlicher Ueberlebenswahrscheinlichkeit von 91 % nach 3 Jahren . Schlussfolgerung : Das Konzept einer generellen praeoperativen Chemotherapie zur Nephroblastombehandlung ist in der GPOH mit gutem Ergebnis und deutlicher Therapiereduktion im Vergleich zur Vorstudie durchzufuehren . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Hintergrund : Die intensive Therapie der von der Gesellschaft fuer Paediatrische Onkologie und Haematologie ( GPOH ) ab 1980 durchgefuehrten Wilmstumorstudie sollte in der Folgestudie unter Wahrung der guten Ergebnisse reduziert werden . Methode 1989 : wurde das Therapiekonzept der International Society of Pediatric Oncology ( SIOP ) mit praeoperativer Chemotherapie nach bildgebender Diagnose uebernommen , wobei der Tumor durch die Vorbehandlung verkleinert wird , damit er bei einem Grossteil der Kinder vollstaendig entfernbar ist . Ergebnisse : Bei 505 in 5,25 Jahren aus 78 Kliniken gemeldeten Patienten hatten 486 ein Nephroblastom , 14 ein anderes Malignom und 5 eine benigne renale Laesion . Von 438 gemeldeten Nephroblastompatienten zwischen 0,5 und 16 Jahren erhielten 85,4 % praeoperativ eine Chemotherapie . Der Anteil bestrahlter Nephroblastompatienten ( 22,8 % ) und die kumulative Adriamycindosis bei hohen Stadien bzw. hoher Malignitaet wurden im Vergleich zur Vorstudie reduziert bei aehnlicher Ueberlebenswahrscheinlichkeit von 91 % nach 3 Jahren . Schlussfolgerung : Das Konzept einer generellen praeoperativen Chemotherapie zur Nephroblastombehandlung ist in der GPOH mit gutem Ergebnis und deutlicher Therapiereduktion im Vergleich zur Vorstudie durchzufuehren .

[ "Hintergrund", ":", "Die", "intensive", "Therapie", "der", "von", "der", "Gesellschaft", "fuer", "Paediatrische", "Onkologie", "und", "Haematologie", "(", "GPOH", ")", "ab", "1980", "durchgefuehrten", "Wilmstumorstudie", "sollte", "in", "der", "Folgestudie", "unter", "Wahrung", "der", "guten", "Ergebnisse", "reduziert", "werden", ".", "Methode", "1989", ":", "wurde", "das", "Therapiekonzept", "der", "International", "Society", "of", "Pediatric", "Oncology", "(", "SIOP", ")", "mit", "praeoperativer", "Chemotherapie", "nach", "bildgebender", "Diagnose", "uebernommen", ",", "wobei", "der", "Tumor", "durch", "die", "Vorbehandlung", "verkleinert", "wird", ",", "damit", "er", "bei", "einem", "Grossteil", "der", "Kinder", "vollstaendig", "entfernbar", "ist", ".", "Ergebnisse", ":", "Bei", "505", "in", "5,25", "Jahren", "aus", "78", "Kliniken", "gemeldeten", "Patienten", "hatten", "486", "ein", "Nephroblastom", ",", "14", "ein", "anderes", "Malignom", "und", "5", "eine", "benigne", "renale", "Laesion", ".", "Von", "438", "gemeldeten", "Nephroblastompatienten", "zwischen", "0,5", "und", "16", "Jahren", "erhielten", "85,4", "%", "praeoperativ", "eine", "Chemotherapie", ".", "Der", "Anteil", "bestrahlter", "Nephroblastompatienten", "(", "22,8", "%", ")", "und", "die", "kumulative", "Adriamycindosis", "bei", "hohen", "Stadien", "bzw", ".", "hoher", "Malignitaet", "wurden", "im", "Vergleich", "zur", "Vorstudie", "reduziert", "bei", "aehnlicher", "Ueberlebenswahrscheinlichkeit", "von", "91", "%", "nach", "3", "Jahren", ".", "Schlussfolgerung", ":", "Das", "Konzept", "einer", "generellen", "praeoperativen", "Chemotherapie", "zur", "Nephroblastombehandlung", "ist", "in", "der", "GPOH", "mit", "gutem", "Ergebnis", "und", "deutlicher", "Therapiereduktion", "im", "Vergleich", "zur", "Vorstudie", "durchzufuehren", "." ]

[ "umlsterm" ]

NOS is a protein, iNOS is a protein, nNOS is a protein, L - arginine methyl ester is a compound, aminoguanidine is a compound, 7-nitroindazole is a compound

DS.d251_task0

Sentence: Effects of inhibition of NOS, iNOS, and nNOS by N-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and 7-nitroindazole, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effects of inhibition of NOS, iNOS, and nNOS by N-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and 7-nitroindazole, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen.

[ "Effects", "of", "inhibition", "of", "NOS", ",", "iNOS", ",", "and", "nNOS", "by", "N", "-", "nitro", "-", "L", "-", "arginine", "methyl", "ester", "(", "L", "-", "NAME", ")", ",", "aminoguanidine", ",", "and", "7-nitroindazole", ",", "respectively", ",", "were", "determined", "on", "the", "antigen", "-", "induced", "systemic", "hypotension", "and", "portal", "hypertension", "in", "conscious", "Sprague", "-", "Dawley", "rats", "sensitized", "with", "the", "ovalbumin", "antigen", "." ]

[ "compound", "protein" ]

NOS is a protein, iNOS is a protein, nNOS is a protein, L - arginine methyl ester is a compound, aminoguanidine is a compound, 7-nitroindazole is a compound

DS.d251_task1

Sentence: Effects of inhibition of NOS, iNOS, and nNOS by N-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and 7-nitroindazole, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen. Instructions: please typing these entity words according to sentence: NOS, iNOS, nNOS, L - arginine methyl ester, aminoguanidine, 7-nitroindazole Options: compound, protein

[ "O", "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effects of inhibition of NOS, iNOS, and nNOS by N-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and 7-nitroindazole, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen.

[ "Effects", "of", "inhibition", "of", "NOS", ",", "iNOS", ",", "and", "nNOS", "by", "N", "-", "nitro", "-", "L", "-", "arginine", "methyl", "ester", "(", "L", "-", "NAME", ")", ",", "aminoguanidine", ",", "and", "7-nitroindazole", ",", "respectively", ",", "were", "determined", "on", "the", "antigen", "-", "induced", "systemic", "hypotension", "and", "portal", "hypertension", "in", "conscious", "Sprague", "-", "Dawley", "rats", "sensitized", "with", "the", "ovalbumin", "antigen", "." ]

[ "compound", "protein" ]

NOS, iNOS, nNOS, L - arginine methyl ester, aminoguanidine, 7-nitroindazole

DS.d251_task2

Sentence: Effects of inhibition of NOS, iNOS, and nNOS by N-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and 7-nitroindazole, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effects of inhibition of NOS, iNOS, and nNOS by N-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and 7-nitroindazole, respectively, were determined on the antigen-induced systemic hypotension and portal hypertension in conscious Sprague-Dawley rats sensitized with the ovalbumin antigen.

[ "Effects", "of", "inhibition", "of", "NOS", ",", "iNOS", ",", "and", "nNOS", "by", "N", "-", "nitro", "-", "L", "-", "arginine", "methyl", "ester", "(", "L", "-", "NAME", ")", ",", "aminoguanidine", ",", "and", "7-nitroindazole", ",", "respectively", ",", "were", "determined", "on", "the", "antigen", "-", "induced", "systemic", "hypotension", "and", "portal", "hypertension", "in", "conscious", "Sprague", "-", "Dawley", "rats", "sensitized", "with", "the", "ovalbumin", "antigen", "." ]

[ "compound", "protein" ]

heart rate is an umlsterm, marker is an umlsterm, dysfunction is an umlsterm, prognosis is an umlsterm, critically ill is an umlsterm, patients is an umlsterm, dysfunction is an umlsterm, patients is an umlsterm, sepsis is an umlsterm, dysfunction is an umlsterm, syndrome is an umlsterm, MODS is an umlsterm

IntensiveMedizin.90360436.eng.abstr_task0

Sentence: Question : Reduced heart rate variability ( HRV ) as a marker of autonomic dysfunction indicates poor prognosis in critically ill patients . The question remains whether the autonomic dysfunction in these patients is primarily the result of sepsis or multiple organ dysfunction syndrome ( MODS ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Question : Reduced heart rate variability ( HRV ) as a marker of autonomic dysfunction indicates poor prognosis in critically ill patients . The question remains whether the autonomic dysfunction in these patients is primarily the result of sepsis or multiple organ dysfunction syndrome ( MODS ) .

[ "Question", ":", "Reduced", "heart", "rate", "variability", "(", "HRV", ")", "as", "a", "marker", "of", "autonomic", "dysfunction", "indicates", "poor", "prognosis", "in", "critically", "ill", "patients", ".", "The", "question", "remains", "whether", "the", "autonomic", "dysfunction", "in", "these", "patients", "is", "primarily", "the", "result", "of", "sepsis", "or", "multiple", "organ", "dysfunction", "syndrome", "(", "MODS", ")", "." ]

[ "umlsterm" ]

heart rate is an umlsterm, marker is an umlsterm, dysfunction is an umlsterm, prognosis is an umlsterm, critically ill is an umlsterm, patients is an umlsterm, dysfunction is an umlsterm, patients is an umlsterm, sepsis is an umlsterm, dysfunction is an umlsterm, syndrome is an umlsterm, MODS is an umlsterm

IntensiveMedizin.90360436.eng.abstr_task1

Sentence: Question : Reduced heart rate variability ( HRV ) as a marker of autonomic dysfunction indicates poor prognosis in critically ill patients . The question remains whether the autonomic dysfunction in these patients is primarily the result of sepsis or multiple organ dysfunction syndrome ( MODS ) . Instructions: please typing these entity words according to sentence: heart rate, marker, dysfunction, prognosis, critically ill, patients, dysfunction, patients, sepsis, dysfunction, syndrome, MODS Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Question : Reduced heart rate variability ( HRV ) as a marker of autonomic dysfunction indicates poor prognosis in critically ill patients . The question remains whether the autonomic dysfunction in these patients is primarily the result of sepsis or multiple organ dysfunction syndrome ( MODS ) .

[ "Question", ":", "Reduced", "heart", "rate", "variability", "(", "HRV", ")", "as", "a", "marker", "of", "autonomic", "dysfunction", "indicates", "poor", "prognosis", "in", "critically", "ill", "patients", ".", "The", "question", "remains", "whether", "the", "autonomic", "dysfunction", "in", "these", "patients", "is", "primarily", "the", "result", "of", "sepsis", "or", "multiple", "organ", "dysfunction", "syndrome", "(", "MODS", ")", "." ]

[ "umlsterm" ]

heart rate, marker, dysfunction, prognosis, critically ill, patients, dysfunction, patients, sepsis, dysfunction, syndrome, MODS

IntensiveMedizin.90360436.eng.abstr_task2

Sentence: Question : Reduced heart rate variability ( HRV ) as a marker of autonomic dysfunction indicates poor prognosis in critically ill patients . The question remains whether the autonomic dysfunction in these patients is primarily the result of sepsis or multiple organ dysfunction syndrome ( MODS ) . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Question : Reduced heart rate variability ( HRV ) as a marker of autonomic dysfunction indicates poor prognosis in critically ill patients . The question remains whether the autonomic dysfunction in these patients is primarily the result of sepsis or multiple organ dysfunction syndrome ( MODS ) .

[ "Question", ":", "Reduced", "heart", "rate", "variability", "(", "HRV", ")", "as", "a", "marker", "of", "autonomic", "dysfunction", "indicates", "poor", "prognosis", "in", "critically", "ill", "patients", ".", "The", "question", "remains", "whether", "the", "autonomic", "dysfunction", "in", "these", "patients", "is", "primarily", "the", "result", "of", "sepsis", "or", "multiple", "organ", "dysfunction", "syndrome", "(", "MODS", ")", "." ]

[ "umlsterm" ]

Analysen is an umlsterm, Amphetamin is an umlsterm, Maennern is an umlsterm, Frauen is an umlsterm, maennlichen is an umlsterm, Geschlechts is an umlsterm, Personen is an umlsterm, Cannabis is an umlsterm, Cannabis is an umlsterm, Alkohol is an umlsterm, Cannabis is an umlsterm, Kokain is an umlsterm, Opiat- is an umlsterm, Opiaten is an umlsterm, Cannabis is an umlsterm, Alkohol is an umlsterm, Kokain is an umlsterm

Rechtsmedizin.80080051.ger.abstr_task0

Sentence: Die Anzahl der chemisch-toxikologischen Analysen mit positivem Nachweis von Amphetaminderivaten und/oder Amphetamin im Koelner Untersuchungsgut der Jahre 1991-1996 zeigt eine deutliche Zunahme . Das Verhaeltnis von Maennern zu Frauen weist eine Ueberrepraesentanz des maennlichen Geschlechts auf , das Alter der untersuchten Personen ist mit um 25 Jahren im Vergleich zu anderen Drogenkonsumenten ohne Auffaelligkeiten . Der Anteil von zusaetzlich konsumierten Drogen stieg in den letzten Jahren auf ueber 90% , wobei die Kombinationen mit Cannabis , Cannabis und Alkohol sowie Cannabis und Kokain ueberwiegen . Der Anteil an Methylendioxyamphetaminderivaten steigt deutlich ab 1994. Die Amphetaminderivatkonsumenten wiesen - mit Ausnahme des Opiat- und Medikamentenkosums - kein wesentlich abweichendes Beikonsumverhalten im Vergleich zum reinen Amphetaminkonsum auf . Eine Verknuepfung der harten Drogenszene " " mit der " Amphetaminszene " im Sinne eines zunehmenden Amphetaminkonsums als Ersatzstoff anderer Drogen kann aus den Auswertungen nicht abgeleitet werden . Der Anteil an Opiaten ist im Vergleich zu Cannabis und Alkohol von geringer Bedeutung , der Anteil an Kokain als zusaetzlich konsumiertem Suchtstoff war in den letzten Jahren schwankend . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Anzahl der chemisch-toxikologischen Analysen mit positivem Nachweis von Amphetaminderivaten und/oder Amphetamin im Koelner Untersuchungsgut der Jahre 1991-1996 zeigt eine deutliche Zunahme . Das Verhaeltnis von Maennern zu Frauen weist eine Ueberrepraesentanz des maennlichen Geschlechts auf , das Alter der untersuchten Personen ist mit um 25 Jahren im Vergleich zu anderen Drogenkonsumenten ohne Auffaelligkeiten . Der Anteil von zusaetzlich konsumierten Drogen stieg in den letzten Jahren auf ueber 90% , wobei die Kombinationen mit Cannabis , Cannabis und Alkohol sowie Cannabis und Kokain ueberwiegen . Der Anteil an Methylendioxyamphetaminderivaten steigt deutlich ab 1994. Die Amphetaminderivatkonsumenten wiesen - mit Ausnahme des Opiat- und Medikamentenkosums - kein wesentlich abweichendes Beikonsumverhalten im Vergleich zum reinen Amphetaminkonsum auf . Eine Verknuepfung der harten Drogenszene " " mit der " Amphetaminszene " im Sinne eines zunehmenden Amphetaminkonsums als Ersatzstoff anderer Drogen kann aus den Auswertungen nicht abgeleitet werden . Der Anteil an Opiaten ist im Vergleich zu Cannabis und Alkohol von geringer Bedeutung , der Anteil an Kokain als zusaetzlich konsumiertem Suchtstoff war in den letzten Jahren schwankend .

[ "Die", "Anzahl", "der", "chemisch", "-", "toxikologischen", "Analysen", "mit", "positivem", "Nachweis", "von", "Amphetaminderivaten", "und", "/", "oder", "Amphetamin", "im", "Koelner", "Untersuchungsgut", "der", "Jahre", "1991", "-", "1996", "zeigt", "eine", "deutliche", "Zunahme", ".", "Das", "Verhaeltnis", "von", "Maennern", "zu", "Frauen", "weist", "eine", "Ueberrepraesentanz", "des", "maennlichen", "Geschlechts", "auf", ",", "das", "Alter", "der", "untersuchten", "Personen", "ist", "mit", "um", "25", "Jahren", "im", "Vergleich", "zu", "anderen", "Drogenkonsumenten", "ohne", "Auffaelligkeiten", ".", "Der", "Anteil", "von", "zusaetzlich", "konsumierten", "Drogen", "stieg", "in", "den", "letzten", "Jahren", "auf", "ueber", "90", "%", ",", "wobei", "die", "Kombinationen", "mit", "Cannabis", ",", "Cannabis", "und", "Alkohol", "sowie", "Cannabis", "und", "Kokain", "ueberwiegen", ".", "Der", "Anteil", "an", "Methylendioxyamphetaminderivaten", "steigt", "deutlich", "ab", "1994", ".", "Die", "Amphetaminderivatkonsumenten", "wiesen", "-", "mit", "Ausnahme", "des", "Opiat-", "und", "Medikamentenkosums", "-", "kein", "wesentlich", "abweichendes", "Beikonsumverhalten", "im", "Vergleich", "zum", "reinen", "Amphetaminkonsum", "auf", ".", "Eine", "Verknuepfung", "der", "harten", "Drogenszene", "\"", "\"", "mit", "der", "\"", "Amphetaminszene", "\"", "im", "Sinne", "eines", "zunehmenden", "Amphetaminkonsums", "als", "Ersatzstoff", "anderer", "Drogen", "kann", "aus", "den", "Auswertungen", "nicht", "abgeleitet", "werden", ".", "Der", "Anteil", "an", "Opiaten", "ist", "im", "Vergleich", "zu", "Cannabis", "und", "Alkohol", "von", "geringer", "Bedeutung", ",", "der", "Anteil", "an", "Kokain", "als", "zusaetzlich", "konsumiertem", "Suchtstoff", "war", "in", "den", "letzten", "Jahren", "schwankend", "." ]

[ "umlsterm" ]

Analysen is an umlsterm, Amphetamin is an umlsterm, Maennern is an umlsterm, Frauen is an umlsterm, maennlichen is an umlsterm, Geschlechts is an umlsterm, Personen is an umlsterm, Cannabis is an umlsterm, Cannabis is an umlsterm, Alkohol is an umlsterm, Cannabis is an umlsterm, Kokain is an umlsterm, Opiat- is an umlsterm, Opiaten is an umlsterm, Cannabis is an umlsterm, Alkohol is an umlsterm, Kokain is an umlsterm

Rechtsmedizin.80080051.ger.abstr_task1

Sentence: Die Anzahl der chemisch-toxikologischen Analysen mit positivem Nachweis von Amphetaminderivaten und/oder Amphetamin im Koelner Untersuchungsgut der Jahre 1991-1996 zeigt eine deutliche Zunahme . Das Verhaeltnis von Maennern zu Frauen weist eine Ueberrepraesentanz des maennlichen Geschlechts auf , das Alter der untersuchten Personen ist mit um 25 Jahren im Vergleich zu anderen Drogenkonsumenten ohne Auffaelligkeiten . Der Anteil von zusaetzlich konsumierten Drogen stieg in den letzten Jahren auf ueber 90% , wobei die Kombinationen mit Cannabis , Cannabis und Alkohol sowie Cannabis und Kokain ueberwiegen . Der Anteil an Methylendioxyamphetaminderivaten steigt deutlich ab 1994. Die Amphetaminderivatkonsumenten wiesen - mit Ausnahme des Opiat- und Medikamentenkosums - kein wesentlich abweichendes Beikonsumverhalten im Vergleich zum reinen Amphetaminkonsum auf . Eine Verknuepfung der harten Drogenszene " " mit der " Amphetaminszene " im Sinne eines zunehmenden Amphetaminkonsums als Ersatzstoff anderer Drogen kann aus den Auswertungen nicht abgeleitet werden . Der Anteil an Opiaten ist im Vergleich zu Cannabis und Alkohol von geringer Bedeutung , der Anteil an Kokain als zusaetzlich konsumiertem Suchtstoff war in den letzten Jahren schwankend . Instructions: please typing these entity words according to sentence: Analysen, Amphetamin, Maennern, Frauen, maennlichen, Geschlechts, Personen, Cannabis, Cannabis, Alkohol, Cannabis, Kokain, Opiat-, Opiaten, Cannabis, Alkohol, Kokain Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Anzahl der chemisch-toxikologischen Analysen mit positivem Nachweis von Amphetaminderivaten und/oder Amphetamin im Koelner Untersuchungsgut der Jahre 1991-1996 zeigt eine deutliche Zunahme . Das Verhaeltnis von Maennern zu Frauen weist eine Ueberrepraesentanz des maennlichen Geschlechts auf , das Alter der untersuchten Personen ist mit um 25 Jahren im Vergleich zu anderen Drogenkonsumenten ohne Auffaelligkeiten . Der Anteil von zusaetzlich konsumierten Drogen stieg in den letzten Jahren auf ueber 90% , wobei die Kombinationen mit Cannabis , Cannabis und Alkohol sowie Cannabis und Kokain ueberwiegen . Der Anteil an Methylendioxyamphetaminderivaten steigt deutlich ab 1994. Die Amphetaminderivatkonsumenten wiesen - mit Ausnahme des Opiat- und Medikamentenkosums - kein wesentlich abweichendes Beikonsumverhalten im Vergleich zum reinen Amphetaminkonsum auf . Eine Verknuepfung der harten Drogenszene " " mit der " Amphetaminszene " im Sinne eines zunehmenden Amphetaminkonsums als Ersatzstoff anderer Drogen kann aus den Auswertungen nicht abgeleitet werden . Der Anteil an Opiaten ist im Vergleich zu Cannabis und Alkohol von geringer Bedeutung , der Anteil an Kokain als zusaetzlich konsumiertem Suchtstoff war in den letzten Jahren schwankend .

[ "Die", "Anzahl", "der", "chemisch", "-", "toxikologischen", "Analysen", "mit", "positivem", "Nachweis", "von", "Amphetaminderivaten", "und", "/", "oder", "Amphetamin", "im", "Koelner", "Untersuchungsgut", "der", "Jahre", "1991", "-", "1996", "zeigt", "eine", "deutliche", "Zunahme", ".", "Das", "Verhaeltnis", "von", "Maennern", "zu", "Frauen", "weist", "eine", "Ueberrepraesentanz", "des", "maennlichen", "Geschlechts", "auf", ",", "das", "Alter", "der", "untersuchten", "Personen", "ist", "mit", "um", "25", "Jahren", "im", "Vergleich", "zu", "anderen", "Drogenkonsumenten", "ohne", "Auffaelligkeiten", ".", "Der", "Anteil", "von", "zusaetzlich", "konsumierten", "Drogen", "stieg", "in", "den", "letzten", "Jahren", "auf", "ueber", "90", "%", ",", "wobei", "die", "Kombinationen", "mit", "Cannabis", ",", "Cannabis", "und", "Alkohol", "sowie", "Cannabis", "und", "Kokain", "ueberwiegen", ".", "Der", "Anteil", "an", "Methylendioxyamphetaminderivaten", "steigt", "deutlich", "ab", "1994", ".", "Die", "Amphetaminderivatkonsumenten", "wiesen", "-", "mit", "Ausnahme", "des", "Opiat-", "und", "Medikamentenkosums", "-", "kein", "wesentlich", "abweichendes", "Beikonsumverhalten", "im", "Vergleich", "zum", "reinen", "Amphetaminkonsum", "auf", ".", "Eine", "Verknuepfung", "der", "harten", "Drogenszene", "\"", "\"", "mit", "der", "\"", "Amphetaminszene", "\"", "im", "Sinne", "eines", "zunehmenden", "Amphetaminkonsums", "als", "Ersatzstoff", "anderer", "Drogen", "kann", "aus", "den", "Auswertungen", "nicht", "abgeleitet", "werden", ".", "Der", "Anteil", "an", "Opiaten", "ist", "im", "Vergleich", "zu", "Cannabis", "und", "Alkohol", "von", "geringer", "Bedeutung", ",", "der", "Anteil", "an", "Kokain", "als", "zusaetzlich", "konsumiertem", "Suchtstoff", "war", "in", "den", "letzten", "Jahren", "schwankend", "." ]

[ "umlsterm" ]

Analysen, Amphetamin, Maennern, Frauen, maennlichen, Geschlechts, Personen, Cannabis, Cannabis, Alkohol, Cannabis, Kokain, Opiat-, Opiaten, Cannabis, Alkohol, Kokain

Rechtsmedizin.80080051.ger.abstr_task2

Sentence: Die Anzahl der chemisch-toxikologischen Analysen mit positivem Nachweis von Amphetaminderivaten und/oder Amphetamin im Koelner Untersuchungsgut der Jahre 1991-1996 zeigt eine deutliche Zunahme . Das Verhaeltnis von Maennern zu Frauen weist eine Ueberrepraesentanz des maennlichen Geschlechts auf , das Alter der untersuchten Personen ist mit um 25 Jahren im Vergleich zu anderen Drogenkonsumenten ohne Auffaelligkeiten . Der Anteil von zusaetzlich konsumierten Drogen stieg in den letzten Jahren auf ueber 90% , wobei die Kombinationen mit Cannabis , Cannabis und Alkohol sowie Cannabis und Kokain ueberwiegen . Der Anteil an Methylendioxyamphetaminderivaten steigt deutlich ab 1994. Die Amphetaminderivatkonsumenten wiesen - mit Ausnahme des Opiat- und Medikamentenkosums - kein wesentlich abweichendes Beikonsumverhalten im Vergleich zum reinen Amphetaminkonsum auf . Eine Verknuepfung der harten Drogenszene " " mit der " Amphetaminszene " im Sinne eines zunehmenden Amphetaminkonsums als Ersatzstoff anderer Drogen kann aus den Auswertungen nicht abgeleitet werden . Der Anteil an Opiaten ist im Vergleich zu Cannabis und Alkohol von geringer Bedeutung , der Anteil an Kokain als zusaetzlich konsumiertem Suchtstoff war in den letzten Jahren schwankend . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Anzahl der chemisch-toxikologischen Analysen mit positivem Nachweis von Amphetaminderivaten und/oder Amphetamin im Koelner Untersuchungsgut der Jahre 1991-1996 zeigt eine deutliche Zunahme . Das Verhaeltnis von Maennern zu Frauen weist eine Ueberrepraesentanz des maennlichen Geschlechts auf , das Alter der untersuchten Personen ist mit um 25 Jahren im Vergleich zu anderen Drogenkonsumenten ohne Auffaelligkeiten . Der Anteil von zusaetzlich konsumierten Drogen stieg in den letzten Jahren auf ueber 90% , wobei die Kombinationen mit Cannabis , Cannabis und Alkohol sowie Cannabis und Kokain ueberwiegen . Der Anteil an Methylendioxyamphetaminderivaten steigt deutlich ab 1994. Die Amphetaminderivatkonsumenten wiesen - mit Ausnahme des Opiat- und Medikamentenkosums - kein wesentlich abweichendes Beikonsumverhalten im Vergleich zum reinen Amphetaminkonsum auf . Eine Verknuepfung der harten Drogenszene " " mit der " Amphetaminszene " im Sinne eines zunehmenden Amphetaminkonsums als Ersatzstoff anderer Drogen kann aus den Auswertungen nicht abgeleitet werden . Der Anteil an Opiaten ist im Vergleich zu Cannabis und Alkohol von geringer Bedeutung , der Anteil an Kokain als zusaetzlich konsumiertem Suchtstoff war in den letzten Jahren schwankend .

[ "Die", "Anzahl", "der", "chemisch", "-", "toxikologischen", "Analysen", "mit", "positivem", "Nachweis", "von", "Amphetaminderivaten", "und", "/", "oder", "Amphetamin", "im", "Koelner", "Untersuchungsgut", "der", "Jahre", "1991", "-", "1996", "zeigt", "eine", "deutliche", "Zunahme", ".", "Das", "Verhaeltnis", "von", "Maennern", "zu", "Frauen", "weist", "eine", "Ueberrepraesentanz", "des", "maennlichen", "Geschlechts", "auf", ",", "das", "Alter", "der", "untersuchten", "Personen", "ist", "mit", "um", "25", "Jahren", "im", "Vergleich", "zu", "anderen", "Drogenkonsumenten", "ohne", "Auffaelligkeiten", ".", "Der", "Anteil", "von", "zusaetzlich", "konsumierten", "Drogen", "stieg", "in", "den", "letzten", "Jahren", "auf", "ueber", "90", "%", ",", "wobei", "die", "Kombinationen", "mit", "Cannabis", ",", "Cannabis", "und", "Alkohol", "sowie", "Cannabis", "und", "Kokain", "ueberwiegen", ".", "Der", "Anteil", "an", "Methylendioxyamphetaminderivaten", "steigt", "deutlich", "ab", "1994", ".", "Die", "Amphetaminderivatkonsumenten", "wiesen", "-", "mit", "Ausnahme", "des", "Opiat-", "und", "Medikamentenkosums", "-", "kein", "wesentlich", "abweichendes", "Beikonsumverhalten", "im", "Vergleich", "zum", "reinen", "Amphetaminkonsum", "auf", ".", "Eine", "Verknuepfung", "der", "harten", "Drogenszene", "\"", "\"", "mit", "der", "\"", "Amphetaminszene", "\"", "im", "Sinne", "eines", "zunehmenden", "Amphetaminkonsums", "als", "Ersatzstoff", "anderer", "Drogen", "kann", "aus", "den", "Auswertungen", "nicht", "abgeleitet", "werden", ".", "Der", "Anteil", "an", "Opiaten", "ist", "im", "Vergleich", "zu", "Cannabis", "und", "Alkohol", "von", "geringer", "Bedeutung", ",", "der", "Anteil", "an", "Kokain", "als", "zusaetzlich", "konsumiertem", "Suchtstoff", "war", "in", "den", "letzten", "Jahren", "schwankend", "." ]

[ "umlsterm" ]

PDGF receptor is a Individual_protein, PDGF - AB is a Individual_protein, mitogen - activated protein kinase is a Protein_family_or_group, ERK is a Gene/protein/RNA, AP-1 is a Gene/protein/RNA

482_task0

Sentence: In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA, Individual_protein, Protein_family_or_group

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O" ]

In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity.

[ "In", "vitro", "studies", "indicated", "that", "suramin", "completely", "blocked", "PDGF", "receptor", "activation", "or", "phosphorylation", "stimulated", "by", "PDGF", "-", "AB", ",", "inhibited", "activation", "of", "mitogen", "-", "activated", "protein", "kinase", "(", "ERK", ")", "kinases", "(", "MEK1/2", ")", "and", "ERK1/2", ",", "and", "abrogated", "transcription", "factor", "AP-1", "DNA", "-", "binding", "activity", "." ]

[ "Protein_family_or_group", "Individual_protein", "Gene/protein/RNA" ]

PDGF receptor is a Individual_protein, PDGF - AB is a Individual_protein, mitogen - activated protein kinase is a Protein_family_or_group, ERK is a Gene/protein/RNA, AP-1 is a Gene/protein/RNA

482_task1

Sentence: In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity. Instructions: please typing these entity words according to sentence: PDGF receptor, PDGF - AB, mitogen - activated protein kinase, ERK, AP-1 Options: Gene/protein/RNA, Individual_protein, Protein_family_or_group

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O" ]

In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity.

[ "In", "vitro", "studies", "indicated", "that", "suramin", "completely", "blocked", "PDGF", "receptor", "activation", "or", "phosphorylation", "stimulated", "by", "PDGF", "-", "AB", ",", "inhibited", "activation", "of", "mitogen", "-", "activated", "protein", "kinase", "(", "ERK", ")", "kinases", "(", "MEK1/2", ")", "and", "ERK1/2", ",", "and", "abrogated", "transcription", "factor", "AP-1", "DNA", "-", "binding", "activity", "." ]

[ "Protein_family_or_group", "Individual_protein", "Gene/protein/RNA" ]

PDGF receptor, PDGF - AB, mitogen - activated protein kinase, ERK, AP-1

482_task2

Sentence: In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O" ]

In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity.

[ "In", "vitro", "studies", "indicated", "that", "suramin", "completely", "blocked", "PDGF", "receptor", "activation", "or", "phosphorylation", "stimulated", "by", "PDGF", "-", "AB", ",", "inhibited", "activation", "of", "mitogen", "-", "activated", "protein", "kinase", "(", "ERK", ")", "kinases", "(", "MEK1/2", ")", "and", "ERK1/2", ",", "and", "abrogated", "transcription", "factor", "AP-1", "DNA", "-", "binding", "activity", "." ]

[ "Protein_family_or_group", "Individual_protein", "Gene/protein/RNA" ]

Farbstoffe is an umlsterm, Farbstoffe is an umlsterm, Quecksilberverbindungen is an umlsterm, Mann is an umlsterm, Entzuendung is an umlsterm, Haut is an umlsterm, Hauttestreaktion is an umlsterm, Farbstoff is an umlsterm, Patient is an umlsterm

DerHautarzt.70480666.ger.abstr_task0

Sentence: Allergische Reaktionen auf Farbstoffe in Taetowierungen sind vergleichsweise selten . In der Mehrzahl sind es Reaktionen auf die roten Farbstoffe . Waehrend frueher hauptsaechlich Quecksilberverbindungen ( Zinnober und Cadmiumsulfid ) dafuer verantwortlich waren , stehen heute die synthetischen anorganischen Azofarbstoffe im Vordergrund . Es wird ein 42jaehriger Mann mit allergischer Reaktion in seinen roten Taetowierungsanteilen vorgestellt . Histologisch imponierte eine chronisch verlaufende granulomatoese , teils fibrosierende Entzuendung mit transfollikulaerer Elimination von Pigmentgranula . Klinisch zeigte sich im Verlauf spontan eine partielle Rueckbildung der entzuendlichen Veraenderungen unter gleichzeitiger Depigmentierung und Vernarbung der Haut . Als Taetowierungsfarbstoff wurde ein aromatischer Azofarbstoff nachgewiesen . Neben der positiven Hauttestreaktion auf diesen Farbstoff zeigte der Patient zusaetzlich eine positive Testreaktion auf den Textilfarbstoffkoppler Napthol AS . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Allergische Reaktionen auf Farbstoffe in Taetowierungen sind vergleichsweise selten . In der Mehrzahl sind es Reaktionen auf die roten Farbstoffe . Waehrend frueher hauptsaechlich Quecksilberverbindungen ( Zinnober und Cadmiumsulfid ) dafuer verantwortlich waren , stehen heute die synthetischen anorganischen Azofarbstoffe im Vordergrund . Es wird ein 42jaehriger Mann mit allergischer Reaktion in seinen roten Taetowierungsanteilen vorgestellt . Histologisch imponierte eine chronisch verlaufende granulomatoese , teils fibrosierende Entzuendung mit transfollikulaerer Elimination von Pigmentgranula . Klinisch zeigte sich im Verlauf spontan eine partielle Rueckbildung der entzuendlichen Veraenderungen unter gleichzeitiger Depigmentierung und Vernarbung der Haut . Als Taetowierungsfarbstoff wurde ein aromatischer Azofarbstoff nachgewiesen . Neben der positiven Hauttestreaktion auf diesen Farbstoff zeigte der Patient zusaetzlich eine positive Testreaktion auf den Textilfarbstoffkoppler Napthol AS .

[ "Allergische", "Reaktionen", "auf", "Farbstoffe", "in", "Taetowierungen", "sind", "vergleichsweise", "selten", ".", "In", "der", "Mehrzahl", "sind", "es", "Reaktionen", "auf", "die", "roten", "Farbstoffe", ".", "Waehrend", "frueher", "hauptsaechlich", "Quecksilberverbindungen", "(", "Zinnober", "und", "Cadmiumsulfid", ")", "dafuer", "verantwortlich", "waren", ",", "stehen", "heute", "die", "synthetischen", "anorganischen", "Azofarbstoffe", "im", "Vordergrund", ".", "Es", "wird", "ein", "42jaehriger", "Mann", "mit", "allergischer", "Reaktion", "in", "seinen", "roten", "Taetowierungsanteilen", "vorgestellt", ".", "Histologisch", "imponierte", "eine", "chronisch", "verlaufende", "granulomatoese", ",", "teils", "fibrosierende", "Entzuendung", "mit", "transfollikulaerer", "Elimination", "von", "Pigmentgranula", ".", "Klinisch", "zeigte", "sich", "im", "Verlauf", "spontan", "eine", "partielle", "Rueckbildung", "der", "entzuendlichen", "Veraenderungen", "unter", "gleichzeitiger", "Depigmentierung", "und", "Vernarbung", "der", "Haut", ".", "Als", "Taetowierungsfarbstoff", "wurde", "ein", "aromatischer", "Azofarbstoff", "nachgewiesen", ".", "Neben", "der", "positiven", "Hauttestreaktion", "auf", "diesen", "Farbstoff", "zeigte", "der", "Patient", "zusaetzlich", "eine", "positive", "Testreaktion", "auf", "den", "Textilfarbstoffkoppler", "Napthol", "AS", "." ]

[ "umlsterm" ]

Farbstoffe is an umlsterm, Farbstoffe is an umlsterm, Quecksilberverbindungen is an umlsterm, Mann is an umlsterm, Entzuendung is an umlsterm, Haut is an umlsterm, Hauttestreaktion is an umlsterm, Farbstoff is an umlsterm, Patient is an umlsterm

DerHautarzt.70480666.ger.abstr_task1

Sentence: Allergische Reaktionen auf Farbstoffe in Taetowierungen sind vergleichsweise selten . In der Mehrzahl sind es Reaktionen auf die roten Farbstoffe . Waehrend frueher hauptsaechlich Quecksilberverbindungen ( Zinnober und Cadmiumsulfid ) dafuer verantwortlich waren , stehen heute die synthetischen anorganischen Azofarbstoffe im Vordergrund . Es wird ein 42jaehriger Mann mit allergischer Reaktion in seinen roten Taetowierungsanteilen vorgestellt . Histologisch imponierte eine chronisch verlaufende granulomatoese , teils fibrosierende Entzuendung mit transfollikulaerer Elimination von Pigmentgranula . Klinisch zeigte sich im Verlauf spontan eine partielle Rueckbildung der entzuendlichen Veraenderungen unter gleichzeitiger Depigmentierung und Vernarbung der Haut . Als Taetowierungsfarbstoff wurde ein aromatischer Azofarbstoff nachgewiesen . Neben der positiven Hauttestreaktion auf diesen Farbstoff zeigte der Patient zusaetzlich eine positive Testreaktion auf den Textilfarbstoffkoppler Napthol AS . Instructions: please typing these entity words according to sentence: Farbstoffe, Farbstoffe, Quecksilberverbindungen, Mann, Entzuendung, Haut, Hauttestreaktion, Farbstoff, Patient Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Allergische Reaktionen auf Farbstoffe in Taetowierungen sind vergleichsweise selten . In der Mehrzahl sind es Reaktionen auf die roten Farbstoffe . Waehrend frueher hauptsaechlich Quecksilberverbindungen ( Zinnober und Cadmiumsulfid ) dafuer verantwortlich waren , stehen heute die synthetischen anorganischen Azofarbstoffe im Vordergrund . Es wird ein 42jaehriger Mann mit allergischer Reaktion in seinen roten Taetowierungsanteilen vorgestellt . Histologisch imponierte eine chronisch verlaufende granulomatoese , teils fibrosierende Entzuendung mit transfollikulaerer Elimination von Pigmentgranula . Klinisch zeigte sich im Verlauf spontan eine partielle Rueckbildung der entzuendlichen Veraenderungen unter gleichzeitiger Depigmentierung und Vernarbung der Haut . Als Taetowierungsfarbstoff wurde ein aromatischer Azofarbstoff nachgewiesen . Neben der positiven Hauttestreaktion auf diesen Farbstoff zeigte der Patient zusaetzlich eine positive Testreaktion auf den Textilfarbstoffkoppler Napthol AS .

[ "Allergische", "Reaktionen", "auf", "Farbstoffe", "in", "Taetowierungen", "sind", "vergleichsweise", "selten", ".", "In", "der", "Mehrzahl", "sind", "es", "Reaktionen", "auf", "die", "roten", "Farbstoffe", ".", "Waehrend", "frueher", "hauptsaechlich", "Quecksilberverbindungen", "(", "Zinnober", "und", "Cadmiumsulfid", ")", "dafuer", "verantwortlich", "waren", ",", "stehen", "heute", "die", "synthetischen", "anorganischen", "Azofarbstoffe", "im", "Vordergrund", ".", "Es", "wird", "ein", "42jaehriger", "Mann", "mit", "allergischer", "Reaktion", "in", "seinen", "roten", "Taetowierungsanteilen", "vorgestellt", ".", "Histologisch", "imponierte", "eine", "chronisch", "verlaufende", "granulomatoese", ",", "teils", "fibrosierende", "Entzuendung", "mit", "transfollikulaerer", "Elimination", "von", "Pigmentgranula", ".", "Klinisch", "zeigte", "sich", "im", "Verlauf", "spontan", "eine", "partielle", "Rueckbildung", "der", "entzuendlichen", "Veraenderungen", "unter", "gleichzeitiger", "Depigmentierung", "und", "Vernarbung", "der", "Haut", ".", "Als", "Taetowierungsfarbstoff", "wurde", "ein", "aromatischer", "Azofarbstoff", "nachgewiesen", ".", "Neben", "der", "positiven", "Hauttestreaktion", "auf", "diesen", "Farbstoff", "zeigte", "der", "Patient", "zusaetzlich", "eine", "positive", "Testreaktion", "auf", "den", "Textilfarbstoffkoppler", "Napthol", "AS", "." ]

[ "umlsterm" ]

Farbstoffe, Farbstoffe, Quecksilberverbindungen, Mann, Entzuendung, Haut, Hauttestreaktion, Farbstoff, Patient

DerHautarzt.70480666.ger.abstr_task2

Sentence: Allergische Reaktionen auf Farbstoffe in Taetowierungen sind vergleichsweise selten . In der Mehrzahl sind es Reaktionen auf die roten Farbstoffe . Waehrend frueher hauptsaechlich Quecksilberverbindungen ( Zinnober und Cadmiumsulfid ) dafuer verantwortlich waren , stehen heute die synthetischen anorganischen Azofarbstoffe im Vordergrund . Es wird ein 42jaehriger Mann mit allergischer Reaktion in seinen roten Taetowierungsanteilen vorgestellt . Histologisch imponierte eine chronisch verlaufende granulomatoese , teils fibrosierende Entzuendung mit transfollikulaerer Elimination von Pigmentgranula . Klinisch zeigte sich im Verlauf spontan eine partielle Rueckbildung der entzuendlichen Veraenderungen unter gleichzeitiger Depigmentierung und Vernarbung der Haut . Als Taetowierungsfarbstoff wurde ein aromatischer Azofarbstoff nachgewiesen . Neben der positiven Hauttestreaktion auf diesen Farbstoff zeigte der Patient zusaetzlich eine positive Testreaktion auf den Textilfarbstoffkoppler Napthol AS . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Allergische Reaktionen auf Farbstoffe in Taetowierungen sind vergleichsweise selten . In der Mehrzahl sind es Reaktionen auf die roten Farbstoffe . Waehrend frueher hauptsaechlich Quecksilberverbindungen ( Zinnober und Cadmiumsulfid ) dafuer verantwortlich waren , stehen heute die synthetischen anorganischen Azofarbstoffe im Vordergrund . Es wird ein 42jaehriger Mann mit allergischer Reaktion in seinen roten Taetowierungsanteilen vorgestellt . Histologisch imponierte eine chronisch verlaufende granulomatoese , teils fibrosierende Entzuendung mit transfollikulaerer Elimination von Pigmentgranula . Klinisch zeigte sich im Verlauf spontan eine partielle Rueckbildung der entzuendlichen Veraenderungen unter gleichzeitiger Depigmentierung und Vernarbung der Haut . Als Taetowierungsfarbstoff wurde ein aromatischer Azofarbstoff nachgewiesen . Neben der positiven Hauttestreaktion auf diesen Farbstoff zeigte der Patient zusaetzlich eine positive Testreaktion auf den Textilfarbstoffkoppler Napthol AS .

[ "Allergische", "Reaktionen", "auf", "Farbstoffe", "in", "Taetowierungen", "sind", "vergleichsweise", "selten", ".", "In", "der", "Mehrzahl", "sind", "es", "Reaktionen", "auf", "die", "roten", "Farbstoffe", ".", "Waehrend", "frueher", "hauptsaechlich", "Quecksilberverbindungen", "(", "Zinnober", "und", "Cadmiumsulfid", ")", "dafuer", "verantwortlich", "waren", ",", "stehen", "heute", "die", "synthetischen", "anorganischen", "Azofarbstoffe", "im", "Vordergrund", ".", "Es", "wird", "ein", "42jaehriger", "Mann", "mit", "allergischer", "Reaktion", "in", "seinen", "roten", "Taetowierungsanteilen", "vorgestellt", ".", "Histologisch", "imponierte", "eine", "chronisch", "verlaufende", "granulomatoese", ",", "teils", "fibrosierende", "Entzuendung", "mit", "transfollikulaerer", "Elimination", "von", "Pigmentgranula", ".", "Klinisch", "zeigte", "sich", "im", "Verlauf", "spontan", "eine", "partielle", "Rueckbildung", "der", "entzuendlichen", "Veraenderungen", "unter", "gleichzeitiger", "Depigmentierung", "und", "Vernarbung", "der", "Haut", ".", "Als", "Taetowierungsfarbstoff", "wurde", "ein", "aromatischer", "Azofarbstoff", "nachgewiesen", ".", "Neben", "der", "positiven", "Hauttestreaktion", "auf", "diesen", "Farbstoff", "zeigte", "der", "Patient", "zusaetzlich", "eine", "positive", "Testreaktion", "auf", "den", "Textilfarbstoffkoppler", "Napthol", "AS", "." ]

[ "umlsterm" ]

Belastung is an umlsterm, diagnoseuebergreifende is an umlsterm, Instruments is an umlsterm

ZfuerGerontologie+Geriatrie.90320231.ger.abstr_task0

Sentence: Mit dem Grad Objektiver Gesundheitlicher Belastung ( OGB ) wird ein Expertenrating zur Erfassung der Beeintraechtigung durch koerperliche Erkrankungen vorgestellt , das unter Beruecksichtigung des Alters eine diagnoseuebergreifende klinische Schweregradeinschaetzung koerperlicher Erkrankungen ermoeglicht . Die fuenf Skalenstufen werden mit klinischen Ankerbeispielen belegt . Die Interrater-Reliabilitaet des OGB ist mit mindestens 0,74 zufriedenstellend . Externe Kriterien geben erste Hinweise auf die Validitaet des Instruments . Seine leichte Erlernbarkeit und Handhabbarkeit sprechen fuer einen breiten klinischen Einsatz sowohl im Rahmen des geriatrischen Basisassessments als auch unter Forschungsaspekten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mit dem Grad Objektiver Gesundheitlicher Belastung ( OGB ) wird ein Expertenrating zur Erfassung der Beeintraechtigung durch koerperliche Erkrankungen vorgestellt , das unter Beruecksichtigung des Alters eine diagnoseuebergreifende klinische Schweregradeinschaetzung koerperlicher Erkrankungen ermoeglicht . Die fuenf Skalenstufen werden mit klinischen Ankerbeispielen belegt . Die Interrater-Reliabilitaet des OGB ist mit mindestens 0,74 zufriedenstellend . Externe Kriterien geben erste Hinweise auf die Validitaet des Instruments . Seine leichte Erlernbarkeit und Handhabbarkeit sprechen fuer einen breiten klinischen Einsatz sowohl im Rahmen des geriatrischen Basisassessments als auch unter Forschungsaspekten .

[ "Mit", "dem", "Grad", "Objektiver", "Gesundheitlicher", "Belastung", "(", "OGB", ")", "wird", "ein", "Expertenrating", "zur", "Erfassung", "der", "Beeintraechtigung", "durch", "koerperliche", "Erkrankungen", "vorgestellt", ",", "das", "unter", "Beruecksichtigung", "des", "Alters", "eine", "diagnoseuebergreifende", "klinische", "Schweregradeinschaetzung", "koerperlicher", "Erkrankungen", "ermoeglicht", ".", "Die", "fuenf", "Skalenstufen", "werden", "mit", "klinischen", "Ankerbeispielen", "belegt", ".", "Die", "Interrater", "-", "Reliabilitaet", "des", "OGB", "ist", "mit", "mindestens", "0,74", "zufriedenstellend", ".", "Externe", "Kriterien", "geben", "erste", "Hinweise", "auf", "die", "Validitaet", "des", "Instruments", ".", "Seine", "leichte", "Erlernbarkeit", "und", "Handhabbarkeit", "sprechen", "fuer", "einen", "breiten", "klinischen", "Einsatz", "sowohl", "im", "Rahmen", "des", "geriatrischen", "Basisassessments", "als", "auch", "unter", "Forschungsaspekten", "." ]

[ "umlsterm" ]

Belastung is an umlsterm, diagnoseuebergreifende is an umlsterm, Instruments is an umlsterm

ZfuerGerontologie+Geriatrie.90320231.ger.abstr_task1

Sentence: Mit dem Grad Objektiver Gesundheitlicher Belastung ( OGB ) wird ein Expertenrating zur Erfassung der Beeintraechtigung durch koerperliche Erkrankungen vorgestellt , das unter Beruecksichtigung des Alters eine diagnoseuebergreifende klinische Schweregradeinschaetzung koerperlicher Erkrankungen ermoeglicht . Die fuenf Skalenstufen werden mit klinischen Ankerbeispielen belegt . Die Interrater-Reliabilitaet des OGB ist mit mindestens 0,74 zufriedenstellend . Externe Kriterien geben erste Hinweise auf die Validitaet des Instruments . Seine leichte Erlernbarkeit und Handhabbarkeit sprechen fuer einen breiten klinischen Einsatz sowohl im Rahmen des geriatrischen Basisassessments als auch unter Forschungsaspekten . Instructions: please typing these entity words according to sentence: Belastung, diagnoseuebergreifende, Instruments Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mit dem Grad Objektiver Gesundheitlicher Belastung ( OGB ) wird ein Expertenrating zur Erfassung der Beeintraechtigung durch koerperliche Erkrankungen vorgestellt , das unter Beruecksichtigung des Alters eine diagnoseuebergreifende klinische Schweregradeinschaetzung koerperlicher Erkrankungen ermoeglicht . Die fuenf Skalenstufen werden mit klinischen Ankerbeispielen belegt . Die Interrater-Reliabilitaet des OGB ist mit mindestens 0,74 zufriedenstellend . Externe Kriterien geben erste Hinweise auf die Validitaet des Instruments . Seine leichte Erlernbarkeit und Handhabbarkeit sprechen fuer einen breiten klinischen Einsatz sowohl im Rahmen des geriatrischen Basisassessments als auch unter Forschungsaspekten .

[ "Mit", "dem", "Grad", "Objektiver", "Gesundheitlicher", "Belastung", "(", "OGB", ")", "wird", "ein", "Expertenrating", "zur", "Erfassung", "der", "Beeintraechtigung", "durch", "koerperliche", "Erkrankungen", "vorgestellt", ",", "das", "unter", "Beruecksichtigung", "des", "Alters", "eine", "diagnoseuebergreifende", "klinische", "Schweregradeinschaetzung", "koerperlicher", "Erkrankungen", "ermoeglicht", ".", "Die", "fuenf", "Skalenstufen", "werden", "mit", "klinischen", "Ankerbeispielen", "belegt", ".", "Die", "Interrater", "-", "Reliabilitaet", "des", "OGB", "ist", "mit", "mindestens", "0,74", "zufriedenstellend", ".", "Externe", "Kriterien", "geben", "erste", "Hinweise", "auf", "die", "Validitaet", "des", "Instruments", ".", "Seine", "leichte", "Erlernbarkeit", "und", "Handhabbarkeit", "sprechen", "fuer", "einen", "breiten", "klinischen", "Einsatz", "sowohl", "im", "Rahmen", "des", "geriatrischen", "Basisassessments", "als", "auch", "unter", "Forschungsaspekten", "." ]

[ "umlsterm" ]

Belastung, diagnoseuebergreifende, Instruments

ZfuerGerontologie+Geriatrie.90320231.ger.abstr_task2

Sentence: Mit dem Grad Objektiver Gesundheitlicher Belastung ( OGB ) wird ein Expertenrating zur Erfassung der Beeintraechtigung durch koerperliche Erkrankungen vorgestellt , das unter Beruecksichtigung des Alters eine diagnoseuebergreifende klinische Schweregradeinschaetzung koerperlicher Erkrankungen ermoeglicht . Die fuenf Skalenstufen werden mit klinischen Ankerbeispielen belegt . Die Interrater-Reliabilitaet des OGB ist mit mindestens 0,74 zufriedenstellend . Externe Kriterien geben erste Hinweise auf die Validitaet des Instruments . Seine leichte Erlernbarkeit und Handhabbarkeit sprechen fuer einen breiten klinischen Einsatz sowohl im Rahmen des geriatrischen Basisassessments als auch unter Forschungsaspekten . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mit dem Grad Objektiver Gesundheitlicher Belastung ( OGB ) wird ein Expertenrating zur Erfassung der Beeintraechtigung durch koerperliche Erkrankungen vorgestellt , das unter Beruecksichtigung des Alters eine diagnoseuebergreifende klinische Schweregradeinschaetzung koerperlicher Erkrankungen ermoeglicht . Die fuenf Skalenstufen werden mit klinischen Ankerbeispielen belegt . Die Interrater-Reliabilitaet des OGB ist mit mindestens 0,74 zufriedenstellend . Externe Kriterien geben erste Hinweise auf die Validitaet des Instruments . Seine leichte Erlernbarkeit und Handhabbarkeit sprechen fuer einen breiten klinischen Einsatz sowohl im Rahmen des geriatrischen Basisassessments als auch unter Forschungsaspekten .

[ "Mit", "dem", "Grad", "Objektiver", "Gesundheitlicher", "Belastung", "(", "OGB", ")", "wird", "ein", "Expertenrating", "zur", "Erfassung", "der", "Beeintraechtigung", "durch", "koerperliche", "Erkrankungen", "vorgestellt", ",", "das", "unter", "Beruecksichtigung", "des", "Alters", "eine", "diagnoseuebergreifende", "klinische", "Schweregradeinschaetzung", "koerperlicher", "Erkrankungen", "ermoeglicht", ".", "Die", "fuenf", "Skalenstufen", "werden", "mit", "klinischen", "Ankerbeispielen", "belegt", ".", "Die", "Interrater", "-", "Reliabilitaet", "des", "OGB", "ist", "mit", "mindestens", "0,74", "zufriedenstellend", ".", "Externe", "Kriterien", "geben", "erste", "Hinweise", "auf", "die", "Validitaet", "des", "Instruments", ".", "Seine", "leichte", "Erlernbarkeit", "und", "Handhabbarkeit", "sprechen", "fuer", "einen", "breiten", "klinischen", "Einsatz", "sowohl", "im", "Rahmen", "des", "geriatrischen", "Basisassessments", "als", "auch", "unter", "Forschungsaspekten", "." ]

[ "umlsterm" ]

survivors of breast cancer : is a Participant_Condition, placebo - controlled is a Intervention_Control, bisphosphonate therapy is a Intervention_Pharmacological, breast cancer survivors . is a Participant_Condition, risedronate is a Intervention_Pharmacological, 12-month changes in spine and hip bone mineral density . is a Outcome_Physical, changes in markers of bone resorption ( urine N - telopeptide cross - linked collagen type I ) and formation ( osteocalcin , N - terminal propeptide of type I procollagen , and bone - specific alkaline phosphatase ) is a Outcome_Physical, Risedronate is a Intervention_Pharmacological, tolerated is a Outcome_Other, retention rate is a Outcome_Other

28357_task0

Sentence: Prevention of bone loss in survivors of breast cancer : A randomized , double-blind , placebo-controlled clinical trial . BACKGROUND Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors . OBJECTIVE Our objective was to determine whether risedronate , 35 mg weekly , is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause . DESIGN The study was a randomized , double-blind , placebo-controlled clinical trial over 12 months . SETTING AND PARTICIPANTS Participants included 87 newly postmenopausal women with status post chemotherapy , recruited from a breast cancer clinic in an academic medical center . INTERVENTION Participants were randomly assigned to receive risedronate 35 mg/wk or placebo . MAIN OUTCOME MEASURES The primary outcomes were the 12-month changes in spine and hip bone mineral density . Secondary outcomes included changes in markers of bone resorption ( urine N-telopeptide cross-linked collagen type I ) and formation ( osteocalcin , N-terminal propeptide of type I procollagen , and bone-specific alkaline phosphatase ) . RESULTS After 12 months , bone mineral density increased by 1.2 % at the spine and 1.3 % at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9 % at the spine and 0.8 % at the hip ( P < 0.01 , difference between groups ) . N-telopeptide cross-linked collagen type I , a marker of bone resorption , decreased by 19.3 % , and N-terminal propeptide of type I procollagen , a marker of bone formation , decreased by 26.6 % in participants on active therapy compared with increases in the control group . Risedronate was well tolerated , and the retention rate was 95 % at 1 yr . CONCLUSIONS Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy . Early measures to prevent bone loss should be considered in this cohort of breast cancer survivors . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other

[ "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Prevention of bone loss in survivors of breast cancer : A randomized , double-blind , placebo-controlled clinical trial . BACKGROUND Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors . OBJECTIVE Our objective was to determine whether risedronate , 35 mg weekly , is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause . DESIGN The study was a randomized , double-blind , placebo-controlled clinical trial over 12 months . SETTING AND PARTICIPANTS Participants included 87 newly postmenopausal women with status post chemotherapy , recruited from a breast cancer clinic in an academic medical center . INTERVENTION Participants were randomly assigned to receive risedronate 35 mg/wk or placebo . MAIN OUTCOME MEASURES The primary outcomes were the 12-month changes in spine and hip bone mineral density . Secondary outcomes included changes in markers of bone resorption ( urine N-telopeptide cross-linked collagen type I ) and formation ( osteocalcin , N-terminal propeptide of type I procollagen , and bone-specific alkaline phosphatase ) . RESULTS After 12 months , bone mineral density increased by 1.2 % at the spine and 1.3 % at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9 % at the spine and 0.8 % at the hip ( P < 0.01 , difference between groups ) . N-telopeptide cross-linked collagen type I , a marker of bone resorption , decreased by 19.3 % , and N-terminal propeptide of type I procollagen , a marker of bone formation , decreased by 26.6 % in participants on active therapy compared with increases in the control group . Risedronate was well tolerated , and the retention rate was 95 % at 1 yr . CONCLUSIONS Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy . Early measures to prevent bone loss should be considered in this cohort of breast cancer survivors .

[ "Prevention", "of", "bone", "loss", "in", "survivors", "of", "breast", "cancer", ":", "A", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "Few", "data", "are", "available", "on", "the", "safety", "and", "efficacy", "of", "once", "-", "weekly", "oral", "bisphosphonate", "therapy", "in", "breast", "cancer", "survivors", ".", "OBJECTIVE", "Our", "objective", "was", "to", "determine", "whether", "risedronate", ",", "35", "mg", "weekly", ",", "is", "efficacious", "and", "safe", "in", "preventing", "bone", "loss", "associated", "with", "chemotherapy", "-", "induced", "menopause", ".", "DESIGN", "The", "study", "was", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", "over", "12", "months", ".", "SETTING", "AND", "PARTICIPANTS", "Participants", "included", "87", "newly", "postmenopausal", "women", "with", "status", "post", "chemotherapy", ",", "recruited", "from", "a", "breast", "cancer", "clinic", "in", "an", "academic", "medical", "center", ".", "INTERVENTION", "Participants", "were", "randomly", "assigned", "to", "receive", "risedronate", "35", "mg", "/", "wk", "or", "placebo", ".", "MAIN", "OUTCOME", "MEASURES", "The", "primary", "outcomes", "were", "the", "12-month", "changes", "in", "spine", "and", "hip", "bone", "mineral", "density", ".", "Secondary", "outcomes", "included", "changes", "in", "markers", "of", "bone", "resorption", "(", "urine", "N", "-", "telopeptide", "cross", "-", "linked", "collagen", "type", "I", ")", "and", "formation", "(", "osteocalcin", ",", "N", "-", "terminal", "propeptide", "of", "type", "I", "procollagen", ",", "and", "bone", "-", "specific", "alkaline", "phosphatase", ")", ".", "RESULTS", "After", "12", "months", ",", "bone", "mineral", "density", "increased", "by", "1.2", "%", "at", "the", "spine", "and", "1.3", "%", "at", "the", "hip", "in", "women", "on", "risedronate", "vs", ".", "significant", "decreases", "for", "women", "in", "the", "placebo", "group", "of", "0.9", "%", "at", "the", "spine", "and", "0.8", "%", "at", "the", "hip", "(", "P", "<", "0.01", ",", "difference", "between", "groups", ")", ".", "N", "-", "telopeptide", "cross", "-", "linked", "collagen", "type", "I", ",", "a", "marker", "of", "bone", "resorption", ",", "decreased", "by", "19.3", "%", ",", "and", "N", "-", "terminal", "propeptide", "of", "type", "I", "procollagen", ",", "a", "marker", "of", "bone", "formation", ",", "decreased", "by", "26.6", "%", "in", "participants", "on", "active", "therapy", "compared", "with", "increases", "in", "the", "control", "group", ".", "Risedronate", "was", "well", "tolerated", ",", "and", "the", "retention", "rate", "was", "95", "%", "at", "1", "yr", ".", "CONCLUSIONS", "Risedronate", "once", "weekly", "prevented", "bone", "loss", "and", "reduced", "bone", "turnover", "in", "women", "with", "breast", "cancer", "treated", "with", "chemotherapy", ".", "Early", "measures", "to", "prevent", "bone", "loss", "should", "be", "considered", "in", "this", "cohort", "of", "breast", "cancer", "survivors", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Outcome_Other" ]

survivors of breast cancer : is a Participant_Condition, placebo - controlled is a Intervention_Control, bisphosphonate therapy is a Intervention_Pharmacological, breast cancer survivors . is a Participant_Condition, risedronate is a Intervention_Pharmacological, 12-month changes in spine and hip bone mineral density . is a Outcome_Physical, changes in markers of bone resorption ( urine N - telopeptide cross - linked collagen type I ) and formation ( osteocalcin , N - terminal propeptide of type I procollagen , and bone - specific alkaline phosphatase ) is a Outcome_Physical, Risedronate is a Intervention_Pharmacological, tolerated is a Outcome_Other, retention rate is a Outcome_Other

28357_task1

Sentence: Prevention of bone loss in survivors of breast cancer : A randomized , double-blind , placebo-controlled clinical trial . BACKGROUND Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors . OBJECTIVE Our objective was to determine whether risedronate , 35 mg weekly , is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause . DESIGN The study was a randomized , double-blind , placebo-controlled clinical trial over 12 months . SETTING AND PARTICIPANTS Participants included 87 newly postmenopausal women with status post chemotherapy , recruited from a breast cancer clinic in an academic medical center . INTERVENTION Participants were randomly assigned to receive risedronate 35 mg/wk or placebo . MAIN OUTCOME MEASURES The primary outcomes were the 12-month changes in spine and hip bone mineral density . Secondary outcomes included changes in markers of bone resorption ( urine N-telopeptide cross-linked collagen type I ) and formation ( osteocalcin , N-terminal propeptide of type I procollagen , and bone-specific alkaline phosphatase ) . RESULTS After 12 months , bone mineral density increased by 1.2 % at the spine and 1.3 % at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9 % at the spine and 0.8 % at the hip ( P < 0.01 , difference between groups ) . N-telopeptide cross-linked collagen type I , a marker of bone resorption , decreased by 19.3 % , and N-terminal propeptide of type I procollagen , a marker of bone formation , decreased by 26.6 % in participants on active therapy compared with increases in the control group . Risedronate was well tolerated , and the retention rate was 95 % at 1 yr . CONCLUSIONS Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy . Early measures to prevent bone loss should be considered in this cohort of breast cancer survivors . Instructions: please typing these entity words according to sentence: survivors of breast cancer :, placebo - controlled, bisphosphonate therapy, breast cancer survivors ., risedronate, 12-month changes in spine and hip bone mineral density ., changes in markers of bone resorption ( urine N - telopeptide cross - linked collagen type I ) and formation ( osteocalcin , N - terminal propeptide of type I procollagen , and bone - specific alkaline phosphatase ), Risedronate, tolerated, retention rate Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other

[ "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Prevention of bone loss in survivors of breast cancer : A randomized , double-blind , placebo-controlled clinical trial . BACKGROUND Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors . OBJECTIVE Our objective was to determine whether risedronate , 35 mg weekly , is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause . DESIGN The study was a randomized , double-blind , placebo-controlled clinical trial over 12 months . SETTING AND PARTICIPANTS Participants included 87 newly postmenopausal women with status post chemotherapy , recruited from a breast cancer clinic in an academic medical center . INTERVENTION Participants were randomly assigned to receive risedronate 35 mg/wk or placebo . MAIN OUTCOME MEASURES The primary outcomes were the 12-month changes in spine and hip bone mineral density . Secondary outcomes included changes in markers of bone resorption ( urine N-telopeptide cross-linked collagen type I ) and formation ( osteocalcin , N-terminal propeptide of type I procollagen , and bone-specific alkaline phosphatase ) . RESULTS After 12 months , bone mineral density increased by 1.2 % at the spine and 1.3 % at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9 % at the spine and 0.8 % at the hip ( P < 0.01 , difference between groups ) . N-telopeptide cross-linked collagen type I , a marker of bone resorption , decreased by 19.3 % , and N-terminal propeptide of type I procollagen , a marker of bone formation , decreased by 26.6 % in participants on active therapy compared with increases in the control group . Risedronate was well tolerated , and the retention rate was 95 % at 1 yr . CONCLUSIONS Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy . Early measures to prevent bone loss should be considered in this cohort of breast cancer survivors .

[ "Prevention", "of", "bone", "loss", "in", "survivors", "of", "breast", "cancer", ":", "A", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "Few", "data", "are", "available", "on", "the", "safety", "and", "efficacy", "of", "once", "-", "weekly", "oral", "bisphosphonate", "therapy", "in", "breast", "cancer", "survivors", ".", "OBJECTIVE", "Our", "objective", "was", "to", "determine", "whether", "risedronate", ",", "35", "mg", "weekly", ",", "is", "efficacious", "and", "safe", "in", "preventing", "bone", "loss", "associated", "with", "chemotherapy", "-", "induced", "menopause", ".", "DESIGN", "The", "study", "was", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", "over", "12", "months", ".", "SETTING", "AND", "PARTICIPANTS", "Participants", "included", "87", "newly", "postmenopausal", "women", "with", "status", "post", "chemotherapy", ",", "recruited", "from", "a", "breast", "cancer", "clinic", "in", "an", "academic", "medical", "center", ".", "INTERVENTION", "Participants", "were", "randomly", "assigned", "to", "receive", "risedronate", "35", "mg", "/", "wk", "or", "placebo", ".", "MAIN", "OUTCOME", "MEASURES", "The", "primary", "outcomes", "were", "the", "12-month", "changes", "in", "spine", "and", "hip", "bone", "mineral", "density", ".", "Secondary", "outcomes", "included", "changes", "in", "markers", "of", "bone", "resorption", "(", "urine", "N", "-", "telopeptide", "cross", "-", "linked", "collagen", "type", "I", ")", "and", "formation", "(", "osteocalcin", ",", "N", "-", "terminal", "propeptide", "of", "type", "I", "procollagen", ",", "and", "bone", "-", "specific", "alkaline", "phosphatase", ")", ".", "RESULTS", "After", "12", "months", ",", "bone", "mineral", "density", "increased", "by", "1.2", "%", "at", "the", "spine", "and", "1.3", "%", "at", "the", "hip", "in", "women", "on", "risedronate", "vs", ".", "significant", "decreases", "for", "women", "in", "the", "placebo", "group", "of", "0.9", "%", "at", "the", "spine", "and", "0.8", "%", "at", "the", "hip", "(", "P", "<", "0.01", ",", "difference", "between", "groups", ")", ".", "N", "-", "telopeptide", "cross", "-", "linked", "collagen", "type", "I", ",", "a", "marker", "of", "bone", "resorption", ",", "decreased", "by", "19.3", "%", ",", "and", "N", "-", "terminal", "propeptide", "of", "type", "I", "procollagen", ",", "a", "marker", "of", "bone", "formation", ",", "decreased", "by", "26.6", "%", "in", "participants", "on", "active", "therapy", "compared", "with", "increases", "in", "the", "control", "group", ".", "Risedronate", "was", "well", "tolerated", ",", "and", "the", "retention", "rate", "was", "95", "%", "at", "1", "yr", ".", "CONCLUSIONS", "Risedronate", "once", "weekly", "prevented", "bone", "loss", "and", "reduced", "bone", "turnover", "in", "women", "with", "breast", "cancer", "treated", "with", "chemotherapy", ".", "Early", "measures", "to", "prevent", "bone", "loss", "should", "be", "considered", "in", "this", "cohort", "of", "breast", "cancer", "survivors", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Outcome_Other" ]

survivors of breast cancer :, placebo - controlled, bisphosphonate therapy, breast cancer survivors ., risedronate, 12-month changes in spine and hip bone mineral density ., changes in markers of bone resorption ( urine N - telopeptide cross - linked collagen type I ) and formation ( osteocalcin , N - terminal propeptide of type I procollagen , and bone - specific alkaline phosphatase ), Risedronate, tolerated, retention rate

28357_task2

Sentence: Prevention of bone loss in survivors of breast cancer : A randomized , double-blind , placebo-controlled clinical trial . BACKGROUND Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors . OBJECTIVE Our objective was to determine whether risedronate , 35 mg weekly , is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause . DESIGN The study was a randomized , double-blind , placebo-controlled clinical trial over 12 months . SETTING AND PARTICIPANTS Participants included 87 newly postmenopausal women with status post chemotherapy , recruited from a breast cancer clinic in an academic medical center . INTERVENTION Participants were randomly assigned to receive risedronate 35 mg/wk or placebo . MAIN OUTCOME MEASURES The primary outcomes were the 12-month changes in spine and hip bone mineral density . Secondary outcomes included changes in markers of bone resorption ( urine N-telopeptide cross-linked collagen type I ) and formation ( osteocalcin , N-terminal propeptide of type I procollagen , and bone-specific alkaline phosphatase ) . RESULTS After 12 months , bone mineral density increased by 1.2 % at the spine and 1.3 % at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9 % at the spine and 0.8 % at the hip ( P < 0.01 , difference between groups ) . N-telopeptide cross-linked collagen type I , a marker of bone resorption , decreased by 19.3 % , and N-terminal propeptide of type I procollagen , a marker of bone formation , decreased by 26.6 % in participants on active therapy compared with increases in the control group . Risedronate was well tolerated , and the retention rate was 95 % at 1 yr . CONCLUSIONS Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy . Early measures to prevent bone loss should be considered in this cohort of breast cancer survivors . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Prevention of bone loss in survivors of breast cancer : A randomized , double-blind , placebo-controlled clinical trial . BACKGROUND Few data are available on the safety and efficacy of once-weekly oral bisphosphonate therapy in breast cancer survivors . OBJECTIVE Our objective was to determine whether risedronate , 35 mg weekly , is efficacious and safe in preventing bone loss associated with chemotherapy-induced menopause . DESIGN The study was a randomized , double-blind , placebo-controlled clinical trial over 12 months . SETTING AND PARTICIPANTS Participants included 87 newly postmenopausal women with status post chemotherapy , recruited from a breast cancer clinic in an academic medical center . INTERVENTION Participants were randomly assigned to receive risedronate 35 mg/wk or placebo . MAIN OUTCOME MEASURES The primary outcomes were the 12-month changes in spine and hip bone mineral density . Secondary outcomes included changes in markers of bone resorption ( urine N-telopeptide cross-linked collagen type I ) and formation ( osteocalcin , N-terminal propeptide of type I procollagen , and bone-specific alkaline phosphatase ) . RESULTS After 12 months , bone mineral density increased by 1.2 % at the spine and 1.3 % at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9 % at the spine and 0.8 % at the hip ( P < 0.01 , difference between groups ) . N-telopeptide cross-linked collagen type I , a marker of bone resorption , decreased by 19.3 % , and N-terminal propeptide of type I procollagen , a marker of bone formation , decreased by 26.6 % in participants on active therapy compared with increases in the control group . Risedronate was well tolerated , and the retention rate was 95 % at 1 yr . CONCLUSIONS Risedronate once weekly prevented bone loss and reduced bone turnover in women with breast cancer treated with chemotherapy . Early measures to prevent bone loss should be considered in this cohort of breast cancer survivors .

[ "Prevention", "of", "bone", "loss", "in", "survivors", "of", "breast", "cancer", ":", "A", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "Few", "data", "are", "available", "on", "the", "safety", "and", "efficacy", "of", "once", "-", "weekly", "oral", "bisphosphonate", "therapy", "in", "breast", "cancer", "survivors", ".", "OBJECTIVE", "Our", "objective", "was", "to", "determine", "whether", "risedronate", ",", "35", "mg", "weekly", ",", "is", "efficacious", "and", "safe", "in", "preventing", "bone", "loss", "associated", "with", "chemotherapy", "-", "induced", "menopause", ".", "DESIGN", "The", "study", "was", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", "over", "12", "months", ".", "SETTING", "AND", "PARTICIPANTS", "Participants", "included", "87", "newly", "postmenopausal", "women", "with", "status", "post", "chemotherapy", ",", "recruited", "from", "a", "breast", "cancer", "clinic", "in", "an", "academic", "medical", "center", ".", "INTERVENTION", "Participants", "were", "randomly", "assigned", "to", "receive", "risedronate", "35", "mg", "/", "wk", "or", "placebo", ".", "MAIN", "OUTCOME", "MEASURES", "The", "primary", "outcomes", "were", "the", "12-month", "changes", "in", "spine", "and", "hip", "bone", "mineral", "density", ".", "Secondary", "outcomes", "included", "changes", "in", "markers", "of", "bone", "resorption", "(", "urine", "N", "-", "telopeptide", "cross", "-", "linked", "collagen", "type", "I", ")", "and", "formation", "(", "osteocalcin", ",", "N", "-", "terminal", "propeptide", "of", "type", "I", "procollagen", ",", "and", "bone", "-", "specific", "alkaline", "phosphatase", ")", ".", "RESULTS", "After", "12", "months", ",", "bone", "mineral", "density", "increased", "by", "1.2", "%", "at", "the", "spine", "and", "1.3", "%", "at", "the", "hip", "in", "women", "on", "risedronate", "vs", ".", "significant", "decreases", "for", "women", "in", "the", "placebo", "group", "of", "0.9", "%", "at", "the", "spine", "and", "0.8", "%", "at", "the", "hip", "(", "P", "<", "0.01", ",", "difference", "between", "groups", ")", ".", "N", "-", "telopeptide", "cross", "-", "linked", "collagen", "type", "I", ",", "a", "marker", "of", "bone", "resorption", ",", "decreased", "by", "19.3", "%", ",", "and", "N", "-", "terminal", "propeptide", "of", "type", "I", "procollagen", ",", "a", "marker", "of", "bone", "formation", ",", "decreased", "by", "26.6", "%", "in", "participants", "on", "active", "therapy", "compared", "with", "increases", "in", "the", "control", "group", ".", "Risedronate", "was", "well", "tolerated", ",", "and", "the", "retention", "rate", "was", "95", "%", "at", "1", "yr", ".", "CONCLUSIONS", "Risedronate", "once", "weekly", "prevented", "bone", "loss", "and", "reduced", "bone", "turnover", "in", "women", "with", "breast", "cancer", "treated", "with", "chemotherapy", ".", "Early", "measures", "to", "prevent", "bone", "loss", "should", "be", "considered", "in", "this", "cohort", "of", "breast", "cancer", "survivors", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Outcome_Other" ]

zoledronic acid is a Intervention_Pharmacological, women is a Participant_Sex, locally advanced breast cancer is a Participant_Condition, bisphosphonates is a Intervention_Pharmacological, disseminated tumour cells ( DTCs ) is a Outcome_Physical, neoadjuvant chemotherapy is a Participant_Condition, clinical stage II - III ( > or = T2 and / or > or = N1 ) newly diagnosed breast cancer is a Participant_Condition, 120 is a Participant_Sample-size, 4 mg zoledronic acid intravenously every is a Intervention_Pharmacological, no zoledronic acid is a Intervention_Pharmacological, four cycles of neoadjuvant epirubicin is a Intervention_Pharmacological, docetaxel is a Intervention_Pharmacological, and two cycles of adjuvant epirubicin plus docetaxel is a Intervention_Pharmacological, detectable DTCs is a Outcome_Physical, baseline bone marrow is a Participant_Condition, 109 is a Participant_Sample-size, bone - marrow samples is a Participant_Condition, osteonecrosis is a Outcome_Adverse-effects, Zoledronic acid is a Intervention_Pharmacological

45221_task0

Sentence: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer : an open label , randomised , phase 2 trial . BACKGROUND Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer . The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells ( DTCs ) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer . METHODS Patients were recruited for this open-label , phase 2 randomised trial between March 17 , 2003 , and May 19 , 2006 , at a single centre . Eligible patients had clinical stage II-III ( > or = T2 and/or > or = N1 ) newly diagnosed breast cancer , Eastern Cooperative Oncology Group performance status of 0 or 1 , and normal cardiac , renal , and liver function . 120 women were randomly assigned , using allocation concealment , to receive 4 mg zoledronic acid intravenously every 3 weeks ( n=60 ) , or no zoledronic acid ( n=60 ) , for 1 year concomitant with four cycles of neoadjuvant epirubicin ( 75 mg/m ( 2 ) ) plus docetaxel ( 75 mg/m ( 2 ) ) and two cycles of adjuvant epirubicin plus docetaxel . The primary endpoint was the number of patients with detectable DTCs at 3 months . Final analysis was done 1 year after the last patient was enrolled . Analyses were done for all patients with available data at 3 months . This study is registered with ClinicalTrials.gov , number NCT00242203 . FINDINGS Of the 120 patients initially enrolled , one withdrew after signing consent and one patient 's baseline bone marrow was not available . Both of these patients were in the control group . At 3 months , 109 bone-marrow samples were available for analysis . In the zoledronic acid group , bone marrow was not collected from one patient because of disease progression , one patient was taken off study because of severe diarrhoea , and two patients had not consented at the time of surgery . In the control group , bone marrow was not collected from two patients because of disease progression , one patient withdrew consent , and three patients were not consented at the time of surgery . At baseline , DTCs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the control group . At 3 months , 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs ( p=0.054 ) . The most common grade 3-4 toxicities were infection ( five of 60 patients in the zoledronic acid group and six of 59 in the control group ) and thrombosis ( five of 60 in the zoledronic acid and two of 59 in the control group ) . There was one documented case of osteonecrosis in the zoledronic acid group . INTERPRETATION Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery . Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs . FUNDING Novartis Pharmaceuticals and Pfizer Inc . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Participant_Sex, Outcome_Physical, Participant_Sample-size

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Sex", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer : an open label , randomised , phase 2 trial . BACKGROUND Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer . The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells ( DTCs ) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer . METHODS Patients were recruited for this open-label , phase 2 randomised trial between March 17 , 2003 , and May 19 , 2006 , at a single centre . Eligible patients had clinical stage II-III ( > or = T2 and/or > or = N1 ) newly diagnosed breast cancer , Eastern Cooperative Oncology Group performance status of 0 or 1 , and normal cardiac , renal , and liver function . 120 women were randomly assigned , using allocation concealment , to receive 4 mg zoledronic acid intravenously every 3 weeks ( n=60 ) , or no zoledronic acid ( n=60 ) , for 1 year concomitant with four cycles of neoadjuvant epirubicin ( 75 mg/m ( 2 ) ) plus docetaxel ( 75 mg/m ( 2 ) ) and two cycles of adjuvant epirubicin plus docetaxel . The primary endpoint was the number of patients with detectable DTCs at 3 months . Final analysis was done 1 year after the last patient was enrolled . Analyses were done for all patients with available data at 3 months . This study is registered with ClinicalTrials.gov , number NCT00242203 . FINDINGS Of the 120 patients initially enrolled , one withdrew after signing consent and one patient 's baseline bone marrow was not available . Both of these patients were in the control group . At 3 months , 109 bone-marrow samples were available for analysis . In the zoledronic acid group , bone marrow was not collected from one patient because of disease progression , one patient was taken off study because of severe diarrhoea , and two patients had not consented at the time of surgery . In the control group , bone marrow was not collected from two patients because of disease progression , one patient withdrew consent , and three patients were not consented at the time of surgery . At baseline , DTCs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the control group . At 3 months , 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs ( p=0.054 ) . The most common grade 3-4 toxicities were infection ( five of 60 patients in the zoledronic acid group and six of 59 in the control group ) and thrombosis ( five of 60 in the zoledronic acid and two of 59 in the control group ) . There was one documented case of osteonecrosis in the zoledronic acid group . INTERPRETATION Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery . Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs . FUNDING Novartis Pharmaceuticals and Pfizer Inc .

[ "Effect", "of", "zoledronic", "acid", "on", "disseminated", "tumour", "cells", "in", "women", "with", "locally", "advanced", "breast", "cancer", ":", "an", "open", "label", ",", "randomised", ",", "phase", "2", "trial", ".", "BACKGROUND", "Treatment", "with", "bisphosphonates", "decreases", "bone", "loss", "and", "can", "increase", "disease", "-", "free", "survival", "in", "patients", "with", "breast", "cancer", ".", "The", "aim", "of", "our", "study", "was", "to", "assess", "the", "effect", "of", "zoledronic", "acid", "on", "clearance", "of", "disseminated", "tumour", "cells", "(", "DTCs", ")", "from", "the", "bone", "marrow", "in", "women", "undergoing", "neoadjuvant", "chemotherapy", "for", "breast", "cancer", ".", "METHODS", "Patients", "were", "recruited", "for", "this", "open", "-", "label", ",", "phase", "2", "randomised", "trial", "between", "March", "17", ",", "2003", ",", "and", "May", "19", ",", "2006", ",", "at", "a", "single", "centre", ".", "Eligible", "patients", "had", "clinical", "stage", "II", "-", "III", "(", ">", "or", "=", "T2", "and", "/", "or", ">", "or", "=", "N1", ")", "newly", "diagnosed", "breast", "cancer", ",", "Eastern", "Cooperative", "Oncology", "Group", "performance", "status", "of", "0", "or", "1", ",", "and", "normal", "cardiac", ",", "renal", ",", "and", "liver", "function", ".", "120", "women", "were", "randomly", "assigned", ",", "using", "allocation", "concealment", ",", "to", "receive", "4", "mg", "zoledronic", "acid", "intravenously", "every", "3", "weeks", "(", "n=60", ")", ",", "or", "no", "zoledronic", "acid", "(", "n=60", ")", ",", "for", "1", "year", "concomitant", "with", "four", "cycles", "of", "neoadjuvant", "epirubicin", "(", "75", "mg", "/", "m", "(", "2", ")", ")", "plus", "docetaxel", "(", "75", "mg", "/", "m", "(", "2", ")", ")", "and", "two", "cycles", "of", "adjuvant", "epirubicin", "plus", "docetaxel", ".", "The", "primary", "endpoint", "was", "the", "number", "of", "patients", "with", "detectable", "DTCs", "at", "3", "months", ".", "Final", "analysis", "was", "done", "1", "year", "after", "the", "last", "patient", "was", "enrolled", ".", "Analyses", "were", "done", "for", "all", "patients", "with", "available", "data", "at", "3", "months", ".", "This", "study", "is", "registered", "with", "ClinicalTrials.gov", ",", "number", "NCT00242203", ".", "FINDINGS", "Of", "the", "120", "patients", "initially", "enrolled", ",", "one", "withdrew", "after", "signing", "consent", "and", "one", "patient", "'", "s", "baseline", "bone", "marrow", "was", "not", "available", ".", "Both", "of", "these", "patients", "were", "in", "the", "control", "group", ".", "At", "3", "months", ",", "109", "bone", "-", "marrow", "samples", "were", "available", "for", "analysis", ".", "In", "the", "zoledronic", "acid", "group", ",", "bone", "marrow", "was", "not", "collected", "from", "one", "patient", "because", "of", "disease", "progression", ",", "one", "patient", "was", "taken", "off", "study", "because", "of", "severe", "diarrhoea", ",", "and", "two", "patients", "had", "not", "consented", "at", "the", "time", "of", "surgery", ".", "In", "the", "control", "group", ",", "bone", "marrow", "was", "not", "collected", "from", "two", "patients", "because", "of", "disease", "progression", ",", "one", "patient", "withdrew", "consent", ",", "and", "three", "patients", "were", "not", "consented", "at", "the", "time", "of", "surgery", ".", "At", "baseline", ",", "DTCs", "were", "detected", "in", "26", "of", "60", "patients", "in", "the", "zoledronic", "acid", "group", "and", "28", "of", "58", "patients", "in", "the", "control", "group", ".", "At", "3", "months", ",", "17", "of", "56", "patients", "receiving", "zoledronic", "acid", "versus", "25", "of", "53", "patients", "who", "did", "not", "receive", "zoledronic", "acid", "had", "detectable", "DTCs", "(", "p=0.054", ")", ".", "The", "most", "common", "grade", "3", "-", "4", "toxicities", "were", "infection", "(", "five", "of", "60", "patients", "in", "the", "zoledronic", "acid", "group", "and", "six", "of", "59", "in", "the", "control", "group", ")", "and", "thrombosis", "(", "five", "of", "60", "in", "the", "zoledronic", "acid", "and", "two", "of", "59", "in", "the", "control", "group", ")", ".", "There", "was", "one", "documented", "case", "of", "osteonecrosis", "in", "the", "zoledronic", "acid", "group", ".", "INTERPRETATION", "Zoledronic", "acid", "administered", "with", "chemotherapy", "resulted", "in", "a", "decreased", "proportion", "of", "patients", "with", "DTCs", "detected", "in", "the", "bone", "marrow", "at", "the", "time", "of", "surgery", ".", "Our", "study", "supports", "the", "hypothesis", "that", "the", "antimetastatic", "effects", "of", "zoledronic", "acid", "may", "be", "through", "effects", "on", "DTCs", ".", "FUNDING", "Novartis", "Pharmaceuticals", "and", "Pfizer", "Inc", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Sex", "Participant_Sample-size" ]

zoledronic acid is a Intervention_Pharmacological, women is a Participant_Sex, locally advanced breast cancer is a Participant_Condition, bisphosphonates is a Intervention_Pharmacological, disseminated tumour cells ( DTCs ) is a Outcome_Physical, neoadjuvant chemotherapy is a Participant_Condition, clinical stage II - III ( > or = T2 and / or > or = N1 ) newly diagnosed breast cancer is a Participant_Condition, 120 is a Participant_Sample-size, 4 mg zoledronic acid intravenously every is a Intervention_Pharmacological, no zoledronic acid is a Intervention_Pharmacological, four cycles of neoadjuvant epirubicin is a Intervention_Pharmacological, docetaxel is a Intervention_Pharmacological, and two cycles of adjuvant epirubicin plus docetaxel is a Intervention_Pharmacological, detectable DTCs is a Outcome_Physical, baseline bone marrow is a Participant_Condition, 109 is a Participant_Sample-size, bone - marrow samples is a Participant_Condition, osteonecrosis is a Outcome_Adverse-effects, Zoledronic acid is a Intervention_Pharmacological

45221_task1

Sentence: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer : an open label , randomised , phase 2 trial . BACKGROUND Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer . The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells ( DTCs ) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer . METHODS Patients were recruited for this open-label , phase 2 randomised trial between March 17 , 2003 , and May 19 , 2006 , at a single centre . Eligible patients had clinical stage II-III ( > or = T2 and/or > or = N1 ) newly diagnosed breast cancer , Eastern Cooperative Oncology Group performance status of 0 or 1 , and normal cardiac , renal , and liver function . 120 women were randomly assigned , using allocation concealment , to receive 4 mg zoledronic acid intravenously every 3 weeks ( n=60 ) , or no zoledronic acid ( n=60 ) , for 1 year concomitant with four cycles of neoadjuvant epirubicin ( 75 mg/m ( 2 ) ) plus docetaxel ( 75 mg/m ( 2 ) ) and two cycles of adjuvant epirubicin plus docetaxel . The primary endpoint was the number of patients with detectable DTCs at 3 months . Final analysis was done 1 year after the last patient was enrolled . Analyses were done for all patients with available data at 3 months . This study is registered with ClinicalTrials.gov , number NCT00242203 . FINDINGS Of the 120 patients initially enrolled , one withdrew after signing consent and one patient 's baseline bone marrow was not available . Both of these patients were in the control group . At 3 months , 109 bone-marrow samples were available for analysis . In the zoledronic acid group , bone marrow was not collected from one patient because of disease progression , one patient was taken off study because of severe diarrhoea , and two patients had not consented at the time of surgery . In the control group , bone marrow was not collected from two patients because of disease progression , one patient withdrew consent , and three patients were not consented at the time of surgery . At baseline , DTCs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the control group . At 3 months , 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs ( p=0.054 ) . The most common grade 3-4 toxicities were infection ( five of 60 patients in the zoledronic acid group and six of 59 in the control group ) and thrombosis ( five of 60 in the zoledronic acid and two of 59 in the control group ) . There was one documented case of osteonecrosis in the zoledronic acid group . INTERPRETATION Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery . Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs . FUNDING Novartis Pharmaceuticals and Pfizer Inc . Instructions: please typing these entity words according to sentence: zoledronic acid, women, locally advanced breast cancer, bisphosphonates, disseminated tumour cells ( DTCs ), neoadjuvant chemotherapy, clinical stage II - III ( > or = T2 and / or > or = N1 ) newly diagnosed breast cancer, 120, 4 mg zoledronic acid intravenously every, no zoledronic acid, four cycles of neoadjuvant epirubicin, docetaxel, and two cycles of adjuvant epirubicin plus docetaxel, detectable DTCs, baseline bone marrow, 109, bone - marrow samples, osteonecrosis, Zoledronic acid Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Participant_Sex, Outcome_Physical, Participant_Sample-size

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Sex", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer : an open label , randomised , phase 2 trial . BACKGROUND Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer . The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells ( DTCs ) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer . METHODS Patients were recruited for this open-label , phase 2 randomised trial between March 17 , 2003 , and May 19 , 2006 , at a single centre . Eligible patients had clinical stage II-III ( > or = T2 and/or > or = N1 ) newly diagnosed breast cancer , Eastern Cooperative Oncology Group performance status of 0 or 1 , and normal cardiac , renal , and liver function . 120 women were randomly assigned , using allocation concealment , to receive 4 mg zoledronic acid intravenously every 3 weeks ( n=60 ) , or no zoledronic acid ( n=60 ) , for 1 year concomitant with four cycles of neoadjuvant epirubicin ( 75 mg/m ( 2 ) ) plus docetaxel ( 75 mg/m ( 2 ) ) and two cycles of adjuvant epirubicin plus docetaxel . The primary endpoint was the number of patients with detectable DTCs at 3 months . Final analysis was done 1 year after the last patient was enrolled . Analyses were done for all patients with available data at 3 months . This study is registered with ClinicalTrials.gov , number NCT00242203 . FINDINGS Of the 120 patients initially enrolled , one withdrew after signing consent and one patient 's baseline bone marrow was not available . Both of these patients were in the control group . At 3 months , 109 bone-marrow samples were available for analysis . In the zoledronic acid group , bone marrow was not collected from one patient because of disease progression , one patient was taken off study because of severe diarrhoea , and two patients had not consented at the time of surgery . In the control group , bone marrow was not collected from two patients because of disease progression , one patient withdrew consent , and three patients were not consented at the time of surgery . At baseline , DTCs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the control group . At 3 months , 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs ( p=0.054 ) . The most common grade 3-4 toxicities were infection ( five of 60 patients in the zoledronic acid group and six of 59 in the control group ) and thrombosis ( five of 60 in the zoledronic acid and two of 59 in the control group ) . There was one documented case of osteonecrosis in the zoledronic acid group . INTERPRETATION Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery . Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs . FUNDING Novartis Pharmaceuticals and Pfizer Inc .

[ "Effect", "of", "zoledronic", "acid", "on", "disseminated", "tumour", "cells", "in", "women", "with", "locally", "advanced", "breast", "cancer", ":", "an", "open", "label", ",", "randomised", ",", "phase", "2", "trial", ".", "BACKGROUND", "Treatment", "with", "bisphosphonates", "decreases", "bone", "loss", "and", "can", "increase", "disease", "-", "free", "survival", "in", "patients", "with", "breast", "cancer", ".", "The", "aim", "of", "our", "study", "was", "to", "assess", "the", "effect", "of", "zoledronic", "acid", "on", "clearance", "of", "disseminated", "tumour", "cells", "(", "DTCs", ")", "from", "the", "bone", "marrow", "in", "women", "undergoing", "neoadjuvant", "chemotherapy", "for", "breast", "cancer", ".", "METHODS", "Patients", "were", "recruited", "for", "this", "open", "-", "label", ",", "phase", "2", "randomised", "trial", "between", "March", "17", ",", "2003", ",", "and", "May", "19", ",", "2006", ",", "at", "a", "single", "centre", ".", "Eligible", "patients", "had", "clinical", "stage", "II", "-", "III", "(", ">", "or", "=", "T2", "and", "/", "or", ">", "or", "=", "N1", ")", "newly", "diagnosed", "breast", "cancer", ",", "Eastern", "Cooperative", "Oncology", "Group", "performance", "status", "of", "0", "or", "1", ",", "and", "normal", "cardiac", ",", "renal", ",", "and", "liver", "function", ".", "120", "women", "were", "randomly", "assigned", ",", "using", "allocation", "concealment", ",", "to", "receive", "4", "mg", "zoledronic", "acid", "intravenously", "every", "3", "weeks", "(", "n=60", ")", ",", "or", "no", "zoledronic", "acid", "(", "n=60", ")", ",", "for", "1", "year", "concomitant", "with", "four", "cycles", "of", "neoadjuvant", "epirubicin", "(", "75", "mg", "/", "m", "(", "2", ")", ")", "plus", "docetaxel", "(", "75", "mg", "/", "m", "(", "2", ")", ")", "and", "two", "cycles", "of", "adjuvant", "epirubicin", "plus", "docetaxel", ".", "The", "primary", "endpoint", "was", "the", "number", "of", "patients", "with", "detectable", "DTCs", "at", "3", "months", ".", "Final", "analysis", "was", "done", "1", "year", "after", "the", "last", "patient", "was", "enrolled", ".", "Analyses", "were", "done", "for", "all", "patients", "with", "available", "data", "at", "3", "months", ".", "This", "study", "is", "registered", "with", "ClinicalTrials.gov", ",", "number", "NCT00242203", ".", "FINDINGS", "Of", "the", "120", "patients", "initially", "enrolled", ",", "one", "withdrew", "after", "signing", "consent", "and", "one", "patient", "'", "s", "baseline", "bone", "marrow", "was", "not", "available", ".", "Both", "of", "these", "patients", "were", "in", "the", "control", "group", ".", "At", "3", "months", ",", "109", "bone", "-", "marrow", "samples", "were", "available", "for", "analysis", ".", "In", "the", "zoledronic", "acid", "group", ",", "bone", "marrow", "was", "not", "collected", "from", "one", "patient", "because", "of", "disease", "progression", ",", "one", "patient", "was", "taken", "off", "study", "because", "of", "severe", "diarrhoea", ",", "and", "two", "patients", "had", "not", "consented", "at", "the", "time", "of", "surgery", ".", "In", "the", "control", "group", ",", "bone", "marrow", "was", "not", "collected", "from", "two", "patients", "because", "of", "disease", "progression", ",", "one", "patient", "withdrew", "consent", ",", "and", "three", "patients", "were", "not", "consented", "at", "the", "time", "of", "surgery", ".", "At", "baseline", ",", "DTCs", "were", "detected", "in", "26", "of", "60", "patients", "in", "the", "zoledronic", "acid", "group", "and", "28", "of", "58", "patients", "in", "the", "control", "group", ".", "At", "3", "months", ",", "17", "of", "56", "patients", "receiving", "zoledronic", "acid", "versus", "25", "of", "53", "patients", "who", "did", "not", "receive", "zoledronic", "acid", "had", "detectable", "DTCs", "(", "p=0.054", ")", ".", "The", "most", "common", "grade", "3", "-", "4", "toxicities", "were", "infection", "(", "five", "of", "60", "patients", "in", "the", "zoledronic", "acid", "group", "and", "six", "of", "59", "in", "the", "control", "group", ")", "and", "thrombosis", "(", "five", "of", "60", "in", "the", "zoledronic", "acid", "and", "two", "of", "59", "in", "the", "control", "group", ")", ".", "There", "was", "one", "documented", "case", "of", "osteonecrosis", "in", "the", "zoledronic", "acid", "group", ".", "INTERPRETATION", "Zoledronic", "acid", "administered", "with", "chemotherapy", "resulted", "in", "a", "decreased", "proportion", "of", "patients", "with", "DTCs", "detected", "in", "the", "bone", "marrow", "at", "the", "time", "of", "surgery", ".", "Our", "study", "supports", "the", "hypothesis", "that", "the", "antimetastatic", "effects", "of", "zoledronic", "acid", "may", "be", "through", "effects", "on", "DTCs", ".", "FUNDING", "Novartis", "Pharmaceuticals", "and", "Pfizer", "Inc", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Sex", "Participant_Sample-size" ]

zoledronic acid, women, locally advanced breast cancer, bisphosphonates, disseminated tumour cells ( DTCs ), neoadjuvant chemotherapy, clinical stage II - III ( > or = T2 and / or > or = N1 ) newly diagnosed breast cancer, 120, 4 mg zoledronic acid intravenously every, no zoledronic acid, four cycles of neoadjuvant epirubicin, docetaxel, and two cycles of adjuvant epirubicin plus docetaxel, detectable DTCs, baseline bone marrow, 109, bone - marrow samples, osteonecrosis, Zoledronic acid

45221_task2

Sentence: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer : an open label , randomised , phase 2 trial . BACKGROUND Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer . The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells ( DTCs ) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer . METHODS Patients were recruited for this open-label , phase 2 randomised trial between March 17 , 2003 , and May 19 , 2006 , at a single centre . Eligible patients had clinical stage II-III ( > or = T2 and/or > or = N1 ) newly diagnosed breast cancer , Eastern Cooperative Oncology Group performance status of 0 or 1 , and normal cardiac , renal , and liver function . 120 women were randomly assigned , using allocation concealment , to receive 4 mg zoledronic acid intravenously every 3 weeks ( n=60 ) , or no zoledronic acid ( n=60 ) , for 1 year concomitant with four cycles of neoadjuvant epirubicin ( 75 mg/m ( 2 ) ) plus docetaxel ( 75 mg/m ( 2 ) ) and two cycles of adjuvant epirubicin plus docetaxel . The primary endpoint was the number of patients with detectable DTCs at 3 months . Final analysis was done 1 year after the last patient was enrolled . Analyses were done for all patients with available data at 3 months . This study is registered with ClinicalTrials.gov , number NCT00242203 . FINDINGS Of the 120 patients initially enrolled , one withdrew after signing consent and one patient 's baseline bone marrow was not available . Both of these patients were in the control group . At 3 months , 109 bone-marrow samples were available for analysis . In the zoledronic acid group , bone marrow was not collected from one patient because of disease progression , one patient was taken off study because of severe diarrhoea , and two patients had not consented at the time of surgery . In the control group , bone marrow was not collected from two patients because of disease progression , one patient withdrew consent , and three patients were not consented at the time of surgery . At baseline , DTCs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the control group . At 3 months , 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs ( p=0.054 ) . The most common grade 3-4 toxicities were infection ( five of 60 patients in the zoledronic acid group and six of 59 in the control group ) and thrombosis ( five of 60 in the zoledronic acid and two of 59 in the control group ) . There was one documented case of osteonecrosis in the zoledronic acid group . INTERPRETATION Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery . Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs . FUNDING Novartis Pharmaceuticals and Pfizer Inc . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Sex", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer : an open label , randomised , phase 2 trial . BACKGROUND Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer . The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells ( DTCs ) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer . METHODS Patients were recruited for this open-label , phase 2 randomised trial between March 17 , 2003 , and May 19 , 2006 , at a single centre . Eligible patients had clinical stage II-III ( > or = T2 and/or > or = N1 ) newly diagnosed breast cancer , Eastern Cooperative Oncology Group performance status of 0 or 1 , and normal cardiac , renal , and liver function . 120 women were randomly assigned , using allocation concealment , to receive 4 mg zoledronic acid intravenously every 3 weeks ( n=60 ) , or no zoledronic acid ( n=60 ) , for 1 year concomitant with four cycles of neoadjuvant epirubicin ( 75 mg/m ( 2 ) ) plus docetaxel ( 75 mg/m ( 2 ) ) and two cycles of adjuvant epirubicin plus docetaxel . The primary endpoint was the number of patients with detectable DTCs at 3 months . Final analysis was done 1 year after the last patient was enrolled . Analyses were done for all patients with available data at 3 months . This study is registered with ClinicalTrials.gov , number NCT00242203 . FINDINGS Of the 120 patients initially enrolled , one withdrew after signing consent and one patient 's baseline bone marrow was not available . Both of these patients were in the control group . At 3 months , 109 bone-marrow samples were available for analysis . In the zoledronic acid group , bone marrow was not collected from one patient because of disease progression , one patient was taken off study because of severe diarrhoea , and two patients had not consented at the time of surgery . In the control group , bone marrow was not collected from two patients because of disease progression , one patient withdrew consent , and three patients were not consented at the time of surgery . At baseline , DTCs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the control group . At 3 months , 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs ( p=0.054 ) . The most common grade 3-4 toxicities were infection ( five of 60 patients in the zoledronic acid group and six of 59 in the control group ) and thrombosis ( five of 60 in the zoledronic acid and two of 59 in the control group ) . There was one documented case of osteonecrosis in the zoledronic acid group . INTERPRETATION Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery . Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs . FUNDING Novartis Pharmaceuticals and Pfizer Inc .

[ "Effect", "of", "zoledronic", "acid", "on", "disseminated", "tumour", "cells", "in", "women", "with", "locally", "advanced", "breast", "cancer", ":", "an", "open", "label", ",", "randomised", ",", "phase", "2", "trial", ".", "BACKGROUND", "Treatment", "with", "bisphosphonates", "decreases", "bone", "loss", "and", "can", "increase", "disease", "-", "free", "survival", "in", "patients", "with", "breast", "cancer", ".", "The", "aim", "of", "our", "study", "was", "to", "assess", "the", "effect", "of", "zoledronic", "acid", "on", "clearance", "of", "disseminated", "tumour", "cells", "(", "DTCs", ")", "from", "the", "bone", "marrow", "in", "women", "undergoing", "neoadjuvant", "chemotherapy", "for", "breast", "cancer", ".", "METHODS", "Patients", "were", "recruited", "for", "this", "open", "-", "label", ",", "phase", "2", "randomised", "trial", "between", "March", "17", ",", "2003", ",", "and", "May", "19", ",", "2006", ",", "at", "a", "single", "centre", ".", "Eligible", "patients", "had", "clinical", "stage", "II", "-", "III", "(", ">", "or", "=", "T2", "and", "/", "or", ">", "or", "=", "N1", ")", "newly", "diagnosed", "breast", "cancer", ",", "Eastern", "Cooperative", "Oncology", "Group", "performance", "status", "of", "0", "or", "1", ",", "and", "normal", "cardiac", ",", "renal", ",", "and", "liver", "function", ".", "120", "women", "were", "randomly", "assigned", ",", "using", "allocation", "concealment", ",", "to", "receive", "4", "mg", "zoledronic", "acid", "intravenously", "every", "3", "weeks", "(", "n=60", ")", ",", "or", "no", "zoledronic", "acid", "(", "n=60", ")", ",", "for", "1", "year", "concomitant", "with", "four", "cycles", "of", "neoadjuvant", "epirubicin", "(", "75", "mg", "/", "m", "(", "2", ")", ")", "plus", "docetaxel", "(", "75", "mg", "/", "m", "(", "2", ")", ")", "and", "two", "cycles", "of", "adjuvant", "epirubicin", "plus", "docetaxel", ".", "The", "primary", "endpoint", "was", "the", "number", "of", "patients", "with", "detectable", "DTCs", "at", "3", "months", ".", "Final", "analysis", "was", "done", "1", "year", "after", "the", "last", "patient", "was", "enrolled", ".", "Analyses", "were", "done", "for", "all", "patients", "with", "available", "data", "at", "3", "months", ".", "This", "study", "is", "registered", "with", "ClinicalTrials.gov", ",", "number", "NCT00242203", ".", "FINDINGS", "Of", "the", "120", "patients", "initially", "enrolled", ",", "one", "withdrew", "after", "signing", "consent", "and", "one", "patient", "'", "s", "baseline", "bone", "marrow", "was", "not", "available", ".", "Both", "of", "these", "patients", "were", "in", "the", "control", "group", ".", "At", "3", "months", ",", "109", "bone", "-", "marrow", "samples", "were", "available", "for", "analysis", ".", "In", "the", "zoledronic", "acid", "group", ",", "bone", "marrow", "was", "not", "collected", "from", "one", "patient", "because", "of", "disease", "progression", ",", "one", "patient", "was", "taken", "off", "study", "because", "of", "severe", "diarrhoea", ",", "and", "two", "patients", "had", "not", "consented", "at", "the", "time", "of", "surgery", ".", "In", "the", "control", "group", ",", "bone", "marrow", "was", "not", "collected", "from", "two", "patients", "because", "of", "disease", "progression", ",", "one", "patient", "withdrew", "consent", ",", "and", "three", "patients", "were", "not", "consented", "at", "the", "time", "of", "surgery", ".", "At", "baseline", ",", "DTCs", "were", "detected", "in", "26", "of", "60", "patients", "in", "the", "zoledronic", "acid", "group", "and", "28", "of", "58", "patients", "in", "the", "control", "group", ".", "At", "3", "months", ",", "17", "of", "56", "patients", "receiving", "zoledronic", "acid", "versus", "25", "of", "53", "patients", "who", "did", "not", "receive", "zoledronic", "acid", "had", "detectable", "DTCs", "(", "p=0.054", ")", ".", "The", "most", "common", "grade", "3", "-", "4", "toxicities", "were", "infection", "(", "five", "of", "60", "patients", "in", "the", "zoledronic", "acid", "group", "and", "six", "of", "59", "in", "the", "control", "group", ")", "and", "thrombosis", "(", "five", "of", "60", "in", "the", "zoledronic", "acid", "and", "two", "of", "59", "in", "the", "control", "group", ")", ".", "There", "was", "one", "documented", "case", "of", "osteonecrosis", "in", "the", "zoledronic", "acid", "group", ".", "INTERPRETATION", "Zoledronic", "acid", "administered", "with", "chemotherapy", "resulted", "in", "a", "decreased", "proportion", "of", "patients", "with", "DTCs", "detected", "in", "the", "bone", "marrow", "at", "the", "time", "of", "surgery", ".", "Our", "study", "supports", "the", "hypothesis", "that", "the", "antimetastatic", "effects", "of", "zoledronic", "acid", "may", "be", "through", "effects", "on", "DTCs", ".", "FUNDING", "Novartis", "Pharmaceuticals", "and", "Pfizer", "Inc", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Sex", "Participant_Sample-size" ]

Previous is a Temporal, thoracic operation is a Procedure, same side is a Qualifier

NCT02469610_exc_task0

Sentence: Previous thoracic operation in the same side. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Procedure, Qualifier

[ "B-Temporal", "B-Procedure", "I-Procedure", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O" ]

Previous thoracic operation in the same side.

[ "Previous", "thoracic", "operation", "in", "the", "same", "side", ".", "\n" ]

[ "Procedure", "Qualifier", "Temporal" ]

Previous is a Temporal, thoracic operation is a Procedure, same side is a Qualifier

NCT02469610_exc_task1

Sentence: Previous thoracic operation in the same side. Instructions: please typing these entity words according to sentence: Previous, thoracic operation, same side Options: Temporal, Procedure, Qualifier

[ "B-Temporal", "B-Procedure", "I-Procedure", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O" ]

Previous thoracic operation in the same side.

[ "Previous", "thoracic", "operation", "in", "the", "same", "side", ".", "\n" ]

[ "Procedure", "Qualifier", "Temporal" ]

Previous, thoracic operation, same side

NCT02469610_exc_task2

Sentence: Previous thoracic operation in the same side. Instructions: please extract entity words from the input sentence

[ "B-Temporal", "B-Procedure", "I-Procedure", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O" ]

Previous thoracic operation in the same side.

[ "Previous", "thoracic", "operation", "in", "the", "same", "side", ".", "\n" ]

[ "Procedure", "Qualifier", "Temporal" ]

IgG is a PROTEINAS, IgA is a PROTEINAS, IgM is a PROTEINAS, C3 is a PROTEINAS, C1q is a PROTEINAS, fibrinógeno is a PROTEINAS, prednisona is a NORMALIZABLES, prednisona is a NORMALIZABLES, Azathioprina is a NORMALIZABLES, Omeprazol is a NORMALIZABLES, carbonato cálcico is a NORMALIZABLES, vitamina D4 is a NO_NORMALIZABLES, Nistatina is a NORMALIZABLES, prednisona is a NORMALIZABLES, Azathiproprina is a NORMALIZABLES

185_task0

Sentence: Paciente varón, de 47 años, casado, acude al departamento de Medicina Oral del Hospital de Clínicas de Porto Alegre y afirma tener lesiones dolorosas en la cavidad oral con aspecto de ampollas sangrantes que se rompen fácilmente y le dejan una superficie como ulcerada desde hace aproximadamente 4 meses. En la anamnesis el paciente declara no ser fumador y trabajar en un fábrica de baterías para coches, lo cual además le ha originado una intoxicación crónica (saturnismo). Dice poseer además una úlcera en la pierna derecha desde hace 20 años. En la exploración física se percibe la inflamación de los ganglios cervicales y submaxilares del lado izquierdo, así como varias lesiones de tipo ulceroso en la mucosa labial, el paladar, la mucosa yugal, el suelo de la boca y la laringe. Se confirma la lesión de la pierna derecha, así como lesiones de tipo erosivo recubiertas por una costra en las axilas y el tronco. Se practicó una biopsia parcial de una de las lesiones del labio inferior, en la cual se observó el signo de Nikolsky positivo en el momento de la toma y se vio que las características histopatológicas de la lesión eran ampollas con acantolisis suprabasal, lo cual es compatible con el pénfigo vulgar. Unos días después de la biopsia el paciente sufrió una exacerbación de las lesiones y tuvo que ser ingresado en el hospital con un cuadro consistente en: lesiones ampollosas en el tórax, la pierna derecha y la cavidad oral, que le impiden la alimentación. Se le hicieron nuevas biopsias de las lesiones del tronco y la boca y se le hizo además un examen de inmunofluorescencia, en el que se observaron depósito de IgG en las uniones intercelulares, IgA en las paredes de los vasos pequeños y ausencia de IgM, C3, C1q y de depósitos de fibrinógeno. Se comenzó el tratamiento con prednisona con dosis gradualmente crecientes hasta alcanzar los 100 mg diarios. El paciente respondió favorablemente al tratamiento y abandonó el hospital con una notable mejoría. Tras la hospitalización se estableció el tratamiento para el paciente a base de 140 mg diarios de prednisona asociados a 100 mg de Azathioprina, 40 mg de Omeprazol, 400 mg de carbonato cálcico, vitamina D4 y enjuagues de Nistatina, éstos últimos 4 veces al día. Tras un mes de tratamiento se observó una remisión casi total del cuadro y se redujo la dosis de prednisona a 120 mg durante 15 días y, posteriormente, a 100 mg. De igual modo, se decidió elevar la dosis de Azathiproprina a 150 mg diarios. El paciente se encuentra todavía bajo control médico. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, PROTEINAS, NO_NORMALIZABLES

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NO_NORMALIZABLES", "I-NO_NORMALIZABLES", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Paciente varón, de 47 años, casado, acude al departamento de Medicina Oral del Hospital de Clínicas de Porto Alegre y afirma tener lesiones dolorosas en la cavidad oral con aspecto de ampollas sangrantes que se rompen fácilmente y le dejan una superficie como ulcerada desde hace aproximadamente 4 meses. En la anamnesis el paciente declara no ser fumador y trabajar en un fábrica de baterías para coches, lo cual además le ha originado una intoxicación crónica (saturnismo). Dice poseer además una úlcera en la pierna derecha desde hace 20 años. En la exploración física se percibe la inflamación de los ganglios cervicales y submaxilares del lado izquierdo, así como varias lesiones de tipo ulceroso en la mucosa labial, el paladar, la mucosa yugal, el suelo de la boca y la laringe. Se confirma la lesión de la pierna derecha, así como lesiones de tipo erosivo recubiertas por una costra en las axilas y el tronco. Se practicó una biopsia parcial de una de las lesiones del labio inferior, en la cual se observó el signo de Nikolsky positivo en el momento de la toma y se vio que las características histopatológicas de la lesión eran ampollas con acantolisis suprabasal, lo cual es compatible con el pénfigo vulgar. Unos días después de la biopsia el paciente sufrió una exacerbación de las lesiones y tuvo que ser ingresado en el hospital con un cuadro consistente en: lesiones ampollosas en el tórax, la pierna derecha y la cavidad oral, que le impiden la alimentación. Se le hicieron nuevas biopsias de las lesiones del tronco y la boca y se le hizo además un examen de inmunofluorescencia, en el que se observaron depósito de IgG en las uniones intercelulares, IgA en las paredes de los vasos pequeños y ausencia de IgM, C3, C1q y de depósitos de fibrinógeno. Se comenzó el tratamiento con prednisona con dosis gradualmente crecientes hasta alcanzar los 100 mg diarios. El paciente respondió favorablemente al tratamiento y abandonó el hospital con una notable mejoría. Tras la hospitalización se estableció el tratamiento para el paciente a base de 140 mg diarios de prednisona asociados a 100 mg de Azathioprina, 40 mg de Omeprazol, 400 mg de carbonato cálcico, vitamina D4 y enjuagues de Nistatina, éstos últimos 4 veces al día. Tras un mes de tratamiento se observó una remisión casi total del cuadro y se redujo la dosis de prednisona a 120 mg durante 15 días y, posteriormente, a 100 mg. De igual modo, se decidió elevar la dosis de Azathiproprina a 150 mg diarios. El paciente se encuentra todavía bajo control médico.

[ "Paciente", "varón", ",", "de", "47", "años", ",", "casado", ",", "acude", "al", "departamento", "de", "Medicina", "Oral", "del", "Hospital", "de", "Clínicas", "de", "Porto", "Alegre", "y", "afirma", "tener", "lesiones", "dolorosas", "en", "la", "cavidad", "oral", "con", "aspecto", "de", "ampollas", "sangrantes", "que", "se", "rompen", "fácilmente", "y", "le", "dejan", "una", "superficie", "como", "ulcerada", "desde", "hace", "aproximadamente", "4", "meses", ".", "En", "la", "anamnesis", "el", "paciente", "declara", "no", "ser", "fumador", "y", "trabajar", "en", "un", "fábrica", "de", "baterías", "para", "coches", ",", "lo", "cual", "además", "le", "ha", "originado", "una", "intoxicación", "crónica", "(", "saturnismo", ")", ".", "Dice", "poseer", "además", "una", "úlcera", "en", "la", "pierna", "derecha", "desde", "hace", "20", "años", ".", "\n", "En", "la", "exploración", "física", "se", "percibe", "la", "inflamación", "de", "los", "ganglios", "cervicales", "y", "submaxilares", "del", "lado", "izquierdo", ",", "así", "como", "varias", "lesiones", "de", "tipo", "ulceroso", "en", "la", "mucosa", "labial", ",", "el", "paladar", ",", "la", "mucosa", "yugal", ",", "el", "suelo", "de", "la", "boca", "y", "la", "laringe", ".", "Se", "confirma", "la", "lesión", "de", "la", "pierna", "derecha", ",", "así", "como", "lesiones", "de", "tipo", "erosivo", "recubiertas", "por", "una", "costra", "en", "las", "axilas", "y", "el", "tronco", ".", "\n\n", "Se", "practicó", "una", "biopsia", "parcial", "de", "una", "de", "las", "lesiones", "del", "labio", "inferior", ",", "en", "la", "cual", "se", "observó", "el", "signo", "de", "Nikolsky", "positivo", "en", "el", "momento", "de", "la", "toma", "y", "se", "vio", "que", "las", "características", "histopatológicas", "de", "la", "lesión", "eran", "ampollas", "con", "acantolisis", "suprabasal", ",", "lo", "cual", "es", "compatible", "con", "el", "pénfigo", "vulgar", ".", "\n\n", "Unos", "días", "después", "de", "la", "biopsia", "el", "paciente", "sufrió", "una", "exacerbación", "de", "las", "lesiones", "y", "tuvo", "que", "ser", "ingresado", "en", "el", "hospital", "con", "un", "cuadro", "consistente", "en", ":", "lesiones", "ampollosas", "en", "el", "tórax", ",", "la", "pierna", "derecha", "y", "la", "cavidad", "oral", ",", "que", "le", "impiden", "la", "alimentación", ".", "Se", "le", "hicieron", "nuevas", "biopsias", "de", "las", "lesiones", "del", "tronco", "y", "la", "boca", "y", "se", "le", "hizo", "además", "un", "examen", "de", "inmunofluorescencia", ",", "en", "el", "que", "se", "observaron", "depósito", "de", "IgG", "en", "las", "uniones", "intercelulares", ",", "IgA", "en", "las", "paredes", "de", "los", "vasos", "pequeños", "y", "ausencia", "de", "IgM", ",", "C3", ",", "C1q", "y", "de", "depósitos", "de", "fibrinógeno", ".", "Se", "comenzó", "el", "tratamiento", "con", "prednisona", "con", "dosis", "gradualmente", "crecientes", "hasta", "alcanzar", "los", "100", "mg", "diarios", ".", "El", "paciente", "respondió", "favorablemente", "al", "tratamiento", "y", "abandonó", "el", "hospital", "con", "una", "notable", "mejoría", ".", "\n\n", "Tras", "la", "hospitalización", "se", "estableció", "el", "tratamiento", "para", "el", "paciente", "a", "base", "de", "140", "mg", "diarios", "de", "prednisona", "asociados", "a", "100", "mg", "de", "Azathioprina", ",", "40", "mg", "de", "Omeprazol", ",", "400", "mg", "de", "carbonato", "cálcico", ",", "vitamina", "D4", "y", "enjuagues", "de", "Nistatina", ",", "éstos", "últimos", "4", "veces", "al", "día", ".", "Tras", "un", "mes", "de", "tratamiento", "se", "observó", "una", "remisión", "casi", "total", "del", "cuadro", "y", "se", "redujo", "la", "dosis", "de", "prednisona", "a", "120", "mg", "durante", "15", "días", "y", ",", "posteriormente", ",", "a", "100", "mg", ".", "De", "igual", "modo", ",", "se", "decidió", "elevar", "la", "dosis", "de", "Azathiproprina", "a", "150", "mg", "diarios", ".", "El", "paciente", "se", "encuentra", "todavía", "bajo", "control", "médico", ".", "\n\n" ]

[ "NORMALIZABLES", "NO_NORMALIZABLES", "PROTEINAS" ]

IgG is a PROTEINAS, IgA is a PROTEINAS, IgM is a PROTEINAS, C3 is a PROTEINAS, C1q is a PROTEINAS, fibrinógeno is a PROTEINAS, prednisona is a NORMALIZABLES, prednisona is a NORMALIZABLES, Azathioprina is a NORMALIZABLES, Omeprazol is a NORMALIZABLES, carbonato cálcico is a NORMALIZABLES, vitamina D4 is a NO_NORMALIZABLES, Nistatina is a NORMALIZABLES, prednisona is a NORMALIZABLES, Azathiproprina is a NORMALIZABLES

185_task1

Sentence: Paciente varón, de 47 años, casado, acude al departamento de Medicina Oral del Hospital de Clínicas de Porto Alegre y afirma tener lesiones dolorosas en la cavidad oral con aspecto de ampollas sangrantes que se rompen fácilmente y le dejan una superficie como ulcerada desde hace aproximadamente 4 meses. En la anamnesis el paciente declara no ser fumador y trabajar en un fábrica de baterías para coches, lo cual además le ha originado una intoxicación crónica (saturnismo). Dice poseer además una úlcera en la pierna derecha desde hace 20 años. En la exploración física se percibe la inflamación de los ganglios cervicales y submaxilares del lado izquierdo, así como varias lesiones de tipo ulceroso en la mucosa labial, el paladar, la mucosa yugal, el suelo de la boca y la laringe. Se confirma la lesión de la pierna derecha, así como lesiones de tipo erosivo recubiertas por una costra en las axilas y el tronco. Se practicó una biopsia parcial de una de las lesiones del labio inferior, en la cual se observó el signo de Nikolsky positivo en el momento de la toma y se vio que las características histopatológicas de la lesión eran ampollas con acantolisis suprabasal, lo cual es compatible con el pénfigo vulgar. Unos días después de la biopsia el paciente sufrió una exacerbación de las lesiones y tuvo que ser ingresado en el hospital con un cuadro consistente en: lesiones ampollosas en el tórax, la pierna derecha y la cavidad oral, que le impiden la alimentación. Se le hicieron nuevas biopsias de las lesiones del tronco y la boca y se le hizo además un examen de inmunofluorescencia, en el que se observaron depósito de IgG en las uniones intercelulares, IgA en las paredes de los vasos pequeños y ausencia de IgM, C3, C1q y de depósitos de fibrinógeno. Se comenzó el tratamiento con prednisona con dosis gradualmente crecientes hasta alcanzar los 100 mg diarios. El paciente respondió favorablemente al tratamiento y abandonó el hospital con una notable mejoría. Tras la hospitalización se estableció el tratamiento para el paciente a base de 140 mg diarios de prednisona asociados a 100 mg de Azathioprina, 40 mg de Omeprazol, 400 mg de carbonato cálcico, vitamina D4 y enjuagues de Nistatina, éstos últimos 4 veces al día. Tras un mes de tratamiento se observó una remisión casi total del cuadro y se redujo la dosis de prednisona a 120 mg durante 15 días y, posteriormente, a 100 mg. De igual modo, se decidió elevar la dosis de Azathiproprina a 150 mg diarios. El paciente se encuentra todavía bajo control médico. Instructions: please typing these entity words according to sentence: IgG, IgA, IgM, C3, C1q, fibrinógeno, prednisona, prednisona, Azathioprina, Omeprazol, carbonato cálcico, vitamina D4, Nistatina, prednisona, Azathiproprina Options: NORMALIZABLES, PROTEINAS, NO_NORMALIZABLES

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NO_NORMALIZABLES", "I-NO_NORMALIZABLES", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Paciente varón, de 47 años, casado, acude al departamento de Medicina Oral del Hospital de Clínicas de Porto Alegre y afirma tener lesiones dolorosas en la cavidad oral con aspecto de ampollas sangrantes que se rompen fácilmente y le dejan una superficie como ulcerada desde hace aproximadamente 4 meses. En la anamnesis el paciente declara no ser fumador y trabajar en un fábrica de baterías para coches, lo cual además le ha originado una intoxicación crónica (saturnismo). Dice poseer además una úlcera en la pierna derecha desde hace 20 años. En la exploración física se percibe la inflamación de los ganglios cervicales y submaxilares del lado izquierdo, así como varias lesiones de tipo ulceroso en la mucosa labial, el paladar, la mucosa yugal, el suelo de la boca y la laringe. Se confirma la lesión de la pierna derecha, así como lesiones de tipo erosivo recubiertas por una costra en las axilas y el tronco. Se practicó una biopsia parcial de una de las lesiones del labio inferior, en la cual se observó el signo de Nikolsky positivo en el momento de la toma y se vio que las características histopatológicas de la lesión eran ampollas con acantolisis suprabasal, lo cual es compatible con el pénfigo vulgar. Unos días después de la biopsia el paciente sufrió una exacerbación de las lesiones y tuvo que ser ingresado en el hospital con un cuadro consistente en: lesiones ampollosas en el tórax, la pierna derecha y la cavidad oral, que le impiden la alimentación. Se le hicieron nuevas biopsias de las lesiones del tronco y la boca y se le hizo además un examen de inmunofluorescencia, en el que se observaron depósito de IgG en las uniones intercelulares, IgA en las paredes de los vasos pequeños y ausencia de IgM, C3, C1q y de depósitos de fibrinógeno. Se comenzó el tratamiento con prednisona con dosis gradualmente crecientes hasta alcanzar los 100 mg diarios. El paciente respondió favorablemente al tratamiento y abandonó el hospital con una notable mejoría. Tras la hospitalización se estableció el tratamiento para el paciente a base de 140 mg diarios de prednisona asociados a 100 mg de Azathioprina, 40 mg de Omeprazol, 400 mg de carbonato cálcico, vitamina D4 y enjuagues de Nistatina, éstos últimos 4 veces al día. Tras un mes de tratamiento se observó una remisión casi total del cuadro y se redujo la dosis de prednisona a 120 mg durante 15 días y, posteriormente, a 100 mg. De igual modo, se decidió elevar la dosis de Azathiproprina a 150 mg diarios. El paciente se encuentra todavía bajo control médico.

[ "Paciente", "varón", ",", "de", "47", "años", ",", "casado", ",", "acude", "al", "departamento", "de", "Medicina", "Oral", "del", "Hospital", "de", "Clínicas", "de", "Porto", "Alegre", "y", "afirma", "tener", "lesiones", "dolorosas", "en", "la", "cavidad", "oral", "con", "aspecto", "de", "ampollas", "sangrantes", "que", "se", "rompen", "fácilmente", "y", "le", "dejan", "una", "superficie", "como", "ulcerada", "desde", "hace", "aproximadamente", "4", "meses", ".", "En", "la", "anamnesis", "el", "paciente", "declara", "no", "ser", "fumador", "y", "trabajar", "en", "un", "fábrica", "de", "baterías", "para", "coches", ",", "lo", "cual", "además", "le", "ha", "originado", "una", "intoxicación", "crónica", "(", "saturnismo", ")", ".", "Dice", "poseer", "además", "una", "úlcera", "en", "la", "pierna", "derecha", "desde", "hace", "20", "años", ".", "\n", "En", "la", "exploración", "física", "se", "percibe", "la", "inflamación", "de", "los", "ganglios", "cervicales", "y", "submaxilares", "del", "lado", "izquierdo", ",", "así", "como", "varias", "lesiones", "de", "tipo", "ulceroso", "en", "la", "mucosa", "labial", ",", "el", "paladar", ",", "la", "mucosa", "yugal", ",", "el", "suelo", "de", "la", "boca", "y", "la", "laringe", ".", "Se", "confirma", "la", "lesión", "de", "la", "pierna", "derecha", ",", "así", "como", "lesiones", "de", "tipo", "erosivo", "recubiertas", "por", "una", "costra", "en", "las", "axilas", "y", "el", "tronco", ".", "\n\n", "Se", "practicó", "una", "biopsia", "parcial", "de", "una", "de", "las", "lesiones", "del", "labio", "inferior", ",", "en", "la", "cual", "se", "observó", "el", "signo", "de", "Nikolsky", "positivo", "en", "el", "momento", "de", "la", "toma", "y", "se", "vio", "que", "las", "características", "histopatológicas", "de", "la", "lesión", "eran", "ampollas", "con", "acantolisis", "suprabasal", ",", "lo", "cual", "es", "compatible", "con", "el", "pénfigo", "vulgar", ".", "\n\n", "Unos", "días", "después", "de", "la", "biopsia", "el", "paciente", "sufrió", "una", "exacerbación", "de", "las", "lesiones", "y", "tuvo", "que", "ser", "ingresado", "en", "el", "hospital", "con", "un", "cuadro", "consistente", "en", ":", "lesiones", "ampollosas", "en", "el", "tórax", ",", "la", "pierna", "derecha", "y", "la", "cavidad", "oral", ",", "que", "le", "impiden", "la", "alimentación", ".", "Se", "le", "hicieron", "nuevas", "biopsias", "de", "las", "lesiones", "del", "tronco", "y", "la", "boca", "y", "se", "le", "hizo", "además", "un", "examen", "de", "inmunofluorescencia", ",", "en", "el", "que", "se", "observaron", "depósito", "de", "IgG", "en", "las", "uniones", "intercelulares", ",", "IgA", "en", "las", "paredes", "de", "los", "vasos", "pequeños", "y", "ausencia", "de", "IgM", ",", "C3", ",", "C1q", "y", "de", "depósitos", "de", "fibrinógeno", ".", "Se", "comenzó", "el", "tratamiento", "con", "prednisona", "con", "dosis", "gradualmente", "crecientes", "hasta", "alcanzar", "los", "100", "mg", "diarios", ".", "El", "paciente", "respondió", "favorablemente", "al", "tratamiento", "y", "abandonó", "el", "hospital", "con", "una", "notable", "mejoría", ".", "\n\n", "Tras", "la", "hospitalización", "se", "estableció", "el", "tratamiento", "para", "el", "paciente", "a", "base", "de", "140", "mg", "diarios", "de", "prednisona", "asociados", "a", "100", "mg", "de", "Azathioprina", ",", "40", "mg", "de", "Omeprazol", ",", "400", "mg", "de", "carbonato", "cálcico", ",", "vitamina", "D4", "y", "enjuagues", "de", "Nistatina", ",", "éstos", "últimos", "4", "veces", "al", "día", ".", "Tras", "un", "mes", "de", "tratamiento", "se", "observó", "una", "remisión", "casi", "total", "del", "cuadro", "y", "se", "redujo", "la", "dosis", "de", "prednisona", "a", "120", "mg", "durante", "15", "días", "y", ",", "posteriormente", ",", "a", "100", "mg", ".", "De", "igual", "modo", ",", "se", "decidió", "elevar", "la", "dosis", "de", "Azathiproprina", "a", "150", "mg", "diarios", ".", "El", "paciente", "se", "encuentra", "todavía", "bajo", "control", "médico", ".", "\n\n" ]

[ "NORMALIZABLES", "NO_NORMALIZABLES", "PROTEINAS" ]

IgG, IgA, IgM, C3, C1q, fibrinógeno, prednisona, prednisona, Azathioprina, Omeprazol, carbonato cálcico, vitamina D4, Nistatina, prednisona, Azathiproprina

185_task2

Sentence: Paciente varón, de 47 años, casado, acude al departamento de Medicina Oral del Hospital de Clínicas de Porto Alegre y afirma tener lesiones dolorosas en la cavidad oral con aspecto de ampollas sangrantes que se rompen fácilmente y le dejan una superficie como ulcerada desde hace aproximadamente 4 meses. En la anamnesis el paciente declara no ser fumador y trabajar en un fábrica de baterías para coches, lo cual además le ha originado una intoxicación crónica (saturnismo). Dice poseer además una úlcera en la pierna derecha desde hace 20 años. En la exploración física se percibe la inflamación de los ganglios cervicales y submaxilares del lado izquierdo, así como varias lesiones de tipo ulceroso en la mucosa labial, el paladar, la mucosa yugal, el suelo de la boca y la laringe. Se confirma la lesión de la pierna derecha, así como lesiones de tipo erosivo recubiertas por una costra en las axilas y el tronco. Se practicó una biopsia parcial de una de las lesiones del labio inferior, en la cual se observó el signo de Nikolsky positivo en el momento de la toma y se vio que las características histopatológicas de la lesión eran ampollas con acantolisis suprabasal, lo cual es compatible con el pénfigo vulgar. Unos días después de la biopsia el paciente sufrió una exacerbación de las lesiones y tuvo que ser ingresado en el hospital con un cuadro consistente en: lesiones ampollosas en el tórax, la pierna derecha y la cavidad oral, que le impiden la alimentación. Se le hicieron nuevas biopsias de las lesiones del tronco y la boca y se le hizo además un examen de inmunofluorescencia, en el que se observaron depósito de IgG en las uniones intercelulares, IgA en las paredes de los vasos pequeños y ausencia de IgM, C3, C1q y de depósitos de fibrinógeno. Se comenzó el tratamiento con prednisona con dosis gradualmente crecientes hasta alcanzar los 100 mg diarios. El paciente respondió favorablemente al tratamiento y abandonó el hospital con una notable mejoría. Tras la hospitalización se estableció el tratamiento para el paciente a base de 140 mg diarios de prednisona asociados a 100 mg de Azathioprina, 40 mg de Omeprazol, 400 mg de carbonato cálcico, vitamina D4 y enjuagues de Nistatina, éstos últimos 4 veces al día. Tras un mes de tratamiento se observó una remisión casi total del cuadro y se redujo la dosis de prednisona a 120 mg durante 15 días y, posteriormente, a 100 mg. De igual modo, se decidió elevar la dosis de Azathiproprina a 150 mg diarios. El paciente se encuentra todavía bajo control médico. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NO_NORMALIZABLES", "I-NO_NORMALIZABLES", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Paciente varón, de 47 años, casado, acude al departamento de Medicina Oral del Hospital de Clínicas de Porto Alegre y afirma tener lesiones dolorosas en la cavidad oral con aspecto de ampollas sangrantes que se rompen fácilmente y le dejan una superficie como ulcerada desde hace aproximadamente 4 meses. En la anamnesis el paciente declara no ser fumador y trabajar en un fábrica de baterías para coches, lo cual además le ha originado una intoxicación crónica (saturnismo). Dice poseer además una úlcera en la pierna derecha desde hace 20 años. En la exploración física se percibe la inflamación de los ganglios cervicales y submaxilares del lado izquierdo, así como varias lesiones de tipo ulceroso en la mucosa labial, el paladar, la mucosa yugal, el suelo de la boca y la laringe. Se confirma la lesión de la pierna derecha, así como lesiones de tipo erosivo recubiertas por una costra en las axilas y el tronco. Se practicó una biopsia parcial de una de las lesiones del labio inferior, en la cual se observó el signo de Nikolsky positivo en el momento de la toma y se vio que las características histopatológicas de la lesión eran ampollas con acantolisis suprabasal, lo cual es compatible con el pénfigo vulgar. Unos días después de la biopsia el paciente sufrió una exacerbación de las lesiones y tuvo que ser ingresado en el hospital con un cuadro consistente en: lesiones ampollosas en el tórax, la pierna derecha y la cavidad oral, que le impiden la alimentación. Se le hicieron nuevas biopsias de las lesiones del tronco y la boca y se le hizo además un examen de inmunofluorescencia, en el que se observaron depósito de IgG en las uniones intercelulares, IgA en las paredes de los vasos pequeños y ausencia de IgM, C3, C1q y de depósitos de fibrinógeno. Se comenzó el tratamiento con prednisona con dosis gradualmente crecientes hasta alcanzar los 100 mg diarios. El paciente respondió favorablemente al tratamiento y abandonó el hospital con una notable mejoría. Tras la hospitalización se estableció el tratamiento para el paciente a base de 140 mg diarios de prednisona asociados a 100 mg de Azathioprina, 40 mg de Omeprazol, 400 mg de carbonato cálcico, vitamina D4 y enjuagues de Nistatina, éstos últimos 4 veces al día. Tras un mes de tratamiento se observó una remisión casi total del cuadro y se redujo la dosis de prednisona a 120 mg durante 15 días y, posteriormente, a 100 mg. De igual modo, se decidió elevar la dosis de Azathiproprina a 150 mg diarios. El paciente se encuentra todavía bajo control médico.

[ "Paciente", "varón", ",", "de", "47", "años", ",", "casado", ",", "acude", "al", "departamento", "de", "Medicina", "Oral", "del", "Hospital", "de", "Clínicas", "de", "Porto", "Alegre", "y", "afirma", "tener", "lesiones", "dolorosas", "en", "la", "cavidad", "oral", "con", "aspecto", "de", "ampollas", "sangrantes", "que", "se", "rompen", "fácilmente", "y", "le", "dejan", "una", "superficie", "como", "ulcerada", "desde", "hace", "aproximadamente", "4", "meses", ".", "En", "la", "anamnesis", "el", "paciente", "declara", "no", "ser", "fumador", "y", "trabajar", "en", "un", "fábrica", "de", "baterías", "para", "coches", ",", "lo", "cual", "además", "le", "ha", "originado", "una", "intoxicación", "crónica", "(", "saturnismo", ")", ".", "Dice", "poseer", "además", "una", "úlcera", "en", "la", "pierna", "derecha", "desde", "hace", "20", "años", ".", "\n", "En", "la", "exploración", "física", "se", "percibe", "la", "inflamación", "de", "los", "ganglios", "cervicales", "y", "submaxilares", "del", "lado", "izquierdo", ",", "así", "como", "varias", "lesiones", "de", "tipo", "ulceroso", "en", "la", "mucosa", "labial", ",", "el", "paladar", ",", "la", "mucosa", "yugal", ",", "el", "suelo", "de", "la", "boca", "y", "la", "laringe", ".", "Se", "confirma", "la", "lesión", "de", "la", "pierna", "derecha", ",", "así", "como", "lesiones", "de", "tipo", "erosivo", "recubiertas", "por", "una", "costra", "en", "las", "axilas", "y", "el", "tronco", ".", "\n\n", "Se", "practicó", "una", "biopsia", "parcial", "de", "una", "de", "las", "lesiones", "del", "labio", "inferior", ",", "en", "la", "cual", "se", "observó", "el", "signo", "de", "Nikolsky", "positivo", "en", "el", "momento", "de", "la", "toma", "y", "se", "vio", "que", "las", "características", "histopatológicas", "de", "la", "lesión", "eran", "ampollas", "con", "acantolisis", "suprabasal", ",", "lo", "cual", "es", "compatible", "con", "el", "pénfigo", "vulgar", ".", "\n\n", "Unos", "días", "después", "de", "la", "biopsia", "el", "paciente", "sufrió", "una", "exacerbación", "de", "las", "lesiones", "y", "tuvo", "que", "ser", "ingresado", "en", "el", "hospital", "con", "un", "cuadro", "consistente", "en", ":", "lesiones", "ampollosas", "en", "el", "tórax", ",", "la", "pierna", "derecha", "y", "la", "cavidad", "oral", ",", "que", "le", "impiden", "la", "alimentación", ".", "Se", "le", "hicieron", "nuevas", "biopsias", "de", "las", "lesiones", "del", "tronco", "y", "la", "boca", "y", "se", "le", "hizo", "además", "un", "examen", "de", "inmunofluorescencia", ",", "en", "el", "que", "se", "observaron", "depósito", "de", "IgG", "en", "las", "uniones", "intercelulares", ",", "IgA", "en", "las", "paredes", "de", "los", "vasos", "pequeños", "y", "ausencia", "de", "IgM", ",", "C3", ",", "C1q", "y", "de", "depósitos", "de", "fibrinógeno", ".", "Se", "comenzó", "el", "tratamiento", "con", "prednisona", "con", "dosis", "gradualmente", "crecientes", "hasta", "alcanzar", "los", "100", "mg", "diarios", ".", "El", "paciente", "respondió", "favorablemente", "al", "tratamiento", "y", "abandonó", "el", "hospital", "con", "una", "notable", "mejoría", ".", "\n\n", "Tras", "la", "hospitalización", "se", "estableció", "el", "tratamiento", "para", "el", "paciente", "a", "base", "de", "140", "mg", "diarios", "de", "prednisona", "asociados", "a", "100", "mg", "de", "Azathioprina", ",", "40", "mg", "de", "Omeprazol", ",", "400", "mg", "de", "carbonato", "cálcico", ",", "vitamina", "D4", "y", "enjuagues", "de", "Nistatina", ",", "éstos", "últimos", "4", "veces", "al", "día", ".", "Tras", "un", "mes", "de", "tratamiento", "se", "observó", "una", "remisión", "casi", "total", "del", "cuadro", "y", "se", "redujo", "la", "dosis", "de", "prednisona", "a", "120", "mg", "durante", "15", "días", "y", ",", "posteriormente", ",", "a", "100", "mg", ".", "De", "igual", "modo", ",", "se", "decidió", "elevar", "la", "dosis", "de", "Azathiproprina", "a", "150", "mg", "diarios", ".", "El", "paciente", "se", "encuentra", "todavía", "bajo", "control", "médico", ".", "\n\n" ]

[ "NORMALIZABLES", "NO_NORMALIZABLES", "PROTEINAS" ]

aim is an umlsterm, wound is an umlsterm, methods is an umlsterm, starter 's is an umlsterm, distances is an umlsterm, distance is an umlsterm, film is an umlsterm, computer is an umlsterm, wound is an umlsterm, distance is an umlsterm, black is an umlsterm, powder is an umlsterm, distance is an umlsterm, findings is an umlsterm, risk of is an umlsterm, injury is an umlsterm, injuries is an umlsterm, eye is an umlsterm, distance is an umlsterm, cornea is an umlsterm

Rechtsmedizin.90090210.eng.abstr_task0

Sentence: In order to describe the wounding capacity in standardized manner , gelatine was used to simulate biological targets in terminal ballistics . The aim was the investigation of blank cartridges with wound ballistic methods . Blank cartridges ( caliber 9 mm x 17 ) produced by RWS , SM , Wadie and Umarex were fired with starter's revolvers of . 380 caliber into 10% gelatine blocks . Shots were fired at 4 °C at distances ranging from close contact and from 1 up to 50 cm distance . The blocks of gelatine and their cross-sections were photographed using slide film which was digitized and analyzed by computer . Contact shots produced penetration from 21 to 63 mm in depth and the maximum diameter of the wound cavity measured from 7 to 42 mm . Up to a distance of 4 cm black powder blank cartridges produced tearing of more than 1 cm depth . Shots from a distance of 10 cm propelled many particles up to 13 mm deep into the gelatine . At a shooting range of 50 cm 13% of the particles penetrated deeper than 3 mm and some penetrated up to 7 mm . The experimental findings give evidence of the well known risk of fatal injury from contact shots . Up to a shooting range of 5 cm injuries of the eye bulb are to be expected and at a 50 cm distance severe lesions of the cornea . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

In order to describe the wounding capacity in standardized manner , gelatine was used to simulate biological targets in terminal ballistics . The aim was the investigation of blank cartridges with wound ballistic methods . Blank cartridges ( caliber 9 mm x 17 ) produced by RWS , SM , Wadie and Umarex were fired with starter's revolvers of . 380 caliber into 10% gelatine blocks . Shots were fired at 4 °C at distances ranging from close contact and from 1 up to 50 cm distance . The blocks of gelatine and their cross-sections were photographed using slide film which was digitized and analyzed by computer . Contact shots produced penetration from 21 to 63 mm in depth and the maximum diameter of the wound cavity measured from 7 to 42 mm . Up to a distance of 4 cm black powder blank cartridges produced tearing of more than 1 cm depth . Shots from a distance of 10 cm propelled many particles up to 13 mm deep into the gelatine . At a shooting range of 50 cm 13% of the particles penetrated deeper than 3 mm and some penetrated up to 7 mm . The experimental findings give evidence of the well known risk of fatal injury from contact shots . Up to a shooting range of 5 cm injuries of the eye bulb are to be expected and at a 50 cm distance severe lesions of the cornea .

[ "In", "order", "to", "describe", "the", "wounding", "capacity", "in", "standardized", "manner", ",", "gelatine", "was", "used", "to", "simulate", "biological", "targets", "in", "terminal", "ballistics", ".", "The", "aim", "was", "the", "investigation", "of", "blank", "cartridges", "with", "wound", "ballistic", "methods", ".", "Blank", "cartridges", "(", "caliber", "9", "mm", "x", "17", ")", "produced", "by", "RWS", ",", "SM", ",", "Wadie", "and", "Umarex", "were", "fired", "with", "starter", "'s", "revolvers", "of", ".", "380", "caliber", "into", "10", "%", "gelatine", "blocks", ".", "Shots", "were", "fired", "at", "4", "°", "C", "at", "distances", "ranging", "from", "close", "contact", "and", "from", "1", "up", "to", "50", "cm", "distance", ".", "The", "blocks", "of", "gelatine", "and", "their", "cross", "-", "sections", "were", "photographed", "using", "slide", "film", "which", "was", "digitized", "and", "analyzed", "by", "computer", ".", "Contact", "shots", "produced", "penetration", "from", "21", "to", "63", "mm", "in", "depth", "and", "the", "maximum", "diameter", "of", "the", "wound", "cavity", "measured", "from", "7", "to", "42", "mm", ".", "Up", "to", "a", "distance", "of", "4", "cm", "black", "powder", "blank", "cartridges", "produced", "tearing", "of", "more", "than", "1", "cm", "depth", ".", "Shots", "from", "a", "distance", "of", "10", "cm", "propelled", "many", "particles", "up", "to", "13", "mm", "deep", "into", "the", "gelatine", ".", "At", "a", "shooting", "range", "of", "50", "cm", "13", "%", "of", "the", "particles", "penetrated", "deeper", "than", "3", "mm", "and", "some", "penetrated", "up", "to", "7", "mm", ".", "The", "experimental", "findings", "give", "evidence", "of", "the", "well", "known", "risk", "of", "fatal", "injury", "from", "contact", "shots", ".", "Up", "to", "a", "shooting", "range", "of", "5", "cm", "injuries", "of", "the", "eye", "bulb", "are", "to", "be", "expected", "and", "at", "a", "50", "cm", "distance", "severe", "lesions", "of", "the", "cornea", "." ]

[ "umlsterm" ]

aim is an umlsterm, wound is an umlsterm, methods is an umlsterm, starter 's is an umlsterm, distances is an umlsterm, distance is an umlsterm, film is an umlsterm, computer is an umlsterm, wound is an umlsterm, distance is an umlsterm, black is an umlsterm, powder is an umlsterm, distance is an umlsterm, findings is an umlsterm, risk of is an umlsterm, injury is an umlsterm, injuries is an umlsterm, eye is an umlsterm, distance is an umlsterm, cornea is an umlsterm

Rechtsmedizin.90090210.eng.abstr_task1

Sentence: In order to describe the wounding capacity in standardized manner , gelatine was used to simulate biological targets in terminal ballistics . The aim was the investigation of blank cartridges with wound ballistic methods . Blank cartridges ( caliber 9 mm x 17 ) produced by RWS , SM , Wadie and Umarex were fired with starter's revolvers of . 380 caliber into 10% gelatine blocks . Shots were fired at 4 °C at distances ranging from close contact and from 1 up to 50 cm distance . The blocks of gelatine and their cross-sections were photographed using slide film which was digitized and analyzed by computer . Contact shots produced penetration from 21 to 63 mm in depth and the maximum diameter of the wound cavity measured from 7 to 42 mm . Up to a distance of 4 cm black powder blank cartridges produced tearing of more than 1 cm depth . Shots from a distance of 10 cm propelled many particles up to 13 mm deep into the gelatine . At a shooting range of 50 cm 13% of the particles penetrated deeper than 3 mm and some penetrated up to 7 mm . The experimental findings give evidence of the well known risk of fatal injury from contact shots . Up to a shooting range of 5 cm injuries of the eye bulb are to be expected and at a 50 cm distance severe lesions of the cornea . Instructions: please typing these entity words according to sentence: aim, wound, methods, starter 's, distances, distance, film, computer, wound, distance, black, powder, distance, findings, risk of, injury, injuries, eye, distance, cornea Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

In order to describe the wounding capacity in standardized manner , gelatine was used to simulate biological targets in terminal ballistics . The aim was the investigation of blank cartridges with wound ballistic methods . Blank cartridges ( caliber 9 mm x 17 ) produced by RWS , SM , Wadie and Umarex were fired with starter's revolvers of . 380 caliber into 10% gelatine blocks . Shots were fired at 4 °C at distances ranging from close contact and from 1 up to 50 cm distance . The blocks of gelatine and their cross-sections were photographed using slide film which was digitized and analyzed by computer . Contact shots produced penetration from 21 to 63 mm in depth and the maximum diameter of the wound cavity measured from 7 to 42 mm . Up to a distance of 4 cm black powder blank cartridges produced tearing of more than 1 cm depth . Shots from a distance of 10 cm propelled many particles up to 13 mm deep into the gelatine . At a shooting range of 50 cm 13% of the particles penetrated deeper than 3 mm and some penetrated up to 7 mm . The experimental findings give evidence of the well known risk of fatal injury from contact shots . Up to a shooting range of 5 cm injuries of the eye bulb are to be expected and at a 50 cm distance severe lesions of the cornea .

[ "In", "order", "to", "describe", "the", "wounding", "capacity", "in", "standardized", "manner", ",", "gelatine", "was", "used", "to", "simulate", "biological", "targets", "in", "terminal", "ballistics", ".", "The", "aim", "was", "the", "investigation", "of", "blank", "cartridges", "with", "wound", "ballistic", "methods", ".", "Blank", "cartridges", "(", "caliber", "9", "mm", "x", "17", ")", "produced", "by", "RWS", ",", "SM", ",", "Wadie", "and", "Umarex", "were", "fired", "with", "starter", "'s", "revolvers", "of", ".", "380", "caliber", "into", "10", "%", "gelatine", "blocks", ".", "Shots", "were", "fired", "at", "4", "°", "C", "at", "distances", "ranging", "from", "close", "contact", "and", "from", "1", "up", "to", "50", "cm", "distance", ".", "The", "blocks", "of", "gelatine", "and", "their", "cross", "-", "sections", "were", "photographed", "using", "slide", "film", "which", "was", "digitized", "and", "analyzed", "by", "computer", ".", "Contact", "shots", "produced", "penetration", "from", "21", "to", "63", "mm", "in", "depth", "and", "the", "maximum", "diameter", "of", "the", "wound", "cavity", "measured", "from", "7", "to", "42", "mm", ".", "Up", "to", "a", "distance", "of", "4", "cm", "black", "powder", "blank", "cartridges", "produced", "tearing", "of", "more", "than", "1", "cm", "depth", ".", "Shots", "from", "a", "distance", "of", "10", "cm", "propelled", "many", "particles", "up", "to", "13", "mm", "deep", "into", "the", "gelatine", ".", "At", "a", "shooting", "range", "of", "50", "cm", "13", "%", "of", "the", "particles", "penetrated", "deeper", "than", "3", "mm", "and", "some", "penetrated", "up", "to", "7", "mm", ".", "The", "experimental", "findings", "give", "evidence", "of", "the", "well", "known", "risk", "of", "fatal", "injury", "from", "contact", "shots", ".", "Up", "to", "a", "shooting", "range", "of", "5", "cm", "injuries", "of", "the", "eye", "bulb", "are", "to", "be", "expected", "and", "at", "a", "50", "cm", "distance", "severe", "lesions", "of", "the", "cornea", "." ]

[ "umlsterm" ]

aim, wound, methods, starter 's, distances, distance, film, computer, wound, distance, black, powder, distance, findings, risk of, injury, injuries, eye, distance, cornea

Rechtsmedizin.90090210.eng.abstr_task2

Sentence: In order to describe the wounding capacity in standardized manner , gelatine was used to simulate biological targets in terminal ballistics . The aim was the investigation of blank cartridges with wound ballistic methods . Blank cartridges ( caliber 9 mm x 17 ) produced by RWS , SM , Wadie and Umarex were fired with starter's revolvers of . 380 caliber into 10% gelatine blocks . Shots were fired at 4 °C at distances ranging from close contact and from 1 up to 50 cm distance . The blocks of gelatine and their cross-sections were photographed using slide film which was digitized and analyzed by computer . Contact shots produced penetration from 21 to 63 mm in depth and the maximum diameter of the wound cavity measured from 7 to 42 mm . Up to a distance of 4 cm black powder blank cartridges produced tearing of more than 1 cm depth . Shots from a distance of 10 cm propelled many particles up to 13 mm deep into the gelatine . At a shooting range of 50 cm 13% of the particles penetrated deeper than 3 mm and some penetrated up to 7 mm . The experimental findings give evidence of the well known risk of fatal injury from contact shots . Up to a shooting range of 5 cm injuries of the eye bulb are to be expected and at a 50 cm distance severe lesions of the cornea . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

In order to describe the wounding capacity in standardized manner , gelatine was used to simulate biological targets in terminal ballistics . The aim was the investigation of blank cartridges with wound ballistic methods . Blank cartridges ( caliber 9 mm x 17 ) produced by RWS , SM , Wadie and Umarex were fired with starter's revolvers of . 380 caliber into 10% gelatine blocks . Shots were fired at 4 °C at distances ranging from close contact and from 1 up to 50 cm distance . The blocks of gelatine and their cross-sections were photographed using slide film which was digitized and analyzed by computer . Contact shots produced penetration from 21 to 63 mm in depth and the maximum diameter of the wound cavity measured from 7 to 42 mm . Up to a distance of 4 cm black powder blank cartridges produced tearing of more than 1 cm depth . Shots from a distance of 10 cm propelled many particles up to 13 mm deep into the gelatine . At a shooting range of 50 cm 13% of the particles penetrated deeper than 3 mm and some penetrated up to 7 mm . The experimental findings give evidence of the well known risk of fatal injury from contact shots . Up to a shooting range of 5 cm injuries of the eye bulb are to be expected and at a 50 cm distance severe lesions of the cornea .

[ "In", "order", "to", "describe", "the", "wounding", "capacity", "in", "standardized", "manner", ",", "gelatine", "was", "used", "to", "simulate", "biological", "targets", "in", "terminal", "ballistics", ".", "The", "aim", "was", "the", "investigation", "of", "blank", "cartridges", "with", "wound", "ballistic", "methods", ".", "Blank", "cartridges", "(", "caliber", "9", "mm", "x", "17", ")", "produced", "by", "RWS", ",", "SM", ",", "Wadie", "and", "Umarex", "were", "fired", "with", "starter", "'s", "revolvers", "of", ".", "380", "caliber", "into", "10", "%", "gelatine", "blocks", ".", "Shots", "were", "fired", "at", "4", "°", "C", "at", "distances", "ranging", "from", "close", "contact", "and", "from", "1", "up", "to", "50", "cm", "distance", ".", "The", "blocks", "of", "gelatine", "and", "their", "cross", "-", "sections", "were", "photographed", "using", "slide", "film", "which", "was", "digitized", "and", "analyzed", "by", "computer", ".", "Contact", "shots", "produced", "penetration", "from", "21", "to", "63", "mm", "in", "depth", "and", "the", "maximum", "diameter", "of", "the", "wound", "cavity", "measured", "from", "7", "to", "42", "mm", ".", "Up", "to", "a", "distance", "of", "4", "cm", "black", "powder", "blank", "cartridges", "produced", "tearing", "of", "more", "than", "1", "cm", "depth", ".", "Shots", "from", "a", "distance", "of", "10", "cm", "propelled", "many", "particles", "up", "to", "13", "mm", "deep", "into", "the", "gelatine", ".", "At", "a", "shooting", "range", "of", "50", "cm", "13", "%", "of", "the", "particles", "penetrated", "deeper", "than", "3", "mm", "and", "some", "penetrated", "up", "to", "7", "mm", ".", "The", "experimental", "findings", "give", "evidence", "of", "the", "well", "known", "risk", "of", "fatal", "injury", "from", "contact", "shots", ".", "Up", "to", "a", "shooting", "range", "of", "5", "cm", "injuries", "of", "the", "eye", "bulb", "are", "to", "be", "expected", "and", "at", "a", "50", "cm", "distance", "severe", "lesions", "of", "the", "cornea", "." ]

[ "umlsterm" ]

Schaedel - Hirn - Verletzungen is an umlsterm, Verletzungen is an umlsterm, unfallchirurgischen is an umlsterm, Patienten is an umlsterm, Schaedel - Hirn - Trauma is an umlsterm, SHT is an umlsterm, Patienten is an umlsterm, Commotio cerebri is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Haematomausraeumung is an umlsterm, Blutungen is an umlsterm, Drainage is an umlsterm, Patienten is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Verletzungen is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, SHT is an umlsterm, Krankenhaeusern is an umlsterm, Roentgendiagnostik is an umlsterm, SHT is an umlsterm, Krankenhaus is an umlsterm, SHT is an umlsterm, lebensbedrohlichen is an umlsterm, Blutungen is an umlsterm, Druckentlastung is an umlsterm, Blutmassen is an umlsterm, Blutungen is an umlsterm, hinteren Schaedelgrube is an umlsterm, Hirnnervenverletzungen is an umlsterm, Schaedelbasisverletzungen is an umlsterm, Liquorfisteln is an umlsterm, Literatur is an umlsterm, Patienten is an umlsterm, SHT is an umlsterm

DerChirurg.60671107.ger.abstr_task0

Sentence: Zusammenfassung . Schaedel-Hirn-Verletzungen sind sowohl bei Polytraumen wie auch als isolierte Verletzungen sehr haeufig . In unserer Klinik der unfallchirurgischen Schwerpunktversorgung wurden in einem Zeitraum von 21 Monaten 489 Patienten mit einem Schaedel-Hirn-Trauma ( SHT ) behandelt . Dies entspricht 6,5 % aller stationaer behandelten Patienten . Waehrend bei Commotio cerebri ( CC 85,9 % , der Patienten ) immer eine konservative Therapie und komplikationsloser Verlauf festzustellen war , musste bei den 69 Patienten mit Contusio cerebri in 18 Faellen eine Craniotomie mit Haematomausraeumung bei sub- und epiduralen Blutungen und Drainage erfolgen . Bei zwei dieser Patienten war eine Revision wegen Nachblutung erforderlich . Eine Bildtelephonverbindung mit einem neurochirurgischen Zentrum wurde zweimal in Anspruch genommen . In vier Faellen mit Komplex-/Begleitverletzungen erfolgte die Verlegung in ein neurochirurgisches Zentrum . Die Letalitaet betrug 14,5 % . Es werden die Diagnostik und Therapie bei den einzelnen Verletzungen und die Voraussetzungen fuer die Behandlung von Patienten mit SHT in peripheren Krankenhaeusern dargestellt : Notarzt Notaufnahmemanagement , Neurologe , , Roentgendiagnostik mit CT , Operationsausstattung und qualifizierte Operateure . Falls diese Voraussetzungen gegeben sind , kann ein Grossteil auch schwerer SHT im peripheren Krankenhaus versorgt werden . Sind einige dieser Voraussetzungen nicht erfuellt , sollte bei jedem potentiell operationspflichtigen SHT die fruehzeitige Verlegung in ein Zentrum erfolgen . Nur bei akut lebensbedrohlichen Blutungen , bei denen aus zeitlichen Gruenden eine Verlegung nicht moeglich ist , muss auch in Kliniken der Grundversorgung ohne adaequate Voraussetzungen eine Craniotomie und Druckentlastung erfolgen . Bei Begleitverletzungen , wie intracerebrale Blutmassen , Ventrikeleinbruch , Blutungen in der hinteren Schaedelgrube , Hirnnervenverletzungen , Carotis- oder Sinus-cavernosus-Verletzung , Schaedelbasisverletzungen mit Liquorfisteln oder Pneumoencephalon sollen auch fuer Kliniken der Schwerpunktversorgung eine Indikation zur Verlegung in ein neurochirurgisches Zentrum sein . Diese Selektion ermoeglicht in peripheren Kliniken vergleichbare Behandlungsergebnisse , wie in der Literatur angegeben , und vermeidet die Ueberlastung neurochirurgischer Zentren mit Patienten nach SHT . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Zusammenfassung . Schaedel-Hirn-Verletzungen sind sowohl bei Polytraumen wie auch als isolierte Verletzungen sehr haeufig . In unserer Klinik der unfallchirurgischen Schwerpunktversorgung wurden in einem Zeitraum von 21 Monaten 489 Patienten mit einem Schaedel-Hirn-Trauma ( SHT ) behandelt . Dies entspricht 6,5 % aller stationaer behandelten Patienten . Waehrend bei Commotio cerebri ( CC 85,9 % , der Patienten ) immer eine konservative Therapie und komplikationsloser Verlauf festzustellen war , musste bei den 69 Patienten mit Contusio cerebri in 18 Faellen eine Craniotomie mit Haematomausraeumung bei sub- und epiduralen Blutungen und Drainage erfolgen . Bei zwei dieser Patienten war eine Revision wegen Nachblutung erforderlich . Eine Bildtelephonverbindung mit einem neurochirurgischen Zentrum wurde zweimal in Anspruch genommen . In vier Faellen mit Komplex-/Begleitverletzungen erfolgte die Verlegung in ein neurochirurgisches Zentrum . Die Letalitaet betrug 14,5 % . Es werden die Diagnostik und Therapie bei den einzelnen Verletzungen und die Voraussetzungen fuer die Behandlung von Patienten mit SHT in peripheren Krankenhaeusern dargestellt : Notarzt Notaufnahmemanagement , Neurologe , , Roentgendiagnostik mit CT , Operationsausstattung und qualifizierte Operateure . Falls diese Voraussetzungen gegeben sind , kann ein Grossteil auch schwerer SHT im peripheren Krankenhaus versorgt werden . Sind einige dieser Voraussetzungen nicht erfuellt , sollte bei jedem potentiell operationspflichtigen SHT die fruehzeitige Verlegung in ein Zentrum erfolgen . Nur bei akut lebensbedrohlichen Blutungen , bei denen aus zeitlichen Gruenden eine Verlegung nicht moeglich ist , muss auch in Kliniken der Grundversorgung ohne adaequate Voraussetzungen eine Craniotomie und Druckentlastung erfolgen . Bei Begleitverletzungen , wie intracerebrale Blutmassen , Ventrikeleinbruch , Blutungen in der hinteren Schaedelgrube , Hirnnervenverletzungen , Carotis- oder Sinus-cavernosus-Verletzung , Schaedelbasisverletzungen mit Liquorfisteln oder Pneumoencephalon sollen auch fuer Kliniken der Schwerpunktversorgung eine Indikation zur Verlegung in ein neurochirurgisches Zentrum sein . Diese Selektion ermoeglicht in peripheren Kliniken vergleichbare Behandlungsergebnisse , wie in der Literatur angegeben , und vermeidet die Ueberlastung neurochirurgischer Zentren mit Patienten nach SHT .

[ "Zusammenfassung", ".", "Schaedel", "-", "Hirn", "-", "Verletzungen", "sind", "sowohl", "bei", "Polytraumen", "wie", "auch", "als", "isolierte", "Verletzungen", "sehr", "haeufig", ".", "In", "unserer", "Klinik", "der", "unfallchirurgischen", "Schwerpunktversorgung", "wurden", "in", "einem", "Zeitraum", "von", "21", "Monaten", "489", "Patienten", "mit", "einem", "Schaedel", "-", "Hirn", "-", "Trauma", "(", "SHT", ")", "behandelt", ".", "Dies", "entspricht", "6,5", "%", "aller", "stationaer", "behandelten", "Patienten", ".", "Waehrend", "bei", "Commotio", "cerebri", "(", "CC", "85,9", "%", ",", "der", "Patienten", ")", "immer", "eine", "konservative", "Therapie", "und", "komplikationsloser", "Verlauf", "festzustellen", "war", ",", "musste", "bei", "den", "69", "Patienten", "mit", "Contusio", "cerebri", "in", "18", "Faellen", "eine", "Craniotomie", "mit", "Haematomausraeumung", "bei", "sub-", "und", "epiduralen", "Blutungen", "und", "Drainage", "erfolgen", ".", "Bei", "zwei", "dieser", "Patienten", "war", "eine", "Revision", "wegen", "Nachblutung", "erforderlich", ".", "Eine", "Bildtelephonverbindung", "mit", "einem", "neurochirurgischen", "Zentrum", "wurde", "zweimal", "in", "Anspruch", "genommen", ".", "In", "vier", "Faellen", "mit", "Komplex-/Begleitverletzungen", "erfolgte", "die", "Verlegung", "in", "ein", "neurochirurgisches", "Zentrum", ".", "Die", "Letalitaet", "betrug", "14,5", "%", ".", "Es", "werden", "die", "Diagnostik", "und", "Therapie", "bei", "den", "einzelnen", "Verletzungen", "und", "die", "Voraussetzungen", "fuer", "die", "Behandlung", "von", "Patienten", "mit", "SHT", "in", "peripheren", "Krankenhaeusern", "dargestellt", ":", "Notarzt", "Notaufnahmemanagement", ",", "Neurologe", ",", ",", "Roentgendiagnostik", "mit", "CT", ",", "Operationsausstattung", "und", "qualifizierte", "Operateure", ".", "Falls", "diese", "Voraussetzungen", "gegeben", "sind", ",", "kann", "ein", "Grossteil", "auch", "schwerer", "SHT", "im", "peripheren", "Krankenhaus", "versorgt", "werden", ".", "Sind", "einige", "dieser", "Voraussetzungen", "nicht", "erfuellt", ",", "sollte", "bei", "jedem", "potentiell", "operationspflichtigen", "SHT", "die", "fruehzeitige", "Verlegung", "in", "ein", "Zentrum", "erfolgen", ".", "Nur", "bei", "akut", "lebensbedrohlichen", "Blutungen", ",", "bei", "denen", "aus", "zeitlichen", "Gruenden", "eine", "Verlegung", "nicht", "moeglich", "ist", ",", "muss", "auch", "in", "Kliniken", "der", "Grundversorgung", "ohne", "adaequate", "Voraussetzungen", "eine", "Craniotomie", "und", "Druckentlastung", "erfolgen", ".", "Bei", "Begleitverletzungen", ",", "wie", "intracerebrale", "Blutmassen", ",", "Ventrikeleinbruch", ",", "Blutungen", "in", "der", "hinteren", "Schaedelgrube", ",", "Hirnnervenverletzungen", ",", "Carotis-", "oder", "Sinus", "-", "cavernosus", "-", "Verletzung", ",", "Schaedelbasisverletzungen", "mit", "Liquorfisteln", "oder", "Pneumoencephalon", "sollen", "auch", "fuer", "Kliniken", "der", "Schwerpunktversorgung", "eine", "Indikation", "zur", "Verlegung", "in", "ein", "neurochirurgisches", "Zentrum", "sein", ".", "Diese", "Selektion", "ermoeglicht", "in", "peripheren", "Kliniken", "vergleichbare", "Behandlungsergebnisse", ",", "wie", "in", "der", "Literatur", "angegeben", ",", "und", "vermeidet", "die", "Ueberlastung", "neurochirurgischer", "Zentren", "mit", "Patienten", "nach", "SHT", "." ]

[ "umlsterm" ]

Schaedel - Hirn - Verletzungen is an umlsterm, Verletzungen is an umlsterm, unfallchirurgischen is an umlsterm, Patienten is an umlsterm, Schaedel - Hirn - Trauma is an umlsterm, SHT is an umlsterm, Patienten is an umlsterm, Commotio cerebri is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Haematomausraeumung is an umlsterm, Blutungen is an umlsterm, Drainage is an umlsterm, Patienten is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Verletzungen is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, SHT is an umlsterm, Krankenhaeusern is an umlsterm, Roentgendiagnostik is an umlsterm, SHT is an umlsterm, Krankenhaus is an umlsterm, SHT is an umlsterm, lebensbedrohlichen is an umlsterm, Blutungen is an umlsterm, Druckentlastung is an umlsterm, Blutmassen is an umlsterm, Blutungen is an umlsterm, hinteren Schaedelgrube is an umlsterm, Hirnnervenverletzungen is an umlsterm, Schaedelbasisverletzungen is an umlsterm, Liquorfisteln is an umlsterm, Literatur is an umlsterm, Patienten is an umlsterm, SHT is an umlsterm

DerChirurg.60671107.ger.abstr_task1

Sentence: Zusammenfassung . Schaedel-Hirn-Verletzungen sind sowohl bei Polytraumen wie auch als isolierte Verletzungen sehr haeufig . In unserer Klinik der unfallchirurgischen Schwerpunktversorgung wurden in einem Zeitraum von 21 Monaten 489 Patienten mit einem Schaedel-Hirn-Trauma ( SHT ) behandelt . Dies entspricht 6,5 % aller stationaer behandelten Patienten . Waehrend bei Commotio cerebri ( CC 85,9 % , der Patienten ) immer eine konservative Therapie und komplikationsloser Verlauf festzustellen war , musste bei den 69 Patienten mit Contusio cerebri in 18 Faellen eine Craniotomie mit Haematomausraeumung bei sub- und epiduralen Blutungen und Drainage erfolgen . Bei zwei dieser Patienten war eine Revision wegen Nachblutung erforderlich . Eine Bildtelephonverbindung mit einem neurochirurgischen Zentrum wurde zweimal in Anspruch genommen . In vier Faellen mit Komplex-/Begleitverletzungen erfolgte die Verlegung in ein neurochirurgisches Zentrum . Die Letalitaet betrug 14,5 % . Es werden die Diagnostik und Therapie bei den einzelnen Verletzungen und die Voraussetzungen fuer die Behandlung von Patienten mit SHT in peripheren Krankenhaeusern dargestellt : Notarzt Notaufnahmemanagement , Neurologe , , Roentgendiagnostik mit CT , Operationsausstattung und qualifizierte Operateure . Falls diese Voraussetzungen gegeben sind , kann ein Grossteil auch schwerer SHT im peripheren Krankenhaus versorgt werden . Sind einige dieser Voraussetzungen nicht erfuellt , sollte bei jedem potentiell operationspflichtigen SHT die fruehzeitige Verlegung in ein Zentrum erfolgen . Nur bei akut lebensbedrohlichen Blutungen , bei denen aus zeitlichen Gruenden eine Verlegung nicht moeglich ist , muss auch in Kliniken der Grundversorgung ohne adaequate Voraussetzungen eine Craniotomie und Druckentlastung erfolgen . Bei Begleitverletzungen , wie intracerebrale Blutmassen , Ventrikeleinbruch , Blutungen in der hinteren Schaedelgrube , Hirnnervenverletzungen , Carotis- oder Sinus-cavernosus-Verletzung , Schaedelbasisverletzungen mit Liquorfisteln oder Pneumoencephalon sollen auch fuer Kliniken der Schwerpunktversorgung eine Indikation zur Verlegung in ein neurochirurgisches Zentrum sein . Diese Selektion ermoeglicht in peripheren Kliniken vergleichbare Behandlungsergebnisse , wie in der Literatur angegeben , und vermeidet die Ueberlastung neurochirurgischer Zentren mit Patienten nach SHT . Instructions: please typing these entity words according to sentence: Schaedel - Hirn - Verletzungen, Verletzungen, unfallchirurgischen, Patienten, Schaedel - Hirn - Trauma, SHT, Patienten, Commotio cerebri, Patienten, Therapie, Patienten, Haematomausraeumung, Blutungen, Drainage, Patienten, Diagnostik, Therapie, Verletzungen, Behandlung, Patienten, SHT, Krankenhaeusern, Roentgendiagnostik, SHT, Krankenhaus, SHT, lebensbedrohlichen, Blutungen, Druckentlastung, Blutmassen, Blutungen, hinteren Schaedelgrube, Hirnnervenverletzungen, Schaedelbasisverletzungen, Liquorfisteln, Literatur, Patienten, SHT Options: umlsterm

[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Zusammenfassung . Schaedel-Hirn-Verletzungen sind sowohl bei Polytraumen wie auch als isolierte Verletzungen sehr haeufig . In unserer Klinik der unfallchirurgischen Schwerpunktversorgung wurden in einem Zeitraum von 21 Monaten 489 Patienten mit einem Schaedel-Hirn-Trauma ( SHT ) behandelt . Dies entspricht 6,5 % aller stationaer behandelten Patienten . Waehrend bei Commotio cerebri ( CC 85,9 % , der Patienten ) immer eine konservative Therapie und komplikationsloser Verlauf festzustellen war , musste bei den 69 Patienten mit Contusio cerebri in 18 Faellen eine Craniotomie mit Haematomausraeumung bei sub- und epiduralen Blutungen und Drainage erfolgen . Bei zwei dieser Patienten war eine Revision wegen Nachblutung erforderlich . Eine Bildtelephonverbindung mit einem neurochirurgischen Zentrum wurde zweimal in Anspruch genommen . In vier Faellen mit Komplex-/Begleitverletzungen erfolgte die Verlegung in ein neurochirurgisches Zentrum . Die Letalitaet betrug 14,5 % . Es werden die Diagnostik und Therapie bei den einzelnen Verletzungen und die Voraussetzungen fuer die Behandlung von Patienten mit SHT in peripheren Krankenhaeusern dargestellt : Notarzt Notaufnahmemanagement , Neurologe , , Roentgendiagnostik mit CT , Operationsausstattung und qualifizierte Operateure . Falls diese Voraussetzungen gegeben sind , kann ein Grossteil auch schwerer SHT im peripheren Krankenhaus versorgt werden . Sind einige dieser Voraussetzungen nicht erfuellt , sollte bei jedem potentiell operationspflichtigen SHT die fruehzeitige Verlegung in ein Zentrum erfolgen . Nur bei akut lebensbedrohlichen Blutungen , bei denen aus zeitlichen Gruenden eine Verlegung nicht moeglich ist , muss auch in Kliniken der Grundversorgung ohne adaequate Voraussetzungen eine Craniotomie und Druckentlastung erfolgen . Bei Begleitverletzungen , wie intracerebrale Blutmassen , Ventrikeleinbruch , Blutungen in der hinteren Schaedelgrube , Hirnnervenverletzungen , Carotis- oder Sinus-cavernosus-Verletzung , Schaedelbasisverletzungen mit Liquorfisteln oder Pneumoencephalon sollen auch fuer Kliniken der Schwerpunktversorgung eine Indikation zur Verlegung in ein neurochirurgisches Zentrum sein . Diese Selektion ermoeglicht in peripheren Kliniken vergleichbare Behandlungsergebnisse , wie in der Literatur angegeben , und vermeidet die Ueberlastung neurochirurgischer Zentren mit Patienten nach SHT .

[ "Zusammenfassung", ".", "Schaedel", "-", "Hirn", "-", "Verletzungen", "sind", "sowohl", "bei", "Polytraumen", "wie", "auch", "als", "isolierte", "Verletzungen", "sehr", "haeufig", ".", "In", "unserer", "Klinik", "der", "unfallchirurgischen", "Schwerpunktversorgung", "wurden", "in", "einem", "Zeitraum", "von", "21", "Monaten", "489", "Patienten", "mit", "einem", "Schaedel", "-", "Hirn", "-", "Trauma", "(", "SHT", ")", "behandelt", ".", "Dies", "entspricht", "6,5", "%", "aller", "stationaer", "behandelten", "Patienten", ".", "Waehrend", "bei", "Commotio", "cerebri", "(", "CC", "85,9", "%", ",", "der", "Patienten", ")", "immer", "eine", "konservative", "Therapie", "und", "komplikationsloser", "Verlauf", "festzustellen", "war", ",", "musste", "bei", "den", "69", "Patienten", "mit", "Contusio", "cerebri", "in", "18", "Faellen", "eine", "Craniotomie", "mit", "Haematomausraeumung", "bei", "sub-", "und", "epiduralen", "Blutungen", "und", "Drainage", "erfolgen", ".", "Bei", "zwei", "dieser", "Patienten", "war", "eine", "Revision", "wegen", "Nachblutung", "erforderlich", ".", "Eine", "Bildtelephonverbindung", "mit", "einem", "neurochirurgischen", "Zentrum", "wurde", "zweimal", "in", "Anspruch", "genommen", ".", "In", "vier", "Faellen", "mit", "Komplex-/Begleitverletzungen", "erfolgte", "die", "Verlegung", "in", "ein", "neurochirurgisches", "Zentrum", ".", "Die", "Letalitaet", "betrug", "14,5", "%", ".", "Es", "werden", "die", "Diagnostik", "und", "Therapie", "bei", "den", "einzelnen", "Verletzungen", "und", "die", "Voraussetzungen", "fuer", "die", "Behandlung", "von", "Patienten", "mit", "SHT", "in", "peripheren", "Krankenhaeusern", "dargestellt", ":", "Notarzt", "Notaufnahmemanagement", ",", "Neurologe", ",", ",", "Roentgendiagnostik", "mit", "CT", ",", "Operationsausstattung", "und", "qualifizierte", "Operateure", ".", "Falls", "diese", "Voraussetzungen", "gegeben", "sind", ",", "kann", "ein", "Grossteil", "auch", "schwerer", "SHT", "im", "peripheren", "Krankenhaus", "versorgt", "werden", ".", "Sind", "einige", "dieser", "Voraussetzungen", "nicht", "erfuellt", ",", "sollte", "bei", "jedem", "potentiell", "operationspflichtigen", "SHT", "die", "fruehzeitige", "Verlegung", "in", "ein", "Zentrum", "erfolgen", ".", "Nur", "bei", "akut", "lebensbedrohlichen", "Blutungen", ",", "bei", "denen", "aus", "zeitlichen", "Gruenden", "eine", "Verlegung", "nicht", "moeglich", "ist", ",", "muss", "auch", "in", "Kliniken", "der", "Grundversorgung", "ohne", "adaequate", "Voraussetzungen", "eine", "Craniotomie", "und", "Druckentlastung", "erfolgen", ".", "Bei", "Begleitverletzungen", ",", "wie", "intracerebrale", "Blutmassen", ",", "Ventrikeleinbruch", ",", "Blutungen", "in", "der", "hinteren", "Schaedelgrube", ",", "Hirnnervenverletzungen", ",", "Carotis-", "oder", "Sinus", "-", "cavernosus", "-", "Verletzung", ",", "Schaedelbasisverletzungen", "mit", "Liquorfisteln", "oder", "Pneumoencephalon", "sollen", "auch", "fuer", "Kliniken", "der", "Schwerpunktversorgung", "eine", "Indikation", "zur", "Verlegung", "in", "ein", "neurochirurgisches", "Zentrum", "sein", ".", "Diese", "Selektion", "ermoeglicht", "in", "peripheren", "Kliniken", "vergleichbare", "Behandlungsergebnisse", ",", "wie", "in", "der", "Literatur", "angegeben", ",", "und", "vermeidet", "die", "Ueberlastung", "neurochirurgischer", "Zentren", "mit", "Patienten", "nach", "SHT", "." ]

[ "umlsterm" ]